Delaware
8071
77-0552594
(State or other jurisdiction of
incorporation or organization)
(Primary Standard Industrial
Classification Code Number)
(I.R.S. Employer
Identification No.)
Stanton D. Wong
Justin D. Hovey Pillsbury Winthrop Shaw Pittman LLP P.O. Box 7880 San Francisco, CA 94120 (415) 983-1000 (415) 983-1200 facsimile |
Gabriella A. Lombardi
Pillsbury Winthrop Shaw Pittman LLP 2475 Hanover Street Palo Alto, CA 94304 (650) 233-4500 (650) 233-4545 facsimile |
William H. Hinman, Jr.
Simpson Thacher & Bartlett LLP 3330 Hillview Avenue Palo Alto, CA 94304 (650) 251-5000 (650) 251-5002 facsimile |
Proposed maximum | ||||||
Title of each class of | aggregate offering | Amount of | ||||
securities to be registered | price(1)(2) | registration fee | ||||
Common Stock, par value $0.0001 per share
|
$75,000,000 | $8,827.50 | ||||
(1) | Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933. |
(2) | Includes shares of common stock issuable upon exercise of underwriters over-allotment option. |
The
information in this prospectus is not complete and may be
changed. We may not sell these securities until the registration
statement filed with the Securities and Exchange Commission is
effective. This prospectus is not an offer to sell these
securities and it is not soliciting any offer to buy these
securities in any state where the offer or sale is not
permitted.
|
Per Share | Total | |||||||
Initial Public Offering Price
|
$ | $ | ||||||
Underwriting Discount
|
$ | $ | ||||||
Proceeds to Genomic Health, Inc. (before expenses)
|
$ | $ |
JPMorgan | Lehman Brothers |
Piper Jaffray | Thomas Weisel Partners LLC |
Page | ||||||||
1 | ||||||||
6 | ||||||||
20 | ||||||||
22 | ||||||||
22 | ||||||||
23 | ||||||||
24 | ||||||||
25 | ||||||||
27 | ||||||||
37 | ||||||||
63 | ||||||||
71 | ||||||||
73 | ||||||||
76 | ||||||||
80 | ||||||||
82 | ||||||||
85 | ||||||||
85 | ||||||||
86 | ||||||||
F-1 | ||||||||
EXHIBIT 1.1 | ||||||||
EXHIBIT 3.1 | ||||||||
EXHIBIT 3.3 | ||||||||
EXHIBIT 3.4 | ||||||||
EXHIBIT 3.5 | ||||||||
EXHIBIT 4.2 | ||||||||
EXHIBIT 10.2 | ||||||||
EXHIBIT 10.4.1 | ||||||||
EXHIBIT 10.4.2 | ||||||||
EXHIBIT 10.4.3 | ||||||||
EXHIBIT 10.5.1 | ||||||||
EXHIBIT 10.5.2 | ||||||||
EXHIBIT 10.5.3 | ||||||||
EXHIBIT 10.5.4 | ||||||||
EXHIBIT 10.6.1 | ||||||||
EXHIBIT 10.6.2 | ||||||||
EXHIBIT 10.7.1 | ||||||||
EXHIBIT 10.7.2 | ||||||||
EXHIBIT 10.8 | ||||||||
EXHIBIT 10.9.1 | ||||||||
EXHIBIT 10.9.2 | ||||||||
EXHIBIT 10.9.3 | ||||||||
EXHIBIT 10.9.4 | ||||||||
EXHIBIT 21.1 | ||||||||
EXHIBIT 23.1 |
1
2
3
Table of Contents
Table of Contents
Improved Quality of Treatment Decisions
. We believe
our approach to genomic-based cancer analysis improves the
quality of cancer treatment decisions by providing an
individualized analysis of each patients tumor that is
correlated to clinical outcome. Our approach represents a
substantial departure from existing approaches to treatment,
which often use subjective, anatomic and qualitative factors to
determine treatments. Onco
type
DX has been shown in
clinical studies to classify many patients into recurrence risk
categories different from classifications based on current
guidelines. Thus, our solution enables patients and physicians
to make more informed decisions about treatment risk-benefit
and, consequently, design an individualized treatment plan.
Improved Economics of Cancer Care
. We believe that
improving the quality of treatment decisions can result in
significant economic benefits. In early stage breast cancer, our
data shows that many patients are misclassified as high or low
risk under existing treatment guidelines. Many low risk patients
misclassified as high risk receive toxic and expensive
chemotherapy treatment regimens. Chemotherapy may cost in excess
of $20,000, as compared to Onco
type
DXs list price
of $3,460. On the other hand, some high risk patients
misclassified as low risk are not provided chemotherapy
treatment, possibly necessitating future treatment costing up to
$50,000 or more if the cancer recurs.
Table of Contents
4
shares
shares
$ to $
We intend to use the net proceeds for general corporate
purposes, including working capital and capital expenditures.
See Use of Proceeds.
GHDX
a 1-for- reverse split of our
common stock;
the automatic conversion of all outstanding shares of our
convertible preferred stock into common stock upon the closing
of this offering; and
no exercise of the over-allotment option granted to the
underwriters.
Table of Contents
5
Period from
Three Months Ended
August 22, 2000
Year Ended December 31,
March 31,
(inception) to
Dec. 31, 2000
2001
2002
2003
2004
2004
2005
(In thousands, except share and per share data)
(Unaudited)
$
$
$
$
$
227
$
$
442
125
100
125
327
442
1,828
624
1,285
169
11,080
7,053
9,069
10,040
2,273
2,205
117
754
2,805
9,856
2,055
3,382
566
2,844
3,753
3,686
3,869
913
1,352
735
14,041
11,560
15,560
25,593
5,865
8,224
1,267
492
185
271
28
196
$
(735
)
$
(12,774
)
$
(11,068
)
$
(15,250
)
$
(24,995
)
$
(5,837
)
$
(7,586
)
$
(3.37
)
$
(6.71
)
$
(3.98
)
$
(4.14
)
$
(4.79
)
$
(1.16
)
$
(1.34
)
218,332
1,903,245
2,777,443
3,679,377
5,213,955
5,044,732
5,681,807
(1)
Includes non-cash charges for stock-based compensation expense
of $191,000, $2,000 and $232,000 for the year ended
December 31, 2004 and the three months ended March 31,
2004 and 2005, respectively.
As of March 31, 2005
Pro Forma
Actual
Pro Forma
As Adjusted
(In thousands)
(Unaudited)
$
32,531
31,281
36,421
1,730
103,212
(71,458
)
on an actual basis;
on a pro forma basis to give effect to the automatic conversion
of all outstanding shares of our convertible preferred stock
into common stock upon the closing of this offering; and
on a pro forma as adjusted basis to give effect to the sale
of shares
of our common stock in this offering at an assumed initial
public offering price of
$ per
share, after deducting the estimated underwriting discount and
estimated offering expenses payable by us.
Table of Contents
| not experimental or investigational, | |
| medically necessary, | |
| appropriate for the specific patient, | |
| cost-effective, and | |
| supported by peer-reviewed publications. |
6
7
| Medicare billing and payment regulations applicable to clinical laboratories; | |
| the federal Medicare and Medicaid Anti-kickback Law, and state anti-kickback prohibitions; | |
| the federal physician self-referral prohibition commonly known as the Stark Law and the state equivalents; | |
| the federal Health Insurance Portability and Accountability Act of 1996; | |
| the Medicare civil money penalty and exclusion requirements; and | |
| the federal civil and criminal False Claims Act. |
8
9
10
11
| conduct substantial research and development; | |
| conduct validation studies; | |
| expend significant funds; and | |
| develop and scale-up our laboratory processes. |
12
| failure of the product at the research or development stage; | |
| difficulty in accessing archival tissue samples, especially tissue samples with known clinical results; or | |
| lack of clinical validation data to support the effectiveness of the product. |
13
14
15
| sustain commercialization of our initial product or enhancements to that product; | |
| increasing our selling and marketing efforts to drive market adoption and address competitive developments; | |
| expand our clinical laboratory operations; | |
| expand our technologies into other areas of cancer; | |
| fund our clinical validation study activities; | |
| expand our research and development activities; | |
| acquire or license technologies; and | |
| finance capital expenditures and our general and administrative expenses. |
| the level of research and development investment required to maintain and improve our technology position; | |
| costs of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights; | |
| our need or decision to acquire or license complementary technologies or acquire complementary businesses; | |
| changes in product development plans needed to address any difficulties in commercialization; | |
| competing technological and market developments; and | |
| changes in regulatory policies or laws that affect our operations. |
16
| demand by physicians and patients for Onco type DX; | |
| reimbursement decisions by third-party payors and announcements of those decisions; | |
| clinical trial results and publication of results in peer-reviewed journals or the presentation at medical conferences; | |
| the inclusion or exclusion of our products in large clinical trials conducted by others; | |
| new or less expensive products and services or new technology introduced or offered by our competitors or us; | |
| the level of our development activity conducted for new products, and our success in commercializing these developments; | |
| the level of our spending on Onco type DX commercialization efforts, licensing and acquisition initiatives, clinical trials, and internal research and development; | |
| changes in the regulatory environment, including any announcement from the FDA regarding its decisions in regulating our activities; |
17
| the impact of seasonality on our business; | |
| changes in recommendations of securities analysts or lack of analyst coverage; | |
| failure to meet analyst expectations regarding our operating results; | |
| additions or departures of key personnel; and | |
| general market conditions. |
18
Number of Restricted | ||||
Shares/% of Total Shares | ||||
Outstanding Following | ||||
Offering | Date of Availability for Resale into the Public Market | |||
/ . % |
180 days (subject to extension in specified circumstances) after the date of this prospectus due to the release of the lock-up agreement these stockholders have with the underwriters | |||
/ . % |
At some point after 180 days (subject to extension in specified circumstances) after the date of this prospectus, subject to vesting requirements and the requirements of Rule 144 (subject, in some cases, to volume limitations), Rule 144 (k) or Rule 701 |
19
| our expectation that, for the foreseeable future, substantially all of our revenues will be derived from Onco type DX; | |
| our expectation that our research and development expense levels will remain high as we seek to enhance Onco type DX and develop new products; | |
| our dependence on collaborative relationships; | |
| our compliance with federal, state and foreign regulatory requirements; | |
| the regulation of Onco type DX by the FDA; | |
| our plans to pursue reimbursement on a case-by-case basis; | |
| our ability, and expectations as to the amount of time it will take, to achieve successful reimbursement from third-party payors, such as insurance companies and health maintenance organizations, and government insurance programs, such as Medicare and Medicaid; | |
| increases in patient and physician demand resulting from our direct sales approach; | |
| plans for enhancements of our existing test, Onco type DX, to address different patient populations of breast cancer; | |
| plans for future products addressing multiple cancers, including colon, prostate, renal cell and lung cancers and melanoma; | |
| the outcome or success of clinical trials; | |
| the ability of genomics to change the diagnosis and treatment of diseases such as cancer and thereby provide significant economic benefits to the healthcare system; | |
| the capacity of our laboratory to process tests; | |
| the ability of our technology to screen increasing numbers of genes in tissue samples; | |
| our intellectual property and our strategies regarding filing additional patent applications to strengthen our intellectual property rights; | |
| our anticipated cash needs and our estimates regarding our capital requirements and our needs for additional financing; and | |
| anticipated trends and challenges in our business and the markets in which we operate. |
20
21
22
| on an actual basis; | |
| on a pro forma basis to give effect to the automatic conversion of all outstanding shares of our convertible preferred stock into common stock upon the closing of this offering; and | |
| on a pro forma as adjusted basis to give effect to the sale of shares of common stock in this offering at an assumed initial public offering price of $ per share, after deducting the estimated underwriting discount and estimated offering expenses payable by us. |
| excludes shares of common stock issuable upon the exercise of stock options outstanding as of March 31, 2005, at a weighted average exercise price of $ per share; and | |
| excludes shares of common stock available for future issuance under our stock option plans as of March 31, 2005. |
23
Assumed initial public offering price per share
|
$ | ||||||||
Pro forma net tangible book value per share at March 31,
2005
|
$ | ||||||||
Increase in pro forma net tangible book value per share
attributable to new investors.
|
|||||||||
Pro forma net tangible book value per share after this offering
|
|||||||||
Dilution in pro forma net tangible book value per share to new
investors
|
$ | ||||||||
Shares Purchased | Total Consideration | ||||||||||||||||||||
Average Price | |||||||||||||||||||||
Number | Percent | Amount | Percent | Per Share | |||||||||||||||||
Existing stockholders
|
% | $ | % | $ | |||||||||||||||||
New investors
|
|||||||||||||||||||||
Total
|
100.0 | % | $ | 100.0 | % | ||||||||||||||||
24
Period from | Three Months Ended | |||||||||||||||||||||||||||||
August 22, 2000 | Year Ended December 31, | March 31, | ||||||||||||||||||||||||||||
(inception) to | ||||||||||||||||||||||||||||||
Dec. 31, 2000 | 2001 | 2002 | 2003 | 2004 | 2004 | 2005 | ||||||||||||||||||||||||
(In thousands, except share and per share data) | ||||||||||||||||||||||||||||||
(Unaudited) | ||||||||||||||||||||||||||||||
Consolidated Statements of Operations Data:
|
||||||||||||||||||||||||||||||
Revenues:
|
||||||||||||||||||||||||||||||
Product revenues
|
$ | | $ | | $ | | $ | | $ | 227 | $ | | $ | 442 | ||||||||||||||||
Contract revenues
|
| | | 125 | 100 | | | |||||||||||||||||||||||
Total revenues
|
| | | 125 | 327 | | 442 | |||||||||||||||||||||||
Operating expenses(1):
|
||||||||||||||||||||||||||||||
Cost of product revenues
|
| | | | 1,828 | 624 | 1,285 | |||||||||||||||||||||||
Research and development
|
169 | 11,080 | 7,053 | 9,069 | 10,040 | 2,273 | 2,205 | |||||||||||||||||||||||
Selling and marketing
|
| 117 | 754 | 2,805 | 9,856 | 2,055 | 3,382 | |||||||||||||||||||||||
General and administrative
|
566 | 2,844 | 3,753 | 3,686 | 3,869 | 913 | 1,352 | |||||||||||||||||||||||
Total operating expenses
|
735 | 14,041 | 11,560 | 15,560 | 25,593 | 5,865 | 8,224 | |||||||||||||||||||||||
Loss from operations
|
(735 | ) | (14,041 | ) | (11,560 | ) | (15,435 | ) | (25,266 | ) | (5,865 | ) | (7,782 | ) | ||||||||||||||||
Interest and other income (expense), net
|
| 1,267 | 492 | 185 | 271 | 28 | 196 | |||||||||||||||||||||||
Net loss
|
$ | (735 | ) | $ | (12,774 | ) | $ | (11,068 | ) | $ | (15,250 | ) | $ | (24,995 | ) | $ | (5,837 | ) | $ | (7,586 | ) | |||||||||
Basic and diluted net loss per share
|
$ | (3.37 | ) | $ | (6.71 | ) | $ | (3.98 | ) | $ | (4.14 | ) | $ | (4.79 | ) | $ | (1.16 | ) | $ | (1.34 | ) | |||||||||
Shares used in computing basic and diluted net loss per share
|
218,332 | 1,903,245 | 2,777,443 | 3,679,377 | 5,213,955 | 5,044,732 | 5,681,807 | |||||||||||||||||||||||
(1) | Includes non-cash charges for stock-based compensation expense as follows: |
Period from | Three Months Ended | |||||||||||||||||||||||||||
August 22, 2000 | Year Ended December 31, | March 31, | ||||||||||||||||||||||||||
(inception) to | ||||||||||||||||||||||||||||
Dec. 31, 2000 | 2001 | 2002 | 2003 | 2004 | 2004 | 2005 | ||||||||||||||||||||||
(In thousands) | ||||||||||||||||||||||||||||
(Unaudited) | ||||||||||||||||||||||||||||
Cost of product revenues
|
$ | | $ | | $ | | $ | | $ | 5 | $ | | $ | 9 | ||||||||||||||
Research and development
|
| | | | 42 | 1 | 69 | |||||||||||||||||||||
Selling and marketing
|
| | | | 38 | 1 | 49 | |||||||||||||||||||||
General and administrative
|
| | | | 106 | | 105 | |||||||||||||||||||||
$ | | $ | | $ | | $ | | $ | 191 | $ | 2 | $ | 232 | |||||||||||||||
25
At December 31,
At March 31,
2000
2001
2002
2003
2004
2005
(In thousands)
(Unaudited)
$
7,503
$
28,678
$
25,318
$
11,062
$
38,275
$
32,531
7,173
26,724
25,165
10,046
36,771
31,281
7,617
30,408
27,376
13,096
41,538
36,421
163
161
385
150
1,730
7,917
41,783
51,073
51,064
103,212
103,212
(735
)
(13,509
)
(24,577
)
(39,827
)
(64,822
)
(72,408
)
(731
)
(13,482
)
(24,502
)
(39,547
)
(64,154
)
(71,458
)
26
27
Revenues |
Cost of Product Revenues |
Research and Development Expenses |
Selling and Marketing Expenses |
General and Administrative Expenses |
28
Revenue Recognition |
| persuasive evidence that an arrangement exists; | |
| delivery has occurred or services rendered; | |
| the fee is fixed and determinable; and | |
| collectibility is reasonably assured. |
Deferred Stock-based Compensation Expense |
29
Clinical Collaborator Costs |
Three Months Ended March 31, 2005 and 2004 |
30
Years Ended December 31, 2004 and 2003 |
31
Years Ended December 31, 2003 and 2002 |
32
Sources of Liquidity |
Cash Flows |
33
Payments Due by Period | ||||||||||||||||||||
More | ||||||||||||||||||||
Less than | than 5 | |||||||||||||||||||
Contractual Obligations | Total | 1 Year | 1-3 Years | 3-5 Years | Years | |||||||||||||||
(In thousands) | ||||||||||||||||||||
Operating lease obligations
|
$ | 944 | $ | 813 | $ | 131 | $ | | $ | |
34
| the rate of progress in establishing reimbursement arrangements with third-party payors; | |
| the cost of expanding our commercial and laboratory operations, including our selling and marketing efforts; | |
| the rate of progress and cost of research and development activities associated with expansion of Onco type DX products for breast cancer; | |
| the rate of progress and cost of research and development activities associated with products in the research phase focused on cancer, other than breast cancer; | |
| the cost of acquiring or achieving access to tissue samples and technologies; | |
| the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; | |
| the effect of competing technological and market developments; | |
| the cost and delays in product development as a result of any changes in regulatory oversight applicable to our products; and | |
| the economic and other terms and timing of any collaborations, licensing or other arrangements into which we may enter. |
35
36
37
38
Improved Quality of Treatment Decisions. We believe our approach to genomic-based cancer analysis improves the quality of cancer treatment decisions by providing an individualized analysis of each patients tumor that is correlated to clinical outcome. Our approach represents a substantial departure from existing approaches to treatment, which often use subjective, anatomic and qualitative factors to determine treatments. Onco type DX has been shown in clinical studies to classify many patients into recurrence risk categories different from classifications based on current guidelines. Thus, our solution enables patients and physicians to make more informed decisions about treatment risk-benefit and, consequently, design an individualized treatment plan. | |
Improved Economics of Cancer Care. We believe that improving the quality of treatment decisions can result in significant economic benefits. In early stage breast cancer, our data shows that many patients are misclassified as high or low risk under existing treatment guidelines. Many low risk patients misclassified as high risk receive toxic and expensive chemotherapy treatment regimens. Chemotherapy may cost in excess of $20,000, as compared to Onco type DXs list price of $3,460. On the other hand, |
39
some high risk patients misclassified as low risk are not provided chemotherapy treatment, possibly necessitating future treatment costing up to $50,000 or more if the cancer recurs. |
Deliver High-value Genomic-based Diagnostics. We believe that treatment decisions are currently being made with little understanding of the molecular profile of each tumor and that economic inefficiencies result in the healthcare system when crucial and expensive treatment decisions are made based on inadequate and often subjective information. Our strategy is to identify treatment decisions that can benefit from, and be guided by, the patients individual genomic information. We are focused on developing high-value tests that address these treatment decisions, with the goal of making our genomic-based tests a standard of care. Our value lies in our ability to deliver individualized information during the crucial period of time after diagnosis but prior to the decision to undergo a specific cancer treatment. | |
Achieve Broad-based Adoption and Reimbursement. We intend to continue to build a strong sales, marketing and reimbursement effort by interacting directly with medical and surgical oncologists, pathologists and payors. Because oncology is a concentrated specialty, we believe that a focused marketing organization and specialized sales force can effectively serve the oncology community and provide us with a competitive advantage. We believe our direct sales approach, coupled with our plans to conduct multiple clinical studies with results published in peer-reviewed journals, will increase patient and physician demand and increase the number of favorable reimbursement coverage decisions by payors. | |
Enhance Existing Products and Technologies. Our goal is to enhance our marketed products by validating additional individualized patient information to improve treatment planning. We also intend to deliver added value by expanding the clinical categories of patients we can address within a cancer population. For example, we plan to expand our breast cancer product to address late-stage breast cancer patients as well as questions about the responsiveness of an individual tumor to therapeutic agents such as aromatase inhibitors and taxanes. We believe that continuous innovation can sustain a competitive advantage by delivering more information to physicians in comparison with new competitive products entering the market. | |
Apply Our Clinical Development Platform to Other Cancers. We intend to use our clinical development platform to address multiple cancers for which quantitative molecular pathology could improve the assessment of the risk of disease progression and the prediction of response to therapy. In the next several years, we plan to expand our focus beyond breast cancer, potentially including colon, prostate, renal cell and lung cancers and melanoma. We designed our clinical development platform to enable us to conduct clinical studies with clinical study groups and opinion leaders using archived biopsy specimens with years of associated patient data to correlate genomic information to clinical outcomes. This approach allowed us to research, develop, validate and commercialize Onco type DX in three years. |
40
Oncotype DX for Breast Cancer |
| the size of the tumor, | |
| node status, referred to as node positive, or N+, where the tumor has spread to the lymph nodes, and node negative, or N-, where the tumor has not spread to the lymph nodes, and | |
| the extent to which the cancer has spread to other parts of the body. |
| the presence or absence of estrogen receptors, referred to as estrogen receptor positive, or ER+, where estrogen receptors are present, and estrogen receptor negative, or ER-, where estrogen receptors are not present, | |
| the abundance of human epidermal growth factor receptor-type 2, or HER2, genes or protein in the tumor, | |
| the age of the patient, and | |
| the histological type and grading of the tumor as reported by the pathologist. |
41
Clinical Development and Validation of Oncotype DX |
Clinical Development of the Oncotype DX Recurrence Score |
42
| a low risk group, with a Recurrence Score of less than 18, classified 51% of patients with an average recurrence rate of 6.8%; | |
| an intermediate risk group, with a Recurrence Score equal to or greater than 18 but less than 31, classified 22% of the patients with an average recurrence rate of 14.3%; and | |
| a high risk group, with a Recurrence Score greater than 31, which included 27% of the patients with an average recurrence rate of 30.5%. |
43
Additional Questions Addressed by Further Studies |
| How do patients in the different Recurrence Score risk groups respond to tamoxifen plus chemotherapy versus tamoxifen alone? | |
| Does the Recurrence Score predict the likelihood of recurrence, the benefit from tamoxifen or both? | |
| Does the Recurrence Score apply to untreated ER- patients and untreated ER+ patients? |
44
Health Economic Benefits of Oncotype DX |
| Clinical Research Phase. In this phase, we establish a product definition and research plan. Our research team initiates the clinical research program with bioinformatics-based screening of the approximately 25,000 genes in the human genome to select candidate genes. The gene selection process uses genomic databases and knowledge of key cancer and drug related pathways. We use internally developed software for optimization and rapid selection of target DNA sequences in order to develop quantitative molecular pathology assays for each gene. To date, we have compiled a library of over 1,000 individual gene tests for use in multiple product opportunities. We secure access to archival tumor biopsy samples for feasibility studies as well as archival tumor biopsy samples correlated with clinical data for gene identification studies. The goal of these studies is to identify genes that correlate with a specific clinical outcome prior to moving the program into development. | |
| Development Phase. We conduct additional clinical studies to refine the gene set in the specific patient population of interest. We select the final gene panel through biostatistical modeling of the gene correlation data to develop the best quantitative correlation to the target clinical outcome. With a gene panel and quantitative methodology established, we then finalize all of the remaining assay parameters. For example, for Onco type DX we tested and verified protocols for RNA extraction and amplification, automated chemistry and reagent quality control and handling to establish a reproducible, scaleable process. Once the genes, assay chemistry, automation and bioanalysis specifications are finalized, tested and verified, we begin clinical validation. | |
| Validation Phase. In this phase, we conduct one or more validation studies with prospectively designed endpoints to test our candidate gene panel and the corresponding quantitative expression score. These |
45
studies are conducted with a different set of archival patient specimens to verify that the test correlates with the predicted clinical outcome in an independent patient population. Since we control the quality and reproducibility of our assays using FPE tissues, we are able to conduct large validation studies with archived samples with years of clinical outcomes. This allows validation studies to be performed more rapidly than would be the case with techniques that require fresh tissue, which must be newly collected and need many years of follow up before study results can be obtained. | ||
| Commercialization and Product Expansion Phase. Once a test is commercialized, we may perform additional studies designed to support the tests clinical utility and potentially to broaden its use in additional patient populations or for additional indications. Such studies may include prospective studies to verify that our test is changing physician behavior as well as testing a commercial product in new populations. Multiple clinical studies are also useful for driving adoption and reimbursement by physicians and payors. |
Our Product Pipeline |
46
Product Development Opportunities in Breast Cancer |
2005 Estimated | ||||||||||
Treatment | ||||||||||
Decisions | ||||||||||
Breast Cancer | in the | Anticipated | ||||||||
Breast Cancer Products | Population | United States | Product Attributes | Product Stage | ||||||
Onco
type
DX
|
N-, ER+ | 125,000 | Recurrence | Commercial | ||||||
Response to chemotherapy | ||||||||||
Response to chemotherapy or other therapeutic regimens |
Product
Expansion |
|||||||||
N+ | 65,000 | Recurrence | Product | |||||||
Response to chemotherapy or other therapeutic regimens | Expansion | |||||||||
Onco
type
DX
|
N-, ER+ and | 190,000 | (1) | Enhanced recurrence | Clinical | |||||
Second Generation
|
N+ | Enhanced response to chemotherapy | Research | |||||||
New Products
|
N-, ER- | 30,000 | Response to taxanes | Clinical | ||||||
Response to chemotherapy | Research | |||||||||
Recurrence | ||||||||||
N+ | 65,000 | (2) | Response to taxanes | Clinical | ||||||
Response to chemotherapy | Research | |||||||||
N-, ER+ | 125,000 | (3) | Response to taxanes |
Clinical
Research |
(1) | Represents the sum of the 125,000 estimated treatment decisions in 2005 for N-, ER+ patients and the 65,000 estimated treatment decisions in 2005 for N+ breast cancer patients listed above. |
(2) | This figure is the same as the 65,000 treatment decisions listed above. |
(3) | This figure is the same as the 125,000 treatment decisions listed above. |
47
48
2005 Estimated | ||||||||||||
Total Incidence | 2005 Estimated | |||||||||||
in the | Addressable | |||||||||||
Product Opportunity | United States | Population | Anticipated Product Attributes | Product Stage | ||||||||
Colon Cancer
|
120,000 | 65,000 | Recurrence | Clinical | ||||||||
Prediction of drug response | Research | |||||||||||
Prostate Cancer
|
250,000 | 195,000 | Progression | Clinical | ||||||||
Recurrence | Research | |||||||||||
Renal Cell Cancer
|
40,000 | 25,000 | Recurrence | Clinical | ||||||||
Prediction of drug response | Research | |||||||||||
Non-small Cell Lung Cancer
|
155,000 | 25,000 |
Recurrence
Prediction of drug response |
Clinical
Research |
||||||||
Melanoma
|
70,000 | 25,000 | Recurrence | Clinical | ||||||||
Prediction of drug response | Research |
49
50
| Sensitivity. We have developed protocols for extracting and quantifying RNA utilizing RT-PCR. Our method for amplifying small fragmented RNA is designed to allow us in the future to conduct studies with hundreds to thousands of genes from 10 micron sections of FPE biopsy tissue. Together with the inherent amplification of PCR, our platform provides us with sophisticated capabilities to quantify RNA levels from minimal amounts of tissue. The ability to amplify RNA allows us to maintain a repository of RNA from limited tissue samples that can be used for later studies. | |
| Specificity. Human tissues contain thousands of different genes that are often highly related in sequence content, making it challenging for genomic tests to specifically identify molecules of interest. Our RT-PCR platform is highly specific because it works only when three different test reagents, called DNA probes and primers, independently match each gene to be measured. In addition, we have designed and implemented proprietary software for selecting optimal probe and primer sequences in an automated, high-throughput process. Our technology is also capable of quantifying non-coding RNA sequences that are present in miniscule quantities within tissues. The ability to utilize these sequences allows us to design highly specific assays for closely related genes. | |
| Precision and Reproducibility. The reagents, materials, instruments and controls in our processes are used by trained personnel following validated standard operating procedures. Validation studies have shown that these standard operating procedures precisely quantify tested RNA with minimal variability in the assay system across days, instruments and operators. This enables our laboratory to produce consistently precise and accurate gene expression results. Our quality control methods for our reagents and processes, along with our software for automation, sample tracking, data quality control and statistical analysis, add to the reproducibility and precision of our test. | |
| Dynamic Range. Because our RT-PCR platform can amplify small amounts of RNA in proportion to the amount present in the sample, we are able to measure RNA levels across as much as a hundred thousand fold range of differing RNA expression. Having a broad range of high resolution testing capability increases the quality of our correlations with clinical outcomes and therefore the predictive power of our tests. |
51
| Test Performance. Onco type DX provides results that are reproducible, sensitive, accurate and specific to the patients tumor. Patients may benefit from treatment decisions based on prediction of recurrence, survival and chemotherapy benefit. | |
| Clinical Utility. Patients are provided a Recurrence Score on a risk continuum that may change decision making regarding the use of adjuvant chemotherapy, which may increase the benefits of treatment while reducing its risks and costs. We believe the large difference in risk of distant recurrence between tumors with low Recurrence Scores and high Recurrence Scores is indicative of the clinical utility of our test. | |
| Peer-reviewed Publication and Consistent Study Outcomes. The 2003 NSABP validation study was peer-reviewed and published in The New England Journal of Medicine in December 2004. Physicians and payors often require one, and many require two or more, peer-reviewed publications to provide a basis for use and reimbursement decisions. The results of the independent Kaiser Permanente study reinforce the findings in the NSABP study. We believe that additional publications, including our findings on chemotherapy response, will increase usage and create a more favorable reimbursement environment. | |
| Patient and Physician Demand. Increasing awareness and demand in the cancer community for Onco type DX will be necessary for widespread payor adoption. Increased usage of the test by physicians can influence payors and facilitate the reimbursement decision process. | |
| Improved Economics. We are sponsoring third-party studies and providing information to payors to demonstrate the economic benefits that can result from the use of Onco type DX. A health economic analysis of Onco type DX was published in The American Journal of Managed Care in May 2005. |
52
53
| the value of the quantitative information Onco type DX provides; | |
| the clinical validation of Onco type DXs ability to predict recurrence and survival, and the demonstration of Onco type DXs ability to predict the likelihood of chemotherapy benefit; | |
| our ability to perform clinical studies using archival tissue as it is currently processed, handled and stored; | |
| our ability to screen hundreds of genes at a time; | |
| the speed with which our clinical development platform can commercialize products; | |
| our clinical collaborations with clinical study groups; and | |
| the level of customer service we provide, both to patients and health care professionals. |
| continue to innovate and maintain scientifically advanced technology; | |
| enhance Onco type DX for breast cancer to provide information in response to additional indications; | |
| continue to validate our products, especially with respect to chemotherapy benefit; | |
| obtain positive reimbursement decisions from payors; | |
| expand Onco type DX for use in other forms of cancer; | |
| attract and retain skilled scientific and sales personnel; | |
| obtain patents or other protection for our products; | |
| obtain and maintain our clinical laboratory accreditations and licenses; and | |
| successfully market and sell Onco type DX. |
54
55
56
57
| denial of payment for the services provided in violation of the prohibition; | |
| refunds of amounts collected by an entity in violation of the Stark Law; | |
| a civil penalty of up to $15,000 for each service arising out of the prohibited referral; | |
| exclusion from federal healthcare programs, including the Medicare and Medicaid programs; and | |
| a civil penalty of up to $100,000 against parties that enter into a scheme to circumvent the Stark Laws prohibition. |
58
59
| day-to-day operation of a clinical laboratory, including training and skill levels required of laboratory personnel; | |
| physical requirements of a facility; | |
| equipment; and | |
| quality control. |
60
61
62
Name | Age | Position(s) | ||
Randal W. Scott, Ph.D.
|
47 | Chairman of the Board and Chief Executive Officer | ||
Kimberly J. Popovits
|
46 | President, Chief Operating Officer and Director | ||
Joffre B. Baker, Ph.D.
|
57 | Chief Scientific Officer | ||
Steven Shak, M.D.
|
54 | Chief Medical Officer | ||
G. Bradley Cole
|
49 | Executive Vice President, Chief Financial Officer and Secretary | ||
Julian C. Baker
|
39 | Director | ||
Brook H. Byers(1)
|
59 | Director | ||
Fred E. Cohen, M.D., Ph.D.(1)(2)
|
48 | Director | ||
Samuel D. Colella(1)(2)(3)
|
65 | Director | ||
Michael D. Goldberg(2)(3)
|
47 | Director | ||
Randall S. Livingston(3)
|
51 | Director |
(1) | Will be a member of the Compensation Committee upon the date of this prospectus. |
(2) | Will be a member of the Nominating and Corporate Governance Committee upon the date of this prospectus. |
(3) | Will be a member of the Audit Committee upon the date of this prospectus. |
63
64
65
66
67
68
69
70
Annual
Long-Term Compensation
Compensation
Restricted
Shares
All Other
Salary
Bonus
Stock Awards
Underlying
Compensation
Name and Position(s)
Year
($)
($)
($)
Options
($)
2004
$
200,000
Chief Executive Officer and Chairman
2004
275,000
President and Chief Operating Officer
2004
275,000
Chief Scientific Officer
2004
275,000
Chief Medical Officer
2004
120,311
Executive Vice President and Chief Financial Officer
(1)
Mr. Cole became our Executive Vice President and Chief
Financial Officer in July 2004 and his annual salary is $250,000.
Individual Grants
Potential Realizable Value at
Number of
% of Total
Assumed Annual Rates of
Securities
Options
Stock Price Appreciation for
Underlying
Granted to
Option Term(3)
Options
Employees in
Exercise Price
Expiration
Name
Granted
Fiscal Year
Per Share(1)
Date(2)
5%($)
10%($)
7.6
%
12/2/2009
7.6
12/2/2014
7.6
12/2/2014
7.6
12/2/2014
1.9
12/2/2014
17.1
6/10/2014
(1)
Except for the grant to Dr. Scott, the exercise price for
each grant is equal to 100% of the fair market value of our
common stock on the date of grant. The exercise price of
Dr. Scotts grant is equal to 110% of the fair market
value of our common stock on the date of grant.
(2)
The options have a term of 10 years, unless issued to a 10%
or greater stockholder, in which case they have a term of five
years. All options are subject to termination in certain events
related to termination
Table of Contents
of employment. The options vest as to 25% of the shares one year
after the date of grant and as to
1
/
48
th
of the shares each month thereafter.
(3)
Potential realizable values are calculated by:
multiplying the number of shares of our common stock subject to
a given option by the mid-point of the initial public offering
price range of
$ per
share;
assuming that the aggregate stock value derived from that
calculation compounds at the annual 5% or 10% rates shown in the
table for the entire ten-year term of the option; and
subtracting from that result the total option exercise price.
Value of Unexercised
Shares
Number of Unexercised
In-the-Money Options at
Acquired on
Value
Options at Fiscal Year-End(#)
Fiscal Year-End($)
Name
Exercise(#)
Realized($)
Exercisable/Unexercisable
Exercisable/Unexercisable
/
/
/
/
/
/
/
/
/
/
Table of Contents
2005 Stock Incentive Plan
Nondiscretionary, automatic grants of nonstatutory stock options
will be made to outside directors. An outside director joining
our board of directors after this offering will be granted
automatically an initial option to
purchase shares
upon first becoming a member of our board. The initial option
will vest and become exercisable over four years, with the first
25% of the shares subject to the initial option vesting on the
first anniversary of the date of grant date and the remainder
vesting monthly thereafter. Immediately after each of our
regularly scheduled annual meetings of stockholders, each
outside director will be automatically granted a nonstatutory
option to
purchase shares
of our common stock, provided the director has served on our
board for at least six months. Each annual option will be fully
vested and exercisable on the first anniversary of the date of
grant or, if earlier, the date of our next annual meeting of
stockholders. The options granted to outside directors will have
a per share exercise price equal to 100% of the fair market
value of the underlying shares on the date of grant, and will
become fully vested if we are subject to a change of control.
Generally, if we merge with or into another corporation, we may
accelerate the vesting or exercisability of outstanding options
and terminate any unexercised options unless they are assumed or
substituted for by any surviving entity or a parent or
subsidiary of the surviving entity.
The plan terminates ten years after its initial adoption, unless
terminated earlier by the board. The board of directors may
amend or terminate the plan at any time, subject to stockholder
approval where required by applicable law. Any amendment or
termination may not impair the rights of holders of outstanding
awards without their consent.
401(k) Plan
Table of Contents
Table of Contents
Founders Stock Purchase Agreements |
Number of Shares of | Aggregate Purchase | |||||||||
Name | Date of Sale | Common Stock | Price | |||||||
Randal W. Scott, Ph.D.
|
October 16, 2000 | $ | 1,800 | |||||||
Joffre B. Baker, Ph.D.
|
October 16, 2000 | 900 | ||||||||
Steven Shak, M.D.
|
October 16, 2000 | 900 |
Sales of Preferred Stock |
| In March 2002, May 2002 and November 2002, we sold shares of series D preferred stock at a price of $ per share for aggregate consideration of approximately $9.4 million to 11 investors. | |
| In February 2004, March 2004, April 2004 and December 2004, we sold shares of series E preferred stock at a price of $ per share for aggregate consideration of approximately $52.3 million to 75 investors. |
Number of Shares of | Number of Shares of | |||||||
Series D Preferred | Series E Preferred | |||||||
Investor | Stock | Stock | ||||||
5% Stockholders:
|
||||||||
Kleiner Perkins Caufield & Byers Affiliated Entities
|
||||||||
Versant Ventures Affiliated Entities
|
||||||||
TPG Ventures Affiliated Entities
|
||||||||
Andrew H., Daniel R., James S. and Thomas J. Tisch
|
||||||||
Julian C. Baker and Felix J. Baker
|
||||||||
J.P. Morgan Direct Venture Capital Affiliated Entities
|
||||||||
Directors and Executive Officers:
|
||||||||
Joffre B. Baker, Ph.D.
|
||||||||
G. Bradley Cole
|
||||||||
Michael D. Goldberg
|
||||||||
Randall S. Livingston
|
||||||||
Kimberly J. Popovits
|
||||||||
Randal W. Scott, Ph.D.
|
||||||||
Steven Shak, M.D.
|
71
Agreements with Incyte Corporation |
72
| each person or group of affiliated persons known by us to be the beneficial owner of more than 5% of our common stock; | |
| each of our directors; | |
| each of our named executive officers; and | |
| all of our executive officers and directors as a group. |
73
Percentage of Common Stock
Number of Shares of
Beneficially Owned
Common Stock
Name of Beneficial Owner
Beneficially Owned
Before Offering
After Offering
12.6
%
%
12.6
10.2
6.5
6.0
5.3
5.0
5.3
%
%
12.6
10.4
12.6
*
*
2.3
*
1.8
12.0
2.3
59.5
%
%
* | Represents beneficial ownership of less than 1%. |
(1) | Principal address for Kleiner Perkins Caufield & Byers affiliated entities is 2750 Sand Hill Road, Menlo Park, California 94025. Includes shares held by Kleiner Perkins Caufield & Byers X-A, L.P. and shares held by Kleiner Perkins Caufield & Byers X-B, L.P. Mr. Byers, who is also one of our directors, is a managing member of KPCB X Associates, LLC, the general partner of these funds and, as such, has shared voting and investment authority over these shares. However, Mr. Byers disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
(2) | Principal address for Versant Ventures affiliated entities is 3000 Sand Hill Road, Bldg 4, Suite 210, Menlo Park, California 94025. Includes shares held by Versant Venture Capital I, L.P., shares held by Versant Affiliates Fund I-A, L.P., shares held by Versant Affiliates Fund I-B, L.P. and shares held by Versant Side Fund I, L.P. Mr. Colella, who is also one of our directors, is a managing director of Versant Ventures I, LLC, the general partner of Versant Venture Capital I, Versant Affiliates Fund I-A, Versant Affiliates Fund I-B and Versant Side Fund. In such capacity, Mr. Colella may be deemed to share voting and investment power with respect to the shares held by Versant Venture Capital I, Versant Affiliates Fund I-A, Versant Affiliates Fund I-B and Versant Side Fund I. Mr. Colella disclaims beneficial ownership of the shares owned by these funds, except to the extent of his pecuniary interest therein. |
(3) | Principal address for TPG Ventures affiliated entities is 345 California Street, Suite 2600, San Francisco, California 94104. Includes shares owned by TPG Ventures, L.P. and shares owned by TPG Biotechnology Partners, L.P. Dr. Cohen, who is also one of our directors, is a managing director of Texas Pacific Group Ventures. In such capacity, Dr. Cohen may be deemed to share voting and investment power with respect to the shares held by TPG Ventures, L.P. and TPG Biotechnology Partners, L.P. Dr. Cohen disclaims beneficial ownership of the shares owned by these funds, except to the extent of his pecuniary interest therein. |
74
(4) | Principal address is 655 Madison Avenue, 19th Floor, New York, New York 10021. Includes shares held by Four Partners. By virtue of their status as managing trustees of the trusts which are the general partners of Four Partners, each of Andrew H. Tisch, James S. Tisch, Daniel R. Tisch and Thomas J. Tisch may be deemed to have shared beneficial ownership of shares owned by Four Partners and shared power to vote or direct the vote and dispose or direct the disposition of these shares. |
(5) | Principal address is Experimental Station, Route 141 & Henry Clay Road, Building E336, Wilmington, Delaware 19880. |
(6) | Principal address is 667 Madison Avenue, New York, New York 10021. Includes shares owned by Baker Bros. Investments, L.P., shares owned by Baker/ Tisch Investments, L.P., shares owned by Baker Bros. Investments II, L.P., shares owned by Baker Biotech Fund I, L.P., shares owned by Baker Biotech Fund II, L.P., shares owned by Baker Biotech Fund II (Z), L.P., shares owned by Baker Biotech Fund III, L.P., shares owned by Baker Biotech Fund III (Z), L.P. and shares owned by FBB Associates, a general partnership. Julian C. Baker, who is also one of our directors, and Felix J. Baker, by virtue of their control of entities that have the power to control the investment decisions of Baker Bros. Investments, L.P., Baker/ Tisch Investments, L.P., Baker Bros. Investments II, L.P., Baker Biotech Fund I, L.P., Baker Biotech Fund II, L.P., Baker Biotech Fund II (Z), L.P., Baker Biotech Fund III, L.P., Baker Biotech Fund III (Z), L.P. and FBB Associates, may each be deemed to be the beneficial owner of shares held by such entities and may be deemed to have shared power to vote or direct the vote of and to dispose or direct the disposition of the shares. |
(7) | Principal address for J.P. Morgan Direct Venture Capital affiliated entities is 522 Fifth Avenue, New York, New York 10036. Includes shares held by J.P. Morgan Direct Venture Capital Institutional Investors II LLC, shares held by J.P. Morgan Direct Venture Capital Private Investors II LLC and shares held by 522 Fifth Avenue Fund, L.P. (collectively, the Global Fund Entities). The investment advisor of the Global Fund Entities is J.P. Morgan Investment Management Inc. (JPMIM). JPMIM has sole voting power with respect to the shares held by the Global Fund Entities. In addition, interests in 522 Fifth Avenue Fund, L.P. are owned both by a wholly owned subsidiary of JPMorgan Chase & Co. (JPM Chase), a publicly traded company, and employees of JPM Chase. As a result, each of JPMIM, JPM Chase and employees of JPM Chase may be deemed beneficial owners of the shares held by the Global Fund Entities, however, each disclaim such beneficial ownership except to the extent of such persons pecuniary interest therein. |
(8) | Includes shares owned by Baker Bros. Investments, L.P., shares owned by Baker/ Tisch Investments, L.P., shares owned by Baker Bros. Investments II, L.P., shares owned by Baker Biotech Fund I, L.P., shares owned by Baker Biotech Fund II, L.P., shares owned by Baker Biotech Fund II (Z), L.P., shares owned by Baker Biotech Fund III, L.P., shares owned by Baker Biotech Fund III (Z), L.P. and shares owned by FBB Associates, a general partnership. Mr. Baker disclaims beneficial ownership of the shares held by these entities except to the extent of his pecuniary interest therein. |
(9) | Includes shares held by Kleiner Perkins Caufield & Byers affiliated entities. Mr. Byers disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
(10) | Includes shares held by TPG Ventures affiliated entities, shares issuable upon exercise of options that are exercisable within 60 days of May 31, 2005 and shares held by family trusts of which Dr. Cohen is a trustee. Dr. Cohen disclaims beneficial ownership of the shares held by the TPG Ventures affiliated entities except to the extent of his pecuniary interest therein. |
(11) | Includes shares held by Versant Ventures affiliated entities. Mr. Colella disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
(12) | Includes shares issuable upon exercise of options that are exercisable within 60 days of May 31, 2005. |
(13) | Includes shares held by a family trust of which Dr. Baker is a trustee. |
(14) | Includes shares issuable upon exercise of options that are exercisable within 60 days of May 31, 2005. |
(15) | Includes shares issuable upon exercise of options that are exercisable within 60 days of May 31, 2005. |
(16) | Includes shares held in trust for the benefit of Dr. Scotts minor children, of which Dr. Scotts sister is the trustee. |
(17) | Includes shares issuable upon exercise of options that are exercisable within 60 days of May 31, 2005. |
75
76
Delaware Law |
| the transaction is approved by the board before the date the interested stockholder attained that status; | |
| upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced; or | |
| on or after the date the business combination is approved by the board and authorized at a meeting of stockholders by at least two-thirds of the outstanding voting stock that is not owned by the interested stockholder. |
| any merger or consolidation involving the corporation and the interested stockholder; | |
| any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder; | |
| subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; | |
| any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; or |
77
| the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. |
Charter and Bylaws |
| our bylaws may be amended or repealed only by a two-thirds vote of our board of directors or a two-thirds stockholder vote; | |
| no action can be taken by stockholders except at an annual or special meeting of the stockholders called in accordance with our bylaws, and stockholders may not act by written consent; | |
| stockholders may not call special meetings of the stockholders or fill vacancies on the board; | |
| the approval of holders of two-thirds of the shares entitled to vote at an election of directors will be required to amend or repeal the provisions of our certificate of incorporation regarding the inability of stockholders to take action by written consent; | |
| our board of directors will be authorized to issue preferred stock without stockholder approval, as described above; and | |
| we will indemnify officers and directors against losses that they may incur in investigations and legal proceedings resulting from their services to us, which may include services in connection with takeover defense measures. |
| for any breach of their duty of loyalty to us or our stockholders; | |
| for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; | |
| for unlawful payment of dividend or unlawful stock repurchase or redemption, as provided under Section 174 of the Delaware General Corporation Law; or | |
| for any transaction from which the director derived an improper personal benefit. |
78
79
| no shares will be eligible for sale prior to 180 days after the date of this prospectus; | |
| shares will be eligible for sale upon the expiration of the lock-up agreements, described below, beginning 180 days after the date of this prospectus (subject to extension) and when permitted under Rule 144, 144(k) or 701; and | |
| shares will be eligible for sale upon the exercise of vested options 180 days after the date of this prospectus. |
80
| 1% of the then outstanding shares of common stock, or approximately shares immediately after this offering, assuming no exercise of the underwriters over-allotment option; or | |
| the average weekly trading volume of the common stock during the four calendar weeks preceding the date on which notice of the sale is filed with the Securities and Exchange Commission. |
81
Number of | |||||
Underwriter | Shares | ||||
J.P. Morgan Securities Inc.
|
|||||
Lehman Brothers Inc.
|
|||||
Piper Jaffray & Co.
|
|||||
Thomas Weisel Partners LLC
|
|||||
JMP Securities LLC
|
|||||
Total
|
| the obligation to purchase all of the shares of common stock offered hereby, if any of the shares are purchased; | |
| the representations and warranties made by us to the underwriters are true in all material respects; | |
| there is no material change in the financial markets; and | |
| we deliver customary closing documents to the underwriters. |
No Exercise | Full Exercise | |||||||
Per share
|
$ | $ | ||||||
Total
|
$ | $ |
82
| during the last 17 days of the 180-day restricted period we issue an earnings release or announce material news or a material event relating to us; or | |
| prior to the expiration of the 180-day restricted period, we announce that we will release earnings results during the 16-day period beginning on the last day of the 180-day period, |
| the history and prospectus for the industry in which we compete, | |
| our financial information, | |
| the ability of our management and our business potential and earning prospects, | |
| the prevailing securities markets at the time of this offering, and | |
| the recent market prices of, and the demand for, publicly traded shares of generally comparable companies. |
| Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. |
83
| A short position involves a sale by the underwriters of shares in excess of the number of shares the underwriters are obligated to purchase in the offering, which creates the syndicate short position. This short position may be either a covered short position or a naked short position. In a covered short position, the number of shares involved in the sales made by the underwriters in excess of the number of shares they are obligated to purchase is not greater than the number of shares that they may purchase by exercising their option to purchase additional shares. In a naked short position, the number of shares involved is greater than the number of shares in their option to purchase additional shares. The underwriters may close out any short position by either exercising their option to purchase additional shares and/or purchasing shares in the open market. In determining the source of shares to close out the short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through their option to purchase additional shares. A naked short position is more likely to be created if the underwriters are concerned that there could be downward pressure on the price of the shares in the open market after pricing that could adversely affect investors who purchase in the offering. | |
| Syndicate covering transactions involve purchases of the common stock in the open market after the distribution has been completed in order to cover syndicate short positions. | |
| Penalty bids permit the representatives to reclaim a selling concession from a syndicate member when the common stock originally sold by the syndicate member is purchased in a stabilizing or syndicate covering transaction to cover syndicate short positions. |
84
85
86
F-2 | ||||
F-3 | ||||
F-4 | ||||
F-5 | ||||
F-6 | ||||
F-7 |
F-1
/s/ Ernst & Young LLP |
F-2
Pro Forma
December 31,
Stockholders
March 31,
Equity at
2003
2004
2005
March 31, 2005
(Unaudited)
(Unaudited)
$
11,062
$
38,275
$
32,531
563
901
1,612
75
75
11,625
39,251
34,218
38
19
1,288
2,116
2,033
50
133
133
151
$
13,096
$
41,538
$
36,421
$
827
$
1,101
$
1,221
342
603
768
249
776
563
385
161
1,579
2,480
2,937
1,730
51,064
103,212
103,212
$
1
1
1
5
279
4,123
4,347
107,555
(3,456
)
(3,398
)
(3,398
)
(39,827
)
(64,822
)
(72,408
)
(72,408
)
(39,547
)
(64,154
)
(71,458
)
$
31,754
$
13,096
$
41,538
$
36,421
F-3
Three Months Ended
December 31,
March 31,
2002
2003
2004
2004
2005
(unaudited)
$
$
$
227
$
$
442
125
100
125
327
442
1,828
624
1,285
7,053
9,069
10,040
2,273
2,205
754
2,805
9,856
2,055
3,382
3,753
3,686
3,869
913
1,352
11,560
15,560
25,593
5,865
8,224
(11,560
)
(15,435
)
(25,266
)
(5,865
)
(7,782
)
502
199
295
50
195
(13
)
(14
)
(4
)
(2
)
3
(20
)
(20
)
1
$
(11,068
)
$
(15,250
)
$
(24,995
)
$
(5,837
)
$
(7,586
)
$
(3.98
)
$
(4.14
)
$
(4.79
)
$
(1.16
)
$
(1.34
)
2,777,443
3,679,377
5,213,955
5,044,732
5,681,807
$
(0.56
)
$
(0.14
)
44,525,648
54,162,626
F-4
Convertible | |||||||||||||||||||||||||||||||||
Preferred Stock | Common Stock | Additional | Deferred | Total | |||||||||||||||||||||||||||||
Paid-In | Stock-based | Stockholders | |||||||||||||||||||||||||||||||
Shares | Amount | Shares | Amount | Capital | Compensation | Accumulated Deficit | Equity (Deficit) | ||||||||||||||||||||||||||
Balance at December 31, 2001
|
25,862,926 | $ | 41,783 | 4,121,250 | $ | | $ | 27 | | $ | (13,509 | ) | $ | (13,482 | ) | ||||||||||||||||||
Issuance of Series D convertible preferred stock in March,
May and November 2002 to investors at $2.30 per share for cash
(net of issuance costs of $79)
|
4,073,913 | 9,290 | | | | | | | |||||||||||||||||||||||||
Issuance of common stock to consultants upon exercise of stock
options at $0.22 to $0.23 per share for cash
|
| | 39,400 | 1 | 9 | | | 10 | |||||||||||||||||||||||||
Issuance of common stock to an employee upon exercise of stock
options at $0.22 per share for cash
|
| | 10,000 | | 2 | | | 2 | |||||||||||||||||||||||||
Stock-based compensation related to consultant options
|
| | | | 36 | | | 36 | |||||||||||||||||||||||||
Net loss and comprehensive loss
|
| | | | | | (11,068 | ) | (11,068 | ) | |||||||||||||||||||||||
Balance at December 31, 2002
|
29,936,839 | 51,073 | 4,170,650 | 1 | 74 | | (24,577 | ) | (24,502 | ) | |||||||||||||||||||||||
Issuance of common stock to consultants upon exercise of stock
options at $0.20 to $0.23 per share for cash
|
| | 109,500 | | 25 | | | 25 | |||||||||||||||||||||||||
Issuance of common stock to employees upon exercise of stock
options at $0.20 to $0.23 per share for cash
|
| | 742,190 | | 163 | | | 163 | |||||||||||||||||||||||||
Series E issuance costs
|
| (9 | ) | | | | | | | ||||||||||||||||||||||||
Stock-based compensation related to consultant options
|
| | | | 17 | | | 17 | |||||||||||||||||||||||||
Net loss and comprehensive loss
|
| | | | | | (15,250 | ) | (15,250 | ) | |||||||||||||||||||||||
Balance at December 31, 2003
|
29,936,839 | 51,064 | 5,022,340 | 1 | 279 | | (39,827 | ) | (39,547 | ) | |||||||||||||||||||||||
Issuance of common stock to consultants upon exercise of stock
options at $0.22 to $0.46 per share for cash
|
| | 3,375 | | 1 | | | 1 | |||||||||||||||||||||||||
Repurchase of common stock issued to founders
|
| | (41,018 | ) | | | | | | ||||||||||||||||||||||||
Issuance of common stock to employees upon exercise of stock
options at $0.22 to $0.46 per share for cash
|
| | 641,893 | | 143 | | | 143 | |||||||||||||||||||||||||
Issuance of Series E convertible preferred stock at
$2.82 per share for cash (net of issuance costs of $146)
|
18,543,980 | 52,148 | | | | | | | |||||||||||||||||||||||||
Deferred stock-based compensation
|
| | | | 3,647 | (3,647 | ) | | | ||||||||||||||||||||||||
Amortization of deferred stock-based compensation
|
| | | | | 191 | | 191 | |||||||||||||||||||||||||
Stock-based compensation related to consultant options
|
| | | | 53 | | | 53 | |||||||||||||||||||||||||
Net loss and comprehensive loss
|
| | | | | | (24,995 | ) | (24,995 | ) | |||||||||||||||||||||||
Balance at December 31, 2004
|
48,480,819 | 103,212 | 5,626,590 | 1 | 4,123 | (3,456 | ) | (64,822 | ) | (64,154 | ) | ||||||||||||||||||||||
Issuance of common stock to employees upon exercise of stock
options at $0.22 to $0.46 per share for cash (unaudited)
|
| | 94,336 | | 29 | | | 29 | |||||||||||||||||||||||||
Stock-based compensation related to consultant options
(unaudited)
|
| | | | 21 | | | 21 | |||||||||||||||||||||||||
Deferred stock-based compensation (unaudited)
|
| | | | 174 | (174 | ) | | | ||||||||||||||||||||||||
Amortization of deferred stock-based compensation (unaudited)
|
| | | | | 232 | | 232 | |||||||||||||||||||||||||
Net loss and comprehensive loss (unaudited)
|
| | | | | | (7,586 | ) | (7,586 | ) | |||||||||||||||||||||||
Balance at March 31, 2005 (unaudited)
|
48,480,819 | $ | 103,212 | 5,720,926 | $ | 1 | $ | 4,347 | $ | (3,398 | ) | $ | (72,408 | ) | $ | (71,458 | ) | ||||||||||||||||
F-5
Three Months Ended
Year Ended December 31,
March 31,
2002
2003
2004
2004
2005
(Unaudited)
$
(11,068
)
$
(15,250
)
$
(24,995
)
$
(5,837
)
$
(7,586
)
642
824
1,008
241
219
191
2
232
36
17
53
3
21
6
20
20
18
(113
)
19
(366
)
(61
)
(338
)
(156
)
(712
)
3
(6
)
(18
)
(105
)
655
274
(373
)
120
(1,527
)
17
116
527
184
(191
)
155
261
26
143
(12,344
)
(13,544
)
(23,112
)
(5,896
)
(7,753
)
(737
)
(739
)
(1,856
)
(512
)
(207
)
106
50
50
(631
)
(739
)
(1,806
)
(462
)
(207
)
313
(152
)
(161
)
(39
)
2,115
11
188
144
12
29
72
9,291
(9
)
52,148
28,306
9,615
27
52,131
28,279
2,216
(3,360
)
(14,256
)
27,213
21,921
(5,744
)
28,678
25,318
11,062
11,062
38,275
$
25,318
$
11,062
$
38,275
$
32,983
$
32,531
$
1
$
26
$
4
$
2
$
F-6
Note 1. | The Company and Summary of Significant Accounting Policies |
Description of Business and Principles of Consolidation |
Use of Estimates |
Unaudited Interim Consolidated Results |
Unaudited Pro Forma Information |
F-7
Cash and Cash Equivalents |
Fair Value of Financial Instruments |
Property and Equipment |
Long-lived Assets |
Research and Development |
Comprehensive Loss |
F-8
Internal Use Software |
Guarantees and Indemnifications |
Income Taxes |
Stock-based Compensation |
December 31, | March 31, | |||||||||||||||||||
2002 | 2003 | 2004 | 2004 | 2005 | ||||||||||||||||
(Unaudited) | ||||||||||||||||||||
Volatility factor
|
80% | 80% | 80% | 80% | 80% | |||||||||||||||
Average risk-free interest rate
|
4.0% | 2.0% | 2.8% | 2.0% | 4.0% | |||||||||||||||
Dividend yield
|
0% | 0% | 0% | 0% | 0% | |||||||||||||||
Expected life of options
|
4 years | 4 years | 4 years | 4 years | 4 years |
F-9
Years Ending December 31, | ||||
2005 (remainder of the year)
|
$ | 716 | ||
2006
|
955 | |||
2007
|
955 | |||
2008 (and thereafter)
|
772 | |||
$ | 3,398 | |||
December 31, | March 31, | ||||||||||||||||||||
2002 | 2003 | 2004 | 2004 | 2005 | |||||||||||||||||
(Unaudited) | |||||||||||||||||||||
Net loss as reported
|
$ | (11,068 | ) | $ | (15,250 | ) | $ | (24,995 | ) | $ | (5,837 | ) | $ | (7,586 | ) | ||||||
Add: Total stock-based employee compensation expense included in
net loss
|
| | 191 | 2 | 232 | ||||||||||||||||
Deduct: Total stock-based employee compensation expense
determined under the fair-value based method for all awards
|
(27 | ) | (87 | ) | (320 | ) | (28 | ) | (299 | ) | |||||||||||
Pro forma net loss
|
$ | (11,095 | ) | $ | (15,337 | ) | $ | (25,124 | ) | $ | (5,863 | ) | $ | (7,653 | ) | ||||||
Loss per share applicable to common stockholders:
|
|||||||||||||||||||||
Basic and diluted, as reported
|
$ | (3.98 | ) | $ | (4.14 | ) | $ | (4.79 | ) | $ | (1.16 | ) | $ | (1.34 | ) | ||||||
Basic and diluted, pro forma
|
$ | (3.99 | ) | $ | (4.17 | ) | $ | (4.82 | ) | $ | (1.16 | ) | $ | (1.35 | ) | ||||||
F-10
Recently Issued Accounting Pronouncements |
Loss Per Share |
F-11
Three Months | |||||||||||||||||||||
Year Ended December 31, | Ended March 31, | ||||||||||||||||||||
2002 | 2003 | 2004 | 2004 | 2005 | |||||||||||||||||
(In thousand, except share and per share data) | |||||||||||||||||||||
(Unaudited) | |||||||||||||||||||||
Historical
|
|||||||||||||||||||||
Numerator:
|
|||||||||||||||||||||
Loss applicable to common stockholders
|
$ | (11,068 | ) | $ | (15,250 | ) | $ | (24,995 | ) | $ | (5,837 | ) | $ | (7,586 | ) | ||||||
Denominator:
|
|||||||||||||||||||||
Weighted-average common shares outstanding
|
4,145,724 | 4,287,113 | 5,213,955 | 5,044,732 | 5,681,807 | ||||||||||||||||
Less: Weighted-average unvested common shares subject to
repurchase
|
(1,368,281 | ) | (607,736 | ) | | | | ||||||||||||||
Denominator for basic and diluted loss per share applicable to
common stockholders
|
2,777,443 | 3,679,377 | 5,213,955 | 5,044,732 | 5,681,807 | ||||||||||||||||
Basic and diluted loss per share allocable to common stockholders
|
$ | (3.98 | ) | $ | (4.14 | ) | $ | (4.79 | ) | $ | (1.16 | ) | $ | (1.34 | ) | ||||||
Pro forma
|
|||||||||||||||||||||
Numerator:
|
|||||||||||||||||||||
Net loss
|
$ | (24,995 | ) | $ | (7,586 | ) | |||||||||||||||
Denominator:
|
|||||||||||||||||||||
Shares used above
|
5,213,955 | 5,681,807 | |||||||||||||||||||
Pro forma adjustments to reflect assumed weighted-average effect
of conversion of preferred stock
|
39,311,693 | 48,480,819 | |||||||||||||||||||
Shares used to compute pro forma basic and diluted net loss
per share
|
44,525,648 | 54,162,626 | |||||||||||||||||||
Pro forma basic and diluted net loss per share
|
$ | (0.56 | ) | $ | (0.14 | ) | |||||||||||||||
Historical outstanding dilutive securities not included in
diluted loss per share applicable to common stockholders
calculation
|
|||||||||||||||||||||
Preferred stock
|
29,936,839 | 29,936,839 | 48,480,819 | 39,167,828 | 48,480,819 | ||||||||||||||||
Options to purchase common stock
|
2,208,500 | 2,049,153 | 4,105,700 | 2,229,244 | 4,089,864 | ||||||||||||||||
32,145,339 | 31,985,992 | 52,586,519 | 41,397,072 | 52,570,683 | |||||||||||||||||
Note 2. | License and Collaborative Agreements |
F-12
Note 3. | Specimen Transfer and Collaboration Agreements |
Milestone | |||||
Payments | |||||
January 2006
|
$ | 300 | |||
January 2007
|
300 | ||||
January 2008
|
475 | ||||
January 2009
|
475 | ||||
January 2010
|
475 | ||||
January 2011
|
475 | ||||
Total
|
$ | 2,500 | |||
Note 4. | Commercial Technology Licensing Agreements |
F-13
Note 5. | Property and Equipment |
December 31, | March 31, | |||||||||||
2003 | 2004 | 2005 | ||||||||||
(Unaudited) | ||||||||||||
Computer equipment and software
|
$ | 688 | $ | 963 | $ | 963 | ||||||
Lab equipment
|
2,022 | 3,273 | 3,448 | |||||||||
Furniture and fixtures
|
153 | 183 | 187 | |||||||||
Leasehold improvements
|
165 | 211 | 239 | |||||||||
3,028 | 4,630 | 4,837 | ||||||||||
Less accumulated depreciation and amortization
|
(1,740 | ) | (2,514 | ) | (2,804 | ) | ||||||
$ | 1,288 | $ | 2,116 | $ | 2,033 | |||||||
Note 6. | Commitments |
Notes Payable |
Annual | |||||
Payment | |||||
Amounts | |||||
(Unaudited) | |||||
Years Ending December 31,
|
|||||
2005
|
$ | 356 | |||
2006
|
721 | ||||
2007
|
721 | ||||
2008
|
637 | ||||
2009
|
173 | ||||
Total minimum payments
|
2,608 | ||||
Less: interest portion
|
(493 | ) | |||
Present value of net minimum payments
|
2,115 | ||||
Less: current portion of obligations
|
(385 | ) | |||
Long-term obligations
|
$ | 1,730 | |||
F-14
Leases |
Annual | |||||
Payment | |||||
Amounts | |||||
Years Ending December 31,
|
|||||
2005
|
$ | 813 | |||
2006
|
122 | ||||
2007
|
9 | ||||
Total minimum payments
|
$ | 944 | |||
Note 7. | Convertible Preferred Stock and Stockholders Equity (Deficit) |
Convertible Preferred Stock |
Per Share | Aggregate | |||||||||||||||||||
Designated | Shares Issued and | Liquidation | Carrying | Liquidation | ||||||||||||||||
Series | Shares | Outstanding | Preference | Amount | Preference | |||||||||||||||
Series A
|
7,935,000 | 7,935,000 | $ | 1.00 | $ | 7,917 | $ | 7,935 | ||||||||||||
Series A-1
|
7,935,000 | | $ | 1.00 | | | ||||||||||||||
Series B
|
15,675,674 | 15,675,674 | $ | 1.85 | 28,947 | 29,000 | ||||||||||||||
Series B-1
|
15,675,674 | | $ | 1.85 | | | ||||||||||||||
Series C
|
2,252,252 | 2,252,252 | $ | 2.22 | 4,919 | 5,000 | ||||||||||||||
Series C-1
|
2,252,252 | | $ | 2.22 | | | ||||||||||||||
Series D
|
4,073,913 | 4,073,913 | $ | 2.30 | 9,290 | 9,370 | ||||||||||||||
Series D-1
|
4,073,913 | | $ | 2.30 | | | ||||||||||||||
Series E
|
20,671,640 | 18,543,980 | $ | 2.82 | 52,139 | 52,294 | ||||||||||||||
Series E-1
|
20,671,640 | | $ | 2.82 | | | ||||||||||||||
101,216,958 | 48,480,819 | $ | 103,212 | $ | 103,599 | |||||||||||||||
F-15
| with respect to shares held by any stockholder, at any time at the stockholders option; | |
| automatically upon the closing of an underwritten public offering with aggregate offering proceeds not less than $20.0 million and a per share price not less than $3.80; and | |
| upon agreement of the majority of holders of the outstanding shares of preferred stock voting as a single class, at the then-effective conversion price. |
Common Stock |
Stock Option Plan |
F-16
Outstanding Options | ||||||||||||
Shares Available | Number of | Weighted Average | ||||||||||
for Grant | Shares | Exercise Price | ||||||||||
Balance at December 31, 2002
|
1,137,100 | 2,208,500 | $ | 0.22 | ||||||||
Options granted
|
(736,500 | ) | 736,500 | $ | 0.33 | |||||||
Options exercised
|
| (851,690 | ) | $ | 0.22 | |||||||
Options canceled
|
44,157 | (44,157 | ) | $ | 0.22 | |||||||
Balance at December 31, 2003
|
444,757 | 2,049,153 | $ | 0.26 | ||||||||
Options authorized
|
4,000,000 | | | |||||||||
Options granted
|
(2,718,300 | ) | 2,718,300 | $ | 0.73 | |||||||
Options exercised
|
| (645,268 | ) | $ | 0.22 | |||||||
Options canceled
|
16,485 | (16,485 | ) | $ | 0.33 | |||||||
Balance at December 31, 2004
|
1,742,942 | 4,105,700 | $ | 0.59 | ||||||||
Options granted (unaudited)
|
(81,500 | ) | 81,500 | $ | 1.00 | |||||||
Options exercised (unaudited)
|
| (94,336 | ) | $ | 0.31 | |||||||
Options canceled (unaudited)
|
3,000 | (3,000 | ) | $ | 0.46 | |||||||
Balance at March 31, 2005 (unaudited)
|
1,664,442 | 4,089,864 | $ | 0.61 | ||||||||
Options Outstanding | Options Exercisable | |||||||||||||||||||
Weighted Average | ||||||||||||||||||||
Number | Years Remaining | Weighted Average | Number | Weighted Average | ||||||||||||||||
Exercise Price | Outstanding | Contractual Life | Exercise Price | Exercisable | Exercise Price | |||||||||||||||
$0.20
|
150,000 | 6.07 | $ | 0.20 | 146,457 | $ | 0.20 | |||||||||||||
$0.22
|
508,714 | 6.97 | $ | 0.22 | 97,102 | $ | 0.22 | |||||||||||||
$0.23
|
430,686 | 7.54 | $ | 0.23 | 150,767 | $ | 0.23 | |||||||||||||
$0.46
|
1,561,300 | 9.39 | $ | 0.46 | 106,902 | $ | 0.46 | |||||||||||||
$1.00
|
1,255,000 | 9.92 | $ | 1.00 | | | ||||||||||||||
$1.10
|
200,000 | 4.92 | $ | 1.10 | | | ||||||||||||||
4,105,700 | 501,228 | |||||||||||||||||||
F-17
Options Outstanding | Options Exercisable | |||||||||||||||||||
Weighted Average | ||||||||||||||||||||
Number | Years Remaining | Weighted Average | Number | Weighted Average | ||||||||||||||||
Exercise Price | Outstanding | Contractual Life | Exercise Price | Exercisable | Exercise Price | |||||||||||||||
$0.20
|
150,000 | 5.83 | $ | 0.20 | 150,000 | $ | 0.20 | |||||||||||||
$0.22
|
471,818 | 6.74 | $ | 0.22 | 165,270 | $ | 0.22 | |||||||||||||
$0.23
|
405,217 | 7.28 | $ | 0.23 | 159,259 | $ | 0.23 | |||||||||||||
$0.46
|
1,527,329 | 9.15 | $ | 0.46 | 167,086 | $ | 0.46 | |||||||||||||
$1.00
|
1,335,500 | 9.69 | $ | 1.00 | | | ||||||||||||||
$1.10
|
200,000 | 4.67 | $ | 1.10 | | | ||||||||||||||
4,089,864 | 641,615 | |||||||||||||||||||
Deferred Stock-based Compensation |
401(k) Plan |
F-18
Stock Options Granted to Nonemployees |
Reserved Shares |
Stock option plan
|
5,848,642 | |||
Conversion of preferred stock
|
48,480,819 | |||
54,329,461 | ||||
Stock option plan
|
5,754,306 | |||
Conversion of preferred stock
|
48,480,819 | |||
54,235,125 | ||||
Note 8. | Related Party Transactions |
Note 9. | Income Taxes |
F-19
December 31, | |||||||||
2003 | 2004 | ||||||||
Deferred tax assets:
|
|||||||||
Net operating loss carryforwards
|
$ | 15,220 | $ | 25,291 | |||||
Research tax credits
|
240 | 274 | |||||||
Total deferred tax assets
|
15,460 | 25,565 | |||||||
Valuation allowance
|
(15,460 | ) | (25,565 | ) | |||||
Net deferred tax assets
|
$ | | $ | | |||||
F-20
II-1
II-2
II-3
$
8,828
8,000
100,000
*
*
*
*
*
*
$
*
*
To be filed by amendment
Table of Contents
Exhibit
Number
Description
Form of Underwriting Agreement.
Restated Certificate of Incorporation of the Registrant.
Form of Restated Certificate of Incorporation of the Registrant
to be filed prior to the effective date of this Registration
Statement.
Form of Restated Certificate of Incorporation of the Registrant,
to be filed upon the closing of the offering to which this
Registration Statement relates.
Bylaws of the Registrant.
Form of Amended and Restated Bylaws of the Registrant, to be
effective upon the closing of the offering to which this
Registration Statement relates.
Specimen Common Stock Certificate.
Amended and Restated Investors Rights Agreement, dated
February 9, 2004 between the Registrant and certain of its
stockholders.
Opinion of Pillsbury Winthrop Shaw Pittman LLP.
Form of Indemnification Agreement between the Registrant and its
officers and directors.
2001 Stock Incentive Plan and forms of agreements thereunder.
2005 Stock Incentive Plan and forms of agreements thereunder.
Sublease Agreement dated June 1, 2001 between the
Registrant and Corixa Corporation.
First Amendment to Sublease Agreement dated October 29,
2003 between the Registrant and Corixa Corporation.
Second Amendment to Sublease Agreement dated January 31,
2005 between the Registrant and Corixa Corporation.
Lifeseq Collaborative Agreement dated March 30, 2001
between the Registrant and Incyte Corporation.
Amendment No. 1 to Lifeseq Collaborative Agreement dated
December 21, 2001 between the Registrant and Incyte
Corporation.
Amendment No. 2 to Lifeseq Collaborative Agreement dated
July 19, 2002 between the Registrant and Incyte Corporation.
Amendment No. 3 to Lifeseq Collaborative Agreement dated
October 25, 2004 between the Registrant and Incyte
Corporation.
Patent License Agreement dated March 30, 2001 between the
Registrant and Incyte Corporation.
Amendment to Patent License Agreement dated December 21,
2001 between the Registrant and Incyte Corporation.
Collaboration and Technology Transfer Agreement dated
March 30, 2001 between the Registrant and Incyte
Corporation.
Amendment to Collaboration and Technology Transfer Agreement
dated December 21, 2001 between the Registrant and Incyte
Corporation.
Table of Contents
Exhibit
Number
Description
PCR Patent License Agreement dated February 21, 2005
between the Registrant and Roche Molecular Systems, Inc.
Master Security Agreement dated March 30, 2005 between the
Registrant and Oxford Finance Corporation.
Form of Promissory Note (Equipment) issued by the Registrant in
favor of Oxford Finance Corporation.
Form of Promissory Note (Computers and Software) issued by the
Registrant in favor of Oxford Finance Corporation.
Schedule of Promissory Notes issued by the Registrant in favor
of Oxford Finance Corporation.
List of Subsidiaries.
Consent of Ernst & Young LLP, independent registered
public accounting firm.
Consent of Pillsbury Winthrop Shaw Pittman LLP (included in
Exhibit 5.1).
Power of Attorney (see page II-4 of this Registration
Statement).
*
To be filed by amendment.
Confidential treatment has been requested for portions of this
exhibit. These portions have been omitted from the Registration
Statement and submitted separately to the Securities and
Exchange Commission.
(1)
For purposes of determining any liability under the Act, the
information omitted from the form of prospectus filed as part of
this registration statement in reliance upon Rule 430A and
contained in a form of prospectus filed by the Registrant
pursuant to Rule 424(b)(1) or (4) or 497(h) under the Act
shall be deemed to be part of this registration statement as of
the time it was declared effective.
(2)
For the purpose of determining any liability under the Act, each
post effective amendment that contains a form of prospectus
shall be deemed to be a new registration statement relating to
the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona
fide offering thereof.
(3)
It will provide to the underwriters at the closing(s) specified
in the underwriting agreement certificates in such denominations
and registered in such names as required by the underwriters to
permit prompt delivery to each purchaser.
Table of Contents
II-4
II-5
Genomic Health, Inc.
By
/s/ Randal W. Scott
Randal W. Scott, Ph.D.
Chief Executive Officer and Chairman
Name
Title
Date
/s/ Randal W. Scott
Chairman of the Board of Directors and Chief Executive Officer
(Principal Executive Officer)
July 15, 2005
/s/ G. Bradley Cole
Executive Vice President and Chief Financial Officer (Principal
Financial and Accounting Officer)
July 15, 2005
/s/ Kimberly J. Popovits
President, Chief Operating Officer and Director
July 15, 2005
/s/ Julian C. Baker
Director
July 15, 2005
/s/ Brook H. Byers
Director
July 15, 2005
Table of Contents
Table of Contents
Exhibit
Number
Description
Form of Underwriting Agreement.
Restated Certificate of Incorporation of the Registrant.
Form of Restated Certificate of Incorporation of the Registrant
to be filed prior to the effective date of this Registration
Statement.
Form of Restated Certificate of Incorporation of the Registrant,
to be filed upon the closing of the offering to which this
Registration Statement relates.
Bylaws of the Registrant.
Form of Amended and Restated Bylaws of the Registrant, to be
effective upon the closing of the offering to which this
Registration Statement relates.
Specimen Common Stock Certificate.
Amended and Restated Investors Rights Agreement, dated
February 9, 2004 between the Registrant and certain of its
stockholders.
Opinion of Pillsbury Winthrop Shaw Pittman LLP.
Form of Indemnification Agreement between the Registrant and its
officers and directors.
2001 Stock Incentive Plan and forms of agreements thereunder.
2005 Stock Incentive Plan and forms of agreements thereunder.
Sublease Agreement dated June 1, 2001 between the
Registrant and Corixa Corporation.
First Amendment to Sublease Agreement dated October 29,
2003 between the Registrant and Corixa Corporation.
Second Amendment to Sublease Agreement dated January 31,
2005 between the Registrant and Corixa Corporation.
Lifeseq Collaborative Agreement dated March 30, 2001
between the Registrant and Incyte Corporation.
Amendment No. 1 to Lifeseq Collaborative Agreement dated
December 21, 2001 between the Registrant and Incyte
Corporation.
Amendment No. 2 to Lifeseq Collaborative Agreement dated
July 19, 2002 between the Registrant and Incyte Corporation.
Amendment No. 3 to Lifeseq Collaborative Agreement dated
October 25, 2004 between the Registrant and Incyte
Corporation.
Patent License Agreement dated March 30, 2001 between the
Registrant and Incyte Corporation.
Amendment to Patent License Agreement dated December 21,
2001 between the Registrant and Incyte Corporation.
Collaboration and Technology Transfer Agreement dated
March 30, 2001 between the Registrant and Incyte
Corporation.
Amendment to Collaboration and Technology Transfer Agreement
dated December 21, 2001 between the Registrant and Incyte
Corporation.
PCR Patent License Agreement dated February 21, 2005
between the Registrant and Roche Molecular Systems, Inc.
Master Security Agreement dated March 30, 2005 between the
Registrant and Oxford Finance Corporation.
Form of Promissory Note (Equipment) issued by the Registrant in
favor of Oxford Finance Corporation.
Form of Promissory Note (Computers and Software) issued by the
Registrant in favor of Oxford Finance Corporation.
Schedule of Promissory Notes issued by the Registrant in favor
of Oxford Finance Corporation.
List of Subsidiaries.
Consent of Ernst & Young LLP, independent registered
public accounting firm.
Table of Contents
Exhibit
Number
Description
Consent of Pillsbury Winthrop Shaw Pittman LLP (included in
Exhibit 5.1).
Power of Attorney (see page II-4 of this Registration
Statement).
*
To be filed by amendment.
Confidential treatment has been requested for portions of this
exhibit. These portions have been omitted from the Registration
Statement and submitted separately to the Securities and
Exchange Commission.
Exhibit 1.1
FORM OF UNDERWRITING AGREEMENT
GENOMIC HEALTH, INC.
Shares of Common Stock
Underwriting Agreement
, 2005
J.P. MORGAN SECURITIES INC.
LEHMAN BROTHERS INC.
PIPER JAFFRAY & CO.
THOMAS WEISEL PARTNERS LLC
JMP SECURITIES LLC
c/o J.P. Morgan Securities Inc.
277 Park Avenue
New York, New York 10172
c/o
Lehman Brothers Inc.
745 Seventh Avenue
New York, New York 10019
Ladies
and Gentlemen:
Genomic Health, Inc., a Delaware corporation (the Company), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the Underwriters), for whom you are acting as representatives (the Representatives), an aggregate of shares and, at the option of the Underwriters, up to an additional shares, of common stock, par value $0.0001 per share (the Stock), of the Company. The aggregate of shares to be sold by the Company is herein called the Underwritten Shares and the aggregate of additional shares to be sold by the Company is herein called the Option Shares. The Underwritten Shares and the Option Shares are herein referred to as the Shares.
The Company hereby confirms its agreement with the several Underwriters concerning the purchase and sale of the Shares, as follows:
2
1. Registration Statement . The Company has prepared and filed with the Securities and Exchange Commission (the Commission) under the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder (collectively, the Securities Act), a registration statement (File No. ) including a prospectus, relating to the Shares. Such registration statement, as amended at the time it became effective, including the information, if any, deemed pursuant to Rule 430A under the Securities Act to be part of the registration statement at the time of its effectiveness (Rule 430 Information), is referred to herein as the Registration Statement; and as used herein, the term Preliminary Prospectus means each prospectus included in such registration statement (and any amendments thereto) before it becomes effective, any prospectus filed with the Commission pursuant to Rule 424(a) under the Securities Act and the prospectus included in the Registration Statement at the time of its effectiveness that omits Rule 430A Information, and the term Prospectus means the prospectus in the form first used to confirm sales of the Shares. If the Company has filed an abbreviated registration statement pursuant to Rule 462(b) under the Securities Act (the Rule 462 Registration Statement), then any reference herein to the term Registration Statement shall be deemed to include such Rule 462 Registration Statement. Capitalized terms used but not defined herein shall have the meanings given to such terms in the Registration Statement and the Prospectus.
2. Purchase of the Shares by the Underwriters . (a) The Company agrees to sell the Shares to the several Underwriters as provided in this Agreement, and each Underwriter, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees, severally and not jointly, to purchase from the Company at a purchase price per share of $ [ ] (the Purchase Price) the number of Underwritten Shares set forth opposite the name of such Underwriter in Schedule I hereto.
In addition, the Company agrees to sell the Option Shares to the several Underwriters and the Underwriters shall have the option to purchase at their election up to [ ] Option Shares at the Purchase Price. The Underwriters, on the basis of the representations and warranties herein contained, but subject to the conditions hereinafter stated, shall have the option to purchase, severally and not jointly, from the Company at the Purchase Price that portion of the number of Option Shares as to which such election shall have been exercised (to be adjusted by you so as to eliminate fractional shares) determined by multiplying such number of Option Shares by a fraction the numerator of which is the number of Underwritten Shares set forth opposite the name of such Underwriter in Schedule 1 hereto (or such number increased as set forth in Section 9 hereof) and the denominator of which is the number of Underwritten Shares being purchased from the Company by the several Underwriters.
The Underwriters may exercise the option to purchase the Option Shares at any time in whole, or from time to time in part, on or before the thirtieth day following the date of this Agreement, by written notice from the Representatives to the Company. Such notice shall set forth the aggregate number of Option Shares as to which the option is being exercised and the date and time when the Option Shares are to be delivered and paid for which may be the same date and time as the Closing Date (as hereinafter defined) but shall not be earlier than the Closing Date nor later than the tenth full business day (as hereinafter defined) after the date of such notice
3
(unless such time and date are postponed in accordance with the provisions of Section 9 hereof). Any such notice shall be given at least two business days prior to the date and time of delivery specified therein.
(b) The Company understands that the Underwriters intend to make a public offering of the Shares as soon after the effectiveness of this Agreement as in the judgment of the Representatives is advisable, and initially to offer the Shares on the terms set forth in the Prospectus. The Company acknowledges and agrees that the Underwriters may offer and sell Shares to or through any affiliate of an Underwriter and that any such affiliate may offer and sell Shares purchased by it to or through any Underwriter.
(c) Payment for the Shares shall be made by wire transfer in immediately available funds to the account specified by the Company to the Representatives in the case of the Underwritten Shares, at the offices of Pillsbury Winthrop Shaw Pittman LLP, 2475 Hanover Street, Palo Alto, CA 94304-1114 at 10:00 A.M. New York City time on ___, 2005, or at such other time or place on the same or such other date, not later than the fifth business day thereafter, as the Representatives and the Company may agree upon in writing or, in the case of the Option Shares, on the date and at the time and place specified by the Representatives in the written notice of the Underwriters election to purchase such Option Shares. The time and date of such payment for the Underwritten Shares are referred to herein as the Closing Date and the time and date for each such payment for the Option Shares, if other than the Closing Date, are herein referred to as the Additional Closing Date.
Payment for the Shares to be purchased on the Closing Date or the Additional Closing Date, as the case may be, shall be made against delivery to the Representatives for the respective accounts of the several Underwriters of the Shares to be purchased on such date in definitive form registered in such names and in such denominations as the Representatives shall request in writing not later than two full business days prior to the Closing Date or the Additional Closing Date, as the case may be, with any transfer taxes payable in connection with the sale of the Shares duly paid by the Company, as the case may be. The certificates for the Shares will be made available for inspection and packaging by the Representatives at the office of Pillsbury Winthrop Shaw Pittman LLP set forth above not later than 1:00 P.M., New York City time, on the business day prior to the Closing Date or the Additional Closing Date, as the case may be.
The Company acknowledges and agrees that the Underwriters are acting solely in the capacity of an arms length contractual counterparty to the Company with respect to the offering of Shares contemplated hereby (including in connection with determining the terms of the offering) and not as a financial advisor or a fiduciary to, or an agent of, the Company or any other person. Additionally, neither the Representatives nor any other Underwriter is advising the Company or any other person as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction. The Company shall consult with its own advisors concerning such matters and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and the Underwriters shall have no responsibility or liability to the Company with respect to such consultations, investigations or appraisals. Any review by the
4
Underwriters of the Company, the transactions contemplated hereby or other matters relating to such transactions will be performed solely for the benefit of the Underwriters and shall not be on behalf of the Company.
3. Representations and Warranties of the Company . The Company represents and warrants to each Underwriter that:
(a) Preliminary Prospectus. No order preventing or suspending the use of any Preliminary Prospectus has been issued by the Commission, and each Preliminary Prospectus, at the time of filing thereof, complied in all material respects with the Securities Act and did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that the Company makes no representation and warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in any Preliminary Prospectus.
(b) Registration Statement and Prospectus. No order suspending the effectiveness of the Registration Statement has been issued by the Commission and no proceeding for that purpose has been initiated or, to the Companys knowledge, threatened by the Commission; as of the applicable effective date of the Registration Statement and any amendment thereto, the Registration Statement complied and will comply in all material respects with the Securities Act, and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading; and as of the applicable filing date of the Prospectus and any amendment or supplement thereto and as of the Closing Date and as of the Additional Closing Date, as the case may be, the Prospectus will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that the Company makes no representation and warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement and the Prospectus and any amendment or supplement thereto.
(c) Financial Statements. The financial statements and the related notes thereto of the Company and its consolidated subsidiaries included in the Registration Statement and the Prospectus comply in all material respects with the applicable requirements of the Securities Act and the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder (collectively, the Exchange Act), as applicable, and present fairly the financial position of the Company and its subsidiaries as of the dates indicated and the results of their operations and the changes in their cash flows for the periods specified; such financial statements have been prepared in conformity with generally accepted accounting principles applied on a consistent basis throughout the periods covered thereby, and the supporting schedules included in the Registration Statement, if any, present fairly the information required
5
to be stated therein; the other financial information included in the Registration Statement and the Prospectus has been derived from the accounting records of the Company and its subsidiaries and presents fairly the information shown thereby.
(d) No Material Adverse Change. Since the date of the most recent financial statements of the Company included in the Registration Statement and the Prospectus, (i) except for the grant of options or issuance of shares of Common Stock pursuant to the Companys existing stock plans and changes in the capital stock and long-term debt described in the Prospectus, there has not been any change in the capital stock or long-term debt of the Company or any of its subsidiaries, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock, or any material adverse change in or affecting the business, properties, management, financial position, stockholders equity, results of operations or prospects of the Company and its subsidiaries taken as a whole; (ii) except as described in the Prospectus, neither the Company nor any of its subsidiaries has entered into any transaction or agreement that is material to the Company and its subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that is material to the Company and its subsidiaries taken as a whole; and (iii) neither the Company nor any of its subsidiaries has sustained any material loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as otherwise disclosed in the Registration Statement and the Prospectus.
(e) Organization and Good Standing. The Company and each of its subsidiaries have been duly organized and are validly existing and in good standing under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction in which their respective ownership or lease of property or the conduct of their respective businesses requires such qualification, and have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they are engaged, except where the failure to be so qualified or have such power or authority would not, individually or in the aggregate, have a material adverse effect on the business, properties, management, financial position, stockholders equity, results of operations or prospects of the Company and its subsidiaries taken as a whole (a Material Adverse Effect). The Company does not own or control, directly or indirectly, any corporation, association or other entity other than the subsidiaries listed in Exhibit 21 to the Registration Statement.
(f) Capitalization. The Company has an authorized capitalization as set forth in the Prospectus under the heading Capitalization; all the outstanding shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and non-assessable and are not subject to any pre-emptive or similar rights; except as described in or expressly contemplated by the Prospectus, there are no outstanding rights (including, without limitation, pre-emptive rights), warrants or options to acquire, or instruments convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company or any of its subsidiaries, or any contract, commitment, agreement, understanding or arrangement of any kind relating to the issuance of any capital stock of the Company or any such subsidiary, any such convertible or
6
exchangeable securities or any such rights, warrants or options; the capital stock of the Company conforms in all material respects to the description thereof contained in the Registration Statement and the Prospectus; and all the outstanding shares of capital stock or other equity interests of each subsidiary of the Company have been duly and validly authorized and issued, are fully paid and non-assessable and are owned directly or indirectly by the Company, free and clear of any lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third party.
(g) Due Authorization. The Company has full right, power and authority to execute and deliver this Agreement and to perform its obligations hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement and the consummation by it of the transactions contemplated hereby have been duly and validly taken.
(h) Underwriting Agreement. This Agreement has been duly authorized, executed and delivered by the Company.
(i) The Shares. The Shares to be issued and sold by the Company hereunder have been duly authorized by the Company and, when issued and delivered and paid for as provided herein, will be duly and validly issued and will be fully paid and nonassessable and will conform to the descriptions thereof in the Prospectus; and the issuance of the Shares is not subject to any preemptive or similar rights. Except as described in the Prospectus and except for the issuance of shares of Common Stock pursuant to the Companys existing stock plans described in the Prospectus, the Company has not sold or issued any shares of Common Stock during the six-month period preceding the date of the Prospectus, including any sales pursuant to Rule 144A under, or Regulation D or Regulation S of the Securities Act.
(j) No Violation or Default. Neither the Company nor any of its subsidiaries is (i) in violation of its charter or by-laws or similar organizational documents; (ii) in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company or any of its subsidiaries is subject; or (iii) in violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of subsections (ii) and (iii) of this subsection (j), for any such default or violation that would not, individually or in the aggregate, have a Material Adverse Effect.
(k) No Conflicts. The execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Shares to be sold by the Company hereunder and the consummation by the Company of the transactions contemplated by this Agreement will not (i) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of
7
its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company or any of its subsidiaries is subject, (ii) result in any violation of the provisions of the charter or by-laws or similar organizational documents of the Company or any of its subsidiaries or (iii) except for violations that would not, individually or in the aggregate have a Material Adverse Effect, result in the violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority.
(l) No Consents Required. No consent, approval, authorization, order, registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Shares to be sold by the Company hereunder and the consummation by the Company of the transactions contemplated by this Agreement, except for the registration of the Shares under the Securities Act, the listing of the Shares on the Nasdaq National Market by The Nasdaq Stock Market, Inc. (the Nasdaq National Market), and such consents, approvals, authorizations, orders and registrations or qualifications as may be required under the Exchange Act and applicable state securities laws in connection with the purchase and distribution of the Shares by the Underwriters, and except as may be required by the National Association of Securities Dealers (the NASD) or under the laws of any foreign jurisdiction in which the Shares may be offered and sold and where the failure to obtain such consent, approval, authorization or order, individually or in the aggregate, would not have a Material Adverse Effect.
(m) Legal Proceedings. Except as described in the Prospectus, there are no legal, governmental or regulatory investigations, actions, suits or proceedings pending to which the Company or any of its subsidiaries is a party or to which any property of the Company or any of its subsidiaries is the subject (or, to the Companys knowledge, any legal, governmental or regulatory investigations, actions, suits or proceedings which have been threatened against the Company, its subsidiaries or related to its property) that, individually or in the aggregate, if determined adversely to the Company or any of its subsidiaries, could reasonably be expected to have a Material Adverse Effect or materially and adversely affect the ability of the Company to perform its obligations under this Agreement; except as described in the Prospectus, no such investigations, actions, suits or proceedings are threatened or, to the best knowledge of the Company, contemplated by any governmental or regulatory authority or threatened by others; and (i) there are no current or pending legal, governmental or regulatory actions, suits or proceedings that are required under the Securities Act to be described in the Prospectus that are not so described and (ii) there are no statutes, regulations or contracts or other documents that are required under the Securities Act to be filed as exhibits to the Registration Statement or described in the Registration Statement or the Prospectus that are not so filed or described.
(n) Independent Accountants. Ernst & Young LLP, who have certified certain financial statements of the Company and its subsidiaries, is an independent registered public accounting firm with respect to the Company and its subsidiaries as required by the Securities Act.
8
(o) Title to Real and Personal Property. Except as disclosed in the Prospectus, the Company and its subsidiaries have good and marketable title in fee simple to, or have valid rights to lease or otherwise use, all items of real and personal property that are material to the respective businesses of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances, claims and defects and imperfections of title except those that (i) do not materially interfere with the use made and proposed to be made of such property by the Company and its subsidiaries or (ii) could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.
(p) Title to Intellectual Property. Except as disclosed in the Prospectus, the Company and its subsidiaries own or possess adequate rights to use all material patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, copyrights, licenses and know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures) reasonably necessary for the conduct of their respective businesses; and except as disclosed in the Prospectus the conduct of their respective businesses do not conflict in any material respect with any such rights of others, and the Company and its subsidiaries have not received any notice of any claim of infringement or conflict with any such rights of others.
(q) No Undisclosed Relationships. No relationship, direct or, to the Companys knowledge, indirect, exists between or among the Company or any of its subsidiaries, on the one hand, and the directors, officers, stockholders, customers or suppliers of the Company or any of its subsidiaries, on the other, that is required by the Securities Act to be described in the Registration Statement and the Prospectus and that is not so described.
(r) Investment Company Act. The Company is not and, after giving effect to the offering and sale of the Shares and the application of the proceeds thereof as described in the Prospectus, will not be required to register as an investment company or an entity controlled by an investment company within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder (collectively, Investment Company Act).
(s) Taxes. Other than with respect to tax returns, which the failure to file would not reasonably be expected to have a Material Adverse Effect, the Company and each of its subsidiaries have paid all federal, state, local and foreign taxes and filed all tax returns required to be paid or filed through the date hereof, or in good faith has requested an extension thereof which has not been denied and has paid all taxes due thereon, and except as otherwise disclosed in the Prospectus, no tax deficiency has been determined adversely to the Company or any of its subsidiaries which has had (nor does the Company have any knowledge of any tax deficiency which, if determined adversely to the Company or any of its subsidiaries, might reasonably be expected to have) a Material Adverse Effect.
(t) Licenses and Permits. The Company and its subsidiaries possess all licenses, certificates, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities that are
9
necessary for the ownership or lease of their respective properties or the conduct of their respective businesses as described in the Registration Statement and the Prospectus, including without limitation all such certificates, authorizations and permits required by the United States Food and Drug Administration (the FDA), the U.S. Department of Health and Human Services (HHS) or any other federal, state or foreign agencies or bodies engaged in the regulation of clinical diagnostic laboratories or biohazardous materials, except where the failure to possess or make the same would not, individually or in the aggregate, have a Material Adverse Effect; and except as described in the Prospectus, neither the Company nor any of its subsidiaries has received notice of any revocation or modification of any such license, certificate, permit or authorization or has any reason to believe that any such license, certificate, permit or authorization will not be renewed in the ordinary course.
(u) No Labor Disputes. No labor disturbance by or dispute with employees of the Company or any of its subsidiaries exists or, to the best knowledge of the Company, is contemplated or threatened which might reasonably be expected to have a Material Adverse Effect.
(v) Compliance With Environmental Laws. The Company and its subsidiaries (i) are in compliance with any and all applicable federal, state, local and foreign laws, rules, regulations, decisions and orders relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (collectively, Environmental Laws); (ii) have received and are in compliance with all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses; and (iii) have not received notice of any actual or potential liability for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, except in the case of subsections (i), (ii) and (iii) of this subsection (v) as would not, individually or in the aggregate, have a Material Adverse Effect.
(w) Compliance With ERISA. Each employee benefit plan, within the meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (ERISA), that is maintained, administered or contributed to by the Company or any of its affiliates for employees or former employees of the Company and its affiliates has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Internal Revenue Code of 1986, as amended (the Code), except for any non-compliance that would not, individually or in the aggregate, have a Material Adverse Effect; no prohibited transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred with respect to any such plan excluding transactions effected pursuant to a statutory or administrative exemption and transactions that would not be material to the Company; and for each such plan that is subject to the funding rules of Section 412 of the Code or Section 302 of ERISA, no accumulated funding deficiency as defined in Section 412 of the Code has been incurred, whether or not waived, and the fair market value of the assets of each such plan (excluding for these purposes accrued but unpaid contributions) exceeds the present value of all benefits accrued under such plan determined using reasonable actuarial assumptions.
10
(x) Accounting and Disclosure Controls. The Company and its subsidiaries maintain systems of internal accounting controls sufficient to provide reasonable assurance that (i) the Company makes and keeps accurate books and records; (ii) transactions are executed in accordance with managements general or specific authorizations; (iii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset accountability; (iv) access to assets is permitted only in accordance with managements general or specific authorization; and (v) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company has established and maintains disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the Exchange Act) that (i) are designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Companys principal executive officer and its principal financial officer by others within those entities in order for timely decisions for required disclosure in the periodic reports that will be filed by the Company under the Exchange Act; and (ii) are effective in all material respects to perform the functions for which they were established.
(y) Insurance. Except as described in the Prospectus, the Company and its subsidiaries have insurance covering their respective properties, operations, personnel and businesses, including product liability and business interruption insurance, which insurance is in amounts and insures against such losses and risks as are adequate and customary for the conduct of their respective businesses; and neither the Company nor any of its subsidiaries has (i) received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such insurance or (ii) any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its business.
(z) No Unlawful Payments. Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, any director, officer, agent, employee or other person associated with or acting on behalf of the Company or any of its subsidiaries has (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; (iii) violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977; or (iv) made any bribe, rebate, payoff, influence payment, kickback or other unlawful payment.
(aa) No Restrictions on Subsidiaries . No subsidiary of the Company is currently prohibited, directly or indirectly, under any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on such subsidiarys capital stock, from repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiarys properties or assets to the Company or any other subsidiary of the Company.
11
(bb) No Brokers Fees. Neither the Company nor any of its subsidiaries is a party to any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against the Company or any of its subsidiaries or any Underwriter for a brokerage commission, finders fee or like payment in connection with the offering and sale of the Shares.
(cc) No Registration Rights . No person has the right to require the Company or any of its subsidiaries to register any securities for sale under the Securities Act by reason of the filing of the Registration Statement with the Commission or the issuance and sale of the Shares to be sold by the Company hereunder, which rights have not been waived.
(dd) No Stabilization. The Company has not taken, directly or indirectly, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Shares.
(ee) Statistical and Market Data. Nothing has come to the attention of the Company that has caused the Company to believe that the statistical and market-related data included in the Registration Statement and the Prospectus is not based on or derived from sources that are reliable and accurate in all material respects.
(ff) Other. The descriptions of the studies and tests described under the heading Business Clinical Development and Validation of Onco type DX, are accurate summaries of such studies in all material respects.
4. Further Agreements of the Company . The Company covenants and agrees with each Underwriter that:
(a) Filing of Prospectus. The Company will file the final Prospectus with the Commission within the time periods specified by Rule 424(b) and Rule 430A under the Securities Act and the Company will furnish copies of the Prospectus to the Underwriters in New York City prior to 10:00 A.M., New York City time, on the business day next succeeding the date of this Agreement in such quantities as the Representatives may reasonably request.
(b) Delivery of Copies. The Company will deliver, without charge, (i) to the Representatives, three signed copies of the Registration Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith; and (ii) to each Underwriter (A) a conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) and (B) during the Prospectus Delivery Period, as many copies of the Prospectus (including all amendments and supplements thereto) as the Representatives may reasonably request. As used herein, the term Prospectus Delivery Period means such period of time after the first date of the public offering of the Shares as in the opinion of counsel for the Underwriters a prospectus relating to the Shares is required by law to be delivered in connection with sales of the Shares by any Underwriter or dealer.
12
(c) Amendments or Supplements. Before filing any amendment or supplement to the Registration Statement or the Prospectus, the Company will furnish to the Representatives and counsel for the Underwriters a copy of the proposed amendment or supplement for review and will not file any such proposed amendment or supplement to which the Representatives reasonably object.
(d) Notice to the Representatives. The Company will advise the Representatives promptly, and confirm such advice in writing, (i) when the Registration Statement becomes effective; (ii) when any amendment to the Registration Statement is filed or becomes effective; (iii) when any supplement to the Prospectus or any amendment to the Prospectus is filed; (iv) of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus or the receipt of any comments from the Commission relating to the Registration Statement or any other request by the Commission for any additional information; (v) of the issuance by the Commission of any order suspending the effectiveness of the Registration Statement or preventing or suspending the use of any Preliminary Prospectus or the Prospectus or the initiation or threatening of any proceeding for that purpose; (vi) of the occurrence of any event within the Prospectus Delivery Period as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, not misleading; and (vii) of the receipt by the Company of any notice with respect to any suspension of the qualification of the Shares for offer and sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and the Company will use its best efforts to prevent the issuance of any such order suspending the effectiveness of the Registration Statement, preventing or suspending the use of any Preliminary Prospectus or the Prospectus or suspending any such qualification of the Shares and, if any such order is issued, will obtain as soon as possible the withdrawal thereof.
(e) Ongoing Compliance of the Prospectus. If during the Prospectus Delivery Period (i) any event shall occur or condition shall exist as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, not misleading or (ii) it is necessary to amend or supplement the Prospectus to comply with law, the Company will immediately notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c) above, file with the Commission and furnish to the Underwriters and to such dealers as the Representatives may designate, such amendments or supplements to the Prospectus as may be necessary so that the statements in the Prospectus as so amended or supplemented will not, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus will comply with law.
(f) Blue Sky Compliance. The Company will qualify the Shares for offer and sale under the securities or Blue Sky laws of such jurisdictions as the Representatives shall reasonably request and will continue such qualifications in effect so long as required for distribution of the Shares; provided that the Company shall not be required to (i) qualify as a foreign corporation or
13
other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii) file any general consent to service of process in any such jurisdiction or (iii) subject itself to taxation in any such jurisdiction if it is not otherwise so subject.
(g) Earning Statement. The Company will make generally available to its security holders and the Representatives as soon as practicable an earning statement that satisfies the provisions of Section 11(a) of the Securities Act and Rule 158 of the Commission promulgated thereunder covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the effective date (as defined in Rule 158) of the Registration Statement.
(h) Clear Market. For a period of 180 days after the date of the initial public offering of the Shares, the Company will not (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of, directly or indirectly, any shares of Stock or any securities convertible into or exercisable or exchangeable for Stock or (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Stock, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Stock or such other securities, in cash or otherwise, without the prior written consent of JP Morgan Securities Inc. and Lehman Brothers Inc. on behalf of the Underwriters, other than the Shares to be sold hereunder, options granted under, and any shares of Stock of the Company issued upon the exercise of options granted under existing stock option plans. Notwithstanding the foregoing, if (1) during the last 17 days of the 180-day restricted period, the Company issues an earnings release or announces material news or a material event relating to the Company; or (2) prior to the expiration of the 180-day restricted period, the Company announces that it will release earnings results during the 16-day period beginning on the last day of the 180-day period, the restrictions in this subsection (h) shall continue to apply until the expiration of the 18-day period beginning on the issuance of the earnings release or the announcement of the material news or material event.
(i) Use of Proceeds. The Company will apply the net proceeds from the sale of the Shares as described in the Prospectus under the heading Use of Proceeds.
(j) No Stabilization. The Company will not take, directly or indirectly, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Shares.
(k) Exchange Listing. The Company will use its best efforts to list for quotation the Shares on the Nasdaq National Market.
(l) Reports. At the request of the Representatives, for a period of five years following the date of the Prospectus, the Company will furnish to the Representatives (to the extent not otherwise available on the SECs Edgar database), as soon as they are available, copies of all reports or other communications (financial or other) furnished to holders of the Shares, and
14
copies of any reports and financial statements furnished to or filed with any national securities exchange or automatic quotation system.
(m) Rule 463. The Company will comply with Rule 463 under the Securities Act.
(n) Embedded Lockups . The Company shall not waive any provisions of any lock-up or similar provision of any agreement entered into by the Company with any securityholder of the Company without the written consent of JP Morgan Securities Inc. and Lehman Brothers Inc. on behalf of the Underwriters, and shall enforce such provisions at the request of the Underwriters.
5. Conditions of Underwriters Obligations. The obligation of each Underwriter to purchase the Underwritten Shares on the Closing Date or the Option Shares on the Additional Closing Date, as the case may be as provided herein is subject to the performance by the Company of its covenants and other obligations hereunder and to the following additional conditions:
(a) Registration Compliance; No Stop Order. The Registration Statement (or if a post-effective amendment thereto is required to be filed under the Securities Act, such post-effective amendment) shall have become effective, and the Representatives shall have received notice thereof, not later than 5:00 P.M., New York City time, on the date hereof; no order suspending the effectiveness of the Registration Statement shall be in effect, and no proceeding for such purpose shall be pending before or threatened by the Commission; the Prospectus shall have been timely filed with the Commission under the Securities Act and in accordance with Section 4(a) hereof; and all requests by the Commission for additional information shall have been complied with to the reasonable satisfaction of the Representatives.
(b) Representations and Warranties. The representations and warranties of the Company contained herein shall be true and correct on the date hereof and on and as of the Closing Date or the Additional Closing Date, as the case may be; and the statements of the Company and its officers made in any certificates delivered pursuant to this Agreement shall be true and correct on and as of the Closing Date or the Additional Closing Date, as the case may be.
(c) No Material Adverse Change. Subsequent to the execution and delivery of this Agreement, no event or condition of a type described in Section 3(d) hereof shall have occurred or shall exist, which event or condition is not described in the Prospectus (excluding any amendment or supplement thereto) and the effect of which in the judgment of the Representatives makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing Date or the Additional Closing Date, as the case may be, on the terms and in the manner contemplated by this Agreement and the Prospectus.
(d) Officers Certificate. The Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, a certificate of the chief financial officer or chief accounting officer of the Company and one additional senior executive
15
officer of the Company who is satisfactory to the Representatives (in each case, executing such certificate in their capacities as officers of the Company) (i) confirming that such officers have carefully reviewed the Registration Statement and the Prospectus and, to the best knowledge of such officers, the representation of the Company set forth in Section 3(b) hereof is true and correct, (ii) confirming that the other representations and warranties of the Company in this Agreement are true and correct and that the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to such Closing Date and (iii) confirming satisfaction of the conditions set forth in paragraphs (a), (c) and (d) above.
(e) Comfort Letters. On the date of this Agreement and on the Closing Date or the Additional Closing Date, as the case may be, Ernst & Young LLP shall have furnished to the Representatives, at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives, containing statements and information of the type customarily included in accountants comfort letters to underwriters with respect to the financial statements and certain financial information contained in the Registration Statement and the Prospectus; provided, that the letter delivered on the Closing Date or the Additional Closing Date, as the case may be shall use a cut-off date no more than three business days prior to such Closing Date or such Additional Closing Date, as the case may be.
(f) Opinion of Counsel for the Company. Pillsbury Winthrop Shaw Pittman LLP, counsel for the Company, shall have furnished to the Representatives, at the request of the Company, their written opinion, dated the Closing Date or the Additional Closing Date, as the case may be, and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives, to the effect set forth in Annex A hereto.
(g) Opinion of IP Counsel. Heller Ehrman White & McAuliffe LLP, intellectual property counsel for Company, shall have furnished to the Representatives, at the request of the Company, their written opinion, dated the Closing Date or the Additional Closing Date, as the case may be, and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives, to the effect set forth in Annex B hereto.
(h) Opinion of Regulatory Counsel. McDermott Will & Emery LLP, regulatory counsel for Company, shall have furnished to the Representatives, at the request of the Company, their written opinion, dated the Closing Date or the Additional Closing Date, as the case may be, and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives, to the effect set forth in Annex C hereto.
(i) Opinion of Counsel for the Underwriters. The Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, an opinion of Simpson Thacher & Bartlett LLP, counsel for the Underwriters, with respect to such matters as the Representatives may reasonably request, and such counsel shall have received such documents and information as they may reasonably request to enable them to pass upon such matters.
16
(j) No Legal Impediment to Issuance. No action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent the issuance or sale of the Shares; and no injunction or order of any federal, state or foreign court shall have been issued that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent the issuance or sale of the Shares.
(k) Good Standing . The Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, satisfactory evidence of the good standing of the Company and its subsidiaries (in the form of a good standing certificate dated no more than one business day prior to the applicable Closing Date) in their respective jurisdictions of organization and their good standing as foreign entities in such other jurisdictions as the Representatives may reasonably request, in each case in writing or any standard form of telecommunication from the appropriate Governmental Authorities of such jurisdictions.
(l) Exchange Listing. The Shares to be delivered on the Closing Date or Additional Closing Date, as the case may be, shall have been approved for listing on the Nasdaq National Market, subject to official notice of issuance.
(m) Lock-up Agreements . The lock-up agreements, each substantially in the form of Exhibit A hereto, between you and substantially all of the stockholders and optionholders of the Company, and each of the officers and directors of the Company, relating to sales and certain other dispositions of shares of Stock or certain other securities, delivered to you on or before the date hereof, shall be full force and effect on the Closing Date or the Additional Closing Date, as the case may be.
(n) Additional Documents. On or prior to the Closing Date or the Additional Closing Date, as the case may be, the Company shall have furnished to the Representatives such further certificates and documents as the Representatives may reasonably request.
All opinions, letters, certificates and evidence mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Underwriters.
6. Indemnification and Contribution .
(a) Indemnification of the Underwriters by the Company. The Company agrees to indemnify and hold harmless each Underwriter, its affiliates, directors and officers and each person, if any, who controls such Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, from and against any and all losses, claims, damages and liabilities (including, without limitation, legal fees and other expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and expenses are incurred), joint or several, that arise out of, or are based upon, any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or the Prospectus (or any
17
amendment or supplement thereto) or any Preliminary Prospectus, or caused by any omission or alleged omission to state therein a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in subsection (b) below; provided further, that the foregoing indemnity agreement with respect to any Preliminary Prospectus shall not inure to the benefit of any Underwriter who it shall be established failed to deliver the Prospectus to the person asserting any losses, claims, damages, liabilities and judgments caused by any untrue statement or alleged untrue statement of a material fact or an omission or alleged omission to state a material fact required to be stated in such Preliminary Prospectus or necessary to make the statements in such Preliminary Prospectus not misleading, if (A) the Company shall have furnished copies of the Prospectus to the several Underwriters in the requisite quantity to permit timely delivery of the Prospectus to such person on or prior to the effective date of the Registration Statement; (B) such misstatement or omission or alleged misstatement or omission was cured in the Prospectus and the Prospectus was required by law to be delivered to such person at or prior to the written confirmation of the sale of Stock to such person and (C) the timely delivery of the Prospectus to such person would have constituted a complete defense to the losses, claims, damages, liabilities and judgments asserted by such person.
(b) Indemnification of the Company. Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act to the same extent as the indemnity set forth in paragraph (a) above, but only with respect to any losses, claims, damages or liabilities that arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to such Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement and the Prospectus (or any amendment or supplement thereto) or any Preliminary Prospectus, it being understood and agreed upon that the only such information furnished by any Underwriter consists of the following information in the Prospectus furnished on behalf of each Underwriter: the concession and reallowance figures appearing in the fourth paragraph under the caption Underwriting and the information contained in the tenth paragraph relating to passive market making/stabilization under the caption Underwriting.
(c) Notice and Procedures. If any suit, action, proceeding (including any governmental or regulatory investigation), claim or demand shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to the preceding paragraphs of this Section 6, such person (the Indemnified Person) shall promptly notify the person against whom such indemnification may be sought (the Indemnifying Person) in writing; provided that the failure to notify the Indemnifying Person shall not relieve it from any
18
liability that it may have under this Section 6 except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and provided , further , that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have to an Indemnified Person otherwise than under this Section 6. If any such proceeding shall be brought or asserted against an Indemnified Person and it shall have notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person to represent the Indemnified Person and any others entitled to indemnification pursuant to this Section 6 that the Indemnifying Person may designate in such proceeding and shall pay the fees and expenses of such counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless (i) the Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary; (ii) the Indemnifying Person has failed within a reasonable time to retain counsel reasonably satisfactory to the Indemnified Person; (iii) the Indemnified Person shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to the Indemnifying Person; or (iv) the named parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified Person and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them. It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceeding in the same jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to any local counsel) for all Indemnified Persons, and that all such fees and expenses shall be paid or reimbursed as they are incurred. Any such separate firm for any Underwriter, its affiliates, directors and officers and any control persons of such Underwriter shall be designated in writing by J.P. Morgan Securities Inc. and Lehman Brothers Inc. and any such separate firm for the Company, its directors, its officers who signed the Registration Statement and any control persons of the Company shall be designated in writing by the Company. The Indemnifying Person shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the Indemnifying Person agrees to indemnify each Indemnified Person from and against any loss or liability by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an Indemnified Person shall have requested that an Indemnifying Person reimburse the Indemnified Person for fees and expenses of counsel as contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by the Indemnifying Person of such request and (ii) the Indemnifying Person shall not have reimbursed the Indemnified Person in accordance with such request prior to the date of such settlement. No Indemnifying Person shall, without the written consent of the Indemnified Person, effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnification could have been sought hereunder by such Indemnified Person, unless such settlement (x) includes an unconditional release of such Indemnified Person, in form and substance reasonably satisfactory to such Indemnified Person, from all liability on claims that are the subject matter of such proceeding and (y) does not include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of any Indemnified Person.
19
(d) Contribution. If the indemnification provided for in paragraphs (a) and (b) above is unavailable to an Indemnified Person or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or payable by such Indemnified Person as a result of such losses, claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriters on the other from the offering of the Shares or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) but also the relative fault of the Company on the one hand and the Underwriters on the other in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Underwriters on the other shall be deemed to be in the same respective proportions as the net proceeds (before deducting expenses) received by the Company from the sale of the Shares and the total underwriting discounts and commissions received by the Underwriters in connection therewith, in each case as set forth in the table on the cover of the Prospectus, bear to the aggregate offering price of the Shares. The relative fault of the Company on the one hand and the Underwriters on the other shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or by the Underwriters and the parties relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.
(e) Limitation on Liability. The Company, and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section 6 were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take account of the equitable considerations referred to in paragraph (d) above. The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities referred to in paragraph (d) above shall be deemed to include, subject to the limitations set forth above, any legal or other expenses incurred by such Indemnified Person in connection with any such action or claim. Notwithstanding the provisions of this Section 6, in no event shall an Underwriter be required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the offering of the Shares exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters obligations to contribute pursuant to this Section 6 are several in proportion to their respective purchase obligations hereunder and not joint.
(f) Non-Exclusive Remedies. The remedies provided for in this Section 6 are not exclusive and shall not limit any rights or remedies which may otherwise be available to any Indemnified Person at law or in equity.
20
7. Effectiveness of Agreement . This Agreement shall become effective upon the execution and delivery hereof by the parties hereto.
8. Termination . This Agreement may be terminated in the absolute discretion of the Representatives, by notice to the Company, if after the execution and delivery of this Agreement and prior to the Closing Date or, in the case of the Option Shares, prior to the Additional Closing Date (i) trading generally shall have been suspended or materially limited on or by any of the New York Stock Exchange, the American Stock Exchange, the National Association of Securities Dealers, Inc., the Chicago Board Options Exchange, the Chicago Mercantile Exchange or the Chicago Board of Trade; (ii) trading of any securities issued or guaranteed by the Company shall have been suspended on any exchange or in any over-the-counter market; (iii) a general moratorium on commercial banking activities shall have been declared by federal or New York State authorities; or (iv) there shall have occurred any outbreak or escalation of hostilities or any change in financial markets or any calamity or crisis, either within or outside the United States, that, in the judgment of the Representatives, is material and adverse and makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing Date or the Additional Closing Date, as the case may be, on the terms and in the manner contemplated by this Agreement and the Prospectus.
9. Defaulting Underwriter . (a) If, on the Closing Date or the Additional Closing Date, as the case may be, any Underwriter defaults on its obligation to purchase the Shares that it has agreed to purchase hereunder on such date, the non-defaulting Underwriters may in their discretion arrange for the purchase of such Shares by other persons satisfactory to the Company on the terms contained in this Agreement. If, within 36 hours after any such default by any Underwriter, the non-defaulting Underwriters do not arrange for the purchase of such Shares, then the Company shall be entitled to a further period of 36 hours within which to procure other persons satisfactory to the non-defaulting Underwriters to purchase such Shares on such terms. If other persons become obligated or agree to purchase the Shares of a defaulting Underwriter, either the non-defaulting Underwriters or the Company may postpone the Closing Date or the Additional Closing Date, as the case may be, for up to five full business days in order to effect any changes that in the opinion of counsel for the Company or counsel for the Underwriters may be necessary in the Registration Statement and the Prospectus or in any other document or arrangement, and the Company agrees to promptly prepare any amendment or supplement to the Registration Statement and the Prospectus that effects any such changes. As used in this Agreement, the term Underwriter includes, for all purposes of this Agreement unless the context otherwise requires, any person not listed in Schedule I hereto that, pursuant to this Section 9, purchases Shares that a defaulting Underwriter agreed but failed to purchase.
(b) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by the non-defaulting Underwriters and the Company as provided in paragraph (a) above, the aggregate number of Shares that remain unpurchased on the Closing Date or the Additional Closing Date, as the case may be does not exceed one-eleventh of the aggregate number of Shares to be purchased on such date, then the Company shall have the right to require each non-defaulting Underwriter to purchase the number of Shares that such
21
Underwriter agreed to purchase hereunder on such date plus such Underwriters pro rata share (based on the number of Shares that such Underwriter agreed to purchase on such date) of the Shares of such defaulting Underwriter or Underwriters for which such arrangements have not been made.
(c) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by the non-defaulting Underwriters, the Company as provided in paragraph (a) above, the aggregate number of Shares that remain unpurchased on the Closing Date or the Additional Closing Date, as the case may be, exceeds one-eleventh of the aggregate amount of Shares to be purchased on such date, or if the Company shall not exercise the right described in paragraph (b) above, then this Agreement or, with respect to any Additional Closing Date, the obligation of the Underwriters to purchase Shares on the Additional Closing Date, as the case may be, shall terminate without liability on the part of the non-defaulting Underwriters. Any termination of this Agreement pursuant to this Section 9 shall be without liability on the part of the Company, except that the Company will continue to be liable for the payment of expenses as set forth in Section 10 hereof (except for the expenses of a defaulting underwriter) and except that the provisions of Section 6 hereof shall not terminate and shall remain in effect.
(d) Nothing contained herein shall relieve a defaulting Underwriter of any liability it may have to the Company or to any non-defaulting Underwriter for damages caused by its default.
10. Payment of Expenses . (a) Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company will pay or cause to be paid all costs and expenses incident to the performance of its obligations hereunder, including without limitation, (i) the costs incident to the authorization, issuance, sale, preparation and delivery of the Shares and any taxes payable in that connection; (ii) the costs incident to the preparation, printing and filing under the Securities Act of the Registration Statement, the Preliminary Prospectus and the Prospectus (including all exhibits, amendments and supplements thereto) and the distribution thereof; (iii) the costs of reproducing and distributing each of the documents, certificates and opinions referred to in Section 5 hereof; (iv) the fees and expenses of the Companys counsel and independent accountants; (v) the fees and expenses incurred in connection with the registration or qualification and determination of eligibility for investment of the Shares under the laws of such jurisdictions as the Representatives may designate and the preparation, printing and distribution of a Blue Sky Memorandum (including the related fees and expenses of counsel for the Underwriters); (vi) the cost of preparing stock certificates; (vii) the costs and charges of any transfer agent and any registrar; (viii) all expenses and application fees incurred in connection with any filing with, and clearance of the offering by, the National Association of Securities Dealers, Inc. (including the related fees and expenses of counsel for the Underwriters); (ix) all expenses incurred by the Company in connection with any road show presentation to potential investors; and (x) all expenses and application fees related to the listing of the Shares on the Nasdaq National Market.
(b) If (i) this Agreement is terminated pursuant to Section 8, (ii) the Company for any reason fails to tender the Shares for delivery to the Underwriters or (iii) the Underwriters decline to
22
purchase the Shares for any reason permitted under this Agreement, the Company agrees to reimburse the Underwriters for all out-of-pocket costs and expenses (including the fees and expenses of their counsel) reasonably incurred by the Underwriters in connection with this Agreement and the offering contemplated hereby.
11. Persons Entitled to Benefit of Agreement . This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective successors and the officers and directors and any controlling persons referred to in Section 6 hereof. Nothing in this Agreement is intended or shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Shares from any Underwriter shall be deemed to be a successor merely by reason of such purchase.
12. Survival . The respective indemnities, rights of contribution, representations, warranties and agreements of the Company and the Underwriters contained in this Agreement or made by or on behalf of the Company, the Underwriters pursuant to this Agreement or any certificate delivered pursuant hereto shall survive the delivery of and payment for the Shares and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company or the Underwriters.
13. Certain Defined Terms . For purposes of this Agreement, (a) except where otherwise expressly provided, the term affiliate has the meaning set forth in Rule 405 under the Securities Act; (b) the term business day means any day other than a day on which banks are permitted or required to be closed in New York City; and (c) the term subsidiary has the meaning set forth in Rule 405 under the Securities Act.
14. Miscellaneous . (a) Authority of the Representatives. Any action by the Underwriters hereunder may be taken by J.P. Morgan Securities Inc. and Lehman Brothers Inc. on behalf of the Underwriters, and any such action taken by J.P. Morgan Securities Inc. and Lehman Brothers Inc. shall be binding upon the Underwriters.
(b) Notices. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or transmitted and confirmed by any standard form of telecommunication. Notices to the Underwriters shall be given to the Representatives c/o J.P. Morgan Securities Inc., 277 Park Avenue, New York, New York 10172, Fax: (212) 622-8358, Attention: Syndicate Desk, and Lehman Brothers Inc., 745 Seventh Avenue, New York, New York 10019, Attention: Syndicate Registration Department, Fax (212) 536-0943, with a copy, in the case of any notice pursuant to Section 6(c), to the Office of the General Counsel, J.P. Morgan Securities Inc., 277 Park Avenue, New York, New York 10172, and the Director of Litigation, Office of the General Counsel, Lehman Brothers Inc., 399 Park Avenue, 15 th Floor, New York, N.Y. 10022.
Notices to the Company shall be given to it at 301 Penobscot Drive, Redwood City, CA 94063 (Fax: (650) 556-1132); Attention: Chief Financial Officer, with a copy to
23
Stanton D. Wong, Pillsbury Winthrop Shaw Pittman LLP, P.O. Box 7880, San Francisco, CA 94120 (Fax: (415) 983-1200).
(c) Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York.
(d) Counterparts. This Agreement may be signed in counterparts (which may include counterparts delivered by any standard form of telecommunication), each of which shall be an original and all of which together shall constitute one and the same instrument.
(e) Amendments or Waivers. No amendment or waiver of any provision of this Agreement, nor any consent or approval to any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto.
(f) Headings. The headings herein are included for convenience of reference only and are not intended to be part of, or to affect the meaning or interpretation of, this Agreement.
24
If the foregoing is in accordance with your understanding, please indicate your acceptance of this Agreement by signing in the space provided below.
Very truly yours,
GENOMIC HEALTH, INC. |
||||
By: | ||||
Name: | ||||
Title: | ||||
Accepted: , 2005
J.P. MORGAN SECURITIES INC.
By__________________
Authorized Signatory
LEHMAN BROTHERS INC.
By__________________
Authorized Signatory
25
Schedule I
Underwriter | Number of Shares | |
|
||
J.P. Morgan Securities Inc.
|
||
Lehman Brothers Inc.
|
||
Piper Jaffray & Co.
|
||
Thomas Weisel Partners LLC
|
||
JMP Securities LLC
|
Total
Exhibit 3.1
RESTATED CERTIFICATE OF INCORPORATION
OF
GENOMIC HEALTH, INC.
Genomic Health, Inc., a corporation organized and existing under the laws of the State of
Delaware, hereby certifies as follows:
FIRST: The name of the corporation is Genomic Health, Inc.
SECOND: The original Certificate of Incorporation of the corporation was filed with the
Secretary of State of Delaware on August 22, 2000.
THIRD: Pursuant to Sections 242 and 245 of the General Corporation Law of the State of
Delaware, this Restated Certificate of Incorporation restates, integrates and further amends the
provisions of the Certificate of Incorporation of the corporation.
FOURTH: The Certificate of Incorporation of the corporation shall be amended and restated to
read in full as follows:
ARTICLE I
The name of the corporation is Genomic Health, Inc.
ARTICLE II
The registered agent and the address of the registered office in the State of Delaware are:
Corporation Service Company, 2711 Centerville Road, Suite 400, Wilmington, Delaware 19808, in New
Castle County.
ARTICLE III
The nature of the business or purposes to be conducted or promoted is to engage in any lawful
act or activity for which corporations may be organized under the General Corporation Law of the
State of Delaware (the General Corporation Law).
ARTICLE IV
A.
Classes of Stock
. The total number of shares of all classes of capital stock that
the corporation shall have authority to issue is two hundred six million two hundred sixteen
thousand nine hundred fifty-eight (206,216,958) of which one hundred five million (105,000,000)
shares, par value of one hundredth of one cent ($.0001) per share, shall be Common Stock (the
Common Stock) and one hundred one million two hundred sixteen thousand nine hundred fifty-eight
(101,216,958) shares, par value of one hundredth of one cent ($.0001) per share, shall be Preferred
Stock (the Preferred Stock).
The Preferred Stock shall be divided into series. The first series shall be designated the
Series A Preferred Stock and shall consist of seven million nine hundred thirty-five thousand
(7,935,000) shares. The second series shall be designated the Series A-1 Preferred Stock and
shall consist of seven million nine hundred thirty-five thousand
(7,935,000) shares. The third series shall be designated Series B Preferred Stock and shall consist of fifteen million six hundred seventy-five thousand six hundred seventy-four (15,675,674) shares. The fourth series shall be designated Series B-1 Preferred Stock and shall consist of fifteen million six hundred seventy-five thousand six hundred seventy-four (15,675,674) shares. The fifth series shall be designated the Series C Preferred Stock and shall consist of two million two hundred fifty-two thousand two hundred fifty two (2,252,252) shares. The sixth series shall be designated the Series C-1 Preferred Stock and shall consist of two million two hundred fifty-two thousand two hundred fifty two (2,252,252) shares. The seventh series shall be designated the Series D Preferred Stock and shall consist of four million seventy-three thousand nine hundred thirteen (4,073,913) shares. The eighth series shall be designated the Series D-1 Preferred Stock and shall consist of four million seventy-three thousand nine hundred thirteen (4,073,913) shares. The ninth series shall be designated the Series E Preferred Stock and shall consist of twenty million six hundred seventy-one thousand six hundred forty (20,671,640) shares. The tenth series shall be designated the Series E-1 Preferred Stock and shall consist of twenty million six hundred seventy-one thousand six hundred forty (20,671,640) shares. Subject to compliance with applicable protective voting rights that have been or may be granted to the Preferred Stock or series thereof in the corporations certificate of incorporation or in the resolution or resolutions of the board of directors of the corporation (the Board of Directors) providing for the issue of such series (Protective Provisions), the Board of Directors is also expressly authorized to decrease the number of shares of any series subsequent to the issue of shares in such series, but not below the number of shares of such series then outstanding. In case the number of shares of any such series shall be so decreased, the shares constituting such decrease shall resume the status that they had prior to the adoption of the resolution originally fixing the number of shares of such series.
B. Rights, Preferences and Restrictions of Series A, Series A-1, Series B, Series B-1, Series C and Series C-1, Series D, Series D-1, Series E and Series E-1 Preferred Stock . The Series A, Series A-1, Series B, Series B-1, Series C, Series C-1, Series D, Series D-1, Series E and Series E-1 Preferred Stock shall have such voting power, preferences and relative, participating, optional or other special rights, and the qualifications, limitations or restrictions thereof, as follows:
1. Dividend Provisions . Subject to the rights of series of Preferred Stock that may from time to time come into existence, the holders of shares of Series A, Series A-1, Series B, Series B-1, Series C, Series C-1, Series D, Series D-1, Series E and Series E-1 Preferred Stock shall be entitled, pari passu , to receive dividends, out of any assets legally available therefor, prior and in preference to any declaration or payment of any dividend (payable other than in Common Stock) on the Common Stock or any other junior equity security of the corporation (collectively, the Junior Securities), at the rate of $0.08, $0.08, $0.148, $0.148, $0.177, $0.177, $0.184, $0.184, $0.226 and $0.226 per share per annum, respectively (as adjusted to reflect any subsequent stock dividends, stock splits, stock combinations or other recapitalizations with respect to such shares) or, if greater (as determined on a per annum basis and on an as converted basis for the Series A, Series A-1, Series B, Series B-1, Series C, Series C-1, Series D, Series D-1, Series E and Series E-1 Preferred Stock), an amount equal to that paid on the Common Stock, payable quarterly when, as and if declared by the Board of Directors. Such
- 2 -
dividends shall not be cumulative. Subject to the rights of series of Preferred Stock that may from time to time come into existence, dividends, if declared, must be declared and paid with respect to all series of Preferred Stock contemporaneously, and if less than full dividends are declared, the same percentage of the dividend rate shall be payable to each series of Preferred Stock. The holders of the outstanding Series A, Series A-1, Series B, Series B-1, Series C, Series C-1, Series D, Series D-1, Series E and Series E-1 Preferred Stock can waive any dividend preference that such holders shall be entitled to receive under this Section 1 upon the affirmative vote or written consent of the holders of at least a majority of the Series A Preferred Stock, at least a majority of the Series A-1 Preferred Stock, at least a majority of the Series B Preferred Stock, at least a majority of the Series B-1 Preferred Stock, at least a majority of the Series C Preferred Stock, at least a majority of the Series C-1 Preferred Stock, at least a majority of the Series D Preferred Stock, at least a majority of the Series D-1 Preferred Stock, at least a majority of the Series E Preferred Stock or at least a majority of the Series E-1 Preferred Stock then outstanding respectively.
2. Liquidation Preference .
(a) In the event of any liquidation, dissolution or winding up of the corporation, either voluntary or involuntary, subject to the rights of series of Preferred Stock that may from time to time come into existence, the holders of Series A Preferred Stock shall be entitled to receive, prior and in preference to any distribution of any of the assets of the corporation to the holders of Common Stock or other Junior Securities by reason of their ownership thereof, an amount per share equal to the sum of (i) $1.00 for each outstanding share of Series A Preferred Stock (the Original Series A Issue Price) and (ii) an amount equal to all declared but unpaid dividends on such share; the holders of Series A-1 Preferred Stock shall be entitled to receive, prior and in preference to any distribution of any of the assets of the corporation to the holders of Common Stock or other Junior Securities by reason of their ownership thereof, an amount per share equal to the sum of (i) $1.00 for each outstanding share of Series A-1 Preferred Stock (the Original Series A-1 Issue Price) and (ii) an amount equal to all declared but unpaid dividends on such share; the holders of Series B Preferred Stock shall be entitled to receive, prior and in preference to any distribution of any of the assets of the corporation to the holders of Common Stock or other Junior Securities by reason of their ownership thereof, an amount per share equal to the sum of (i) $1.85 for each outstanding share of Series B Preferred Stock (the Original Series B Issue Price) and (ii) an amount equal to all declared but unpaid dividends on such share; the holders of Series B-1 Preferred Stock shall be entitled to receive, prior and in preference to any distribution of any of the assets of the corporation to the holders of Common Stock or other Junior Securities by reason of their ownership thereof, an amount per share equal to the sum of (i) $1.85 for each outstanding share of Series B-1 Preferred Stock (the Original Series B-1 Issue Price) and (ii) an amount equal to all declared but unpaid dividends on such share; the holders of Series C Preferred Stock shall be entitled to receive, prior and in preference to any distribution of any of the assets of the corporation to the holders of Common Stock or other Junior Securities by reason of their ownership thereof, an amount per share equal to the sum of (i) $2.22 for each outstanding share of Series C Preferred Stock (the Original Series C Issue Price) and (ii) an amount equal to all declared but unpaid dividends on such share; and the holders of Series C-1 Preferred Stock shall be entitled to receive, prior and in preference to any distribution of any of the assets of the corporation to the holders of Common Stock or other Junior Securities by reason of their
- 3 -
ownership thereof, an amount per share equal to the sum of (i) $2.22 for each outstanding share of Series C-1 Preferred Stock (the Original Series C-1 Issue Price) and (ii) an amount equal to all declared but unpaid dividends on such share; the holders of Series D Preferred Stock shall be entitled to receive, prior and in preference to any distribution of any of the assets of the corporation to the holders of Common Stock or other Junior Securities by reason of their ownership thereof, an amount per share equal to the sum of (i) $2.30 for each outstanding share of Series D Preferred Stock (the Original Series D Issue Price) and (ii) an amount equal to all declared but unpaid dividends on such share; and the holders of Series D-1 Preferred Stock shall be entitled to receive, prior and in preference to any distribution of any of the assets of the corporation to the holders of Common Stock or other Junior Securities by reason of their ownership thereof, an amount per share equal to the sum of (i) $2.30 for each outstanding share of Series D-1 Preferred Stock (the Original Series D-1 Issue Price) and (ii) an amount equal to all declared but unpaid dividends on such share; the holders of Series E Preferred Stock shall be entitled to receive, prior and in preference to any distribution of any of the assets of the corporation to the holders of Common Stock or other Junior Securities by reason of their ownership thereof, an amount per share equal to the sum of (i) $2.82 for each outstanding share of Series E Preferred Stock (the Original Series E Issue Price) and (ii) an amount equal to all declared but unpaid dividends on such share; and the holders of Series E-1 Preferred Stock shall be entitled to receive, prior and in preference to any distribution of any of the assets of the corporation to the holders of Common Stock or other Junior Securities by reason of their ownership thereof, an amount per share equal to the sum of (i) $2.82 for each outstanding share of Series E-1 Preferred Stock (the Original Series E-1 Issue Price) and (ii) an amount equal to all declared but unpaid dividends on such share. If upon the occurrence of such event, the assets and funds thus distributed among the holders of the Series A, Series A-1, Series B, Series B-1, Series C, Series C-1, Series D, Series D-1, Series E and Series E-1 Preferred Stock shall be insufficient to permit the payment to such holders of the full aforesaid preferential amounts, then, subject to the rights of series of Preferred Stock that may from time to time come into existence, the entire assets and funds of the corporation legally available for distribution shall be distributed ratably among the holders of the Series A, Series A-1, Series B, Series B-1, Series C, Series C-1, Series D, Series D-1, Series E and Series E-1 Preferred Stock in proportion to the aggregate liquidation preference of such stock.
(b) Upon the completion of the distribution required by subparagraph (a) of this Section 2 and any other distribution that may be required with respect to series of Preferred Stock that may from time to time come into existence, the remaining assets of the corporation available for distribution to stockholders shall be distributed among the holders of Common Stock pro rata based on the number of shares of Common Stock held by each.
(c) (i) For purposes of this Section 2, a liquidation, dissolution or winding up of the corporation shall be deemed to be occasioned by, or to include, (A) the acquisition of the corporation by another entity by means of any transaction or series of related transactions (including, without limitation, any reorganization, merger or consolidation but, excluding any merger effected exclusively for the purpose of changing the domicile of the corporation); or (B) a sale of all or substantially all of the assets of the corporation (any such acquisition or sale, an Acquisition ); unless the corporations stockholders of record as constituted immediately prior to such Acquisition will, immediately after such Acquisition (by virtue of securities issued as consideration for the corporations acquisition or sale or otherwise) hold at least 50% of the
- 4 -
voting power of the surviving or acquiring entity in approximately the same relative percentages after such acquisition or sale as before such acquisition or sale. In such event, the holders of Preferred Stock and Common Stock shall be entitled to receive at the closing of such Acquisition in cash, securities or other property amounts as specified in subsections (a) and (b) of this Section 2; provided, however, that if the holders of at least a majority of the then outstanding shares of each of: Series A and Series A-1 Preferred Stock (voting together as a single class), Series B and Series B-1 Preferred Stock (voting together as a single class), Series C and Series C-1 Preferred Stock (voting together as a single class), Series D and Series D-1 Preferred Stock (voting together as a single class) and Series E and Series E-1 Preferred Stock (voting together as a single class) vote affirmatively to approve an Acquisition in accordance with Section 7 below and, in connection with such vote, agree that the cash, securities or other property shall be distributed among the holders of Preferred Stock and Common Stock in accordance with the agreement or agreements setting forth the terms and conditions of such Acquisition, the holders of Preferred Stock and Common Stock shall be entitled to receive such amounts upon the closing of such Acquisition as are set forth in such agreement or agreements.
(ii) In any of such events, if the consideration received by the corporation is other than cash, its value will be deemed its fair market value, as mutually determined by the corporation and the holders of at least a majority of the voting power of all then outstanding shares Preferred Stock. Any securities shall be valued as follows:
(A) Securities not subject to investment letter or other similar restrictions on free marketability:
(1) If traded on a securities exchange or other last sale reporting system such as The Nasdaq Stock Market, the value shall be deemed to be the average of the closing prices of the securities on such exchange over the 30-day period ending three days prior to the closing;
(2) If actively traded over-the-counter (but not on a last sale reporting system), the value shall be deemed to be the average of the closing bid prices over the 30-day period ending three days prior to the closing; and
(3) If there is no active public market, the value shall be the fair market value thereof, as mutually determined by the corporation and the holders of at least a majority of the voting power of all then outstanding shares of Preferred Stock.
(B) The method of valuation of securities subject to investment letter or other restrictions on free marketability (other than restrictions arising solely by virtue of a stockholders status as an affiliate or former affiliate) shall be to make an appropriate discount from the market value determined as above in (A) (1), (2) or (3) to reflect the approximate fair market value thereof, as mutually determined by the corporation and the holders of at least a majority of the voting power of all then outstanding shares of Preferred Stock.
- 5 -
(C) Notwithstanding anything to the contrary in this Section 2, if a holder of Preferred Stock would receive, by converting such shares of Preferred Stock into shares of Common Stock, a greater liquidation amount than such holder is entitled to receive pursuant to Section 2(a) hereof, then such holder will not receive any amounts under Section 2(a) hereof, but will be treated for purposes of this Section 2 as though such holder had converted the shares of Preferred Stock held by such holder into shares of Common Stock, whether or not such holder had elected to so convert.
3. Redemption . The Series A, Series A-1, Series B, Series B-1, Series C, Series C-1, Series D, Series D-1, Series E and Series E-1 Preferred Stock shall not be redeemable.
4. Conversion . The holders of the Series A, Series A-1, Series B, Series B-1, Series C, Series C-1, Series D, Series D-1, Series E and Series E-1 Preferred Stock shall have conversion rights as follows (the Conversion Rights):
(a) Right to Convert . Each share of Series A, Series A-1, Series B, Series B-1, Series C, Series C-1, Series D, Series D-1, Series E and Series E-1 Preferred Stock shall be convertible at the option of the holder thereof, at any time after the date of issuance of such share, at the office of the corporation or any transfer agent for such stock, into such number of fully paid and nonassessable shares of Common Stock as is determined by dividing its respective Original Issue Price (as defined below) by the Conversion Price applicable to such share, determined as hereafter provided, in effect on the date the certificate is surrendered for conversion. The term Original Issue Price shall mean (i) with respect to the Series A Preferred Stock, the Original Series A Issue Price, (ii) with respect to the Series A-1 Preferred Stock, the initial Conversion Price for the Series A-1 Preferred Stock determined upon the issuance of the Series A-1 Preferred Stock determined in accordance with subsection 5(b), (iii) with respect to the Series B Preferred Stock, the Original Series B Issue Price, (iv) with respect to the Series B-1 Preferred Stock, the Conversion Price then in effect upon the issuance of the Series B-1 Preferred Stock determined in accordance with subsection 5(b), (v) with respect to the Series C Preferred Stock, the Original Series C Issue Price, (vi) with respect to the Series C-1 Preferred Stock, the Conversion Price then in effect upon the issuance of the Series C-1 Preferred Stock determined in accordance with subsection 5(b), (vii) with respect to the Series D Preferred Stock, the Original Series D Issue Price, (viii) with respect to the Series D-1 Preferred Stock, the Conversion Price then in effect upon the issuance of the Series D-1 Preferred Stock determined in accordance with subsection 5(b), (ix) with respect to the Series E Preferred Stock, the Original Series E Issue Price and (x) with respect to the Series E-1 Preferred Stock, the Conversion Price then in effect upon the issuance of the Series E-1 Preferred Stock determined in accordance with subsection 5(b). The initial Conversion Price per share for shares of Series A, Series B, Series C, Series D and Series E Preferred Stock shall be the Original Issue Price for such series and the initial Conversion Price per share for shares of Series A-1, Series B-1, Series C-1, Series D-1 and Series E-1 Preferred Stock shall be determined as set forth in subsection 5(b); provided, however, that the Conversion Price for each of the Series A, Series A-1, Series B, Series B-1, Series C, Series C-1, Series D, Series D-1, Series E and Series E-1 Preferred Stock shall be subject to adjustment as set forth in subsection 4(d) and the conversion price for the Series E Preferred Stock shall also be subject to adjustment as set forth in subsection 4(b).
- 6 -
(b) Automatic Conversion . Each share of Series A, Series A-1, Series B, Series B-1, Series C, Series C-1, Series D, Series D-1, Series E and Series E-1 Preferred Stock shall automatically be converted into shares of Common Stock at the respective Conversion Prices at the time in effect for such series of Preferred Stock immediately upon the earlier of (i) except as provided below in subsection 4(c), the closing of the sale by the corporation of Common Stock in a firm commitment underwritten public offering pursuant to a registration statement under the Securities Act of 1933, as amended (the Securities Act), that results in gross offering proceeds to the corporation and/or any selling stockholders (before deduction for underwriters discounts and commissions and expenses) of not less than twenty million dollars ($20,000,000) and the public offering price (before deduction for underwriters discounts and commissions and expenses) of which was not less than $3.80 per share (as adjusted for any subsequent stock splits, stock dividends, shares combinations and the like) (a Qualified IPO) or (ii) the date specified by written consent or agreement of the holders of a majority of the then outstanding shares of Series A, Series A-1, Series B, Series B-1, Series C, Series C-1, Series D, Series D-1, Series E and Series E-1 Preferred Stock, voting together as a single class on an as-converted basis. Notwithstanding the foregoing, in the event that an automatic conversion is to be effected pursuant to clause (ii) of the preceding sentence in connection with an underwritten public offering that does not meet the criteria for a Qualified IPO, then the Conversion Price of the Series E Preferred Stock shall be reduced (but shall not be increased) to $2.50 per share (as adjusted for any subsequent stock splits, stock dividends, share combinations and the like) immediately prior to such conversion.
(c) Mechanics of Conversion . Before any holder of a series of Preferred Stock shall be entitled to convert the same into shares of Common Stock, such holder shall surrender the certificate or certificates therefor, duly endorsed, at the office of the corporation or of any transfer agent for such series of Preferred Stock, and shall give written notice to the corporation at its principal corporate office, of the election to convert the same and shall state therein the name or names in which the certificate or certificates for shares of Common Stock are to be issued. The corporation shall, as soon as practicable thereafter, issue and deliver at such office to such holder of such series of Preferred Stock, or to the nominee or nominees of such holder, a certificate or certificates, for the number of shares of Common Stock to which such holder shall be entitled as aforesaid. Such conversion shall be deemed to have been made immediately prior to the close of business on the date of such surrender of the shares of such series of Preferred Stock to be converted, and the person or persons entitled to receive the shares of Common Stock issuable upon such conversion shall be treated for all purposes as the record holder or holders of such shares of Common Stock as of such date. If the conversion is in connection with an underwritten offering of securities registered pursuant to the Securities Act, the conversion may, at the option of any holder tendering shares of such series of Preferred Stock for conversion, be conditioned upon the closing with the underwriters of the sale of securities pursuant to such offering, in which event the person(s) entitled to receive the Common Stock issuable upon such conversion of such series of Preferred Stock shall not be deemed to have converted such shares of such series of Preferred Stock until immediately prior to the closing of such sale of securities.
(d) Conversion Price Adjustments of Series A, Series A-1, Series B, Series B-1, Series C, Series C-1, Series D, Series D-1, Series E and Series E-1 Preferred Stock for Certain Dilutive Issuances, Splits and Combinations . The Conversion Price of the Series A,
- 7 -
Series B, Series C, Series D and Series E Preferred Stock and (with respect to subsections 4(d)(iii) and (iv) only) the Series A-1, Series B-1, Series C-1, Series D1 and Series E-1 Preferred Stock shall be subject to adjustment from time to time as follows:
(i) (A) (1) If the corporation shall issue, after the date upon which any shares of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were first issued (such date of first issuance with respect to a series of Preferred Stock, the Purchase Date), any Additional Stock (as defined below) without consideration or for a consideration per share less than the Conversion Price for such series of Preferred Stock in effect immediately prior to the issuance of such Additional Stock, the Conversion Price for such series of Preferred Stock in effect immediately prior to each such issuance shall forthwith (except as otherwise provided in this clause (i)) be adjusted to a price determined by multiplying such Conversion Price by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately prior to such issuance plus the number of shares of Common Stock that the aggregate consideration received by the corporation for such issuance would purchase at such Conversion Price; and the denominator of which shall be the number of shares of Common Stock outstanding immediately prior to such issuance plus the number of shares of such Additional Stock. For the purpose of the foregoing calculation, the number of shares of Common Stock outstanding immediately prior to such issuance shall be calculated on a fully diluted basis, as if all shares of Preferred Stock and all other outstanding securities convertible into or exchangeable for Common Stock (Convertible Securities) had been fully converted into shares of Common Stock immediately prior to such issuance and any currently exercisable warrants, options or other outstanding rights for the purchase of shares of stock or convertible securities had been fully exercised immediately prior to such issuance (and the resulting securities fully converted into shares of Common Stock, if so convertible), but not including in such calculation any additional shares of Common Stock issuable with respect to shares of Preferred Stock, Convertible Securities, or currently exercisable options, warrants or other rights for the purchase of shares of stock or Convertible Securities, solely as a result of the adjustment of such Conversion Price (or other conversion ratios) resulting from the issuance of Additional Stock causing such adjustment.
(2) If the corporation shall issue, after the Purchase Date for the Series E Preferred Stock, any Additional Stock without consideration or for a consideration per share less than the Conversion Price for the Series D Preferred Stock or the Series E Preferred Stock, as the case may be, in effect immediately prior to the issuance of such Additional Stock, the Conversion Price for the Series D Preferred Stock, or the Series E Preferred Stock, as the case may be, in effect immediately prior to each such issuance shall forthwith (except as otherwise provided in this clause (i)) be adjusted to a price determined as follows:
(X) if the consideration per share of such Additional Stock is greater than or equal to $2.22 per share (as appropriately adjusted for stock splits, stock dividends, share combinations and the like) but less than the Conversion Price for the Series D Preferred Stock in effect immediately prior to the issuance of such Additional Stock, the Conversion Price for the Series D Preferred Stock
- 8 -
shall be adjusted to a price equal to the price per share for such Additional Stock, and, if the consideration per share of such Additional Stock is greater than or equal to $2.22 per share (as appropriately adjusted for stock splits, stock dividends, share combinations and the like) but less than the Conversion Price for the Series E Preferred Stock in effect immediately prior to the issuance of such Additional Stock, the Conversion Price for the Series E Preferred Stock shall be adjusted to a price equal to the price per share for such Additional Stock, or
(Y) if the consideration per share of such Additional Stock is less than $2.22 per share (as appropriately adjusted for stock splits, stock dividends, share combinations and the like), then the Conversion Price for the Series D Preferred Stock and the Series E Preferred Stock shall be adjusted in two steps: (A) first, to $2.22 per share (as appropriately adjusted for stock splits, stock dividends, share combinations and the like) (which $2.22 per share Conversion Price is referred to as the Interim Conversion Price), at which point the number of shares of Common Stock outstanding (calculated in the same manner as subsection (A)(1) above, i.e., as if all outstanding Convertible Securities had been fully converted and any currently exercisable securities had been fully exercised) shall be adjusted to reflect Interim Conversion Price (such adjusted number of shares of Common Stock outstanding is referred to as the Interim Outstanding Common), and (B) second, to an amount determined by multiplying such Interim Conversion Price by a fraction, the numerator of which shall be the number of Interim Outstanding Common plus the number of shares of Common Stock that the aggregate consideration received by the corporation for such issuance would purchase at such Interim Conversion Price; and the denominator of which shall be the number of Interim Outstanding Common plus the number of shares of such Additional Stock so issued.
(B) No adjustment of the Conversion Price for a series of Preferred Stock shall be made in an amount less than one cent per share, provided that any adjustments which are not required to be made by reason of this sentence shall be carried forward and shall be either taken into account in any subsequent adjustment made prior to three years from the date of the event giving rise to the adjustment being carried forward, or shall be made at the end of three years from the date of the event giving rise to the adjustment being carried forward. Except to the limited extent provided for in subsections (E)(3) and (E)(4), no adjustment of such Conversion Price pursuant to this subsection 4(d)(i) shall have the effect of increasing the Conversion Price above the Conversion Price in effect immediately prior to such adjustment.
(C) In the case of the issuance of Common Stock for cash, the consideration shall be deemed to be the amount of cash paid therefor before deducting any reasonable discounts, commissions or other expenses allowed, paid or incurred by the corporation for any underwriting or otherwise in connection with the issuance and sale thereof.
(D) In the case of the issuance of the Common Stock for a consideration in whole or in part other than cash, the consideration other than cash shall be deemed to be
- 9 -
the fair value thereof as determined by the Board of Directors irrespective of any accounting treatment.
(E) In the case of the issuance (whether before, on or after the applicable Purchase Date) of options to purchase or rights to subscribe for Common Stock, Convertible Securities, or options to purchase or rights to subscribe for Convertible Securities, the following provisions shall apply for all purposes of this subsection 4(d)(i) and subsection 4(d)(ii):
(1) The aggregate maximum number of shares of Common Stock deliverable upon exercise (assuming the satisfaction of any conditions to exercisability, including without limitation, the passage of time, but without taking into account potential antidilution adjustments) of such options to purchase or rights to subscribe for Common Stock shall be deemed to have been issued at the time such options or rights were issued and for a consideration equal to the consideration (determined in the manner provided in subsections 4(d)(i)(C) and (d)(i)(D)), if any, received by the corporation upon the issuance of such options or rights plus the minimum exercise price provided in such options or rights (without taking into account potential antidilution adjustments) for the Common Stock covered thereby.
(2) The aggregate maximum number of shares of Common Stock deliverable upon conversion of or in exchange (assuming the satisfaction of any conditions to convertibility or exchangeability, including, without limitation, the passage of time, but without taking into account potential antidilution adjustments) for any such Convertible Securities or upon the exercise of options to purchase or rights to subscribe for such Convertible Securities and subsequent conversion or exchange thereof shall be deemed to have been issued at the time such securities were issued or such options or rights were issued and for a consideration equal to the consideration, if any, received by the corporation for any such securities and related options or rights (excluding any cash received on account of accrued interest or accrued dividends), plus the minimum additional consideration, if any, to be received by the corporation (without taking into account potential antidilution adjustments) upon the conversion or exchange of such securities or the exercise of any related options or rights (the consideration in each case to be determined in the manner provided in subsections 4(d)(i)(C) and (d)(i)(D)).
(3) In the event of any change in the number of shares of Common Stock deliverable or in the consideration payable to the corporation upon exercise of such options or rights or upon conversion of or in exchange for such Convertible Securities, including, but not limited to, a change resulting from the antidilution provisions thereof, the Conversion Price of a series of Preferred Stock, to the extent in any way affected by or computed using such options, rights or securities, shall be recomputed to reflect such change, but no further adjustment shall be made for the actual issuance of Common Stock or any payment of such consideration upon the exercise of any such options or rights or
- 10 -
the conversion or exchange of such securities; provided, however, that this subsection shall not have any effect on any conversion of such series of Preferred Stock prior to such change or increase.
(4) Upon the expiration of any such options or rights, the termination of any such rights to convert or exchange or the expiration of any options or rights related to such Convertible Securities, the Conversion Price of a series of Preferred Stock, to the extent in any way affected by or computed using such options, rights or securities or options or rights related to such securities, shall be recomputed to reflect the issuance of only the number of shares of Common Stock (and convertible or exchangeable securities that remain in effect) actually issued upon the exercise of such options or rights, upon the conversion or exchange of such securities or upon the exercise of the options or rights related to such securities; provided, however, that this subsection shall not have any effect on any conversion of such series of Preferred Stock prior to such expiration or termination.
(5) The number of shares of Common Stock deemed issued and the consideration deemed paid therefor pursuant to subsections 4(d)(i)(E)(1) and (2) shall be appropriately adjusted to reflect any change, termination or expiration of the type described in either subsection 4(d)(i)(E)(3) or (4).
(ii) Additional Stock shall mean any shares of Common Stock issued (or deemed to have been issued pursuant to subsection 4(d)(i)(E)) by the corporation after the Purchase Date other than
(A) Common Stock issued pursuant to a transaction described in subsection 4(d)(iii) hereof,
(B) shares of Common Stock issuable or issued to directors, officers or employees of, consultants or advisors to, or vendors (if in transactions with primarily non-financing purposes) of, the corporation pursuant to a stock option, stock purchase or restricted stock plan or agreement approved by the Board of Directors or an authorized committee thereof, at any time when the total number of shares of Common Stock so issuable or issued (and not repurchased at cost by the corporation in connection with the termination of employment) does not exceed 7,500,000,
(C) Common Stock issued or issuable upon conversion of the Preferred Stock,
(D) shares of Common Stock issued or issuable (I) in a public offering before or in connection with which all outstanding shares of Series A, Series A-1, Series B, Series B-1, Series C, Series C-1, Series D, Series D-1, Series E and Series E-1 Preferred Stock will be converted to Common Stock or (II) upon exercise of warrants or rights granted to underwriters in connection with such a public offering; or
(E) Common Stock issued or issuable to a lender or equipment lessor or in connection with bona fide acquisitions, strategic licensing transactions, mergers or
- 11 -
similar transactions, the terms of which have been approved by at least 75% of the members of the Board of Directors.
(iii) In the event the corporation should at any time or from time to time after the Purchase Date fix a record date for the effectuation of a split or subdivision of the outstanding shares of Common Stock or the determination of holders of Common Stock entitled to receive a dividend or other distribution payable in additional shares of Common Stock or other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly, additional shares of Common Stock (hereinafter referred to as Common Stock Equivalents) without payment of any consideration by such holder for the additional shares of Common Stock or the Common Stock Equivalents (including the additional shares of Common Stock issuable upon conversion or exercise thereof), then, as of such record date (or the date of such dividend distribution, split or subdivision if no record date is fixed), the Conversion Price of each series of Preferred Stock shall be appropriately decreased so that the number of shares of Common Stock issuable on conversion of each share of such series shall be increased in proportion to such increase of the aggregate of shares of Common Stock outstanding and those issuable with respect to such Common Stock Equivalents with the number of shares issuable with respect to Common Stock Equivalents determined from time to time in the manner provided for deemed issuance, in subsection 4(d)(i)(E).
(iv) If the number of shares of Common Stock outstanding at any time after the Purchase Date is decreased by a combination of the outstanding shares of Common Stock, then, following the record date of such combination, the Conversion Price for each series of Preferred Stock shall be appropriately increased so that the number of shares of Common Stock issuable on conversion of each share of such series shall be decreased in proportion to such decrease in outstanding shares.
(e) Other Distributions . In the event the corporation shall declare a distribution payable in securities of other persons, evidences of indebtedness issued by the corporation or other persons, assets (excluding cash dividends) or options or rights not referred to in subsection 4(d)(iii), then, in each such case for the purpose of this subsection 4(e), the holders of Preferred Stock shall be entitled to a proportionate share of any such distribution as though they were the holders of the number of shares of Common Stock into which their shares of Preferred Stock are convertible as of the record date fixed for the determination of the holders of Common Stock entitled to receive such distribution.
(f) Recapitalizations . If at any time or from time to time there shall be a recapitalization of the Common Stock (other than a subdivision, combination or merger or sale of assets transaction provided for elsewhere in this Section 4 or Section 2) provision shall be made so that the holders of the Series A, Series A-1, Series B, Series B-1, Series C, Series C-1, Series D, Series D-1, Series E and Series E-1 Preferred Stock shall thereafter be entitled to receive, upon conversion thereof, the number of shares of stock or other securities or property of the corporation or otherwise, to which a holder of Common Stock deliverable upon conversion would have been entitled on such recapitalization. In any such case, appropriate adjustment shall be made in the application of the provisions
- 12 -
of this Section 4 with respect to the rights of the holders of each series of Preferred Stock after the recapitalization to the end that the provisions of this Section 4 (including adjustment of the Conversion Price then in effect and the number of shares purchasable upon conversion of such series of Preferred Stock) shall be applicable after that event as nearly equivalent as may be practicable.
(g) No Impairment . The corporation will not, by amendment of its certificate of incorporation or through any reorganization, recapitalization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder by the corporation, but will at all times in good faith assist in the carrying out of all the provisions of this Section 4 and in the taking of all such action as may be necessary or appropriate in order to protect the Conversion Rights of the holders of the Series A, Series A-1, Series B, Series B-1, Series C, Series C-1, Series D, Series D-1, Series E and Series E-1 Preferred Stock against impairment.
(h) No Fractional Shares and Certificate as to Adjustments .
(i) No fractional shares shall be issued upon the conversion of any share or shares of Preferred Stock and the number of shares of Common Stock to be issued shall be rounded to the nearest whole share. Whether or not fractional shares are issuable upon such conversion shall be determined on the basis of the total number of shares of Preferred Stock the holder is at the time converting into Common Stock and the number of shares of Common Stock issuable upon such aggregate conversion.
(ii) Upon the occurrence of each adjustment or readjustment of the Conversion Price of any series of Preferred Stock pursuant to this Section 4, the corporation, at its expense, shall promptly compute such adjustment or readjustment in accordance with the terms hereof and prepare and furnish to each holder of such series of Preferred Stock a certificate setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment or readjustment is based. The corporation shall, upon the written request at any time of any holder of such series of Preferred Stock, furnish or cause to be furnished to such holder a like certificate setting forth (A) such adjustment and readjustment, (B) the Conversion Price for such series of Preferred Stock at the time in effect, and (C) the number of shares of Common Stock and the amount, if any, of other property which at the time would be received upon the conversion of a share of such series of Preferred Stock.
(i) Notices of Record Date . In the event of any taking by the corporation of a record of the holders of any class of securities for the purpose of determining the holders thereof who are entitled to receive any dividend (other than a cash dividend) or other distribution, any right to subscribe for, purchase or otherwise acquire any shares of stock of any class or any other securities or property, or to receive any other right, the corporation shall mail to each holder of Series A, Series A-1, Series B, Series B-1, Series C, Series C-1, Series D, Series D-1, Series E and Series E-1 Preferred Stock, at least 10 days prior to the date specified therein, a notice specifying the date on which any such record is to be taken for the purpose of such dividend, distribution or right, and the amount and character of such dividend, distribution or right.
- 13 -
(j) Reservation of Stock Issuable Upon Conversion . The corporation shall at all times reserve and keep available out of its authorized but unissued shares of Common Stock, solely for the purpose of effecting the conversion of all outstanding shares of Series A, Series A-1, Series B, Series B-1, Series C, Series C-1, Series D, Series D-1, Series E and Series E-1 Preferred Stock, such number of shares of Common Stock as shall from time to time be sufficient to effect such conversion; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect such conversion, in addition to such other remedies as shall be available to the holder of such Preferred Stock, the corporation will take such corporate action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes.
(k) Notices . Any notice required by the provisions of this Section 4 to be given to the holders of shares of Series A, Series A-1, Series B, Series B-1, Series C, Series C-1, Series D, Series D-1, Series E and Series E-1 Preferred Stock shall be deemed given if deposited in the United States mail, postage prepaid, and addressed to each holder of record at such holders address appearing on the books of the corporation.
5. Conversion Into Series A-1, B-1, C-1, D-1 and E-1 Preferred Stock .
(a) Shares of Series A, Series B, Series C, Series D and Series E Preferred Stock held by a holder who does not exercise in full the Purchase Right (as defined below) shall convert automatically into shares of Series A-1, Series B-1, Series C-1, Series D-1 or Series E-1 Preferred Stock in accordance with the terms of this Section 5. Each holder of Series A, Series B, Series C, Series D or Series E Preferred Stock shall be entitled to receive written notice (the Notice) in the event that the corporation shall at any time propose to sell any securities having voting rights in the election of the Board of Directors not contingent upon default and of any security convertible into the foregoing (Equity Securities). Notwithstanding the foregoing, Equity Securities shall not include, and the corporation shall not be required to send the Notice with respect to the issuance of, and this Section 5 and the Purchase Right (as defined below) shall not apply to the issuance of, any of the following:
(i) Securities excluded from the definition of Additional Shares of Common Stock in Section 4(d)(ii) above; and
(ii) Securities issued for consideration per share (calculated in accordance with subsection 4(d)(i)) that is equal to or greater than the Conversion Price then in effect for the Series A, Series B, Series C, Series D or Series E Preferred Stock, as applicable, held by such holder.
The Notice shall state (1) the corporations bona fide intention to sell such Equity Securities, (2) the number of Equity Securities proposed to be sold, (3) the per share price of the Equity Securities proposed to be sold, (4) other material terms of the offering and (5) the maximum number of Equity Securities which each holder may purchase assuming pro rata participation. For purposes of this Section, each holders pro rata participation shall be calculated, and each holder of Series A, Series B, Series C, Series D and Series E Preferred Stock shall have the right to purchase, that number of shares of Equity Securities determined by
- 14 -
multiplying the total number of Equity Securities proposed to be sold by the corporation times a fraction, the numerator of which is the number of shares of Common Stock into which the shares of Series A, Series B, Series C, Series D or Series E Preferred Stock, respectively, held by the holder as of the date of the Notice are convertible, and the denominator of which is the total number of shares of Common Stock of the corporation outstanding (assuming full conversion and exercise of all convertible or exercisable securities) on the date of the Notice (the Purchase Right). The holder may exercise the Purchase Right by providing the corporation with written notice of exercise within fifteen (15) business days after the receipt of the Notice.
(b) The corporation shall deliver to any holder who has not exercised in full his, her or its Purchase Right written notice within ten (10) business days after the first close of the sale of Equity Securities on the same terms (including the price per share and the aggregate offering amount) set forth in the Notice (the Closing), and that percentage of shares of Series A, Series B, Series C, Series D or Series E Preferred Stock, as applicable, held by any such holder equal to the Conversion Percentage (as defined below) shall convert into shares of Series A-1, Series B-1, Series C-1, Series D-1 or Series E-1 Preferred Stock (which shares shall have an initial Conversion Price equal to the Conversion Price in effect for the Series A, Series B, Series C, Series D and Series E Preferred Stock, respectively, immediately prior to the Closing), respectively, on a share for share basis on the twentieth (20th) day after such notice is given, provided that such holder may, instead, by giving written notice to the corporation on or before such twentieth (20th) day, convert such holders Series A, Series B, Series C, Series D or Series E Preferred Stock into Common Stock at the current Conversion Price then in effect with respect to such shares immediately prior to the Closing. Conversion Percentage shall mean, as to a holder of Series A, Series B, Series C, Series D or Series E Preferred Stock (i) one (1) minus (ii) a fraction, the numerator of which is that number of shares equal to the number of Equity Securities actually purchased by such holder and the denominator of which is the number of Equity Securities that such holder was entitled to purchase pursuant to the Purchase Right; provided , however , that the Conversion Percentage shall equal one hundred percent (100%) in the event that none of the Equity Securities are purchased by such holder, and shall equal zero percent (0%) with respect to any series of Preferred Stock not entitled to a Purchase Right pursuant to subsection 5(a) hereof.
(c) On or after the twentieth day following the notice from the corporation as set forth in (b) above, notwithstanding that any certificates for the Series A, Series B, Series C, Series D or Series E Preferred Stock being converted into Series A-1, Series B-1, Series C-1, Series D-1 or Series E-1 Preferred Stock, respectively, shall have not been surrendered for conversion, the shares of Series A, Series B, Series C, Series D or Series E Preferred Stock evidenced thereby shall be deemed to be no longer outstanding, and all rights with respect thereto shall forthwith cease and terminate, except only the rights of the holder (1) to receive the shares of Series A-1, Series B-1, Series C-1, Series D-1 or Series E-1 Preferred Stock to which such holder shall be entitled upon conversion thereof, and (2) with respect to dividends declared but unpaid on such Series A, Series B, Series C, Series D or Series E Preferred Stock prior to such date. In the event that any holder of Series A, Series B, Series C, Series D or Series E Preferred Stock presents such holders certificate therefor for surrender to the corporation or its transfer agent upon such conversion into Series A-1, Series B-1, Series C-1, Series D-1 or Series E-1 Preferred Stock, respectively, a certificate for the number of shares of Series A-1, Series B-1, C-1, Series D-1 or Series E-1 Preferred Stock into which the shares of Series A, Series B, Series C, Series D or
- 15 -
Series E Preferred Stock surrendered were convertible on such conversion date promptly will be issued and delivered to such holder.
(d) In the event that any Series A-1, Series B-1, Series C-1, Series D-1 or Series E-1 Preferred Stock shares are issued, concurrently with such issuance, the corporation shall use all reasonable efforts to take all such actions as may be required, including amending its Certificate of Incorporation, (i) to cancel all authorized shares of Series A-1, Series B-1, Series C-1, Series D-1 or Series E-1 Preferred Stock that remain unissued after such issuance, (ii) to create and reserve for issuance upon conversion of the Series A, Series B, Series C, Series D or Series E Preferred Stock a new series of Preferred Stock equal in number to the number of shares of Series A-1, Series B-1, Series C-1, Series D-1 or Series E-1 Preferred Stock so cancelled, which shall be designated Series A-2, Series B-2, Series C-2, Series D-2 and Series E-2 Preferred Stock, respectively, with the designations, powers, preferences and rights and the qualifications, limitations and restrictions identical to those then applicable to the Series A-1, Series B-1, Series C-1, Series D-1 or Series E-1 Preferred Stock, as applicable, except that the initial Conversion Price for such shares of Series A-2, Series B-2, Series C-2, Series D-2 and Series E-2 Preferred Stock once issued shall be the Series A, Series B, Series C, Series D or Series E Conversion Price, as applicable, in effect immediately prior to the Closing immediately preceding issuance of Series A-2, Series B-2, Series C-2, Series D-2 and Series E-2 Preferred Stock and (iii) to amend the provisions of this Section 5 to provide that any subsequent conversion pursuant to the terms of this section will be into shares of Series A-2, Series B-2, Series C-2, Series D-2 or Series E-2 Preferred Stock rather than Series A-1, Series B-1, Series C-1, Series D-1 or Series E-1 Preferred Stock. The corporation shall take the same actions with respect to the Series A-2, Series B-2, Series C-2, Series D-2 or Series E-2 Preferred Stock and each series of Preferred Stock subsequently authorized pursuant to this Section 5 upon initial issuance of shares of the last such series to be authorized.
(e) The corporation shall reserve and keep available for issuance out of its authorized but unissued Preferred Stock such number of shares as shall from time to time be sufficient to permit conversion of the Series A, Series B, Series C, Series D and Series E Preferred Stock pursuant to the provisions of this Section 5.
6. Voting Rights; Directors .
(a) Voting Rights . The holder of each share of Series A, Series A-1, Series B, Series B-1, Series C, Series C-1, Series D, Series D-1, Series E and Series E-1 Preferred Stock shall have the right to one vote for each share of Common Stock into which such series of Preferred Stock could then be converted, and with respect to such vote, such holder shall have full voting rights and powers equal to the voting rights and powers of the holders of Common Stock (except as otherwise required by law, voting together with the Common Stock as a single class), and shall be entitled, notwithstanding any provision hereof, to notice of any stockholders meeting in accordance with the bylaws of the corporation, and shall be entitled to vote, together with holders of Common Stock, with respect to any question upon which holders of Common Stock have the right to vote. Fractional votes shall not, however, be permitted and any fractional voting rights available on an as-converted basis (after aggregating all shares into which shares of a series of Preferred Stock held by each holder could be converted) shall be rounded to the nearest whole number (with one-half being rounded upward).
- 16 -
(b) Directors .
(i) The Board of Directors shall consist of nine (9) members. The holders of Common Stock, voting as a separate class, shall be entitled to elect one (1) director. The holders of shares of Series B Preferred Stock, voting as a separate class, shall be entitled to elect three (3) directors. The holders of shares of Series D Preferred Stock, voting as a separate class, shall be entitled to elect one (1) director. The holders of shares of Series E Preferred Stock, voting as a separate class, shall be entitled to elect (1) director. The remaining three (3) directors shall be elected by the holders of the Series A, Series A-1, Series B, Series B-1, Series C, Series C-1, Series D, Series D-1, Series E and Series E-1 Preferred Stock, and the holders of the Common Stock, voting together as a class.
(ii) So long as at least 1,000,000 shares of Series C Preferred Stock are outstanding, in the event that (A) the corporation issues Equity Securities (as defined in Section B.5(a) of Article IV hereof) and (B) holders of the Series C Preferred Stock exercise in full their Purchase Right (as defined in Section B.5(a) of Article IV hereof), then (x) the Board of Directors shall be expanded from nine (9) to ten (10) directors and (y) holders of shares of Series C Preferred Stock, voting as a separate class, shall be entitled to elect one (1) director, as set forth in the Amended and Restated Investors Rights Agreement, dated as of February 9, 2004, by and among the corporation and certain of the corporations stockholders.
7. Protective Provisions . Subject to the rights of series of Preferred Stock that may from time to time come into existence, so long as any shares of Series A, Series A-1, Series B, Series B-1, Series C, Series C-1, Series D, Series D-1, Series E and Series E-1 Preferred Stock are outstanding, the corporation shall not without first obtaining the approval (by vote or written consent, as provided by law) of the holders of at least a majority of the then outstanding shares of Series A, Series A-1, Series B, Series B-1, Series C, Series C-1, Series D, Series D-1, Series E and Series E-1 Preferred Stock (voting together as a single class):
(a) amend this Restated Certificate of Incorporation in a manner that would alter or change the rights, preferences or privileges of the shares of Series A, Series A-1, Series B, Series B-1, Series C, Series C-1, Series D, Series D-1, Series E and Series E-1 Preferred Stock so as to affect adversely such shares;
(b) increase or decrease the total number of authorized shares of Preferred Stock;
(c) authorize or issue, or obligate itself to issue, any other equity security (including any security convertible into or exercisable for any equity security) senior or pari passu to the Series A, Series A-1, Series B, Series B-1, Series C, Series C-1, Series D, Series D-1, Series E and Series E-1 Preferred Stock as to dividend rights, liquidation preferences, voting rights or antidilution provisions;
- 17 -
(d) redeem, purchase or otherwise acquire for value (or pay into or set aside for a sinking fund for such purpose) any share or shares of Preferred Stock otherwise than by conversion in accordance with Section B.4 hereof;
(e) redeem, purchase or otherwise acquire (or pay into or set aside for a sinking fund for such purpose) any share or shares of Common Stock; provided, however, that this restriction shall not apply to the repurchase of shares of Common Stock from employees, officers, directors, consultants or other persons performing services for the corporation or any subsidiary pursuant to agreements under which the corporation has the option to repurchase such shares at cost upon the occurrence of certain events, such as the termination of employment;
(f) pay or declare any dividend on its Common Stock or any other Junior Securities;
(g) effect any sale, lease, assignment, transfer or other conveyance of all or substantially all of the assets of the corporation or any consolidation or merger involving the corporation, or any reclassification or other change of any stock, or any recapitalization of the corporation (excluding any transaction in which the stockholders of the corporation immediately prior to the closing of such transaction retain immediately after such closing majority voting control of the surviving corporation);
(h) increase or decrease the authorized size of the Board of Directors as it exists on the date hereof; or
(i) permit any subsidiary to issue or sell, or obligate itself to issue or sell, except to the corporation or any wholly owned subsidiary of the corporation, any equity security of such subsidiary.
8. Status of Converted Stock . In the event any shares of Preferred Stock shall be redeemed or converted pursuant to Section B.4 or Section B.5 hereof, the shares so converted or redeemed shall be cancelled and shall not be issuable by the corporation. This Restated Certificate of Incorporation of the corporation shall be appropriately amended to effect the corresponding reduction in the corporations authorized capital stock.
C. Common Stock .
1. Relative Rights of Preferred Stock and Common Stock . All preferences, voting powers, relative, participating, optional or other special rights and privileges, and qualifications, limitations, or restrictions of the Common Stock are expressly made subject and subordinate to those that may be fixed with respect to any shares of the Preferred Stock.
2. Voting Rights . Except as otherwise required by law or this Restated Certificate of Incorporation, each holder of Common Stock shall have one vote in respect of each share of stock held by such holder of record on the books of the corporation for the election of directors and on all matters submitted to a vote of stockholders of the corporation.
3. Dividends . Subject to the preferential rights of the Preferred Stock, the holders of shares of Common Stock shall be entitled to receive, when and if declared by the Board of
- 18 -
Directors, out of the assets of the corporation which are by law available therefor, dividends payable either in cash, in property or in shares of capital stock.
4. Dissolution, Liquidation or Winding Up . In the event of any dissolution, liquidation or winding up of the affairs of the corporation, after distribution in full of the preferential amounts, if any, to be distributed to the holders of shares of the Preferred Stock, holders of Common Stock shall be entitled to participate in any distribution of the assets of the corporation in accordance with Section B.2 of this Article IV.
ARTICLE V
In furtherance and not in limitation of the powers conferred by the laws of the State of Delaware:
A. The Board of Directors is expressly authorized to adopt, amend or repeal the bylaws of the corporation, provided, however, that the bylaws may only be amended in accordance with the provisions thereof.
B. Elections of directors need not be by written ballot unless the bylaws of the corporation shall so provide.
C. The books of the corporation may be kept at such place within or without the State of Delaware as the bylaws of the corporation may provide or as may be designated from time to time by the Board of Directors.
ARTICLE VI
A director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (1) for any breach of the directors duty of loyalty to the corporation or its stockholders; (2) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; (3) under Section 174 of the General Corporation Law; or (4) for any transaction from which the director derived an improper personal benefit.
If the General Corporation Law hereafter is amended to further eliminate or limit the liability of directors, then the liability of a director of the corporation, in addition to the limitation on personal liability provided herein, shall be limited to the fullest extent permitted by the amended General Corporation Law. Any repeal or modification of the foregoing provisions of this Article VI, or the adoption of any provision in an amended or Restated Certificate of Incorporation inconsistent with this Article VI, shall be prospective only, and shall not adversely affect any right or protection of any director of the corporation existing at the time of such repeal, modification or adoption.
ARTICLE VII
Except as otherwise provided in this Restated Certificate of Incorporation, the corporation reserves the right to amend or repeal any provision, rescind or amend in any respect any provision contained in this Restated Certificate of Incorporation, in the manner now or
- 19 -
hereafter prescribed by statute, and all rights conferred upon a stockholder herein are granted subject to this reservation.
* * *
FIFTH: This Restated Certificate of Incorporation was duly adopted by the Board of Directors of the corporation.
SIXTH: This Restated Certificate of Incorporation was duly adopted by the stockholders in accordance with the provisions of Sections 242 and 245 of the General Corporation Law of the State of Delaware. Written consent of the stockholders has been given with respect to this Restated Certificate of Incorporation in accordance with Section 228 of the General Corporation Law of the State of Delaware, and written notice has been given as provided in Section 228.
IN WITNESS WHEREOF, Genomic Health, Inc. has caused this certificate to be signed by its Chief Executive Officer this 27th day of December, 2004.
|
/s/ Randal W. Scott | |
|
||
|
Randal W. Scott | |
|
Chief Executive Officer |
- 20 -
Exhibit 3.3
RESTATED CERTIFICATE OF INCORPORATION
OF GENOMIC HEALTH, INC.
Genomic Health, Inc., a corporation organized and existing under the laws of the State of
Delaware, hereby certifies as follows:
FIRST: The name of the corporation is Genomic Health, Inc..
SECOND: The original Certificate of Incorporation of the corporation was filed with the
Secretary of State of the State of Delaware on August 22, 2000.
THIRD: Pursuant to Sections 242 and 245 of the General Corporation Law of the State of
Delaware, this Restated Certificate of Incorporation restates, integrates and further amends the
provisions of the Certificate of Incorporation of the corporation.
FOURTH: The Certificate of Incorporation of the corporation shall be amended and restated to
read in full as follows:
ARTICLE I
The name of the corporation is Genomic Health, Inc..
ARTICLE II
The address of the registered office of the corporation in the State of Delaware is 2711
Centerville Road, Suite 400, in the City of Wilmington, County of New Castle. The name of its
registered agent at such address is Corporation Service Company.
ARTICLE III
The nature of the business or purposes to be conducted or promoted is to engage in any lawful
act or activity for which corporations may be organized under the General Corporation Law of the
State of Delaware (the DGCL).
ARTICLE IV
A.
Classes of Stock
. The total number of shares of all classes of classes of capital
stock that the corporation shall have authority to issue is one hundred five million (105,000,000),
of which one hundred million (100,000,000) shares of the par value of one one- hundredth of one
cent ($0.0001) each shall be Common Stock (the Common Stock) and five million (5,000,000) shares
of the par value of one one-hundredth of one cent ($0.0001) each shall be Preferred Stock (the
Preferred Stock). The number of authorized shares of Common Stock or Preferred Stock may be
increased or decreased (but not below the number of shares thereof then outstanding) by the
affirmative vote of the holders of a majority of the then outstanding shares of Common Stock, without a vote of the holders of the Preferred Stock, or of any series
thereof, unless a vote of any such Preferred Stock holders is required pursuant to the provisions established by the Board of Directors of the corporation (the Board of Directors) in the resolution or resolutions providing for the issue of such Preferred Stock, and if such holders of such Preferred Stock are so entitled to vote thereon, then, except as may otherwise be set forth in this Restated Certificate of Incorporation, the only stockholder approval required shall be the affirmative vote of a majority of the combined voting power of the Common Stock and the Preferred Stock so entitled to vote.
B. Preferred Stock . The Preferred Stock may be issued from time to time in one or more series, as determined by the Board of Directors. The Board of Directors is expressly authorized to provide for the issue, in one or more series, of all or any of the remaining shares of Preferred Stock and, in the resolution or resolutions providing for such issue, to establish for each such series the number of its shares, the voting powers, full or limited, of the shares of such series, or that such shares shall have no voting powers, and the designations, preferences and relative, participating, optional or other special rights of the shares of such series, and the qualifications, limitations or restrictions thereof. The Board of Directors is also expressly authorized (unless forbidden in the resolution or resolutions providing for such issue) to increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series subsequent to the issuance of shares of that series. In case the number of shares of any such series shall be so decreased, the shares constituting such decrease shall resume the status that they had prior to the adoption of the resolution originally fixing the number of shares of such series.
C. Common Stock .
1. Relative Rights of Preferred Stock and Common Stock . All preferences, voting powers, relative, participating, optional or other special rights and privileges, and qualifications, limitations, or restrictions of the Common Stock are expressly made subject and subordinate to those that may be fixed with respect to any shares of the Preferred Stock.
2. Voting Rights . Except as otherwise required by law or this Restated Certificate of Incorporation, each holder of Common Stock shall have one vote in respect of each share of stock held by such holder of record on the books of the corporation for the election of directors and on all matters submitted to a vote of stockholders of the corporation.
3. Dividends . Subject to the preferential rights of the Preferred Stock, the holders of shares of Common Stock shall be entitled to receive, when and if declared by the Board of Directors, out of the assets of the corporation which are by law available therefor, dividends payable either in cash, in property or in shares of capital stock.
4. Dissolution, Liquidation or Winding Up . In the event of any dissolution, liquidation or winding up of the affairs of the corporation, after distribution in full of the preferential amounts, if any, to be distributed to the holders of shares of the Preferred Stock, holders of Common Stock shall be entitled, unless otherwise provided by law or this Restated Certificate of Incorporation, to receive all of the remaining assets of the corporation of whatever kind available for distribution to stockholders ratably in proportion to the number of shares of Common Stock held by them respectively.
2
ARTICLE V
In furtherance and not in limitation of the powers conferred by the laws of the State of Delaware:
A. The Board of Directors is expressly authorized to adopt, amend or repeal the bylaws of the corporation, provided, however, that the bylaws may only be amended in accordance with the provisions thereof.
B. Elections of directors need not be by written ballot unless the bylaws of the corporation shall so provide.
C. The books of the corporation may be kept at such place within or without the State of Delaware as the bylaws of the corporation may provide or as may be designated from time to time by the Board of Directors.
ARTICLE VI
No action required or permitted to be taken at any annual or special meeting of the stockholders may be taken without a meeting and the power of stockholders to consent in writing, without a meeting, to the taking of any action is specifically denied. Special meetings of the stockholders of the corporation may be called only by the Chairman of the Board or the Chief Executive Officer of the corporation or by a resolution adopted by the affirmative vote of a majority of the Board of Directors.
ARTICLE VII
A. Limitation on Liability . To the fullest extent permitted by the DGCL, as the same exists or as may hereafter be amended, a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director.
B. Indemnification . Each person who is or was a director or officer of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, employee benefit plan or other enterprise (including the heirs, executors, administrators or estate of such person), shall be indemnified and advanced expenses by the corporation, in accordance with the bylaws of the corporation, to the fullest extent authorized by the DGCL, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the corporation to provide broader indemnification rights than said law permitted the corporation to provide prior to such amendment) or any other applicable laws as presently or hereinafter in effect. The right to indemnification and advancement of expenses hereunder shall not be exclusive of any other right that any person may have or hereafter acquire under any statute, provision of the Restated Certificate of Incorporation, by-law, agreement, vote of stockholders or disinterested directors or otherwise.
C. Insurance . The corporation may, to the fullest extent permitted by law, purchase and maintain insurance on behalf of any person who is or was a director, officer,
3
employee or agent of the corporation or another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise against any expense, liability or loss incurred by such person in any such capacity or arising out of such persons status as such, whether or not the corporation would have the power to indemnify such person against such expense, liability or loss under the DGCL.
D. Repeal and Modification . Any repeal or modification of the foregoing provisions of this Article VII shall not adversely affect any right or protection existing hereunder immediately prior to such repeal or modification.
ARTICLE VIII
Notwithstanding any other provision of this Restated Certificate of Incorporation, the affirmative vote of the holders of at least sixty-six and two-thirds percent (66-2/3%) of the voting power of all of the then outstanding shares of the stock of the corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to amend in any respect or repeal this Article VIII, or Articles VI and VII.
* * *
FIFTH: This Restated Certificate of Incorporation was duly adopted by the Board of Directors of the corporation.
SIXTH: This Restated Certificate of Incorporation was duly adopted by the stockholders in accordance with the provisions of Sections 242 and 245 of the General Corporation Law of the State of Delaware. Written consent of the stockholders has been given with respect to this Restated Certificate of Incorporation in accordance with Section 228 of the General Corporation Law of the State of Delaware, and written notice has been given as provided in Section 228.
IN WITNESS WHEREOF, the corporation has caused this certificate to be signed by its Chief Executive Officer and attested by its Secretary this ___day of ___, 2005.
GENOMIC HEALTH, INC.
|
||||
By | ||||
Randal W. Scott, Chief Executive Officer | ||||
Attest:
|
||||
By | ||||
G. Bradley Cole, Secretary | ||||
4
TABLE OF CONTENTS
|
Page | |||||
ARTICLE 1 Offices | 1 | |||||
1.1
|
Principal Office | 1 | ||||
1.2
|
Additional Offices | 1 | ||||
|
||||||
ARTICLE 2 Meeting of Stockholders | 1 | |||||
2.1
|
Place of Meeting | 1 | ||||
2.2
|
Annual Meeting | 1 | ||||
2.3
|
Special Meetings | 1 | ||||
2.4
|
Notice of Meetings | 2 | ||||
2.5
|
Business Matter of a Special Meeting | 2 | ||||
2.6
|
List of Stockholders | 2 | ||||
2.7
|
Organization and Conduct of Business | 2 | ||||
2.8
|
Quorum and Adjournments | 2 | ||||
2.9
|
Voting Rights | 3 | ||||
2.10
|
Majority Vote | 3 | ||||
2.11
|
Record Date for Stockholder Notice and Voting | 3 | ||||
2.12
|
Proxies | 3 | ||||
2.13
|
Inspectors of Election | 4 | ||||
2.14
|
Action Without Meeting by Written Consent | 4 | ||||
|
||||||
ARTICLE 3 Directors | 4 | |||||
3.1
|
Number; Qualifications | 4 | ||||
3.2
|
Resignation and Vacancies | 4 | ||||
3.3
|
Removal of Directors | 4 | ||||
3.4
|
Powers | 5 | ||||
3.5
|
Place of Meetings | 5 | ||||
3.6
|
Annual Meetings | 5 | ||||
3.7
|
Regular Meetings | 5 | ||||
3.8
|
Special Meetings | 5 | ||||
3.9
|
Quorum and Adjournments | 5 | ||||
3.10
|
Action Without Meeting | 5 | ||||
3.11
|
Telephone Meetings | 5 | ||||
3.12
|
Waiver of Notice | 5 | ||||
3.13
|
Fees and Compensation of Directors | 6 | ||||
3.14
|
Rights of Inspection | 6 | ||||
|
||||||
ARTICLE 4 Committees of Directors | 6 | |||||
4.1
|
Selection | 6 | ||||
4.2
|
Power | 6 | ||||
4.3
|
Committee Minutes | 7 | ||||
|
||||||
ARTICLE 5 Officers | 7 | |||||
5.1
|
Officers Designated | 7 |
-i-
|
Page | |||||
5.2
|
Appointment of Officers | 7 | ||||
5.3
|
Subordinate Officers | 7 | ||||
5.4
|
Removal and Resignation of Officers | 7 | ||||
5.5
|
Vacancies in Offices | 7 | ||||
5.6
|
Compensation | 7 | ||||
5.7
|
The Chairman of the Board | 8 | ||||
5.8
|
The President | 8 | ||||
5.9
|
The Vice President | 8 | ||||
5.10
|
The Secretary | 8 | ||||
5.11
|
The Assistant Secretary | 8 | ||||
5.12
|
The Treasurer | 9 | ||||
5.13
|
The Assistant Treasurer | 9 | ||||
|
||||||
ARTICLE 6 Indemnification of Directors, Officers, Employees and Other Agents | 9 | |||||
6.1
|
Indemnification of Directors And Officers | 9 | ||||
6.2
|
Indemnification of Others | 9 | ||||
6.3
|
Payment Of Expenses In Advance | 10 | ||||
6.4
|
Indemnity Not Exclusive | 10 | ||||
6.5
|
Insurance | 10 | ||||
6.6
|
Conflicts | 10 | ||||
|
||||||
ARTICLE 7 Stock Certificates | 10 | |||||
7.1
|
Certificates for Shares | 10 | ||||
7.2
|
Signatures on Certificates | 11 | ||||
7.3
|
Transfer of Stock | 11 | ||||
7.4
|
Registered Stockholders | 11 | ||||
7.5
|
Record Date | 11 | ||||
7.6
|
Lost, Stolen or Destroyed Certificates | 11 | ||||
|
||||||
ARTICLE 8 Notices | 12 | |||||
8.1
|
Notice | 12 | ||||
8.2
|
Waiver | 12 | ||||
|
||||||
ARTICLE 9 General Provisions | 12 | |||||
9.1
|
Dividends | 12 | ||||
9.2
|
Dividend Reserve | 12 | ||||
9.3
|
Annual Statement | 12 | ||||
9.4
|
Checks | 12 | ||||
9.5
|
Corporate Seal | 13 | ||||
9.6
|
Execution of Corporate Contracts and Instruments | 13 | ||||
|
||||||
ARTICLE 10 Amendments | 13 |
-ii-
BYLAWS
OF
GENOMIC HEALTH, INC.
(a Delaware corporation)
ARTICLE 1
Offices
1.1 Principal Office . The Board of Directors shall fix the location of the principal executive office of the corporation at any place within or outside the State of Delaware.
1.2 Additional Offices . The Board of Directors (the Board) may at any time establish branch or subordinate offices at any place or places.
ARTICLE 2
Meeting of Stockholders
2.1 Place of Meeting . All meetings of the stockholders for the election of directors shall be held at the principal office of the Corporation, at such place as may be fixed from time to time by the Board or at such other place either within or without the State of Delaware as shall be designated from time to time by the Board and stated in the notice of the meeting. [Meetings of stockholders for any purpose may be held at such time and place within or without the State of Delaware as the Board may fix from time to time and as shall be stated in the notice of the meeting or in a duly executed waiver of notice thereof.]
2.2 Annual Meeting . Annual meetings of stockholders shall be held each year at such date and time as shall be designated from time to time by the Board and stated in the notice of the meeting. At such annual meetings, the stockholders shall elect by a plurality vote [the number of directo and transact such other business as may properly be brought before the meetings.
2.3 Special Meetings . Special meetings of the stockholders may be called for any purpose or purposes, unless otherwise prescribed by the statute or by the Certificate of Incorporation, at the request of the Board, the Chairman of the Board, the President or the holders of shares entitled to cast not less than ten percent (10%) of the votes at the meeting or such additional persons as may be provided in the certificate of incorporation or bylaws. Such request shall state the purpose or purposes of the proposed meeting. Upon request in writing that a special meeting of stockholders be called for any proper purpose, directed to the chairman of the board of directors, the president, the vice president or the secretary by any person (other than the board of directors) entitled to call a special meeting of stockholders, the person forthwith shall cause notice to be given to the stockholders entitled to vote that a meeting will be held at a time requested by the person or persons calling the meeting, such time not to be less than thirty-
-1-
five (35) nor more than sixty (60) days after receipt of the request. Such request shall state the purpose or purposes of the proposed meeting.
2.4 Notice of Meetings . Written notice of stockholders meetings, stating the place, date and time of the meeting and the purpose or purposes for which the meeting is called, shall be given to each stockholder entitled to vote at such meeting not less than ten (10) nor more than sixty (60) days prior to the meeting.
When a meeting is adjourned to another place, date or time, written notice need not be given of the adjourned meeting if the place, date and time thereof are announced at the meeting at which the adjournment is taken; provided, however, that if the date of any adjourned meeting is more than thirty (30) days after the date for which the meeting was originally noticed, or if a new record date is fixed for the adjourned meeting, written notice of the place, date and time of the adjourned meeting shall be given in conformity herewith. At any adjourned meeting, any business may be transacted which might have been transacted at the original meeting.
2.5 Business Matter of a Special Meeting . Business transacted at any special meeting of stockholders shall be limited to the purposes stated in the notice.
2.6 List of Stockholders . The officer in charge of the stock ledger of the Corporation or the transfer agent shall prepare and make, at least ten (10) days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for a period of at least ten (10) days prior to the meeting, at a place within the city where the meeting is to be held, which place, if other than the place of the meeting, shall be specified in the notice of the meeting. The list shall also be produced and kept at the place of the meeting during the whole time thereof, and may be inspected by any stockholder who is present in person thereat.
2.7 Organization and Conduct of Business . The Chairman of the Board or, in his or her absence, the President of the Corporation or, in their absence, such person as the Board may have designated or, in the absence of such a person, such person as may be chosen by the holders of a majority of the shares entitled to vote who are present, in person or by proxy, shall call to order any meeting of the stockholders and act as Chairman of the meeting. In the absence of the Secretary of the Corporation, the Secretary of the meeting shall be such person as the Chairman appoints.
The Chairman of any meeting of stockholders shall determine the order of business and the procedure at the meeting, including such regulation of the manner of voting and the conduct of discussion as seems to him or her in order.
2.8 Quorum and Adjournments . Except where otherwise provided by law or the Certificate of Incorporation or these Bylaws, the holders of a majority of the stock issued and outstanding and entitled to vote, present in person or represented in proxy, shall constitute a quorum at all meetings of the stockholders. The stockholders present at a duly called or held meeting at which a quorum is present may continue to do business until adjournment,
-2-
notwithstanding the withdrawal of enough stockholders to have less than a quorum if any action taken (other than adjournment) is approved by at least a majority of the shares required to constitute a quorum. At such adjourned meeting at which a quorum is present or represented, any business may be transacted which might have been transacted at the meeting as originally notified. If, however, a quorum shall not be present or represented at any meeting of the stockholders, the stockholders entitled to vote thereat who are present in person or represented by proxy shall have the power to adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum shall be present or represented.
2.9 Voting Rights . Unless otherwise provided in the Certificate of Incorporation, each stockholder shall at every meeting of the stockholders be entitled to one vote in person or by proxy for each share of the capital stock having voting power held by such stockholder.
2.10 Majority Vote . When a quorum is present at any meeting, the vote of the holders of a majority of the stock having voting power present in person or represented by proxy shall decide any question brought before such meeting, unless the question is one upon which by express provision of the statutes or of the Certificate of Incorporation or of these Bylaws, a different vote is required in which case such express provision shall govern and control the decision of such question.
2.11 Record Date for Stockholder Notice and Voting . For purposes of determining the stockholders entitled to notice of any meeting or to vote, or entitled to receive payment of any dividend or other distribution, or entitled to exercise any right in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board may fix, in advance, a record date, which shall not be more than sixty (60) days nor less than ten (10) days before the date of any such meeting nor more than sixty (60) days before any other action.
If the Board does not so fix a record date, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the business day next preceding the day on which notice is given or, if notice is waived, at the close of business on the business day next preceding the day on which the meeting is held.
2.12 Proxies . Every person entitled to vote for directors or on any other matter shall have the right to do so either in person or by one or more agents authorized by a written proxy signed by the person and filed with the Secretary of the Corporation. A proxy shall be deemed signed if the stockholders name is placed on the proxy (whether by manual signature, typewriting, telegraphic transmission or otherwise) by the stockholder or the stockholders attorney-in-fact. A validly executed proxy which does not state that it is irrevocable shall continue in full force and effect unless (i) revoked by the person executing it, before the vote pursuant to that proxy, by a writing delivered to the Corporation stating that the proxy is revoked or by a subsequent proxy executed by, or attendance at the meeting and voting in person by, the person executing the proxy; or (ii) written notice of the death or incapacity of the maker of that proxy is received by the Corporation before the vote pursuant to that proxy is counted; provided, however, that no proxy shall be valid after the expiration of eleven months from the date of the proxy, unless otherwise provided in the proxy.
-3-
2.13 Inspectors of Election . Before any meeting of stockholders the Board may appoint any person other than nominees for office to act as inspectors of election at the meeting or its adjournment. If no inspectors of election are so appointed, the Chairman of the meeting may, and on the request of any stockholder or a stockholders proxy shall, appoint inspectors of election at the meeting. The number of inspectors shall be either one (1) or three (3). If inspectors are appointed at a meeting on the request of one or more stockholders or proxies, the holders of a majority of shares or their proxies present at the meeting shall determine whether one (1) or three (3) inspectors are to be appointed. If any person appointed as inspector fails to appear or fails or refuses to act, the Chairman of the meeting may, and upon the request of any stockholder or a stockholders proxy shall, appoint a person to fill that vacancy.
2.14 Action Without Meeting by Written Consent . All actions required to be taken at any annual or special meeting may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the Corporation by delivery to its registered office, its principal place of business, or an officer or agent of the corporation having custody of the book in which proceedings of meetings or stockholders are recorded.
ARTICLE 3
Directors
3.1 Number; Qualifications . The authorized number of the directors shall be nine (9). The authorized number of directors may be amended from time to time by resolution of the Board. All directors shall be elected at the annual meeting or any special meeting of the stockholders, except as provided in Section 3.2 hereof, and each director so elected shall hold office until the next annual meeting or any special meeting or until his successor is elected and qualified or until his earlier resignation or removal. Directors need not be stockholders.
3.2 Resignation and Vacancies . A vacancy or vacancies in the Board shall be deemed to exist in the case of the death, resignation or removal of any director, or if the authorized number of directors is increased. Vacancies may be filled by a majority of the remaining directors, though less than a quorum, or by a sole remaining director, unless otherwise provided in the Certificate of Incorporation. The stockholders may elect a director or directors at any time to fill any vacancy or vacancies not filled by the directors. If the Board accepts the resignation of a director tendered to take effect at a future time, the Board shall have power to elect a successor to take office when the resignation is to become effective. If there are no directors in office, then an election of directors may be held in the manner provided by statute.
3.3 Removal of Directors . Unless otherwise restricted by statute, the Certificate of Incorporation or these Bylaws, any director or the entire Board may be removed, with or without cause, by the holders of at least a majority of the shares entitled to vote at an election of directors.
-4-
3.4 Powers . The business of the Corporation shall be managed by or under the direction of the Board which may exercise all such powers of the Corporation and do all such lawful acts and things which are not by statute or by the Certificate of Incorporation or by these Bylaws directed or required to be exercised or done by the stockholders.
3.5 Place of Meetings . The Board may hold meetings, both regular and special, either within or without the State of Delaware.
3.6 Annual Meetings . The annual meetings of the Board shall be held immediately following the annual meeting of stockholders, and no notice of such meeting shall be necessary to the Board, provided a quorum shall be present. The annual meetings shall be for the purposes of organization, and an election of officers and the transaction of other business.
3.7 Regular Meetings . Regular meetings of the Board may be held without notice at such time and place as may be determined from time to time by the Board.
3.8 Special Meetings . Special meetings of the Board may be called by the Chairman of the Board, the President, a Vice President or a majority of the Board upon one (1) days notice to each director.
3.9 Quorum and Adjournments . At all meetings of the Board, a majority of the directors then in office shall constitute a quorum for the transaction of business, and the act of a majority of the directors present at any meeting at which there is a quorum shall be the act of the Board, except as may otherwise be specifically provided by law or the Certificate of Incorporation. If a quorum is not present at any meeting of the Board, the directors present may adjourn the meeting from time to time, without notice other than announcement at the meeting at which the adjournment is taken, until a quorum shall be present. A meeting at which a quorum is initially present may continue to transact business notwithstanding the withdrawal of directors, if any action taken is approved of by at least a majority of the required quorum for that meeting.
3.10 Action Without Meeting . Unless otherwise restricted by the Certificate of Incorporation or these Bylaws, any action required or permitted to be taken at any meeting of the Board or of any committee thereof may be taken without a meeting, if all members of the Board or committee, as the case may be, consent thereto in writing, and the writing or writings are filed with the minutes of proceedings of the Board or committee.
3.11 Telephone Meetings . Unless otherwise restricted by the Certificate of Incorporation or these Bylaws, any member of the Board or any committee may participate in a meeting by means of conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and such participation in a meeting shall constitute presence in person at the meeting.
3.12 Waiver of Notice . Notice of a meeting need not be given to any director who signs a waiver of notice or a consent to holding the meeting or an approval of the minutes thereof, whether before or after the meeting, or who attends the meeting without protesting, prior thereto or at its commencement, the lack of notice to such director. All such waivers, consents and approvals shall be filed with the corporate records or made a part of the minutes of the meeting.
-5-
3.13 Fees and Compensation of Directors . Unless otherwise restricted by the Certificate of Incorporation or these Bylaws, the Board shall have the authority to fix the compensation of directors. The directors may be paid their expenses, if any, of attendance at each meeting of the Board and may be paid a fixed sum for attendance at each meeting of the Board or a stated salary as director. No such payment shall preclude any director from serving the Corporation in any other capacity and receiving compensation therefor. Members of special or standing committees may be allowed like compensation for attending committee meetings.
3.14 Rights of Inspection . Every director shall have the absolute right at any reasonable time to inspect and copy all books, records and documents of every kind and to inspect the physical properties of the Corporation and also of its subsidiary corporations, domestic or foreign. Such inspection by a director may be made in person or by agent or attorney and includes the right to copy and obtain extracts.
ARTICLE 4
Committees of Directors
4.1 Selection . The Board may, by resolution passed by a majority of the entire Board, designate one or more committees, each committee to consist of one or more of the directors of the Corporation. The Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee.
In the absence or disqualification of a member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not he or she or they constitute a quorum, may unanimously appoint another member of the Board to act at the meeting in the place of any such absent or disqualified member.
4.2 Power . Any such committee, to the extent provided in the resolution of the Board, shall have and may exercise all the powers and authority of the Board in the management of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers which may require it; but no such committee shall have the power or authority in reference to amending the Certificate of Incorporation (except that a committee may, to the extent authorized in the resolution or resolutions providing for the issuance of shares of stock adopted by the Board as provided in Section 151(a) of the General Corporation Law of Delaware, fix any of the preferences or rights of such shares relating to dividends, redemption, dissolution, any distribution of assets of the Corporation or the conversion into, or the exchange of such shares for, shares of any other class or classes or any other series of the same or any other class or classes of stock of the Corporation), adopting an agreement of merger or consolidation, recommending to the stockholders the sale, lease or exchange of all or substantially all of the Corporations property and assets, recommending to the stockholders a dissolution of the Corporation or a revocation of dissolution, removing or indemnifying directors or amending the Bylaws of the Corporation; and, unless the resolution or the Certificate of Incorporation expressly so provides, no such committee shall have the power or authority to declare a dividend or to authorize the issuance of stock or to adopt a certificate of ownership and
-6-
merger. Such committee or committees shall have such name or names as may be determined from time to time by resolution adopted by the Board.
4.3 Committee Minutes . Each committee shall keep regular minutes of its meetings and report the same to the Board when required.
ARTICLE 5
Officers
5.1 Officers Designated . The officers of the Corporation shall be chosen by the Board and shall be a President, a Secretary and a Treasurer. The Board may also choose a Chairman of the Board, one or more Vice Presidents, and one or more assistant Secretaries and assistant Treasurers. Any number of offices may be held by the same person, unless the Certificate of Incorporation or these Bylaws otherwise provide.
5.2 Appointment of Officers . The Board at its first meeting after each annual meeting of stockholders shall choose a Chief Executive Officer, a President, a Secretary and a Chief Financial Officer or Treasurer. Other officers may be appointed by the Board of Directors at such meeting, at any other meeting, or by written consent or may be appointed by the Chief Executive Officer pursuant to a delegation of authority from the Board.
5.3 Subordinate Officers . The Board may appoint, and may empower the President to appoint, such other officers and agents as the business of the Corporation may require, each of whom shall hold office for such period, have such authority and perform such duties as are provided in the Bylaws or as the Board may from time to time determine.
5.4 Removal and Resignation of Officers . Subject to the rights, if any, of an officer under any contract of employment, any officer may be removed, either with or without cause, by an affirmative vote of the majority of the Board, at any regular or special meeting of the Board, or, except in case of an officer chosen by the Board, by any officer upon whom such power of removal may be conferred by the Board.
Any officer may resign at any time by giving written notice to the Corporation. Any resignation shall take effect at the date of the receipt of that notice or at any later time specified in that notice; and, unless otherwise specified in that notice, the acceptance of the resignation shall not be necessary to make it effective. Any resignation is without prejudice to the rights, if any, of the Corporation under any contract to which the officer is a party.
5.5 Vacancies in Offices . A vacancy in any office because of death, resignation, removal, disqualification or any other cause shall be filled in the manner prescribed in these Bylaws for regular appointment to that office.
5.6 Compensation . The salaries of all officers of the Corporation shall be fixed from time to time by the Board and no officer shall be prevented from receiving a salary because he is also a director of the Corporation.
-7-
5.7 The Chairman of the Board . The Chairman of the Board, if such an officer were elected, shall, if present, perform such other powers and duties as may be assigned to him from time to time by the Board. If there is no President, the Chairman of the Board shall also be the Chief Executive Officer of the Corporation and shall have the powers and duties prescribed in Section 5.8 hereof.
5.8 The President . Subject to such supervisory powers, if any, as may be given by the Board to the Chairman of the Board, if there be such an officer, the President shall be the Chief Executive Officer of the Corporation, shall preside at all meetings of the stockholders and in the absence of the Chairman of the Board, or if there be none, at all meetings of the Board, shall have general and active management of the business of the Corporation and shall see that all orders and resolutions of the Board are carried into effect. He or she shall execute bonds, mortgages and other contracts requiring a seal, under the seal of the Corporation, except where required or permitted by law to be otherwise signed and executed and except where the signing and execution thereof shall be expressly delegated by the Board to some other officer or agent of the Corporation.
5.9 The Vice President . The Vice President (or in the event there be more than one, the Vice Presidents in the order designated by the directors, or in the absence of any designation, in the order of their election), shall, in the absence of the President or in the event of his disability or refusal to act, perform the duties of the President, and when so acting, shall have the powers of and subject to all the restrictions upon the President. The Vice President(s) shall perform such other duties and have such other powers as may from time to time be prescribed for them by the Board, the President, the Chairman of the Board or these Bylaws.
5.10 The Secretary . The Secretary shall attend all meetings of the Board and the stockholders and record all votes and the proceedings of the meetings in a book to be kept for that purpose and shall perform like duties for the standing committees, when required. The Secretary shall give, or cause to be given, notice of all meetings of stockholders and special meetings of the Board, and shall perform such other duties as may from time to time be prescribed by the Board, the Chairman of the Board or the President, under whose supervision he or she shall act. The Secretary shall have custody of the seal of the Corporation, and the Secretary, or an Assistant Secretary, shall have authority to affix the same to any instrument requiring it, and, when so affixed, the seal may be attested by his or her signature or by the signature of such Assistant Secretary. The Board may give general authority to any other officer to affix the seal of the Corporation and to attest the affixing thereof by his or her signature. The Secretary shall keep, or cause to be kept, at the principal executive office or at the office of the Corporations transfer agent or registrar, as determined by resolution of the Board, a share register, or a duplicate share register, showing the names of all stockholders and their addresses, the number and classes of shares held by each, the number and date of certificates issued for the same and the number and date of cancellation of every certificate surrendered for cancellation.
5.11 The Assistant Secretary . The Assistant Secretary, or if there be more than one, the Assistant Secretaries in the order designated by the Board (or in the absence of any designation, in the order of their election) shall, in the absence of the Secretary or in the event of his or her inability or refusal to act, perform the duties and exercise the powers of the Secretary
-8-
and shall perform such other duties and have such other powers as may from time to time be prescribed by the Board.
5.12 The Treasurer . The Treasurer shall have the custody of the Corporate funds and securities and shall keep full and accurate accounts of receipts and disbursements in books belonging to the Corporation and shall deposit all moneys and other valuable effects in the name and to the credit of the Corporation in such depositories as may be designated by the Board. The Treasurer shall disburse the funds of the Corporation as may be ordered by the Board, taking proper vouchers for such disbursements, and shall render to the President and the Board, at its regular meetings, or when the Board so requires, an account of all his or her transactions as Treasurer and of the financial condition of the Corporation.
5.13 The Assistant Treasurer . The Assistant Treasurer, or if there shall be more than one, the Assistant Treasurers in the order designated by the Board (or in the absence of any designation, in the order of their election) shall, in the absence of the Treasurer or in the event of his or her inability or refusal to act, perform the duties and exercise the powers of the Treasurer and shall perform such other duties and have such other powers as may from time to time be prescribed by the Board.
ARTICLE 6
Indemnification of Directors, Officers,
Employees and Other Agents
6.1 Indemnification of Directors And Officers . The corporation shall, to the maximum extent and in the manner permitted by the General Corporation Law of Delaware, indemnify each of its directors and officers against expenses (including attorneys fees), judgments, fines, settlements and other amounts actually and reasonably incurred in connection with any proceeding, arising by reason of the fact that such person is or was an agent of the corporation. For purposes of this Section 6.1, a director or officer of the corporation includes any person (i) who is or was a director or officer of the corporation, (ii) who is or was serving at the request of the corporation as a director or officer of another corporation, partnership, joint venture, trust or other enterprise, or (iii) who was a director or officer of a corporation which was a predecessor corporation of the corporation or of another enterprise at the request of such predecessor corporation.
6.2 Indemnification of Others . The corporation shall have the power, to the maximum extent and in the manner permitted by the General Corporation Law of Delaware, to indemnify each of its employees and agents (other than directors and officers) against expenses (including attorneys fees), judgments, fines, settlements and other amounts actually and reasonably incurred in connection with any proceeding, arising by reason of the fact that such person is or was an agent of the corporation. For purposes of this Section 6.2, an employee or agent of the corporation (other than a director or officer) includes any person (i) who is or was an employee or agent of the corporation, (ii) who is or was serving at the request of the corporation as an employee or agent of another corporation, partnership, joint venture, trust or other enterprise, or (iii) who was an employee or agent of a corporation which was a predecessor
-9-
corporation of the corporation or of another enterprise at the request of such predecessor corporation.
6.3 Payment Of Expenses In Advance . Expenses incurred in defending any action or proceeding for which indemnification is required pursuant to Section 6.1 hereof or for which indemnification is permitted pursuant to Section 6.2 hereof following authorization thereof by the Board of Directors shall be paid by the corporation in advance of the final disposition of such action or proceeding upon receipt of an undertaking by or on behalf of the indemnified party to repay such amount if it shall ultimately be determined that the indemnified party is not entitled to be indemnified as authorized in this Article 6.
6.4 Indemnity Not Exclusive . The indemnification provided by this Article 6 shall not be deemed exclusive of any other rights to which those seeking indemnification may be entitled under any bylaw, agreement, vote of shareholders or disinterested directors or otherwise, both as to action in an official capacity and as to action in another capacity while holding such office, to the extent that such additional rights to indemnification are authorized in the certificate of incorporation.
6.5 Insurance . The corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against him or her and incurred by him or her in any such capacity, or arising out of his or her status as such, whether or not the corporation would have the power to indemnify him or her against such liability under the provisions of the General Corporation Law of Delaware.
6.6 Conflicts . No indemnification or advance shall be made under this Article 6, except where such indemnification or advance is mandated by law or the order, judgment or decree of any court of competent jurisdiction, in any circumstance where it appears:
(a) That it would be inconsistent with a provision of the certificate of incorporation, these Bylaws, a resolution of the stockholders or an agreement in effect at the time of the accrual of the alleged cause of the action asserted in the proceeding in which the expenses were incurred or other amounts were paid, which prohibits or otherwise limits indemnification; or
(b) That it would be inconsistent with any condition expressly imposed by a court in approving a settlement.
ARTICLE 7
Stock Certificates
7.1 Certificates for Shares . The shares of the Corporation shall be represented by certificates or shall be uncertificated. Certificates shall be signed by or in the name of the Corporation by, the Chairman of the Board, or the President or a Vice President and by the Treasurer or an Assistant Treasurer, or the Secretary or an Assistant Secretary of the Corporation.
-10-
Within a reasonable time after the issuance or transfer of uncertified stock, the Corporation shall send to the registered owner thereof a written notice containing the information required by the General Corporation Law of the State of Delaware or a statement that the Corporation will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights.
7.2 Signatures on Certificates . Any or all of the signatures on a certificate may be a facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if he were such officer, transfer agent or registrar at the date of issue.
7.3 Transfer of Stock . Upon surrender to the Corporation or the transfer agent of the Corporation of a certificate of shares duly endorsed or accompanied by proper evidence of succession, assignation or authority to transfer, it shall be the duty of the Corporation to issue a new certificate to the person entitled thereto, cancel the old certificate and record the transaction upon its books. Upon receipt of proper transfer instructions from the registered owner of uncertificated shares, such uncertificated shares shall be canceled and issuance of new equivalent uncertificated shares or certificated shares shall be made to the person entitled thereto and the transaction shall be recorded upon the books of the Corporation.
7.4 Registered Stockholders . The Corporation shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends, and to vote as such owner, and to hold liable for calls and assessments a percent registered on its books as the owner of shares, and shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any other person, whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of Delaware.
7.5 Record Date . In order that the Corporation may determine the stockholders of record who are entitled to receive notice of, or to vote at, any meeting of stockholders or any adjournment thereof or to express consent to corporate action in writing without a meeting, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or to exercise any rights in respect of any change, conversion, or exchange of stock or for the purpose of any lawful action, the Board may fix, in advance, a record date which shall not be more than sixty (60) nor less than ten (10) days prior to the date of such meeting, nor more than sixty (60) days prior to the date of any other action. A determination of stockholders of record entitled to notice or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board may fix a new record date for the adjourned meeting.
7.6 Lost, Stolen or Destroyed Certificates . The Board may direct that a new certificate or certificates be issued to replace any certificate or certificates theretofore issued by the Corporation alleged to have been lost, stolen or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost, stolen or destroyed. When authorizing the issue of a new certificate or certificates, the Board may, in its discretion and as a condition precedent to the issuance thereof, require the owner of the lost, stolen or destroyed
-11-
certificate or certificates, or his or her legal representative, to advertise the same in such manner as it shall require, and/or to give the Corporation a bond in such sum as it may direct as indemnity against any claim that may be made against the Corporation with respect to the certificate alleged to have been lost, stolen or destroyed.
ARTICLE 8
Notices
8.1 Notice . Whenever, under the provisions of the statutes or of the Certificate of Incorporation or of these Bylaws, notice is required to be given to any director or stockholder it shall not be construed to mean personal notice, but such notice may be given in writing, by mail, addressed to such director or stockholder, at his or her address as it appears on the records of the Corporation, with postage thereon prepaid, and such notice shall be deemed to be given at the time when the same shall be deposited in the United States mail. Notice to directors may also be given by telegram or telephone.
8.2 Waiver . Whenever any notice is required to be given under the provisions of the statutes or of the Certificate of Incorporation or of these Bylaws, a waiver thereof in writing, signed by the person or persons entitled to said notice, whether before or after the time stated therein, shall be deemed equivalent thereto.
ARTICLE 9
General Provisions
9.1 Dividends . Dividends upon the capital stock of the Corporation, subject to any restrictions contained in the General Corporation Laws of Delaware or the provisions of the Certificate of Incorporation, if any, may be declared by the Board at any regular or special meeting. Dividends may be paid in cash, in property or in shares of the capital stock, subject to the provisions of the Certificate of Incorporation.
9.2 Dividend Reserve . Before payment of any dividend, there may be set aside out of any funds of the Corporation available for dividends such sum or sums as the directors from time to time, in their absolute discretion, think proper as a reserve or reserves to meet contingencies, or for equalizing dividends, or for repairing or maintaining any property of the Corporation, or for such other purpose as the directors shall think conducive to the interest of the Corporation, and the directors may modify or abolish any such reserve in the manner in which it was created.
9.3 Annual Statement . The Board shall present at each annual meeting and at any special meeting of the stockholders when called for by vote of the stockholders, a full and clear statement of the business and condition of the Corporation.
9.4 Checks . All checks or demands for money and notes of the Corporation shall be signed by such officer or officers or such other person or persons as the Board may from time to time designate.
-12-
9.5 Corporate Seal . The Board may provide a suitable seal, containing the name of the Corporation, which seal shall be in charge of the Secretary. If and when so directed by the Board or a committee thereof, duplicates of the seal may be kept and used by the Treasurer or by an Assistant Secretary or Assistant Treasurer.
9.6 Execution of Corporate Contracts and Instruments . The Board, except as otherwise provided in these Bylaws, may authorize any officer or officers, or agent or agents, to enter into any contract or execute any instrument in the name of and on behalf of the Corporation; such authority may be general or confined to specific instances. Unless so authorized or ratified by the Board or within the agency power of an officer, no officer, agent or employee shall have any power or authority to bind the Corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any amount.
ARTICLE 10
Amendments
In addition to the right of the stockholders of the corporation to make, alter, amend, change, add to or repeal the bylaws of the corporation, the Board of Directors shall have the power (without the assent or vote of the stockholders) to make, alter, amend, change, add to or repeal the bylaws of the corporation.
-13-
CERTIFICATE OF SECRETARY
I, the undersigned, hereby certify:
1. That I am a duly elected, acting and qualified Secretary of Genomic Health, Inc., a Delaware corporation; and
2. That the foregoing Bylaws is a full, true and correct copy of the Bylaws of the corporation with all amendments to date of this Certificate.
3. That effective as of the date hereof, Section 3.1 under Article 3 of the Bylaws of the Company was amended to read as follows:
The authorized number of the directors shall be nine (9). The authorized number of directors may be amended from time to time by resolution of the Board.
IN WITNESS WHEREOF, I have hereunto subscribed my name as of the 13th day of December 2004.
|
/s/ Randal W. Scott | |
|
||
|
Randal W. Scott | |
|
Secretary |
-14-
Exhibit 3.5
AMENDED AND RESTATED
B Y L A W S
OF
GENOMIC HEALTH, INC.
(a Delaware corporation)
TABLE OF CONTENTS
Page | ||||||
ARTICLE 1 Offices | 1 | |||||
1.1
|
Registered Office | 1 | ||||
1.2
|
Other Offices | 1 | ||||
|
||||||
ARTICLE 2 Meeting of Stockholders | 1 | |||||
|
||||||
2.1
|
Place of Meeting | 1 | ||||
2.2
|
Annual Meeting | 1 | ||||
2.3
|
Special Meetings | 2 | ||||
2.4
|
Notice of Meetings | 3 | ||||
2.5
|
List of Stockholders | 3 | ||||
2.6
|
Organization and Conduct of Business | 3 | ||||
2.7
|
Quorum | 3 | ||||
2.8
|
Adjournments | 4 | ||||
2.9
|
Voting Rights | 4 | ||||
2.10
|
Majority Vote | 4 | ||||
2.11
|
Record Date for Stockholder Notice and Voting | 4 | ||||
2.12
|
Proxies | 4 | ||||
2.13
|
Inspectors of Election | 5 | ||||
2.14
|
Action Without a Meeting | 5 | ||||
|
||||||
ARTICLE 3 Directors | 5 | |||||
|
||||||
3.1
|
Number, Election, Tenure and Qualifications | 5 | ||||
3.2
|
Enlargement and Vacancies | 6 | ||||
3.3
|
Resignation and Removal | 6 | ||||
3.4
|
Powers | 7 | ||||
3.5
|
Chairman of the Board | 7 | ||||
3.6
|
Place of Meetings | 7 | ||||
3.7
|
Annual Meetings | 7 | ||||
3.8
|
Regular Meetings | 7 | ||||
3.9
|
Special Meetings | 7 | ||||
3.10
|
Quorum, Action at Meeting, Adjournments | 7 | ||||
3.11
|
Action Without Meeting | 8 | ||||
3.12
|
Telephone Meetings | 8 | ||||
3.13
|
Committees | 8 | ||||
3.14
|
Fees and Compensation of Directors | 8 | ||||
|
||||||
ARTICLE 4 Officers | 9 | |||||
|
||||||
4.1
|
Officers Designated | 9 | ||||
4.2
|
Election | 9 | ||||
4.3
|
Tenure | 9 | ||||
4.4
|
The Chief Executive Officer | 9 |
i
TABLE OF CONTENTS
(continued)
Page | ||||||
4.5
|
The President | 9 | ||||
4.6
|
The Vice President | 10 | ||||
4.7
|
The Secretary | 10 | ||||
4.8
|
The Assistant Secretary | 10 | ||||
4.9
|
The Chief Financial Officer | 10 | ||||
4.10
|
The Treasurer and Assistant Treasurers | 11 | ||||
4.11
|
Bond | 11 | ||||
4.12
|
Delegation of Authority | 11 | ||||
|
||||||
ARTICLE 5 Notices | 11 | |||||
|
||||||
5.1
|
Delivery | 11 | ||||
5.2
|
Waiver of Notice | 11 | ||||
|
||||||
ARTICLE 6 Indemnification and Insurance | 12 | |||||
|
||||||
6.1
|
Indemnification | 12 | ||||
6.2
|
Advance Payment | 13 | ||||
6.3
|
Non-Exclusivity and Survival of Rights; Amendments | 14 | ||||
6.4
|
Insurance | 14 | ||||
6.5
|
Severability | 14 | ||||
6.6
|
Definitions | 15 | ||||
6.7
|
Notices | 16 | ||||
|
||||||
ARTICLE 7 Capital Stock | 16 | |||||
|
||||||
7.1
|
Certificates for Shares | 16 | ||||
7.2
|
Signatures on Certificates | 17 | ||||
7.3
|
Transfer of Stock | 17 | ||||
7.4
|
Registered Stockholders | 17 | ||||
7.5
|
Lost, Stolen or Destroyed Certificates | 17 | ||||
|
||||||
ARTICLE 8 Certain Transactions | 18 | |||||
|
||||||
8.1
|
Transactions with Interested Parties | 18 | ||||
8.2
|
Quorum | 18 | ||||
|
||||||
ARTICLE 9 General Provisions | 18 | |||||
|
||||||
9.1
|
Dividends | 18 | ||||
9.2
|
Dividend Reserve | 18 | ||||
9.3
|
Checks | 19 | ||||
9.4
|
Corporate Seal | 19 | ||||
9.5
|
Execution of Corporate Contracts and Instruments | 19 | ||||
9.6
|
Representation of Shares of Other Corporations | 19 |
-ii-
TABLE OF CONTENTS
(continued)
Page | ||||||
ARTICLE 10 Amendments | 19 |
-iii-
AMENDED AND RESTATED
B Y L A W S
OF
GENOMIC HEALTH, INC.
(a Delaware corporation)
ARTICLE 1
Offices
1.1 Registered Office . The registered office of the corporation shall be set forth in the certificate of incorporation of the corporation.
1.2 Other Offices . The corporation may also have offices at such other places, either within or without the State of Delaware, as the board of directors of the corporation (the Board) may from time to time designate or the business of the corporation may require.
ARTICLE 2
Meeting of Stockholders
2.1 Place of Meeting . Meetings of stockholders may be held at such place, either within or without of the State of Delaware, as may be designated by or in the manner provided in these bylaws, or, if not so designated, at the registered office of the corporation or the principal executive offices of the corporation.
2.2 Annual Meeting . Annual meetings of stockholders shall be held each year at such date and time as shall be designated from time to time by the Board or the Chief Executive Officer and stated in the notice of the meeting. At each such annual meeting, the stockholders shall elect by a plurality vote the Board. The stockholders shall also transact such other business as may properly be brought before the meeting.
To be properly brought before the annual meeting, business must be (a) specified in the notice of meeting (or any supplement thereto) given by or at the direction of the Board or the Chief Executive Officer, (b) otherwise properly brought before the meeting by or at the direction of the Board or the Chief Executive Officer, or (c) otherwise properly brought before the meeting by a stockholder of record. A motion related to business proposed to be brought before any stockholders meeting may be made by any stockholder entitled to vote if the business proposed is otherwise proper to be brought before the meeting. However, any such stockholder may propose business to be brought before a meeting only if such stockholder has given timely notice to the Secretary of the corporation in proper written form of the stockholders intent to propose such business. To be timely, the stockholders notice must be delivered by a nationally recognized courier service or mailed by first class United States mail, postage or delivery charges prepaid, and received at the principal executive offices of the corporation addressed to
-1-
the attention of the Secretary of the corporation not earlier than ninety (90) days nor more than one hundred twenty (120) days in advance of the date the corporations proxy statement was released to the stockholders in connection with the previous years annual meeting of stockholders; provided, however , that in the event that no annual meeting was held in the previous year or the date of the annual meeting has been changed by more than thirty (30) days from the date contemplated at the time of the previous years proxy statement, notice by the stockholder must be received by the Secretary of the corporation not later than the close of business on the later of (x) the ninetieth (90th) day prior to such annual meeting and (y) the seventh (7th) days following the day on which public announcement of the date of such meeting is first made. For the purposes of these bylaws, public announcement shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or a comparable national news service or in a document publicly filed by the corporation with the Securities and Exchange Commission. In no event shall the public announcement of an adjournment or postponement of an annual meeting commence a new time period (or extend any time period) for the giving of stockholders notice as described above. A stockholders notice to the Secretary shall set forth as to each matter the stockholder proposes to bring before the annual meeting (i) a brief description of the business desired to be brought before the annual meeting, the text of the proposal or business (including the text of any resolutions proposed for consideration and in the event that such business includes a proposal to amend the Bylaws of the Corporation, the language of the proposed amendment), and the reasons for conducting such business at the annual meeting, (ii) the name and record address of the stockholder proposing such business and the beneficial owner, if any, on whose behalf the proposal is made, (iii) the class, series and number of shares of the corporation that are owned beneficially and of record by the stockholder and such beneficial owner, (iv) any material interest of the stockholder in such business, and (v) any other information that is required to be provided by the stockholder pursuant to Section 14 of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder (collectively, the 1934 Act) in such stockholders capacity as a proponent of a stockholder proposal.
Notwithstanding anything in these bylaws to the contrary, no business shall be conducted at the annual meeting except in accordance with the procedures set forth in this Section; provided, however , that nothing in this Section shall be deemed to preclude discussion by any stockholder of any business properly brought before the annual meeting.
The Chairman of the Board (or such other person presiding at the meeting in accordance with these bylaws) shall, if the facts warrant, determine and declare to the meeting that business was not properly brought before the meeting in accordance with the provisions of this Section, and if he or she should so determine, he or she shall so declare to the meeting and any such business not properly brought before the meeting shall not be transacted.
2.3 Special Meetings . Special meetings of the stockholders may be called for any purpose or purposes, unless otherwise prescribed by statute or by the certificate of incorporation, by the Secretary only at the request of the Chairman of the Board, the Chief Executive Officer or by a resolution duly adopted by the affirmative vote of a majority of the Board. Such request shall state the purpose or purposes of the proposed meeting. Business transacted at any special meeting shall be limited to matters relating to the purpose or purposes stated in the notice of meeting.
-2-
2.4 Notice of Meetings . Except as otherwise provided by law, written notice of each meeting of stockholders, annual or special, stating the place, if any, date and time of the meeting, the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting, and, in the case of a special meeting, the purpose or purposes for which such special meeting is called, shall be given to each stockholder entitled to vote at such meeting not less than ten (10) nor more than sixty (60) days before the date of the meeting.
When a meeting is adjourned to another place, date or time, notice need not be given of the adjourned meeting if the place, date and time thereof are announced at the meeting at which the adjournment is taken; provided, however , that if the date of any adjourned meeting is more than thirty (30) days after the date for which the meeting was originally noticed, or if a new record date is fixed for the adjourned meeting, written notice of the place, if any, date, time and means of remote communications, if any, of the adjourned meeting shall be given in conformity herewith. At any adjourned meeting, any business may be transacted that might have been transacted at the original meeting.
2.5 List of Stockholders . The officer in charge of the stock ledger of the corporation or the transfer agent shall prepare and make, at least ten (10) days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, for a period of at least ten days prior to the meeting, (i) on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (ii) during ordinary business hours, at the principal place of business of the corporation. If the meeting is to be held at a place, then the list shall also be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder who is present. If the meeting is to be held solely by means of remote communication, then the list shall also be open to the examination of any stockholder during the whole time of the meeting on a reasonably accessible electronic network, and the information required to gain access to such list shall be provided with the notice of the meeting.
2.6 Organization and Conduct of Business . The Chairman of the Board or, in his or her absence, the Chief Executive Officer or President of the corporation or, in their absence, such person as the Board may have designated or, in the absence of such a person, such person as may be chosen by the holders of a majority of the shares entitled to vote who are present, in person or by proxy, shall call to order any meeting of the stockholders and act as chairman of the meeting. In the absence of the Secretary of the corporation, the secretary of the meeting shall be such person as the chairman of the meeting appoints.
The chairman of any meeting of stockholders shall determine the order of business and the procedure at the meeting, including such regulation of the manner of voting and the conduct of discussion as seems to him or her in order.
2.7 Quorum . Except where otherwise provided by law or the certificate of incorporation of the corporation or these bylaws, the holders of a majority of the stock issued and
-3-
outstanding and entitled to vote, present in person or represented in proxy, shall constitute a quorum at all meetings of the stockholders.
2.8 Adjournments . Any meeting of stockholders may be adjourned from time to time to any other time and to any other place at which a meeting of stockholders may be held under these bylaws, which time and place shall be announced at the meeting, by a majority of the stockholders present in person or represented by proxy at the meeting and entitled to vote, though less than a quorum, or, if no stockholder is present or represented by proxy, by any officer entitled to preside at or to act as secretary of such meeting, without notice other than announcement at the meeting, until a quorum shall be present or represented. At such adjourned meeting at which a quorum shall be present or represented, any business may be transacted which might have been transacted at the original meeting. If the adjournment is for more than thirty days, or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.
2.9 Voting Rights . Unless otherwise provided in the certificate of incorporation of the corporation, each stockholder shall at every meeting of the stockholders be entitled to one vote for each share of the capital stock having voting power held by such stockholder.
2.10 Majority Vote . When a quorum is present at any meeting, the vote of the holders of a majority of the stock having voting power present in person or represented by proxy shall decide any question brought before such meeting, unless the question is one upon which by express provision of the statutes or of the certificate of incorporation of the corporation or of these bylaws, a different vote is required in which case such express provision shall govern and control the decision of such question.
2.11 Record Date for Stockholder Notice and Voting . For purposes of determining the stockholders entitled to notice of, or to vote at, any meeting of stockholders or any adjournment thereof, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any right in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board may fix, in advance, a record date, which shall not be more than sixty (60) days nor fewer than ten (10) days before the date of any such meeting nor more than sixty (60) days before any other action to which the record date relates. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however , that the Board may fix a new record date for the adjourned meeting. If the Board does not so fix a record date, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the business day next preceding the day on which notice is given or, if notice is waived, at the close of business on the business day next preceding the day on which the meeting is held. The record date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board adopts the resolution relating to such purpose.
2.12 Proxies . Each stockholder entitled to vote at a meeting of stockholders may authorize another person or persons to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer
-4-
period. All proxies must be filed with the Secretary of the corporation at the beginning of each meeting in order to be counted in any vote at the meeting. Subject to the limitation set forth in the last clause of the first sentence of this Section 2.12, a duly executed proxy that does not state that it is irrevocable shall continue in full force and effect unless (i) revoked by the person executing it, before the vote pursuant to that proxy, by a writing delivered to the corporation stating that the proxy is revoked or by a subsequent proxy executed by, or attendance at the meeting and voting in person by, the person executing the proxy, or (ii) written notice of the death or incapacity of the maker of that proxy is received by the corporation before the vote pursuant to that proxy is counted.
2.13 Inspectors of Election . The corporation shall, in advance of any meeting of stockholders, appoint one or more inspectors of election to act at the meeting and make a written report thereof. The corporation may designate one or more persons to act as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders, the person presiding at the meeting shall appoint one or more inspectors to act at the meeting. Each inspector, before entering upon the discharge of his or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of his or her ability.
2.14 Action Without a Meeting . No action required or permitted to be taken at any annual or special meeting of the stockholders of the corporation may be taken without a meeting and the power of the stockholders to consent in writing, without a meeting, to the taking of any action is specifically denied.
ARTICLE 3
Directors
3.1 Number, Election, Tenure and Qualifications . The authorized number of directors shall be determined from time to time by resolution adopted by the Board, provided the Board shall consist of at least one member. No decrease in the number of authorized directors shall have the effect of removing any director before that directors term of office expires.
At each annual meeting of the stockholders, the directors shall be elected, except as otherwise provided in Section 3.2, and each director so elected shall hold office until such directors successor is duly elected and qualified or until such directors earlier resignation, removal, death or incapacity.
Subject to the rights of holders of any class or series of stock having a preference over the common stock as to dividends or upon liquidation, nominations of persons for election to the Board, by or at the direction of the Board may be made by any nominating committee or person appointed by the Board; nominations may also be made by any stockholder of record of the corporation entitled to vote for the election of directors at the applicable meeting who complies with the notice procedures set forth in this Section. Such nominations, other than those made by or at the direction of the Board, shall be made pursuant to timely notice in writing to the Secretary of the corporation. To be timely, a stockholders notice shall be delivered by a nationally recognized courier service or mailed by first class United States mail, postage or
-5-
delivery charges prepaid, and received at the principal executive offices of the corporation addressed to the attention of the Secretary of the corporation not earlier than ninety (90) days nor more than one hundred twenty (120) days in advance of the date the corporations proxy statement was released to the stockholders in connection with the previous years annual meeting of stockholders; provided, however , that in the event that no annual meeting was held in the previous year or the date of the annual meeting has been changed by more than thirty (30) days from the date contemplated at the time of the previous years proxy statement, notice by the stockholder must be received by the Secretary of the corporation not later than the close of business on the later of (x) the ninetieth (90th) day prior to such annual meeting and (y) the seventh (7th) day following the day on which public announcement of the date of such meeting is first made. Such stockholders notice to the Secretary shall set forth (a) as to each person whom the stockholder proposes to nominate for election or reelection as a director, (i) the name, age, business address and residence address of the person, (ii) the principal occupation or employment of the person, (iii) the class, series and number of shares of capital stock of the corporation that are owned beneficially by the person, (iv) a statement as to the persons citizenship, and (v) any other information relating to the person that is required to be disclosed in solicitations for proxies for election of directors pursuant to Section 14 of the 1934 Act, and (b) as to the stockholder giving the notice, (i) the name and record address of the stockholder and (ii) the class, series and number of shares of capital stock of the corporation that are owned beneficially by the stockholder. The corporation may require any proposed nominee to furnish such other information as may reasonably be required by the corporation to determine the eligibility of such proposed nominee to serve as director of the corporation. No person shall be eligible for election as a director of the corporation unless nominated in accordance with the procedures set forth herein.
In connection with any annual meeting of the stockholders (or, if and as applicable, any special meeting of the stockholders), the Chairman of the Board (or such other person presiding at such meeting in accordance with these bylaws) shall, if the facts warrant, determine and declare to the meeting that a nomination was not made in accordance with the foregoing procedure, and if he or she should so determine, he or she shall so declare to the meeting and the defective nomination shall be disregarded.
3.2 Enlargement and Vacancies . The number of members of the Board may be enlarged at any time as provided in Section 3.1 above. Sole power to fill vacancies and newly created directorships resulting from any increase in the authorized number of directors shall be vested in the Board through action by a majority of the directors then in office, though less than a quorum, or by a sole remaining director, and each director so chosen shall hold office until the next annual election and until such directors successor is duly elected and qualified or until such directors earlier resignation, removal from office, death or incapacity. If there are no directors in office, then an election of directors may be held in the manner provided by statute. In the event of a vacancy in the Board, the remaining directors, except as otherwise provided by law or these bylaws, may exercise the powers of the full board until the vacancy is filled.
3.3 Resignation and Removal . Any director may resign at any time upon written notice to the corporation at its principal place of business or to the Chief Executive Officer or the Secretary. Such resignation shall be effective upon receipt of such notice unless the notice specifies such resignation to be effective at some other time or upon the happening of some other
-6-
event. Any director or the entire Board may be removed, but only for cause, by the holders of a majority of the shares then entitled to vote at an election of directors, unless otherwise specified by law or the certificate of incorporation of the corporation.
3.4 Powers . The business of the corporation shall be managed by or under the direction of the Board, which may exercise all such powers of the corporation and do all such lawful acts and things as are not by statute or by the certificate of incorporation of the corporation or by these bylaws directed or required to be exercised or done by the stockholders.
3.5 Chairman of the Board . If the Board appoints a Chairman of the Board, such Chairman shall, when present, preside at all meetings of the stockholders and the Board. The Chairman shall perform such duties and possess such powers as are customarily vested in the office of the Chairman of the Board or as may be vested in the Chairman by the Board.
3.6 Place of Meetings . The Board may hold meetings, both regular and special, either within or without the State of Delaware.
3.7 Annual Meetings . The annual meetings of the Board shall be held immediately following the annual meeting of stockholders, and no notice of such meeting shall be necessary to the Board, provided a quorum shall be present. The annual meetings shall be for the purposes of organization, and an election of officers and the transaction of other business.
3.8 Regular Meetings . Regular meetings of the Board may be held without notice at such time and place as may be determined from time to time by the Board; provided that any director who is absent when such a determination is made shall be given prompt notice of such determination.
3.9 Special Meetings . Special meetings of the Board may be called by the Chairman of the Board, the Chief Executive Officer, the President or the Secretary, or on the written request of two or more directors, or by one director in the event that there is only one director in office. Notice of the time and place, if any, of special meetings shall be delivered personally or by telephone to each director, or sent by first-class mail or commercial delivery service, facsimile transmission, or by electronic mail or other electronic means, charges prepaid, sent to such directors business or home address as they appear upon the records of the corporation. In case such notice is mailed, it shall be deposited in the United States mail at least four (4) days prior to the time of holding of the meeting. In case such notice is delivered personally or by telephone or by commercial delivery service, facsimile transmission, or electronic mail or other electronic means, it shall be so delivered at least twenty-four (24) hours prior to the time of the holding of the meeting. A notice or waiver of notice of a meeting of the Board need not specify the purposes of the meeting.
3.10 Quorum, Action at Meeting, Adjournments . At all meetings of the Board, a majority of directors then in office, but in no event less than one-third (1/3) of the entire Board, shall constitute a quorum for the transaction of business and the act of a majority of the directors present at any meeting at which there is a quorum shall be the act of the Board, except as may be otherwise specifically provided by law or by the certificate of incorporation of the corporation. For purposes of this Section, the term entire Board shall mean the number of directors last
-7-
fixed by directors in accordance with these bylaws; provided, however , that if fewer than all the number of directors so fixed have been elected (by the stockholders or the Board), the entire Board shall mean the greatest number of directors so elected to hold office at any one time pursuant to such authorization. If a quorum shall not be present at any meeting of the board of directors, a majority of the directors present thereat may adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum shall be present.
3.11 Action Without Meeting . Unless otherwise restricted by the certificate of incorporation of the corporation or these bylaws, any action required or permitted to be taken at any meeting of the Board or of any committee thereof may be taken without a meeting, if all members of the Board or committee, as the case may be, consent thereto in writing or by electronic transmission, and the writing or writings or electronic transmission or transmissions are filed with the minutes of proceedings of the Board or committee.
3.12 Telephone Meetings . Unless otherwise restricted by the certificate of incorporation of the corporation or these bylaws, any member of the Board or any committee thereof may participate in a meeting of the Board or of any committee, as the case may be, by means of conference telephone or by any form of communications equipment by means of which all persons participating in the meeting can hear each other, and such participation in a meeting shall constitute presence in person at the meeting.
3.13 Committees . The Board may, by resolution passed by a majority of the whole Board, designate one or more committees, each committee to consist of one or more of the directors of the corporation. The Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of a committee, the member or members present at any meeting and not disqualified from voting, whether or not the member or members present constitute a quorum, may unanimously appoint another member of the Board to act at the meeting in the place of any such absent or disqualified member. Any such committee, to the extent provided in the resolution of the Board, shall have and may exercise all the powers and authority of the Board in the management of the business and affairs of the corporation, and may authorize the seal of the corporation to be affixed to all papers which may require it; but no such committee shall have the power or authority in reference to (i) approving or adopting, or recommending to the stockholders, any action or matter expressly required by the DGCL to be submitted to stockholders for approval or (ii) adopting, amending or repealing any of these bylaws. Such committee or committees shall have such name or names as may be determined from time to time by resolution adopted by the Board. Each committee shall keep regular minutes of its meetings and make such reports to the Board as the Board may request. Except as the Board may otherwise determine, any committee may make rules for the conduct of its business, but unless otherwise provided by the directors or in such rules, its business shall be conducted as nearly as possible in the same manner as is provided in these bylaws for the conduct of its business by the Board.
3.14 Fees and Compensation of Directors . Unless otherwise restricted by the certificate of incorporation of the corporation or these bylaws, the Board shall have the authority to fix the compensation of directors. The directors may be paid their expenses, if any, of attendance at each meeting of the Board and may be paid a fixed sum for attendance at each
-8-
meeting of the Board or a stated salary as director. No such payment shall preclude any director from serving the corporation in any other capacity and receiving compensation therefor. Members of special or standing committees may be allowed like compensation for attending committee meetings.
ARTICLE 4
Officers
4.1 Officers Designated . The officers of the corporation shall be chosen by the Board and shall be a Chief Executive Officer, a President, a Secretary and a Chief Financial Officer or Treasurer. The Board may also choose a Chief Operating Officer, one or more Vice Presidents, and one or more assistant Secretaries or assistant Treasurers. Any number of offices may be held by the same person, unless the certificate of incorporation of the corporation or these bylaws otherwise provide.
4.2 Election . The Board at its first meeting after each annual meeting of stockholders shall choose a Chief Executive Officer, a President, a Secretary and a Chief Financial Officer or Treasurer. Other officers may be appointed by the Board of Directors at such meeting, at any other meeting, or by written consent or may be appointed by the Chief Executive Officer pursuant to a delegation of authority from the Board.
4.3 Tenure . Each officer of the corporation shall hold office until such officers successor is elected and qualified, unless a different term is specified in the vote choosing or appointing such officer, or until such officers earlier death, resignation, removal or incapacity. Any officer elected or appointed by the Board or by the Chief Executive Officer may be removed with or without cause at any time by the affirmative vote of a majority of the Board or a committee duly authorized to do so, except that any officer appointed by the Chief Executive Officer may also be removed at any time by the Chief Executive Officer. Any vacancy occurring in any office of the corporation may be filled by the Board, at its discretion. Any officer may resign by delivering such officers written resignation to the corporation at its principal place of business or to the Chief Executive Officer or the Secretary. Such resignation shall be effective upon receipt unless it is specified to be effective at some other time or upon the happening of some other event.
4.4 The Chief Executive Officer . Subject to such supervisory powers, if any, as may be given by the Board to the Chairman of the Board, the Chief Executive Officer shall preside at all meetings of the stockholders and in the absence of the Chairman of the Board, or if there be none, at all meetings of the Board, shall have general and active management of the business of the corporation and shall see that all orders and resolutions of the Board are carried into effect. He or she shall execute bonds, mortgages and other contracts requiring a seal, under the seal of the corporation, except where required or permitted by law to be otherwise signed and executed and except where the signing and execution thereof shall be expressly delegated by the Board to some other officer or agent of the corporation.
4.5 The President . The President shall, in the event there be no Chief Executive Officer or in the absence of the Chief Executive Officer or in the event of his or her disability or
-9-
refusal to act, perform the duties of the Chief Executive Officer, and when so acting, shall have the powers of and be subject to all the restrictions upon the Chief Executive Officer. The President shall perform such other duties and have such other powers as may from time to time be prescribed for such person by the Board, the Chairman of the Board, the Chief Executive Officer or these bylaws.
4.6 The Vice President . The Vice President (or in the event there be more than one, the Vice Presidents in the order designated by the directors, or in the absence of any designation, in the order of their election), shall, in the absence of the President or in the event of his or her disability or refusal to act, perform the duties of the President, and when so acting, shall have the powers of and be subject to all the restrictions upon the President. The Vice President(s) shall perform such other duties and have such other powers as may from time to time be prescribed for them by the Board, the President, the Chairman of the Board or these bylaws.
4.7 The Secretary . The Secretary shall attend all meetings of the Board and the stockholders and record all votes and the proceedings of the meetings in a book to be kept for that purpose and shall perform like duties for the standing committees, when required. The Secretary shall give, or cause to be given, notice of all meetings of stockholders and special meetings of the Board, and shall perform such other duties as may from time to time be prescribed by the Board, the Chairman of the Board or the Chief Executive Officer, under whose supervision he or she shall act. The Secretary shall have custody of the seal of the corporation, and the Secretary, or an Assistant Secretary, shall have authority to affix the same to any instrument requiring it, and, when so affixed, the seal may be attested by his or her signature or by the signature of such Assistant Secretary. The Board may give general authority to any other officer to affix the seal of the corporation and to attest the affixing thereof by his or her signature. The Secretary shall keep, or cause to be kept, at the principal executive office or at the office of the corporations transfer agent or registrar, as determined by resolution of the Board, a share register, or a duplicate share register, showing the names of all stockholders and their addresses, the number and classes of shares held by each, the number and date of certificates issued for the same and the number and date of cancellation of every certificate surrendered for cancellation.
4.8 The Assistant Secretary . The Assistant Secretary, or if there be more than one, any Assistant Secretaries in the order designated by the Board (or in the absence of any designation, in the order of their election) shall assist the Secretary in the performance of his or her duties and, in the absence of the Secretary or in the event of his or her inability or refusal to act, perform the duties and exercise the powers of the Secretary and shall perform such other duties and have such other powers as may from time to time be prescribed by the Board.
4.9 The Chief Financial Officer . The Chief Financial Officer shall have the custody of the corporate funds and securities and shall keep full and accurate accounts of receipts and disbursements in books belonging to the corporation and shall deposit all moneys and other valuable effects in the name and to the credit of the corporation in such depositories as may be designated by the Board. The Chief Financial Officer shall disburse the funds of the corporation as may be ordered by the Board, taking proper vouchers for such disbursements, and shall render to the Chief Executive Officer and the Board, at its regular meetings, or when the Board so requires, an account of all his or her transactions as Chief Financial Officer and of the financial
-10-
condition of the corporation. The Chief Financial Officer shall perform such other duties and have other powers as may from time to time be prescribed by the Board of Directors or the Chief Executive Officer.
4.10 The Treasurer and Assistant Treasurers . The Treasurer (if one is appointed) shall have such duties as may be specified by the Chief Financial Officer to assist the Chief Financial Officer in the performance of his or her duties and to perform such other duties and have other powers as may from time to time be prescribed by the Board or the Chief Executive Officer. It shall be the duty of any Assistant Treasurers to assist the Treasurer in the performance of his or her duties and to perform such other duties and have other powers as may from time to time be prescribed by the Board or the Chief Executive Officer.
4.11 Bond . If required by the Board, any officer shall give the corporation a bond in such sum and with such surety or sureties and upon such terms and conditions as shall be satisfactory to the Board, including without limitation a bond for the faithful performance of the duties of such officers office and for the restoration to the corporation of all books, papers, vouchers, money and other property of whatever kind in such officers possession or under such officers control and belonging to the corporation.
4.12 Delegation of Authority . The Board may from time to time delegate the powers or duties of any officer to any other officers or agents, notwithstanding any provision hereof.
ARTICLE 5
Notices
5.1 Delivery . Whenever, under the provisions of law, or of the certificate of incorporation of the corporation or these bylaws, written notice is required to be given to any director or stockholder, such notice may be given by mail, addressed to such director or stockholder, at such persons address as it appears on the records of the corporation, with postage thereon prepaid, and such notice shall be deemed to be given at the time when the same shall be deposited in the United States mail or delivered to a nationally recognized courier service. Unless written notice by mail is required by law, written notice may also be given by commercial delivery service, facsimile transmission, electronic means or similar means addressed to such director or stockholder at such persons address as it appears on the records of the corporation, in which case such notice shall be deemed to be given when delivered into the control of the persons charged with effecting such transmission, the transmission charge to be paid by the corporation or the person sending such notice and not by the addressee. Oral notice or other in-hand delivery, in person or by telephone, shall be deemed given at the time it is actually given.
5.2 Waiver of Notice . Whenever any notice is required to be given under the provisions of law or of the certificate of incorporation of the corporation or of these bylaws, a written waiver, signed by the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice, whether before or after the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not
-11-
lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders, directors or members of a committee of directors need be specified in any written waiver of notice or any waiver by electronic transmission unless so required by the certificate of incorporation or these bylaws.
ARTICLE 6
Indemnification and Insurance
6.1 Indemnification .
(a) Each person who was or is made a party or is threatened to be made a party to or is involved in any action, suit, or proceeding, whether civil, criminal, administrative or investigative (hereinafter a proceeding), by reason of the fact that he or she or a person of whom he or she is the legal representative is or was a director or officer of the corporation (or any predecessor) or is or was serving at the request of the corporation (or any predecessor) as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, employee benefit plan sponsored or maintained by the corporation, or other enterprise (or any predecessor of any of such entities), whether the basis of such proceeding is alleged action in an official capacity as a director, officer, employee or agent or in any other capacity while serving as a director, officer, employee or agent, shall be indemnified and held harmless by the corporation to the fullest extent authorized by the General Corporation Law of the State of Delaware, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the corporation to provide broader indemnification rights than said law permitted the corporation to provide prior to such amendment), against all expense, liability and loss (including attorneys fees, judgments, fines, ERISA excise taxes or penalties, and amounts paid or to be paid in settlement) reasonably incurred or suffered by such person in connection therewith; provided, however , that except as provided in Section 6.1(c), the corporation shall indemnify any such person seeking indemnification in connection with a proceeding (or part thereof) initiated by such person only if such proceeding (or part thereof) was authorized by the Board. The right to indemnification conferred in this Section 6.1 shall be a contract right.
(b) To obtain indemnification under this Section 6.1, a claimant shall submit to the corporation a written request, including therein or therewith such documentation and information as is reasonably available to the claimant and is reasonably necessary to determine whether and to what extent the claimant is entitled to indemnification. Upon written request by a claimant for indemnification pursuant to the preceding sentence, a determination, if required by applicable law, with respect to the claimants entitlement thereto shall be made as follows: (i) if requested by the claimant, by Independent Counsel (as hereinafter defined), or (ii) if no request is made by the claimant for a determination by Independent Counsel, (A) by the Board by a majority vote of the Disinterested Directors (as hereinafter defined), even though less than a quorum, or (B) by a committee of Disinterested Directors designated by majority vote of the Disinterested Directors, even though less than a quorum, or (C) if there are no Disinterested Directors or the Disinterested Directors so direct, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to the claimant, or (D) if a quorum of Disinterested Directors so
-12-
directs, by the stockholders of the corporation. In the event the determination of entitlement to indemnification is to be made by Independent Counsel at the request of the claimant, the Independent Counsel shall be selected by the Board unless there shall have occurred within two years prior to the date of the commencement of the proceeding for which indemnification is claimed a Change of Control (as hereinafter defined), in which case Independent Counsel shall be selected by the claimant unless the claimant shall request that such selection be made by the Board. If it is so determined that the claimant is entitled to indemnification, payment to the claimant shall be made within ten (10) days after such determination.
(c) If a claim for the indemnification under this Section 6.1 is not paid in full by the corporation within thirty (30) days after a written claim pursuant to Section 6.1(b) has been received by the corporation, the claimant may at any time thereafter bring suit against the corporation to recover the unpaid amount of the claim and, if successful in whole or in part, the claimant shall be entitled to be paid also the expense of prosecuting such claim. It shall be a defense to any such action (other than an action brought to enforce a claim for expenses incurred in defending any proceeding in advance of its final disposition where the required undertaking, if any is required, has been tendered to the corporation) that the claimant has not met the standard of conduct that makes it permissible under the General Corporation Law of the State of Delaware for the corporation to indemnify the claimant for the amount claimed, but the burden of proving such defense shall be on the corporation. Neither the failure of the corporation (including its board of directors, Independent Counsel or stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because he or she has met the applicable standard of conduct set forth in the General Corporation Law of the State of Delaware, nor an actual determination by the corporation (including its board of directors, Independent Counsel or stockholders) that the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that the claimant has not met the applicable standard of conduct.
(d) If a determination shall have been made pursuant to this Section 6.1 that the claimant is entitled to indemnification, the corporation shall be bound by such determination in any judicial proceeding commenced pursuant to Section 6.1(c). The corporation shall be precluded from asserting in any judicial proceeding commenced pursuant to the Section 6.1(c) that the procedures and presumptions of this Article 6 are not valid, binding and enforceable and shall stipulate in such proceeding that the corporation is bound by all the provisions of this Article 6.
6.2 Advance Payment . The right to indemnification under this Article 6 shall include the right to be paid by the corporation the expenses incurred in defending any such proceeding in advance of its final disposition, such advances to be paid by the corporation within twenty (20) days after the receipt by the corporation of a statement or statements from the claimant requesting such advance or advances from time to time; provided, however, that if the General Corporation Law of the State of Delaware requires, the payment of such expenses incurred by a director or officer in his or her capacity as a director or officer (and not in any other capacity in which service was or is rendered by such person while a director or officer, including, without limitation, service to an employee benefit plan) in advance of the final disposition of a proceeding, shall be made only upon delivery to the corporation of an undertaking by or on behalf of such director or officer to repay all amounts so advanced if it shall ultimately be
-13-
determined that such director or officer is not entitled to be indemnified under Section 6.1 or otherwise.
Notwithstanding the foregoing, unless otherwise determined pursuant to Section 6.3, no advance shall be made by the corporation to an officer of the corporation (except by reason of the fact that such officer is or was a director of the corporation, in which event this paragraph shall not apply) in any action, suit or proceeding, whether civil, criminal, administrative or investigative, if a determination is reasonably and promptly made (i) by the Board by a majority vote of the Disinterested Directors, even though less than a quorum, or (B) by a committee of Disinterested Directors designated by majority vote of the Disinterested Directors, even though less than a quorum, or (C) if there are no Disinterested Directors or the Disinterested Directors so direct, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to the claimant, that the facts known to the decision-making party at the time such determination is made demonstrate clearly and convincingly that such person acted in bad faith or in a manner that such person did not believe to be in or not opposed to the best interests of the corporation.
6.3 Non-Exclusivity and Survival of Rights; Amendments . The right to indemnification and the payment of expenses incurred in defending a proceeding in advance of its final disposition conferred in this Article 6 shall not be deemed exclusive of any other right which any person may have or hereafter acquire under any statute, provision of the certificate of incorporation of the corporation, bylaws, agreement, vote of stockholders or Disinterested Directors or otherwise, both as to action in such persons official capacity and as to action in another capacity while holding such office, and shall continue as to a person who has ceased to be a director, officer, employee or agent of the corporation and shall inure to the benefit of the heirs, executors and administrators of such a person. Any repeal or modification of the provisions of this Article 6 shall not in any way diminish or adversely affect the rights of any director, officer, employee or agent of the corporation hereunder in respect of any occurrence or matter arising prior to any such repeal or modification.
6.4 Insurance . The corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise against any expense, liability or loss asserted against such person and incurred by such person in any such capacity, or arising out of such persons status as such, whether or not the corporation would have the power to indemnify such person against such liability under the provisions of the General Corporation Law of State of Delaware.
6.5 Severability . If any word, clause, provision or provisions of this Article 6 shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (i) the validity, legality and enforceability of the remaining provisions of this Article 6 (including, without limitation, each portion of any section or paragraph of this Article 6 containing any such provision held to be invalid, illegal or unenforceable, that is not itself held to be invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby; and (ii) to the fullest extent possible, the provisions of this Article 6 (including, without limitation, each such portion of any section or paragraph of this Article 6 containing any such provision held to be invalid, illegal or
-14-
unenforceable) shall be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable.
6.6 Definitions . For the purpose of this Article 6:
Change of Control shall mean:
(1) the acquisition by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the 1934 Act (a Person)), directly or indirectly, of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the 1934 Act) of 20% or more of either (i) the then outstanding shares of common stock of the corporation (the Outstanding Corporation Common Stock) or (ii) the combined voting power of the then outstanding voting securities of the corporation entitled to vote generally in the election of directors (the Outstanding Corporation Voting Securities); provided, however, that for purposes of this part (1), the following acquisitions shall not constitute a Change of Control: (i) any acquisition directly from the corporation or any acquisition from other stockholders where (A) such acquisition was approved in advance by the Board and (B) such acquisition would not constitute a Change of Control under part (2) or part (4) of this definition, (ii) any acquisition by the corporation, (iii) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the corporation or any corporation controlled by the corporation, or (iv) any acquisition by any corporation pursuant to a transaction that complies with clauses (i), (ii) and (iii) of part (4) of this definition; or
(2) the acquisition by any Person, directly or indirectly, of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the 1934 Act) of 50% or more of either (i) the Outstanding Corporation Common Stock or (ii) the Outstanding Corporation Voting Securities; or
(3) individuals who, as of the date hereof, constitute the Board (the Incumbent Board) cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to the date hereof whose election, or nomination for election by the stockholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board (or such committee thereof that shall then have the authority to nominate persons for election as directors) shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies of consents by or on behalf of a Person other than the Board; or
(4) consummation of a reorganization, merger or consolidation or sale or other disposition of all or substantially all of the assets of the corporation (a Business Combination), in each case, unless, immediately following such Business Combination, (i) all or substantially all of the individuals and entities who were the beneficial owners, respectively, of the Outstanding Corporation Common Stock and Outstanding Corporation Voting Securities immediately prior to such Business Combination
-15-
beneficially own, directly or indirectly, more than 50% of, respectively, the then outstanding shares of common stock and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the corporation resulting from such Business Combination (including, without limitation, a corporation that as a result of such transaction owns the corporation or all or substantially all of the corporations assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership, immediately prior to such Business Combination of the Outstanding Corporation Common Stock and Outstanding Corporation Voting Securities, as the case may be, (ii) no Person (excluding any corporation resulting from such Business Combination or any employee benefit plan (or related trust) of the corporation or such corporation resulting from such Business Combination) beneficially owns, directly or indirectly, 20% or more of, respectively, the then outstanding shares of common stock of the corporation resulting from such Business Combination or the combined voting power of the then outstanding voting securities of such corporation except to the extent that such ownership existed prior to the Business Combination, and (iii) at least a majority of the members of the board of directors of the corporation resulting from such Business Combination were members of the Incumbent Board at the time of the execution of the initial agreement, or of the action of the Board, providing for such Business Combination; or
(5) approval by the stockholders of a complete liquidation or dissolution of the corporation.
Disinterested Director shall mean a director of the corporation who is not and was not a party to the matter in respect of which indemnification is sought by the claimant.
Independent Counsel shall mean a law firm, a member of a law firm, or an independent practitioner, that is experienced in matters of corporation law and shall include any person who, under the applicable standards of professional conduct then prevailing, would not have a conflict of interest in representing either the corporation or the claimant in an action to determine the claimants rights under this Article 6.
6.7 Notices . Any notice, request or other communication required or permitted to be given to the corporation under this Article 6 shall be in writing and either delivered in person or sent by telecopy, telex, telegram, overnight mail or courier service, or certified or registered mail, postage or charges prepaid, return copy requested, to the Secretary of the corporation and shall be effective only upon receipt by the Secretary.
ARTICLE 7
Capital Stock
7.1 Certificates for Shares . The shares of the corporation shall be represented by certificates or shall be uncertificated. Certificates shall be signed by, or in the name of the corporation by, the Chairman of the Board, the Chief Executive Officer, the President or a Vice President and by the Chief Financial Officer, the Treasurer or an Assistant Treasure, or the Secretary or an Assistant Secretary of the corporation. Certificates may be issued for partly paid
-16-
shares and in such case upon the face or back of the certificates issued to represent any such partly paid shares, the total amount of the consideration to be paid therefor, and the amount paid thereon shall be specified.
Within a reasonable time after the issuance or transfer of uncertificated stock, the corporation shall send to the registered owner thereof a written notice containing the information required by the General Corporation Law of the State of Delaware or a statement that the corporation will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights.
7.2 Signatures on Certificates . Any or all of the signatures on a certificate may be a facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the corporation with the same effect as if he were such officer, transfer agent or registrar at the date of issue.
7.3 Transfer of Stock . Upon surrender to the corporation or the transfer agent of the corporation of a certificate of shares duly endorsed or accompanied by proper evidence of succession, assignation or authority to transfer, and proper evidence of compliance of other conditions to rightful transfer, it shall be the duty of the corporation to issue a new certificate to the person entitled thereto, cancel the old certificate and record the transaction upon its books. Upon receipt of proper transfer instructions and proper evidence of compliance of other conditions to rightful transfer from the registered owner of uncertificated share, such uncertificated shares shall be canceled and issuance of new equivalent uncertificated shares or certificated shares shall be made to the person entitled thereto and the transaction shall be recorded upon the books of the corporation.
7.4 Registered Stockholders . The corporation shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends, and to vote as such owner, and to hold liable for calls and assessments a person registered on its books as the owner of shares, and shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any other person, whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of Delaware.
7.5 Lost, Stolen or Destroyed Certificates . The corporation may direct that a new certificate or certificates be issued to replace any certificate or certificates theretofore issued by the corporation alleged to have been lost, stolen or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost, stolen or destroyed and on such terms and conditions as the corporation may require. When authorizing the issue of a new certificate or certificates, the corporation may, in its discretion and as a condition precedent to the issuance thereof, require the owner of the lost, stolen or destroyed certificate or certificates, or his or her legal representative, to advertise the same in such manner as it shall require, to indemnify the corporation in such manner as it may require, and/or to give the corporation a bond or other adequate security in such sum as it may direct as indemnity against any claim that
-17-
may be made against the corporation with respect to the certificate alleged to have been lost, stolen or destroyed.
ARTICLE 8
Certain Transactions
8.1 Transactions with Interested Parties . No contract or transaction between the corporation and one or more of its directors or officers, or between the corporation and any other corporation, partnership, association or other organization in which one or more of its directors or officers are directors or have a financial interest, shall be void or voidable solely for this reason, or solely because the director or officer is present at or participates in the meeting of the board or committee thereof which authorizes the contract or transaction or solely because the vote or votes of such director or officer are counted for such purpose, if:
(a) the material facts as to such directors or officers relationship or interest and as to the contract or transaction are disclosed or are known to the Board or the committee, and the Board or committee in good faith authorizes the contract or transaction by the affirmative votes of a majority of the disinterested directors, even though the disinterested directors be less than a quorum; or
(b) the material facts as to such directors or officers relationship or interest and as to the contract or transaction are disclosed or are known to the stockholders entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the stockholders; or
(c) the contract or transaction is fair as to the corporation as of the time it is authorized, approved or ratified, by the Board, a committee thereof or the stockholders.
8.2 Quorum . Common or interested directors may be counted in determining the presence of a quorum at a meeting of the Board or of a committee which authorizes the contract or transaction.
ARTICLE 9
General Provisions
9.1 Dividends . Dividends upon the capital stock of the corporation, subject to any restrictions contained in the General Corporation Law of the State of Delaware or the provisions of the certificate of incorporation of the corporation, if any, may be declared by the Board at any regular or special meeting or by unanimous written consent. Dividends may be paid in cash, in property or in shares of capital stock, subject to the provisions of the certificate of incorporation of the corporation.
9.2 Dividend Reserve . Before payment of any dividend, there may be set aside out of any funds of the corporation available for dividends such sum or sums as the directors from time to time, in their absolute discretion, think proper as a reserve or reserves to meet contingencies,
-18-
or for equalizing dividends, or for repairing or maintaining any property of the corporation, or for such other purpose as the directors shall think conducive to the interest of the corporation, and the directors may modify or abolish any such reserve in the manner in which it was created.
9.3 Checks . All checks or demands for money and notes of the corporation shall be signed by such officer or officers or such other person or persons as the Board may from time to time designate.
9.4 Corporate Seal . The Board of Directors may, by resolution, adopt a corporate seal. The corporate seal shall have inscribed thereon the name of the corporation, the year of its organization and the word Delaware. The seal may be used by causing it or a facsimile thereof to be impressed or affixed or otherwise reproduced. The seal may be altered from time to time by the Board.
9.5 Execution of Corporate Contracts and Instruments . The Board, except as otherwise provided in these bylaws, may authorize any officer or officers, or agent or agents, to enter into any contract or execute any instrument in the name of and on behalf of the corporation; such authority may be general or confined to specific instances. Unless so authorized or ratified by the Board or within the agency power of an officer, no officer, agent or employee shall have any power or authority to bind the corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any amount.
9.6 Representation of Shares of Other Corporations . The Chief Executive Officer, the President or any Vice President, the Chief Financial Officer or the Treasurer or any Assistant Treasurer, or the Secretary or any Assistant Secretary of the corporation is authorized to vote, represent and exercise on behalf of the corporation all rights incident to any and all shares of any corporation or corporations standing in the name of the corporation. The authority herein granted to said officers to vote or represent on behalf of the corporation any and all shares held by the corporation in any other corporation or corporations may be exercised either by such officers in person or by any other person authorized so to do by proxy or power of attorney duly executed by said officers.
ARTICLE 10
Amendments
The Board is expressly empowered to adopt, amend or repeal these bylaws; provided, however , that any adoption, amendment or repeal of these bylaws by the Board shall require the approval of at least sixty-six and two-thirds percent of the total number of directors then in office. The stockholders shall also have power to adopt, amend or repeal these bylaws at any regular or special meeting of stockholders; provided, however , that in addition to any vote of the holders of any class or series of stock of the corporation required by law or by the certificate of incorporation of the corporation, the affirmative vote of the holders of at least sixty-six and two-thirds percent of the voting power of all of the then outstanding shares of the stock of the corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required for such adoption, amendment or repeal by the stockholders of any
-19-
provision of these bylaws and notice of such adoption, amendment or repeal shall be contained in the notice of such meeting.
-20-
Exhibit 4.2
GENOMIC HEALTH, INC.
AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT
February 9, 2004
TABLE OF CONTENTS
Page | ||||||
1. Registration Rights | 1 | |||||
|
||||||
1.1
|
Definitions | 1 | ||||
1.2
|
Request for Registration | 2 | ||||
1.3
|
Company Registration | 3 | ||||
1.4
|
Form S-3 Registration | 4 | ||||
1.5
|
Obligations of the Company | 4 | ||||
1.6
|
Furnish Information | 6 | ||||
1.7
|
Expenses of Registration | 6 | ||||
1.8
|
Underwriting Requirements | 7 | ||||
1.9
|
Delay of Registration | 7 | ||||
1.10
|
Indemnification | 8 | ||||
1.11
|
Reports Under Securities Exchange Act of 1934 | 9 | ||||
1.12
|
Assignment of Registration Rights | 10 | ||||
1.13
|
Limitations on Subsequent Registration Rights | 11 | ||||
1.14
|
Market Stand-Off Agreement | 11 | ||||
1.15
|
Limitations | 12 | ||||
1.16
|
Transferees Bound | 12 | ||||
1.17
|
Termination of Registration Rights | 12 | ||||
|
||||||
2. Covenants of the Company | 12 | |||||
|
||||||
2.1
|
Delivery of Financial Statements | 12 | ||||
2.2
|
Inspection | 13 | ||||
2.3
|
Termination of Information and Inspection Covenants | 13 | ||||
2.4
|
Right of First Offer | 13 | ||||
2.5
|
Key-Man Insurance; Fire and Casualty Insurance | 15 | ||||
2.6
|
Board of Directors | 15 | ||||
2.7
|
Observer Rights | 17 | ||||
2.8
|
Common Stock Vesting | 18 | ||||
2.9
|
Confidentiality | 18 | ||||
2.10
|
Qualified Small Business Stock Status | 18 | ||||
2.11
|
Termination of Certain Covenants | 19 | ||||
|
||||||
3. Miscellaneous | 19 | |||||
|
||||||
3.1
|
Successors and Assigns | 19 | ||||
3.2
|
Governing Law | 19 | ||||
3.3
|
Counterparts | 19 | ||||
3.4
|
Titles and Subtitles | 19 | ||||
3.5
|
Notices | 19 | ||||
3.6
|
Expenses | 19 | ||||
3.7
|
Amendments and Waivers | 19 | ||||
3.8
|
Severability | 19 | ||||
3.9
|
Aggregation of Stock | 20 | ||||
3.10
|
Entire Agreement | 20 |
-i-
Page | ||||||
3.11
|
Termination of Prior Agreement | 20 | ||||
3.12
|
Subsequent Closings | 20 | ||||
3.13
|
Agreement as to Voting Shares | 20 |
-ii-
AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT
THIS AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT (this Agreement) is made as of February 9, 2004, by and among Genomic Health, Inc., a Delaware corporation (the Company), and the investors listed on Schedule A hereto, each of which is herein referred to as an Investor.
WHEREAS, the Company and certain Investors are parties to that certain Amended and Restated Investors Rights Agreement dated as of March 15, 2002, pursuant to which the Company granted to such Investors certain registration, information and first offer rights with respect to the shares of Company capital stock held by such Investors (the Prior Agreement), and the parties thereto agree to amend and restate the Prior Agreement in its entirety as set forth herein; and
WHEREAS, to induce certain other of the Investors to purchase shares of Series E Preferred Stock from the Company and to enter into that certain Series E Preferred Stock Purchase Agreement, dated as of the date hereof (the Purchase Agreement), the Company and the Investors desire to enter into this Agreement.
NOW, THEREFORE, in consideration of the mutual promises and covenants set forth herein, the parties hereto further agree as follows:
1. Registration Rights . The Company covenants and agrees as follows:
1.1 Definitions . For purposes of this Section 1:
(a) Act means the Securities Act of 1933, as amended, or any similar successor federal statute and the rules and regulations thereunder, all as the same shall be in effect from time to time.
(b) Form S-3 means such form under the Act as in effect on the date hereof or any registration form under the Act subsequently adopted by the SEC in lieu of Form S-3 that permits inclusion or incorporation of substantial information by reference to other documents filed by the Company with the SEC.
(c) Holder means any person owning or having the right to acquire Registrable Securities or any assignee thereof in accordance with Section 1.12 hereof.
(d) 1934 Act shall mean the Securities Exchange Act of 1934, as amended, or any similar successor federal statute and the rules and regulations thereunder, all as the same shall be in effect from time to time.
(e) Qualified IPO means the firm commitment underwritten public offering by the Company by shares of its Common Stock pursuant to a registration statement on Form S-1 (or any successor form) under the Securities Act which results in aggregate cash proceeds to the Company of at least $20,000,000 (before deduction for underwriters discounts and commissions and expenses).
-1-
(f) Register, registered, and registration refer to a registration effected by preparing and filing a registration statement or similar document in compliance with the Act, and the declaration or ordering of effectiveness of such registration statement or document.
(g) Registrable Securities means (i) the Common Stock issuable or issued upon conversion of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock, and (ii) any Common Stock of the Company issued as (or issuable upon the conversion or exercise of any warrant, right or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of the shares referenced in (i) above, excluding in all cases, however, any Registrable Securities sold by a person in a transaction in which his rights under this Section 1 are not assigned.
(h) The number of shares of Registrable Securities then outstanding shall be determined by the number of shares of Common Stock outstanding which are, and the number of shares of Common Stock issuable pursuant to then exercisable or convertible securities which are exercisable or convertible into, Registrable Securities.
(i) SEC shall mean the Securities and Exchange Commission or any other federal agency at the time administering the Act.
1.2 Request for Registration .
(a) If the Company shall receive at any time after six (6) months after the effective date of the first registration statement for a public offering of securities of the Company (other than a registration statement relating either to the sale of securities to employees of the Company pursuant to a stock option, stock purchase or similar plan or an SEC Rule 145 transaction under the Act), a written request from the Holders of a majority of the Registrable Securities then outstanding that the Company file a registration statement under the Act covering the registration of Registrable Securities with an expected aggregate offering price to the public of at least $10,000,000 (before deduction of underwriting discounts and commissions), then the Company shall:
(i) within ten (10) days of the receipt thereof, give written notice of such request to all Holders; and
(ii) file as soon as practicable, and in any event within seventy-five (75) days of the receipt of such request, a registration statement under the Act covering all Registrable Securities that the Holders request to be registered, subject to the limitations of Section 1.2(b), within twenty (20) days of the mailing of such notice by the Company in accordance with Section 3.5.
(b) If the Holders initiating the registration request hereunder (Initiating Holders) intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 1.2(a) and the Company shall include such information in the written notice referred to in Section 1.2(a). The underwriter or underwriters shall be selected by the Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holders Registrable Securities in such registration shall be conditioned upon such Holders participation in such underwriting and the inclusion of such Holders Registrable Securities in the underwriting (unless otherwise mutually agreed by a majority in interest of the Initiating Holders and such Holder) to the extent provided herein. All Holders proposing to
-2-
distribute their securities through such underwriting shall (together with the Company as provided in Section 1.5(e)) enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting. Notwithstanding any other provision of this Section 1.2, if the underwriter advises the Initiating Holders in writing that marketing factors require a limitation of the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that would otherwise be underwritten pursuant hereto, and the number of shares of Registrable Securities that may be included in the underwriting shall be allocated among all Holders thereof, including the Initiating Holders, in proportion (as nearly as practicable) to the amount of Registrable Securities owned by each Holder; provided, however, that the number of shares of Registrable Securities to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting.
(c) Notwithstanding the foregoing, if the Company shall furnish to Initiating Holders a certificate signed by the Chief Executive Officer or President of the Company stating that in the good faith judgment of the Board of Directors of the Company, it would be seriously detrimental to the Company and its stockholders for such registration statement to be filed and it is therefore essential to defer the filing of such registration statement, the Company shall have the right to defer such filing for a period of not more than ninety (90) days after receipt of the request of the Initiating Holders; provided, however, that the Company may not utilize this right more than once in any twelve (12) month period.
(d) In addition, the Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to this Section 1.2:
(i) After the Company has effected two (2) registrations pursuant to this Section 1.2 and such registrations have been declared or ordered effective;
(ii) During the period starting with the date sixty (60) days prior to the Companys good faith estimate of the date of filing of, and ending on a date one hundred eighty (180) days after the effective date of, a registration subject to Section 1.3 hereof; provided that the Company is actively employing in good faith all reasonable efforts to cause such registration statement to become effective; or
(iii) If the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 1.4 below.
1.3 Company Registration . If (but without any obligation to do so) the Company proposes to register (including for this purpose a registration effected by the Company for stockholders other than the Holders) any of its Common Stock under the Act in connection with a firm commitment underwritten public offering solely of Common Stock and solely for cash (other than a registration relating solely to the sale of securities to participants in a Company stock plan, a registration on any form which does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities, or a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered), the Company shall, at such time, promptly give each Holder written notice of such registration. Upon the written request of each Holder given within twenty (20) days after mailing of such notice by the Company in accordance
-3-
with Section 3.5, the Company shall, subject to the provisions of Section 1.8, cause to be registered under the Act all of the Registrable Securities that each such Holder has requested to be registered.
1.4 Form S-3 Registration . In case the Company shall receive from any Holder or Holders a written request or requests that the Company effect a registration on Form S-3 and any related qualification or compliance with respect to all or a part of the Registrable Securities owned by such Holder or Holders, the Company will:
(a) promptly give written notice of the proposed registration, and any related qualification or compliance, to all other Holders; and
(b) as soon as practicable, use all reasonable efforts to effect such registration and all such qualifications and compliances as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Holders or Holders Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any other Holder or Holders joining in such request as are specified in a written request given within fifteen (15) days after receipt of such written notice from the Company; provided, however, that the Company shall not be obligated to effect any such registration, qualification or compliance, pursuant to this Section 1.4: (i) if Form S-3 is not available for such offering by the Holders; (ii) if the Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public (before deduction of any underwriters discounts or commissions) of less than $2,500,000; (iii) if the Company shall furnish to the Holders a certificate signed by the Chief Executive Officer or President of the Company stating that in the good faith judgment of the Board of Directors of the Company, it would be seriously detrimental to the Company and its stockholders for such Form S-3 Registration to be effected at such time, in which event the Company shall have the right to defer the filing of the Form S-3 registration statement for a period of not more than ninety (90) days after receipt of the request of the Holder or Holders under this Section 1.4; provided, however, that the Company shall not utilize this right more than once in any twelve (12) month period; (iv) if the Company has, within the nine (9) month period preceding the date of such request, already effected one (1) registration on Form S-3 for the Holders pursuant to this Section 1.4; (v) in any particular jurisdiction in which the Company would be required to qualify to do business or to execute a general consent to service of process in effecting such registration, qualification or compliance; or (vi) after the Company has effected four (4) registrations pursuant to this Section 1.4 and such registrations have been declared or ordered effective.
(c) Subject to the foregoing, the Company shall file a registration statement covering the Registrable Securities and other securities so requested to be registered as soon as practicable after receipt of the request or requests of the Holders. Registrations effected pursuant to this Section 1.4 shall not be counted as demands for registration or registrations effected pursuant to Sections 1.2 or 1.3, respectively.
1.5 Obligations of the Company . Whenever required under this Section 1 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible:
(a) Prepare and file with the SEC a registration statement with respect to such Registrable Securities and use all reasonable efforts to cause such registration statement to become effective, and keep such registration statement effective for a period of up to one hundred
-4-
eighty (180) days or until the distribution contemplated in the Registration Statement has been completed (the Effectiveness Period); provided, however, that the Effectiveness Period shall be extended for a period of time equal to the period the Holder refrains from selling any securities included in such registration at the request of an underwriter of Common Stock (or other securities) of the Company. In the event that, in the judgment of the Company, it is advisable to suspend use of the prospectus relating to such registration statement for a discrete period of time (a Deferral Period) due to pending material corporate developments or similar material events that have not yet been publicly disclosed and as to which the Company believes public disclosure will be prejudicial to the Company, the Company shall deliver a certified resolution of the Board of Directors of the Company, signed by a duly authorized officer of the Company, to each Holder of Registrable Securities covered by such registration statement to the effect of the foregoing and, upon receipt of such certificate, such Holders agree not to dispose of such Holders Registrable Securities covered by such registration or prospectus (other than in transactions exempt from the registration requirements under the Securities Act); provided, however, that such Deferral Period shall be no longer than 60 days. The Effectiveness Period shall be extended for a period of time equal to such Deferral Period.
(b) Prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Act with respect to the disposition of all securities covered by such registration statement.
(c) Furnish to the Holders of Registrable Securities covered by such registration statement such numbers of copies of a prospectus, including a preliminary prospectus, and any amendment or supplement thereto, all in conformity with the requirements of the Act, and such other documents as they may reasonably request in order to facilitate the disposition of such Registrable Securities.
(d) Use all reasonable efforts to register and qualify the securities covered by such registration statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders; provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions.
(e) In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering. Each Holder participating in such underwriting shall also enter into and perform such Holders obligations under such an agreement.
(f) Promptly notify each Holder of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto is required to be delivered under the Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading or, if for any reason it shall be necessary during such time period to amend or supplement the registration statement or the prospectus in order to comply with the Securities Act, whereupon, in either case, each Holder shall immediately cease to use such registration statement or prospectus for any purpose and, as promptly as practicable thereafter, the Company shall prepare and file with the SEC, and furnish without
-5-
charge to the appropriate Holders and managing underwriters, if any, a supplement or amendment to such registration statement or prospectus which will correct such statement or omission or effect such compliance and such copies thereof as the Holders and any underwriters may reasonably request.
(g) Cause all such Registrable Securities registered pursuant hereunder to be listed on each securities exchange or automated quotation system on which similar securities issued by the Company are then listed.
(h) Provide a transfer agent and registrar for all Registrable Securities registered pursuant hereunder and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration.
(i) Use its reasonable efforts to furnish, at the request of the underwriter pursuant to an underwriting agreement, on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a registration pursuant to Section 1.2, (i) an opinion, dated such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, and (ii) a letter, dated such date, from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters.
1.6 Furnish Information .
(a) It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 1 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as shall be required to effect the registration of such Holders Registrable Securities.
(b) The Company shall have no obligation with respect to any registration requested pursuant to Section 1.2 or Section 1.4 if, due to the operation of Section 1.6(a), the number of shares or the anticipated aggregate offering price of the Registrable Securities to be included in the registration does not equal or exceed the number of shares or the anticipated aggregate offering price required to originally trigger the Companys obligation to initiate such registration as specified in Section 1.2(a) or Section 1.4(b)(ii), whichever is applicable.
1.7 Expenses of Registration .
(a) Except as set forth in Section 1.7(b), the Company shall bear and pay all expenses incurred in connection with any registration, filing or qualification of Registrable Securities with respect to the registrations pursuant to Sections 1.2, 1.3 and 1.4 hereof, including (without limitation) all registration, filing, and qualification fees, printers and accounting fees, blue sky fees and expenses, including fees and disbursements of counsel related to all blue sky matters, fees and expenses of listing any Registrable Securities on any securities exchange or automated quotation system on which shares of Common Stock are then listed, fees and disbursements of counsel for the Company and the reasonable fees and disbursements of one counsel for the selling Holders not to exceed $20,000, but excluding stock transfer taxes that may be payable by the selling Holders and underwriting discounts and commissions relating to Registrable Securities covered by such registration, which shall be borne by the Holders.
-6-
(b) Notwithstanding Section 1.7(a), the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 1.2 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all participating Holders shall bear such expenses), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one demand registration pursuant to Section 1.2 or one S-3 registration pursuant to Section 1.4, as applicable; provided further, however, that if such withdrawal occurs prior to the date the registration statement shall have become effective and at the time of such withdrawal, the Holders have learned of a material adverse change in the financial condition, business, properties or results of operations of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness following disclosure by the Company of such material adverse change, then the Holders shall not be required to pay any of such expenses and shall retain their rights pursuant to Section 1.2 and 1.4, as applicable.
1.8 Underwriting Requirements . In connection with any offering involving an underwriting of shares being issued by the Company, the Company shall not be required under Section 1.3 to include any of the Holders securities in such underwriting unless they accept the terms of the underwriting as agreed upon between the Company and the underwriters selected by it (or by other persons entitled to select the underwriters), and then only in such quantity as the underwriters determine in their sole discretion will not jeopardize the success of the offering by the Company. If the total amount of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the amount of securities sold other than by the Company that the underwriters determine in their sole discretion is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters determine in their sole discretion will not jeopardize the success of the offering (the securities so included to be apportioned pro rata among the selling stockholders according to the total amount of securities entitled to be included therein owned by each selling stockholder or in such other proportions as shall mutually be agreed to by such selling stockholders) but provided, however, that the number of shares of (i) Registrable Securities, and (ii) securities of the Company (i.e., primary shares) to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting; provided further that in no event shall the amount of securities of the selling Holders included in the offering be reduced below twenty-five percent (25%) of the total amount of securities included in such offering, unless such offering is the initial public offering of the Companys securities in which case the selling Holders may be excluded if the underwriters make the determination described above. For purposes of the preceding parenthetical concerning apportionment, for any selling stockholder that is a Holder of Registrable Securities and that is a partnership, limited liability company or corporation, the partners, retired partners, members and stockholders of such Holder, or the estates and family members of any such partners and retired partners or members and any trusts for the benefit of any of the foregoing persons and affiliates of such Holder shall be deemed to be a single selling stockholder, and any pro rata reduction with respect to such selling stockholder shall be based upon the aggregate amount of Registrable Securities owned by all entities and individuals included in such selling stockholder, as defined in this sentence.
1.9 Delay of Registration . No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 1.
-7-
1.10 Indemnification . In the event any Registrable Securities are included in a registration statement under this Section 1:
(a) To the extent permitted by law, the Company will indemnify and hold harmless each Holder, the officers, directors, partners of each Holder, any underwriter (as defined in the Act) for such Holder and each person. if any, who controls such Holder or underwriter within the meaning of the Act or the 1934 Act, against any losses, claims, damages, or liabilities (joint or several) to which they may become subject under the Act, the 1934 Act or other federal or state securities law, insofar as such losses, claims, damages, or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively, a Violation): (i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Act, the 1934 Act, any state securities law or any rule or regulation promulgated under the Act, the 1934 Act or any state securities law; and the Company will reimburse, as incurred, each such Holder, officer, director, partner, underwriter or controlling person, for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity agreement contained in this Section 1.10(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability, or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld), nor shall the Company be liable in any such case for any such loss, claim, damage, liability, or action to the extent that it arises out of or is based upon a Violation that occurs in reliance upon and in conformity with written information furnished expressly for use in connection with such registration by any such Holder, officer, director, partner, underwriter or controlling person.
(b) To the extent permitted by law, each selling Holder will indemnify and hold harmless the Company, each of its directors, each of its officers who has signed the registration statement, each person, if any, who controls the Company within the meaning of the Act, any underwriter, any other Holder selling securities in such registration statement and any officer, director or controlling person of any such Holder, against any losses, claims, damages, or liabilities (joint or several) to which any of the foregoing persons may become subject, under the Act, the 1934 Act or other federal or state securities law insofar as such losses, claims, damages, or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written information furnished by such Holder expressly for use in connection with such registration; and each such Holder will reimburse any legal or other expenses reasonably incurred by any person intended to be indemnified pursuant to this Section 1.10(b), in connection with investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity agreement contained in this Section 1.10(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; provided further, that, in no event shall any indemnity under this Section 1.10(b) exceed the aggregate gross proceeds from the sale of the Registrable Securities received by such Holder from the shares sold by such Holder in the offering in question, except in the case of willful fraud by such Holder.
(c) Promptly after receipt by an indemnified party under this Section 1.10 of notice of the commencement of any action (including any governmental action), such indemnified
-8-
party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 1.10, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if prejudicial to its ability to defend such action, shall relieve such indemnifying party of any liability to the indemnified party under this Section 1.10, but the omission so to deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 1.10. An indemnifying party shall not, without the prior written consent of the indemnified parties, settle, compromise or consent to the entry of any judgment with respect to any pending or threatened claim, action, suit or proceeding in respect of which indemnification may be sought hereunder by such indemnified parties (whether or not the indemnified parties are actual or potential parties to such claim or action) unless such settlement, compromise or consent includes a release of such indemnified party reasonably acceptable to such indemnified party from all liability arising out of such claim, action, suit or proceeding.
(d) If the indemnification provided for in this Section 1.10 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage or expense referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as any other relevant equitable considerations; provided, that in no event shall any contribution by a Holder under this Section 1.10(d) exceed the net proceeds from the offering received by such Holder, except in the case of willful fraud by such Holder. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission.
(e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control.
(f) The obligations of the Company and Holders under this Section 1.10 shall survive the completion of any offering of Registrable Securities in a registration statement under this Section 1, and otherwise.
1.11 Reports Under Securities Exchange Act of 1934 . With a view to making available to the Holders the benefits of Rule 144 promulgated under the Act and any other rule or
-9-
regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company agrees to:
(a) make and keep public information available, as those terms are understood and defined in SEC Rule 144, at all times after ninety (90) days after the effective date of the first registration statement filed by the Company for the offering of its securities to the general public;
(b) take such action, including the voluntary registration of its Common Stock under Section 12 of the 1934 Act, as is necessary to enable the Holders to utilize Form S-3 for the sale of their Registrable Securities, such action to be taken as soon as practicable after the end of the fiscal year in which the first registration statement filed by the Company for the offering of its securities to the general public is declared effective;
(c) file with the SEC in a timely manner all reports and other documents required of the Company under the Act and the 1934 Act; and
(d) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the first registration statement filed by the Company), the Act and the 1934 Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after it so qualifies), (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration or pursuant to such form.
1.12 Assignment of Registration Rights . The rights to cause the Company to register Registrable Securities pursuant to this Section 1 may be assigned (but only with all related obligations) by (a) a Holder to a transferee or assignee of such securities who, after such assignment or transfer, holds at least 250,000 shares of such Holders Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations and other recapitalizations and including for purposes of such calculation the shares of Common Stock then issuable upon conversion of Preferred Stock), (b) any Holder who transfers all of its Registrable Securities, or (c) a Holder to its shareholders, partners, members, former partners or former members (or their estates), subsidiaries or affiliates; provided, however: (i) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee or assignee and the securities with respect to which such registration rights are being assigned; (ii) such transferee or assignee agrees in writing to be bound by and subject to the terms and conditions of this Agreement; and (iii) such assignment shall be effective only if immediately following such transfer the further disposition of such securities by the transferee or assignee is restricted under the Act. For the purposes of determining the number of shares of Registrable Securities held by a transferee or assignee, the holdings of transferees and assignees of a partnership or limited liability company who are partners or retired partners of such partnership or members of such limited liability company (including spouses and ancestors, lineal descendants and siblings of such partners or members or spouses who acquire Registrable Securities by gift, will or intestate succession) shall be aggregated together and with the partnership or limited liability company, as the case may be; provided that all assignees and transferees who would not qualify individually for assignment of registration rights
-10-
shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices or taking any action under this Section 1. For purposes of this Agreement, the terms affiliates or affiliated shall mean, which respect to any person or entity, any person or entity that, directly or indirectly, controls or is controlled by or is under common control with such person or entity. For the purposes of the preceding sentence, the term control shall mean the possession, directly or indirectly, through one or more intermediaries in the case of any person or entity, of the power or authority, through ownership of voting securities, by contract or otherwise, to direct the management, activities or policies of the person or entity.
1.13 Limitations on Subsequent Registration Rights . From and after the date of this Agreement, the Company shall not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that would allow such holder or prospective holder (a) to include such securities in any registration filed under Section 1.2 hereof, unless under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of such holders securities will not reduce the amount of the Registrable Securities of the Holders that is included or (b) to make a demand registration that could result in such registration statement being declared effective prior to the earlier of either of the dates set forth in Section 1.2(a) or within one hundred twenty (120) days of the effective date of any registration effected pursuant to Section 1.2.
1.14 Market Stand-Off Agreement . Each Holder hereby agrees that during the period of duration specified by the Company and an underwriter of common stock or other securities of the Company following the date of the first sale to the public pursuant to a registration statement of the Company filed under the Act, it shall not, to the extent requested by the Company and such underwriter, (i) lend, offer, pledge, sell, contract to sell (including, without limitation, any short sale), sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock, other than to donees who agree to be similarly bound, or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise, except for securities to be sold to such underwriter pursuant to such registration statement; provided, however, that:
(a) such agreement shall not be applicable to shares of common stock of the Company acquired by the Holders in a public offering or in an open market transaction;
(b) such agreement shall be applicable only to the first such registration statement of the Company that covers common stock (or other securities) to be sold on its behalf to the public in an underwritten offering;
(c) such market stand-off time period shall not exceed one hundred eighty (180) days; and
(d) all of the officers, directors and all other persons with registration rights (whether or not pursuant to this Agreement) enter into similar agreements.
-11-
In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to the Registrable Securities of each Holder (and the shares or securities of every other person subject to the foregoing restriction) until the end of such period.
Notwithstanding the foregoing, the obligations described in this Section 1.14 shall not apply to a registration relating solely to employee benefit plans on Form S-1 or Form S-8 or similar forms that may be promulgated in the future, or a registration relating solely to a Rule 145 transaction under the Act.
1.15 Limitations . The obligations described in Section 1.14(a) shall apply only if all officers and directors of the Company and all other persons with registration rights (whether or not pursuant to this Agreement) enter into similar agreements. If the Company or the underwriter of any public offering of the Companys securities waive or terminate any standoff or lockup restrictions imposed on any holder of securities of the Company, then such waiver or termination shall be granted to all Holders subject to standoff or lockup restrictions pro rata based on the number of shares of Common Stock beneficially held by such holder and the Holders. From and after the date of this Agreement, the Company shall use all reasonable efforts to ensure that all holders of capital stock of the Company agree to be bound by terms substantially similar to those set forth in Section 1.14.
1.16 Transferees Bound . Each Holder agrees that prior to the Companys initial public offering it will not transfer securities of the Company unless each transferee agrees in writing to be bound by all of the provisions of Section 1.14.
1.17 Termination of Registration Rights . The right of any Holder to request registration or inclusion in any registration pursuant to Section 1.2, Section 1.3 or Section 1.4 shall terminate on the earlier of (a) five (5) years following the consummation of a Qualified IPO, or (b) on the consummation of a Qualified IPO if all shares of Registrable Securities held or entitled to be held upon conversion by such Holder may immediately be sold under Rule 144 during any 90-day period, or on such date after the consummation of a Qualified IPO as all shares of Registrable Securities held or entitled to be held upon conversion by such Holder may immediately be sold under Rule 144 during any 90 day period; provided, however, that the provisions of this subsection (b) shall not apply to any Holder who owns more than one percent (1%) of the Companys outstanding stock until such time as such Holder owns less than one percent (1%) of the outstanding stock of the Company.
2. Covenants of the Company .
2.1 Delivery of Financial Statements . The Company shall deliver to each Major Investor:
(a) as soon as practicable, but in any event within ninety (90) days after the end of each fiscal year of the Company, a statement of operations for such fiscal year, a balance sheet of the Company, a statement of cash flows for such fiscal year, and statement of stockholders equity as of the end of such year, such year-end financial reports to be in reasonable detail, prepared in accordance with generally accepted accounting principles (GAAP), and audited and certified by independent public accountants of nationally recognized standing selected by the Company;
(b) as soon as practicable, but in any event within forty-five (45) days after the end of each of the first three (3) quarters of each fiscal year of the Company, an unaudited
-12-
statement of operations, statement of cash flows, and balance sheet for and as of the end of such fiscal quarter;
(c) within thirty (30) days of the end of each month, an unaudited income statement, statement of cash flows, and balance sheet for and as of the end of such month, in reasonable detail;
(d) as soon as practicable, but in any event thirty (30) days prior to the end of each fiscal year, a budget and business plan for the next fiscal year, prepared on a monthly basis, including balance sheets and sources and applications of funds statements for such months and, as soon as prepared, any other budgets or revised budgets prepared by the Company;
(e) with respect to the financial statements called for in subsections (b) and (c) of this Section 2.1, an instrument executed by the Chief Financial Officer or President of the Company and certifying that such financials were prepared in accordance with GAAP consistently applied with prior practice for earlier periods (with the exception of footnotes that may be required by GAAP) and fairly present the financial condition of the Company and its results of operations for the period specified, subject to year-end audit adjustment;
(f) such other information relating to the financial condition, business, prospects or corporate affairs of the Company as the Investor or any assignee of the Investor may from time to time request, provided, however, that the Company shall not be obligated under this Section 2.1 to provide information which it reasonably considers to be a trade secret or similar confidential information;
(g) The term Major Investor means a person or entity that, together with its affiliates, holds at least 700,000 shares (subject to appropriate adjustment for stock splits, stock dividends, combinations or other recapitalizations) of Common Stock (including for this purpose shares issuable upon conversion of outstanding Preferred Stock).
2.2 Inspection . The Company shall permit each Major Investor, at such Major Investors expense, to visit and inspect the Companys properties, to examine its books of account and records and to discuss the Companys affairs, finances and accounts with its officers, all at such reasonable times as may be requested by the Major Investor; provided, however, that the Company shall not be obligated pursuant to this Section 2.2 to provide access to any information that it reasonably considers to be a trade secret or similar confidential information.
2.3 Termination of Information and Inspection Covenants . The covenants set forth in Section 2.1 and Section 2.2 shall terminate as to Investors and be of no further force or effect when the sale of securities pursuant to a registration statement filed by the Company under the Act in connection with the firm commitment underwritten offering of its securities to the general public is consummated or when the Company first becomes subject to the periodic reporting requirements of Sections 12(g) or 15(d) of the 1934 Act, whichever event shall first occur.
2.4 Right of First Offer . Subject to the terms and conditions specified in this Section 2.4, the Company hereby grants to each Investor owning at least 700,000 shares of Preferred Stock (each a Significant Investor) a right of first offer with respect to future sales by the Company of its Shares (as hereinafter defined).
-13-
Each time the Company proposes to offer any shares of, or securities convertible into or exercisable for any shares of, any class of its capital stock (Shares), the Company shall first make an offering of such Shares to each Significant Investor in accordance with the following provisions:
(a) The Company shall deliver a notice by certified mail (Notice) to the Significant Investors stating (i) its bona fide intention to offer such Shares, (ii) the number of such Shares to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such Shares.
(b) Within 15 calendar days after delivery of the Notice, the Significant Investor may elect to purchase or obtain, at the price and on the terms specified in the Notice, up to that portion of such Shares that equals the proportion that the number of shares of Common Stock issued and held, or issuable upon conversion of the Preferred Stock then held, by such Significant Investor bears to the total number of shares of Common Stock of the Company then outstanding (assuming full conversion and exercise of all convertible or exercisable securities). The Company shall promptly, in writing, inform each holder of Preferred Stock that is a Significant Investor that purchases all the shares available to it (Fully-Exercising Investor) of any other Significant Investors failure to do likewise. During the ten-day period commencing after such information is given, each Fully-Exercising Investor shall be entitled to obtain that portion of the Shares not subscribed for by the Significant Investors that is equal to the proportion that the number of shares of Preferred Stock then held (or common stock issued as a result of conversion of shares of Preferred Stock and held) by such Fully-Exercising Investor bears to the total number of shares of Preferred Stock then held (or common stock issued as a result of conversion of shares of Preferred Stock then held) by all Fully-Exercising Investors who wish to purchase some of the unsubscribed shares.
(c) If all Shares referred to in the Notice are not elected to be obtained as provided in Section 2.4(b) hereof, the Company may, during the 30-day period following the expiration of the period provided in Section 2.4(b) hereof, offer the remaining unsubscribed portion of such Shares to any person or persons at a price not less than, and upon terms no more favorable to the offeree than those specified in the Notice. If the Company does not enter into an agreement for the sale of the Shares within such period, or if such agreement is not consummated within 30 days of the execution thereof, the right provided hereunder shall be deemed to be revived and such Shares shall not be offered unless first reoffered to the Significant Investors in accordance herewith.
(d) The right of first offer in this Section 2.4 shall not be applicable (i) to the issuance or sale of Common Stock (or options therefor) to employees, directors, consultants or advisors of the Company (for the primary purpose of soliciting or retaining their employment or services), (ii) to or after consummation of a bona fide, firmly underwritten public offering of shares of common stock, registered under the Act pursuant to a registration statement on Form S-1, (iii) the issuance of securities pursuant to the conversion or exercise of convertible or exercisable securities, (iv) the issuance of securities in connection with a bona fide business acquisition of or by the Company, whether by merger, consolidation, sale of assets, sale or exchange of stock or otherwise, (v) the issuance of stock, warrants or other securities or rights with the approval of the Board of Directors to persons or entities with which the Company has business relationships or (vi) to the sale and issuance by the Company of up to ten million six hundred thirty-eight thousand two hundred ninety eight (10,638,298) shares of Series E Preferred Stock pursuant to the Purchase Agreement. Investors who are party to the Prior Agreement hereby agree to waive notice and observance of the right of first offer set forth in Section 2.4 of the Prior Agreement.
-14-
(e) The right of first offer set forth in this Section 2.4 may not be assigned or transferred, except that (i) such right is assignable by each Investor to any wholly owned subsidiary or parent of, or to any corporation or entity that is, within the meaning of the Act, controlling, controlled by or under common control with, any such Investor, and (ii) such right is assignable between and among any of the Investors.
2.5 Key-Man Insurance; Fire and Casualty Insurance . The Company has as of the date hereof or shall within 90 days of the date hereof use all reasonable efforts to obtain from financially sound and reputable insurers term life insurance on the lives of each of Randal W. Scott, Joffre B. Baker and Steven Shak in the amount or amounts decided in accordance with policies adopted by the Companys Board of Directors. The Company will cause to be maintained the term life insurance required by this Section 2.5 hereof, except as otherwise decided in accordance with policies adopted by the Companys Board of Directors. Such policies shall name the Company as loss payee and shall not be cancelable by the Company without prior approval of the Board of Directors. The Company shall also within 90 days of the date hereof use all reasonable efforts to obtain fire and casualty insurance policies, with extended coverage, sufficient in amount (subject to reasonable deductibles) to allow it to replace any of its properties that might be damaged or destroyed.
2.6 Board of Directors .
(a) Voting .
(i) Board Composition . During the term of this Section 2.6 and subject to Section B.6 of Article IV of the Companys Restated Certificate of Incorporation (the Certificate of Incorporation) and the relevant sections of the Companys Bylaws (if any), each Investor agrees to vote all shares of Company capital stock now or hereafter directly or indirectly acquired (of record or beneficially) by such Investor, in such manner as may be necessary to elect (and maintain in office) as members of the Companys Board of Directors, the following individuals:
(1) three (3) individuals designated by the Investors of Series B Preferred Stock from time to time (each a Series B Designee), as follows:
a) one (1) individual designated by Versant Ventures; so long as Versant Ventures holds at least 1,000,000 shares of Series B Preferred Stock (as appropriately adjusted for all stock splits, dividends, combinations, subdivisions, recapitalizations and the like) (or Common Stock issued upon conversion thereof);
b) one (1) individual designated by Kleiner Perkins Caufield & Byers (KPCB); so long as KPCB holds at least 1,000,000 shares of Series B Preferred Stock (as appropriately adjusted for all stock splits, dividends, combinations, subdivisions, recapitalizations and the like) (or Common Stock issued upon conversion thereof) ;
c) one (1) individual designated by Baker/Tisch Investments; so long as Baker/Tisch Investments holds at least 1,000,000 shares of Series B Preferred Stock (as appropriately adjusted for all stock splits, dividends, combinations, subdivisions, recapitalizations and the like) (or Common Stock issued upon conversion thereof);
(2) one (1) individual designated by a majority of the holders of the Common Stock of the Company from time to time (the Common Stock Designee);
-15-
(3) one (1) individual jointly designated by TPG Biotechnology Partners, L.P. and TPG Ventures, L.P.; so long as there are outstanding at least 1,000,000 shares of Series D Preferred Stock (as appropriately adjusted for all stock splits, dividends, combinations, subdivisions, recapitalizations and the like) (or Common Stock issued upon conversion thereof) (the Series D Designee);
(4) one (1) individual designated by a majority of the holders of the Series E Preferred Stock of the Company from time to time (the Series E Designee);
(5) in the event that holders of the Series C Preferred Stock become entitled, pursuant to the Companys Restated Certificate of Incorporation, to elect one member of the Board of Directors, and so long as Incyte Genomics, Inc. (Incyte) holds at least 1,000,000 shares (as appropriately adjusted for all stock splits, dividends, combinations, subdivisions, recapitalizations and the like) of Series C Preferred Stock (or Common Stock issued upon conversion thereof), the number of members of the Board of Directors shall be increased by one and Incyte shall be entitled to designate the individual to fill such newly created vacancy;
(6) that remaining number of individuals authorized to be elected as directors pursuant to the Companys Bylaws or Certificate of Incorporation designated by a majority of the holders of the Preferred Stock and the Common Stock, voting together as a single class (with the Preferred Stock voting on an as-converted basis) (each such director, an Investors Designee).
For purposes of this Agreement: (i) any individual who is designated for election to the Companys Board of Directors pursuant to the foregoing provisions of this Section 2.6(a) is hereinafter referred to as a Board Designee; and (ii) any individual, entity, or group of individuals and/or entities who has the right to designate one or more Board Designees for election the Companys Board of Directors pursuant to the foregoing provisions of this Section 2.6(a) is hereinafter referred to as a Designator or as Designators, as applicable.
(b) Initial Board Members . The initial Series B Designees shall be Samuel D. Colella, Brook H. Byers and Julian C. Baker; the initial Series D Designee shall be Fred Cohen; the initial Series E Designee shall be Parag Saxena; the initial Investors Designees shall be Kim Popovits and Michael Goldberg; and the initial Common Stock Designee shall be Randal W. Scott.
(c) Changes in Board Designees . From time to time during the term of this Agreement, a Designator or Designators shall, in their sole discretion, have the sole right to:
(i) elect to remove from the Companys Board of Directors any incumbent Board Designee who occupies a Board of Directors seat for which such Designator or Designators are entitled to designate the Board Designee under Section 2.6(a); and/or
(ii) designate a new Board Designee for election to a Board of Directors seat for which such Designator or Designators are entitled to designate the Board Designee under Section 2.6(a) (whether to replace a prior Board Designee or to fill a vacancy in such Board of Directors seat); provided, however, that, such removal and/or designation of a Board Designee is approved in a writing signed by Designators who are entitled to designate such Board Designee under Section 2.6(a), in which case such election to remove a Board Designee and/or elect a new Board Designee will be binding on all such Designators. In the event of such a removal and/or
-16-
designation of a Board Designee under this Section 2.6(c), the Investors shall vote their shares of the Companys capital stock as provided in Section 2.6(a) to cause: the removal from the Companys Board of Directors of the Board Designee or Designees so designated for removal by the appropriate Designator or Designators; and the election to the Companys Board of Directors of any new Board Designee or Designees so designated for election to the Companys Board of Directors by the appropriate Designator or Designators.
(d) Notice . The Company shall promptly give each of the Investors written notice of any change in composition of the Companys Board of Directors and of any proposal by a Designator or Designators to remove or elect a new Board Designee.
(e) Further Assurances . Each of the Investors and the Company agree not to vote any shares of Company capital stock, or to take any other actions, that would in any manner defeat, impair, be inconsistent with or adversely affect the stated intentions of the parties under Section 2.6 of this Agreement.
(f) Term . The provisions of this Section 2.6 shall commence on the initial closing of the sale of shares of Series E Preferred Stock and shall terminate upon the first to occur of the following:
(i) The execution by the Investors holding a majority of the shares of Series A Preferred Stock and Series B Preferred Stock, voting together as a single class, of Investors holding a majority of the shares of Series C Preferred Stock, voting as a single class, of Investors holding a majority of the shares of Series D Preferred Stock, voting as a single class, and of Investors holding a majority of the shares of Series E Preferred Stock, voting as a single class of a written agreement to terminate the provisions of this Section 2.6;
(ii) The consummation of a Qualified IPO; or
(iii) Immediately prior to the closing of a transaction described in Section B.7(g) of Article IV of the Restated Certificate of Incorporation.
2.7 Observer Rights .
(a) As long as Integral Capital Partners VI, L.P., J.P. Morgan Direct Venture Capital Institutional Investors II LLC or CSFB Fund Co-Investment Program, L.P. (in each case individually or together with their respective affiliates) own not less than 700,000 shares (as appropriately adjusted for all stock splits, dividends, combinations, subdivisions, recapitalizations and the like) of Series E Preferred Stock (or Common Stock issued upon conversion thereof) (such shares the Sufficient Observer Shares), the Company shall allow each such party holding Sufficient Observer Shares to designate one representative to attend all meetings of the Companys Board of Directors in a nonvoting capacity, and in connection therewith, the Company shall give such representative copies of all notices, minutes, consents and other materials, financial or otherwise, which the Company provides to its Board of Directors which materials shall be sent to such representative at the same time that they are sent to the Companys Board of Directors; provided, however, that the Company reserves the right to exclude such representative from access to any material or meeting or portion thereof if the Company believes upon advice of counsel that such exclusion is reasonably necessary to preserve the attorney-client privilege, to protect highly confidential information or for other similar reasons. The decision of the Board with respect to the privileged or confidential nature of such information shall be final and binding.
-17-
(b) Term . The provisions of this Section 2.7 shall commence on the initial closing of the sale of shares of Series E Preferred Stock and shall terminate upon the first to occur of the following:
(i) upon the sale of securities pursuant to a registration statement filed by the Company under the Act in connection with the firm commitment underwritten offering of its securities to the general public is consummated or when the Company first becomes subject to the periodic reporting requirements of Sections 12(g) or 15(d) of the 1934 Act, whichever event shall first occur; or
(ii) Immediately prior to the closing of a transaction described in Section B.7(g) of Article IV of the Restated Certificate of Incorporation.
2.8 Common Stock Vesting . Except as otherwise approved by the Board of Directors, all shares of the Companys Common Stock and all options exercisable for shares of the Companys Common Stock (collectively, for purposes of this paragraph only, the Stock) issued or granted, respectively, after the date of this Agreement to employees, directors, consultants and other service providers of the Company (each referred to herein as a Service Provider) shall be subject to a corresponding right of repurchase in favor of the Company (in the case of any outstanding Common Stock) or shall be cancelable by the Company (in the case of any outstanding options for Common Stock), respectively (for purposes of this paragraph only, either such right shall hereinafter be referred to as the Company Right). Unless otherwise approved by the Board of Directors, the Company Right on all such Stock will lapse according to the following vesting schedule: twenty-five percent (25%) of the Stock shall vest, and the Company Right shall lapse accordingly with respect thereto, upon the Service Providers completion of one (1) year of continuous service to the Company from the date of first issuance or grant of the Stock and the remaining seventy-five percent (75%) of the Stock shall thereafter vest, and the Company Right shall lapse accordingly with respect thereto, in successive equal monthly installments upon the Service Providers completion of each of the next thirty-six (36) months of service to the Company.
2.9 Confidentiality . Each Major Investor receiving information under Section 2.1 or Section 2.2 hereby agrees to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided.
2.10 Qualified Small Business Stock Status . If the Company proposes to take an action or engage in a transaction that would reasonably be expected to result in the shares sold to the Investors pursuant to the Purchase Agreement no longer being qualified small business stock within the meaning of Section 1202(c) of the Internal Revenue Code of 1986, as amended (the Code), the Company shall notify the Investors and consult in good faith to devise a mutually agreeable and reasonable alternative course of action or transaction structure that would preserve such status. In addition, the Company shall submit to the Investors and to the Internal Revenue Service any reports that may be required under Section 1202(d)(1)(C) of the Code and any related Treasury Regulations. In addition, within ten days after any Investor has delivered to the Company a written request therefor, the Company shall deliver to such Investor a written statement informing the Investor whether, in the Companys good-faith judgment after a reasonable investigation, such Investors interest in the Company constitutes qualified small business stock as defined in Section 1202(c) of the Code. The Companys obligation to furnish a written statement pursuant to this Section 2.10 shall continue notwithstanding the fact that a class of the Companys stock may be traded on an established securities market.
-18-
2.11 Termination of Certain Covenants . The covenants set forth in Section 2.8 shall terminate and be of no further force or effect upon the consummation of the sale of securities pursuant to a registration statement filed by the Company under the Act in connection with the firm underwritten offering of its securities to the general public.
3. Miscellaneous .
3.1 Successors and Assigns . Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties (including transferees of any shares of Registrable Securities). Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.
3.2 Governing Law . This Agreement shall be governed by and construed under the laws of the State of California as applied to agreements among California residents entered into and to be performed entirely within California.
3.3 Counterparts . This Agreement may be executed in two or more counterparts, including counterparts transmitted by facsimile, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
3.4 Titles and Subtitles . The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.
3.5 Notices . Unless otherwise provided, any notice required or permitted under this Agreement shall be given in writing and shall be deemed effectively given upon personal delivery to the party to be notified, or when sent by telecopier (with receipt confirmed and promptly confirmed by personal delivery, U.S. first class mail, or courier), or upon receipt from overnight courier service, with fees prepaid and addressed to the party to be notified, or upon deposit with the United States Post Office, by registered or certified mail, postage prepaid and addressed to the party to be notified at the address indicated for such party on the signature page hereof, or at such other address as such party may designate by ten (10) days advance written notice to the other parties.
3.6 Expenses . If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable attorneys fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled.
3.7 Amendments and Waivers . Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), other than Section 2.6 which is specifically set forth therein, only with the written consent of the Company and the holders of a majority of the Registrable Securities then outstanding. Any amendment or waiver effected in accordance with this paragraph shall be binding upon each holder of any Registrable Securities then outstanding, each future holder of all such Registrable Securities, the Investors, and the Company.
3.8 Severability . If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms.
-19-
3.9 Aggregation of Stock . Notwithstanding anything to the contrary herein, all shares of Registrable Securities held or acquired by affiliated entities or persons shall be aggregated together for the purpose of determining the availability of any rights under this Agreement.
3.10 Entire Agreement . This Agreement constitutes the entire understanding of the parties with respect to the matters covered herein and supersedes all prior agreements and understandings, written or oral, between the parties relating to the subject matter hereof.
3.11 Termination of Prior Agreement . Pursuant to Section 2.6 and Section 3.7 of the Prior Agreement, Company and the Investors hereby consent to the amendment and restatement of the Prior Agreement as set forth herein effective upon the date of this Agreement, and thereafter the Prior Agreement shall be terminated and be of no further force and effect, and shall be superseded and replaced in its entirety by this Agreement.
3.12 Subsequent Closings . In the event that the Company shall conduct subsequent sales of Series E Preferred Stock pursuant to and in accordance with the terms of Section 1.3 of the Purchase Agreement, as the same may be amended from time to time, any holder of such shares of Series E Preferred Stock shall be deemed an Investor with all of the rights of an Investor under this Agreement; provided, that as a condition thereto such Investor and the Company shall sign a counterpart signature page to this Agreement.
3.13 Agreement as to Voting Shares . In the event the Company is required, in accordance with Section B.5(d) of Article IV of the Certificate of Incorporation, to create and reserve for issuance new series of Preferred Stock, each Investor agrees to vote their shares and to take all such actions as may be required, including voting in favor of amending the Companys Certificate of Incorporation, in order to effectuate the provisions of Section B.5(d) of Article IV of the Certificate of Incorporation.
[remainder of page intentionally left blank]
-20-
IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.
GENOMIC HEALTH, INC. | ||||||
|
||||||
By: | /s/ Randal W. Scott | |||||
|
Name: | Randal W. Scott | ||||
|
Title: | Chief Executive Officer | ||||
|
||||||
Address: | 301 Penobscot Drive | |||||
|
Redwood City, CA 94063 |
-21-
INVESTOR SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT
BY AND AMONG
GENOMIC HEALTH, INC.
AND EACH INVESTOR NAMED THEREIN
The undersigned hereby executes and delivers the Genomic Health, Inc. Amended and Restated Investors Rights Agreement (the Agreement) to which this Signature Page is attached effective as of the date of this Agreement, which Agreement and Signature Page, together with all counterparts of such Agreement and signature pages of the other Investors named in such Investors Rights Agreement, shall constitute one and the same document in accordance with the terms of such Agreement.
|
/s/ Investors as set forth on Schedule A | |
|
||
|
Name: | |
|
Title: |
SCHEDULE A
Schedule of Investors
Randal W. Scott
Morgan Stanley DW Inc., Custodian for Randal W. Scott, IRA
Marian N. Marra
Joffre B. Baker and Diana J. Baker 1998 Trust dtd. October 29, 1998
Donald N. Scott Living Trust dtd. 11/20/95
Patricia E. Scott Living Trust dtd. 11/20/95
Mike E. Todd
Terri E. Todd
Richard E. Crowder DDS, Profit Sharing Plan f/b/o Richard E. Crowder
Richard E. Crowder DDS, Profit Sharing Plan f/b/o Deborah E. Crowder
Deborah E. Crowder
Fred E. Cohen
Craig G. Wilde
Steven Shak
Stanton D. Wong
PM&S Venture Fund III, LLC
The Jon S. Saxe & Myrna G. Marshall 1997 Trust
Evergreen Trust
Incyte Genomics, Inc.
CHL Medical Partners, L.P.
Todd Henderson
Versant Affiliates Fund I-A, L.P.
Versant Affiliates Fund I-B L.P.
Versant Side Fund I, L.P.
Versant Venture Capital I, L.P.
KPCB Holdings Inc., as nominee
Four Partners
Baker Brothers Investments, L.P.
Baker Tisch Investments, L.P.
Baker Biotech Fund I, L.P.
Baker Biotech Fund II, L.P.
Baker Biotech Fund II (Z), L.P.
Baker Biotech Fund III, L.P.
Baker Biotech Fund III (Z), L.P.
Baker Brothers Investments II, L.P.
FBB Associates
TPG Ventures, L.P.
TPG Biotechnology Partners, L.P.
Lisa Janssen
J.P. Morgan Partners (BHCA) , L.P.
J.P. Morgan Partners Global Investors, L.P.
J.P. Morgan Partners Global Investors (Cayman), L.P.
J.P. Morgan Partners Global Investors A, L.P.
J.P. Morgan Partners Global Investors (Cayman) II, L.P.
J.P. Morgan Direct Venture Capital Institutional Investors II LLC
J.P. Morgan Direct Venture Capital Private Investors II LLC
552 Fifth Avenue Fund, L.P.
Hornthal Investment Partners, L.P.
Kevin and Haeyoung Tang
The Tang Fund
Tang Capital Partners, LP
Integral Capital Partners VI, L.P
CSFB Fund Co-Investment Program, L.P.
Citiventure 2000, L.P.
Chancellor V, L.P.
Chancellor V-A, L.P.
The V Foundation for Cancer Research
Duke VC Coinvestment Fund
SF Growth Fund
Richard and Deborah Crowder
Mario Family Partners
Joseph Klein III
Gene Early
Marguerite Montgomery
David H. Logan
Patrick M. Hall
Kathleen and Roger Konrad
James L. Snable
Karen Burns
Patricia D. McClay and Thomas S. McClay
Invesco/Chancellor BioMedical Fund, L.P.
Invesco/Chancellor BioMedical Fund (C), L.P.
Alpha Technology, Ltd.
Pfizer Overseas Pharmaceuticals
The Jason and Jennifer Lurie Revocable Trust dated June 5, 2003
Daniel and Ruth Dashiell Family Trust
Goldberg Family Trust
Randall S. Livingston and Lori Livingston, as Community Property
G. Bradley Cole
Rina and Richard A. Wolf
Martha Nash Haskins
Andrew Todd Sundberg
Susan Liebowitz and Michael Liebowitz
Kristan J. Weinberg
Jean Heanue Crowley
Dominick V. Sinicropi
UBS for Benefit of Kimberly Popovits
Aikaterini Gekas and Constantine Gekas
James Ross Hackett and Shala Ruth Ball
Michael Paletta
Albert S. Petty
James J. Vaughn and Margaret Vaughn, as trustees of the James and Margaret Vaughn, 2001 Trust
Larry Fitzgerald and Jessica Fitzgerald
Jeff Allan Jankowski
RP & NP L.L.C.
Edward O. Snelgrove
Mei-Lan Liu and Yung-Hsiang Kao
Dean Schorno IRA Charles Schwab Custodian
Yifan Mao and Xitong Li
Laura and Kenneth A. Beggrow
Patty Dumond
Exhibit 10.2
Genomic Health, Inc.
2001 Stock Incentive Plan
Adopted by the Board on January 3, 2001
Approved by Stockholders on January 3, 2001
TABLE OF CONTENTS
Page | ||||||
SECTION 1.
|
PURPOSE | 1 | ||||
|
||||||
SECTION 2.
|
DEFINITIONS | 1 | ||||
2.1
|
Award | 1 | ||||
2.2
|
Board | 1 | ||||
2.3
|
Change in Control | 1 | ||||
2.4
|
Code | 2 | ||||
2.5
|
Committee | 2 | ||||
2.6
|
Company | 2 | ||||
2.7
|
Consultant | 2 | ||||
2.8
|
Disability | 2 | ||||
2.9
|
Employee | 2 | ||||
2.10
|
Exchange Act | 2 | ||||
2.11
|
Exercise Price | 3 | ||||
2.12
|
Fair Market Value | 3 | ||||
2.13
|
ISO | 3 | ||||
2.14
|
NSO | 3 | ||||
2.15
|
Offeree | 3 | ||||
2.16
|
Option | 3 | ||||
2.17
|
Optionee | 3 | ||||
2.18
|
Outside Director | 3 | ||||
2.19
|
Parent | 3 | ||||
2.20
|
Plan | 4 | ||||
2.21
|
Purchase Price | 4 | ||||
2.22
|
Purchaser | 4 | ||||
2.23
|
Restricted Share | 4 | ||||
2.24
|
Restricted Share Agreement | 4 | ||||
2.25
|
Securities Act | 4 | ||||
2.26
|
Service | 4 | ||||
2.27
|
Share | 4 | ||||
2.28
|
Stock | 4 | ||||
2.29
|
Stock Option Agreement | 4 | ||||
2.30
|
Subsidiary | 4 | ||||
2.31
|
Ten-Percent Stockholder | 4 | ||||
|
||||||
SECTION 3.
|
ADMINISTRATION | 5 | ||||
3.1
|
General Rule | 5 | ||||
3.2
|
Committee Composition | 5 | ||||
3.3
|
Committee Procedures | 5 | ||||
3.4
|
Board Responsibilities | 5 | ||||
|
||||||
SECTION 4.
|
ELIGIBILITY | 7 | ||||
4.1
|
General Rule | 7 |
-i-
Page | ||||||
SECTION 5.
|
STOCK SUBJECT TO PLAN | 7 | ||||
5.1
|
Share Limit | 7 | ||||
5.2
|
Additional Shares | 7 | ||||
|
||||||
SECTION 6.
|
RESTRICTED SHARES | 7 | ||||
6.1
|
Restricted Share Agreement | 7 | ||||
6.2
|
Duration of Offers | 7 | ||||
6.3
|
Payment for Awards | 7 | ||||
6.4
|
Purchase Price | 8 | ||||
6.5
|
Vesting and Right to Repurchase | 8 | ||||
|
||||||
SECTION 7.
|
STOCK OPTIONS | 8 | ||||
7.1
|
Stock Option Agreement | 8 | ||||
7.2
|
Number of Shares; Kind of Option | 8 | ||||
7.3
|
Exercise Price | 9 | ||||
7.4
|
Term | 9 | ||||
7.5
|
Exercisability | 9 | ||||
7.6
|
Vesting | 9 | ||||
7.7
|
Effect of Change in Control | 10 | ||||
7.8
|
Payment for Option Shares | 10 | ||||
7.9
|
Leaves of Absence | 11 | ||||
7.10
|
Exercise of Options on Termination of Service | 11 | ||||
7.11
|
No Rights as a Stockholder | 12 | ||||
7.12
|
Modification, Extension and Renewal of Options | 12 | ||||
7.13
|
Buyout Provisions | 12 | ||||
|
||||||
SECTION 8.
|
ADJUSTMENT OF SHARES | 12 | ||||
8.1
|
Adjustments | 12 | ||||
8.2
|
Dissolution or Liquidation | 12 | ||||
8.3
|
Reorganizations | 12 | ||||
8.4
|
Reservation of Rights | 13 | ||||
|
||||||
SECTION 9.
|
TRANSFER RESTRICTIONS AND REPURCHASE RIGHTS | 13 | ||||
9.1
|
Nontransferability of Rights | 13 | ||||
9.2
|
Transfer of Restricted Shares to Trusts | 13 | ||||
9.3
|
Transferability of Options | 13 | ||||
9.4
|
Assignment | 13 | ||||
9.5
|
Restrictions on Transfer of Shares | 13 | ||||
9.6
|
Companys Right To Repurchase Shares | 14 | ||||
|
||||||
SECTION 10.
|
WITHHOLDING TAXES | 14 | ||||
10.1
|
General | 14 | ||||
10.2
|
Share Withholding | 14 | ||||
10.3
|
Cashless Exercise/Pledge | 15 | ||||
10.4
|
Other Forms of Payment | 15 |
-ii-
Page | ||||||
SECTION 11.
|
SECURITIES LAW REQUIREMENTS | 15 | ||||
11.1
|
General | 15 | ||||
11.2
|
Voting and Dividend Rights | 15 | ||||
11.3
|
Financial Reports | 15 | ||||
|
||||||
SECTION 12.
|
NO EMPLOYMENT RIGHTS | 15 | ||||
|
||||||
SECTION 13.
|
DURATION AND AMENDMENTS | 15 | ||||
13.1
|
Term of the Plan | 15 | ||||
13.2
|
Right to Amend or Terminate the Plan | 16 | ||||
13.3
|
Effect of Amendment or Termination | 16 | ||||
|
||||||
SECTION 14.
|
EXECUTION | 16 |
-iii-
No Early Exercise
Genomic Health, Inc.
2001 Stock Incentive Plan
SECTION 1. PURPOSE .
The Plan was adopted by the Board of Directors effective January 2, 2001. The purpose of the Plan is to promote the long-term success of the Company and the creation of stockholder value by (a) encouraging Employees, Outside Directors and Consultants to focus on critical long-range objectives; (b) encouraging the attraction and retention of Employees, Outside Directors and Consultants with exceptional qualifications; and (c) linking Employees, Outside Directors and Consultants directly to stockholder interests through increased stock ownership. The Plan seeks to achieve this purpose by providing for awards in the form of Restricted Shares and Options (which may constitute incentive stock options or nonstatutory stock options).
The grant of Awards and Options under the Plan is intended to be exempt from the securities qualification requirements of the California Corporations Code by satisfying the exemption under section 25102(o) of the California Corporations Code. However, Awards and Options may be awarded in reliance upon other state securities law exemptions. To the extent that such other exemptions are relied upon, the terms of this Plan which are included only to comply with section 25102(o) shall be disregarded to the extent provided in the Stock Option Agreement or Restricted Share Agreement.
SECTION 2. DEFINITIONS .
2.1 | Award shall mean any award of the right to purchase Restricted Shares under the Plan. | |||
2.2 | Board shall mean the Board of Directors of the Company, as constituted from time to time. If a Committee has been appointed to administer the Plan, any reference to the Board in the Plan shall be construed as a reference to the Committee to whom the Board has assigned a particular function. | |||
2.3 | Change in Control shall mean the occurrence of any of the following events: |
(a) | The consummation of a merger or consolidation of the Company with or into another entity or any other corporate reorganization, if persons who were not stockholders of the Company immediately prior to such merger, consolidation or other reorganization own immediately after such merger, consolidation or other reorganization fifty percent (50%) or more of the voting power of the outstanding securities of each of (A) the continuing or surviving entity and (B) any direct or indirect parent corporation of such continuing or surviving entity; | |||
(b) | The consummation of the sale, transfer or other disposition of all or substantially all of the Companys assets or the stockholders of the Company approve a plan of complete liquidation of the Company; or |
No Early Exercise
(c) | Any person (as defined below) who, by the acquisition or aggregation of securities, is or becomes the beneficial owner (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the combined voting power of the Companys then outstanding securities ordinarily (and apart from rights accruing under special circumstances) having the right to vote at elections of directors (the Base Capital Stock); except that any change in the relative beneficial ownership of the Companys securities by any person resulting solely from a reduction in the aggregate number of outstanding shares of Base Capital Stock, and any decrease thereafter in such persons ownership of securities, shall be disregarded until such person increases in any manner, directly or indirectly, such persons beneficial ownership of any securities of the Company. |
For purposes of Section 2.3(c), the term person shall have the same meaning as when used in sections 13(d) and 14(d) of the Exchange Act but shall exclude (1) a trustee or other fiduciary holding securities under an employee benefit plan maintained by the Company or a Parent or Subsidiary and (2) a corporation owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of the Stock.
Notwithstanding the foregoing, the term Change in Control shall not include a transaction the sole purpose of which is (a) to change the state of the Companys incorporation, (b) to form a holding company that will be owned in substantially the same proportions by the persons who held the Companys securities immediately before such transaction; or (c) to make an initial public offering of the Companys Stock.
2.4
Code
shall mean the Internal Revenue Code of 1986, as amended.
2.5
Committee
shall mean the committee designated by the Board, which is
authorized to administer the Plan, as described in Section 3 hereof.
2.6
Company
shall mean Genomic Health, Inc., a Delaware corporation.
2.7
Consultant
shall mean a consultant or advisor who is not an Employee and who
provides bona fide services to the Company, its Parent or Subsidiary as an independent
contractor or a member of the board of directors of a Parent or a Subsidiary. Service as a
Consultant shall be considered Service for all purposes of the Plan.
2.8
Disability
shall mean a condition that renders an individual unable to
engage in substantial gainful activity by reason of any medically determinable physical or
mental impairment.
2.9
Employee
shall mean any individual who is a common-law employee of the
Company, a Parent or a Subsidiary and who is an employee within the meaning of section
3401(c) of the Code and regulations issued thereunder.
2.10
Exchange Act
shall mean the Securities and Exchange Act of 1934, as
amended.
No Early Exercise
2.11 | Exercise Price shall mean the amount for which one Share may be purchased upon the exercise of an Option, as specified in a Stock Option Agreement. | |||
2.12 | Fair Market Value means, with respect to a Share, the market price of one Share of Stock, determined by the Board as follows: |
(a) | If the Stock was traded over-the-counter on the date in question but was not traded on The Nasdaq Stock Market, then the Fair Market Value shall be equal to the last transaction price quoted for such date by the OTC Bulletin Board or, if not so quoted, shall be equal to the mean between the last reported representative bid and asked prices quoted for such date by the principal automated inter-dealer quotation system on which the Stock is quoted or, if the Stock is not quoted on any such system, by the Pink Sheets published by the National Quotation Bureau, Inc.; | |||
(b) | If the Stock was traded on The Nasdaq Stock Market, then the Fair Market Value shall be equal to the last reported sale price quoted for such date by The Nasdaq Stock Market; | |||
(c) | If the Stock was traded on a United States stock exchange on the date in question, then the Fair Market Value shall be equal to the closing price reported for such date by the applicable composite-transactions report; and | |||
(d) | If none of the foregoing provisions is applicable, then the Fair Market Value shall be determined by the Board in good faith on such basis as it deems appropriate. |
In all cases, the determination of Fair Market Value by the Board shall be conclusive and binding on all persons.
2.13
ISO
shall mean an incentive stock option described in section 422(b) of the Code.
2.14
NSO
shall mean an stock option that is not an ISO.
2.15
Offeree
shall mean an Employee, Consultant or Outside Director to whom the Board
has granted an Award of Restricted Shares under the Plan.
2.16
Option
shall mean an ISO or NSO granted under the Plan and entitling the holder to
purchase Shares.
2.17
Optionee
shall mean an individual or estate that holds an Option.
2.18
Outside Director
shall mean a member of the Board of the Company, a Parent or a
Subsidiary who is not a common-law employee of the Company, Parent or a Subsidiary. Service
as an Outside Director shall be considered Service for all purposes of the Plan.
2.19
Parent
shall mean any corporation (other than the Company) in an unbroken chain of
corporations ending with the Company, if each of the corporations other than the Company owns
stock possessing fifty percent (50%) or more of the total combined voting power of all classes
of stock in one of the other corporations in such chain. A
No Early Exercise
corporation that attains the
status of a Parent on a date after the adoption of the Plan shall be considered a Parent
commencing as of such date.
2.20
Plan
shall mean the Genomic Health, Inc. 2001 Stock Incentive Plan.
2.21
Purchase Price
shall mean the consideration for which a Restricted Share may be
acquired under the Plan.
2.22
Purchaser
shall mean an eligible individual who has acquired Stock under the Plan
through an Award of Restricted Shares or through the exercise of an Option.
2.23
Restricted Share
shall mean a Share awarded under the Plan which is either
nontransferable, subject to a substantial risk of forfeiture, or both.
2.24
Restricted Share Agreement
shall mean the agreement between the Company and the
recipient of a Restricted Share which contains the terms, conditions and restrictions
pertaining to such Restricted Shares.
2.25
Securities Act
shall mean the Securities Act of 1933, as amended.
2.26
Service
shall mean service as an Employee, a Consultant or an Outside Director.
2.27
Share
shall mean one share of Stock, as adjusted in accordance with Section 8 (if
applicable).
2.28
Stock
shall mean the common stock of the Company.
2.29
Stock Option Agreement
shall mean the agreement between the Company and an
Optionee which contains the terms, conditions and restrictions pertaining to the Optionees
Option.
2.30
Subsidiary
means any corporation (other than the Company) in an unbroken chain of
corporations beginning with the Company, if each of the corporations other than the last
corporation in the unbroken chain owns stock possessing fifty percent (50%) or more of the
total combined voting power of all classes of stock in one of the other corporations in such
chain. A corporation that attains the status of a Subsidiary on a date after the adoption
of the Plan shall be considered a Subsidiary commencing as of such date.
2.31
Ten-Percent Stockholder
means an individual who owns more than ten percent (10%)
of the total combined voting power of all classes of outstanding stock of the Company, its
Parent or any of its Subsidiaries. In determining stock ownership, the attribution rules of
section 424(d) of the Code shall apply solely for purposes of Sections 7.3(a) and 7.4 hereof.
An individual shall be deemed to own the stock owned, directly or indirectly, by or for his or
her brothers, sisters, spouse, ancestors and lineal descendants. Stock owned, directly or
indirectly, by or for a corporation, partnership, estate or trust shall be deemed to be owned
proportionately by or for its stockholders, partners or beneficiaries. Stock with respect to
which such individual holds an Option shall not be counted. Outstanding
No Early Exercise
stock shall include all stock actually issued and outstanding immediately after the grant but shall not include Shares authorized for issuance under outstanding Options held by any individual.
SECTION 3. ADMINISTRATION.
3.1 | General Rule . The Plan shall be administered by the Board. However, the Board may delegate any or all administrative functions under the Plan otherwise exercisable by the Board to a Committee. The Board shall designate one of the members of the Committee as chairman. Members of the Committee shall serve for such period of time as the Board may determine and shall be subject to removal by the Board at any time. The Board may also at any time terminate the functions of the Committee and reassume all powers and authority of the Board previously delegated to the Committee. If a Committee has been appointed, any reference to the Board in the Plan shall be construed as a reference to the Committee to whom the Board has assigned a particular function. | |||
3.2 | Committee Composition . The Committee shall consist of one or more members of the Board who have been appointed by the Board. If the Companys Stock becomes publicly traded, the composition of the Committee shall satisfy (i) such requirements as the Securities and Exchange Commission may establish for administrators acting under plans intended to qualify for exemption under Rule 16b-3 (or its successor) under the Exchange Act; and (ii) such requirements as the Internal Revenue Service may establish for outside directors acting under plans intended to qualify for exemption under section 162(m)(4)(C) of the Code. The Board may also appoint one or more separate committees of the Board, each composed of one or more directors of the Company who need not satisfy the requirements of the previous sentence, who may administer the Plan with respect to Employees who are not considered officers or directors of the Company under section 16 of the Exchange Act, may grant Awards or Options under the Plan to such Employees and may determine all terms of such grants. Within the limitations of the preceding sentence, any reference in the Plan to the Committee shall include such committee or committees appointed pursuant to the preceding sentence. | |||
3.3 | Committee Procedures . The Committee may hold meetings at such times and places as it shall determine. The acts of a majority of the Committee members present at meetings at which a quorum exists, or acts reduced to or approved in writing by all Committee members, shall be valid acts of the Committee. | |||
3.4 | Board Responsibilities . Subject to the provisions of the Plan, the Board shall have the discretionary authority to take the following actions: |
(a) | To interpret the Plan and to apply its provisions; | |||
(b) | To adopt, amend or rescind rules, procedures and forms relating to the Plan; | |||
(c) | To authorize any person to execute, on behalf of the Company, any instrument required to carry out the purposes of the Plan; |
No Early Exercise
(d) | To determine when Restricted Shares are to be awarded or offered for sale and when Options are to be granted under the Plan; | |||
(e) | To select Offerees and Optionees; | |||
(f) | To determine the number of Restricted Shares to be offered to each Offeree or to be made subject to each Option; | |||
(g) | To prescribe the terms and conditions of each Award of Shares, including (without limitation) the Purchase Price and the vesting of the Award (including accelerating the vesting of awards), and to specify the provisions of the Restricted Share Agreement relating to such Award; | |||
(h) | To prescribe the terms and conditions of each Option, including (without limitation) the Exercise Price, the vesting or duration of the Option (including accelerating the vesting of the Option), to determine whether such Option is to be classified as an ISO or as an NSO, and to specify the provisions of the Stock Option Agreement relating to such Option; | |||
(i) | To amend any outstanding Restricted Share Agreement or Stock Option Agreement, subject to applicable legal restrictions and to the consent of the Purchaser or Optionee who entered into such agreement; | |||
(j) | To prescribe the consideration for the grant of Award under the Plan and to determine the sufficiency of such consideration; | |||
(k) | To determine the disposition of each Option or Award under the Plan in the event of an Optionees or Offerees divorce or dissolution of marriage; | |||
(l) | To determine whether Options or Awards under the Plan will be granted in replacement of other grants under an incentive or other compensation plan of an acquired business; | |||
(m) | To determine all questions relating to Service of an Employee, Consultant or Outside Director, including, but not limited to, the date on which such Service has commenced and ended and the length of such Service for purposes of vesting under the Plan; | |||
(n) | To process claims; | |||
(o) | To correct any defect, supply any omission or reconcile any inconsistency in the Plan, any Stock Option Agreement or any Restricted Share Agreement; and | |||
(p) | To take any other actions deemed necessary or advisable for the administration of the Plan. |
All decisions, interpretations and other actions of the Board shall be final and binding on all persons. No member of the Board shall be liable for any action that he or she has
No Early Exercise
taken or has failed to take in good faith with respect to the Plan, any Option, or any Award of Restricted Shares under the Plan.
SECTION 4. ELIGIBILITY .
4.1 | General Rule . Only Employees shall be eligible for the grant of ISOs. Only Employees, Consultants and Outside Directors shall be eligible for the grant of Restricted Shares or NSOs. |
SECTION 5. STOCK SUBJECT TO PLAN .
5.1 | Share Limit . Shares offered under the Plan shall be authorized but unissued Shares. Subject to Section 5.2, the aggregate number of Shares which may be issued or transferred under the Plan shall not exceed 3,500,000 Shares, subject to adjustment pursuant to Section 8. The number of Shares which are subject to Awards and Options shall not exceed the number of Shares which then remain available for issuance under the Plan, and the Company, during the term of the Plan, shall at all times reserve and keep available sufficient Shares to satisfy the requirements of the Plan. Notwithstanding the foregoing, at no time shall the total number of Shares that may be issued upon the exercise of all outstanding Options and the total number of Shares provided under any stock bonus or similar plan of the Company exceed thirty percent (30%) of all outstanding shares of the Company, unless a higher percentage is approved by an affirmative vote of at least two-thirds (2/3) of the Companys Shares entitled to vote. | |||
5.2 | Additional Shares . In the event that any outstanding Option or Award expires or is canceled for any reason, the Shares allocable to the unexercised portion of such Option or Award shall again be available for the purposes of the Plan. If a Share acquired under the Plan is forfeited or repurchased, then such Share shall again become available for award under the Plan, except that the aggregate number of Shares that may be issued upon the exercise of ISOs shall in no event exceed 3,500,000, as adjusted pursuant to Section 8. |
SECTION 6. RESTRICTED SHARES .
6.1 | Restricted Share Agreement . Each Award of Restricted Shares shall be evidenced by a Restricted Share Agreement between the recipient and the Company. Such Award shall be subject to all applicable terms and conditions of the Plan and may be subject to any other terms and conditions imposed by the Board, as set forth in the Restricted Share Agreement, that are not inconsistent with the Plan. The provisions of the various Restricted Share Agreements entered into under the Plan need not be identical. | |||
6.2 | Duration of Offers . Any right to acquire Restricted Shares shall automatically expire if not exercised by the Offeree within thirty (30) days after the Board communicated the grant of such right to the Offeree. | |||
6.3 | Payment for Awards . The Purchase Price for Restricted Shares may be paid with cash, cash equivalents or a full-recourse promissory note. Restricted Shares also may be awarded in consideration of past services to the Company, a Parent or Subsidiary. |
No Early Exercise
However, if the Restricted Shares to be awarded are newly issued, payment in the form of a promissory note shall only be permitted if the Offeree pays the par value of the Restricted Shares in cash or cash equivalents. In the case of a promissory note, the Restricted Shares shall be pledged as security for the payment of the principal amount of the promissory note and interest thereon.
6.4 | Purchase Price . The Purchase Price per Share to be offered under the Plan shall not be less than eighty-five percent (85%) of the Fair Market Value of a Share on the date of grant. The Purchase Price per Share to be offered under the Plan to a Ten-Percent Stockholder shall not be less than one hundred percent (100%) of the Fair Market Value of a Share on the date of grant. Subject to the foregoing in this Section 6.4, the amount of the Purchase Price shall be determined by the Board in its discretion. | |||
6.5 | Vesting and Right to Repurchase . Each Award of Restricted Shares may or may not be subject to vesting or to a right of repurchase by the Company. Vesting shall occur, in full or in installments, upon satisfaction of the conditions specified in the Restricted Share Agreement. The Companys right of repurchase shall comply with the requirements of Section 9. A Restricted Share Agreement may provide for accelerated vesting in the event of the Offerees death, Disability or retirement or other events. The Board may determine, at the time of the Award of Restricted Shares or thereafter, that all or part of such Restricted Shares shall become vested in the event that a Change in Control occurs with respect to the Company. |
SECTION 7. STOCK OPTIONS .
7.1 | Stock Option Agreement . Each grant of an Option under the Plan shall be evidenced by a Stock Option Agreement between the Optionee and the Company. Such Option shall be subject to all applicable terms and conditions of the Plan and may be subject to any other terms and conditions imposed by the Board, as set forth in the Stock Option Agreement, which are not inconsistent with the Plan. The provisions of the various Stock Option Agreements entered into under the Plan need not be identical. A Stock Option Agreement may provide that a new Option will be granted automatically to the Optionee when he or she exercises a prior Option and pays the Exercise Price. | |||
7.2 | Number of Shares; Kind of Option . Each Stock Option Agreement shall specify the number of Shares that are subject to the Option and shall provide for the adjustment of such number in accordance with Section 8. The Stock Option Agreement shall also specify whether the Option is an ISO or an NSO. Of all Options held by an Optionee that become exercisable in the same calendar year, only Options covering Stock with an aggregate Fair Market Value of $100,000 or less will qualify as ISOs and any Options in excess of $100,000 shall be treated as NSOs. For purposes of the requirement in the previous sentence, ISOs shall be taken into account in the order in which they were granted, and the Fair Market Value of the Stock shall be determined on the date that the Option was granted. |
No Early Exercise
7.3 | Exercise Price . Each Stock Option Agreement shall set forth the Exercise Price. Subject to the following requirements, the Exercise Price under any Option shall be determined by the Board in its sole discretion: |
(a) | Minimum Exercise Price for ISOs . The Exercise Price per Share of an ISO shall not be less than one hundred percent (100%) of the Fair Market Value of a Share on the date of grant. The Exercise Price per Share of an ISO granted to a Ten-Percent Stockholder shall not be less than one hundred ten percent (110%) of the Fair Market Value of a Share on the date of grant. | |||
(b) | Minimum Exercise Price for NSOs . The Exercise Price per Share of an NSO shall not be less than eighty-five percent (85%) of the Fair Market Value of a Share on the date of grant. The Exercise Price per Share of an NSO granted to a Ten-Percent Stockholder shall not be less than one hundred ten percent (110%) of the Fair Market Value of a Share on the date of grant. |
7.4 | Term . Each Stock Option Agreement shall specify the term of the Option. The term of an Option shall in no event exceed ten (10) years from the date of grant. The term of an ISO granted to a Ten-Percent Stockholder shall not exceed five (5) years from the date of grant. Subject to the foregoing, the Board in its sole discretion shall determine when an Option shall expire. | |||
7.5 | Exercisability . Each Stock Option Agreement also shall specify the date when all or any installment of the Option is to become exercisable. Subject to the following restrictions, the Board in its sole discretion shall determine when all or any installment of an Option is to become exercisable and may, in its discretion, provide for accelerated exercisability in the event of a Change in Control, the Optionees death, Disability or retirement or other events: |
(a) | Options Granted to Employees . An Option granted to an Employee who is not an officer of the Company, a Parent or a Subsidiary shall be exercisable at the minimum rate of twenty percent (20%) per year for each of the first five (5) years starting from the date of grant, subject to reasonable conditions such as continued Service. | |||
(b) | Options Granted to Outside Directors, Consultants or Officers . An Option granted to an Outside Director, a Consultant or an officer of the Company, a Parent or a Subsidiary shall be exercisable at any time or during any period established by the Board, subject to reasonable conditions such as continued Service. | |||
(c) | Exercise Prior to Vesting . A Stock Option Agreement may permit the Optionee to exercise the Option as to Shares that have not vested, subject to the Companys right to repurchase any Shares that have not vested when the Optionees Service terminates at the original Exercise Price, in accordance with Section 9.5. |
7.6 | Vesting . Each Stock Option Agreement shall specify the date when all or any Shares subject to the Option shall be vested. Subject to the following restrictions, the Board in |
No Early Exercise
its sole discretion shall determine when all or any portion of the Shares subject to an Option shall be vested and may, in its discretion, provide for accelerated vesting in the event of a Change in Control, the Optionees death, Disability or retirement or other events and may provide for the cessation of vesting prior to the end of its term in the event of the termination of the Optionees Service:
(a) | Options Granted to Employees . An Option granted to an Employee who is not an officer of the Company, a Parent or a Subsidiary shall provide that the Shares subject to such Option shall become vested at the minimum rate of twenty percent (20%) per year for each of the first five (5) years starting from the date of grant, subject to reasonable conditions such as continued Service. | |||
(b) | Options Granted to Outside Directors, Consultants or Officers . An Option granted to an Outside Director, a Consultant or an officer of the Company, a Parent or a Subsidiary shall provide that the Shares subject to such Option shall become vested at any time or during any period established by the Board, subject to reasonable conditions such as continued Service. |
7.7 | Effect of Change in Control . The Board may determine, at the time of granting an Option or thereafter, that such Option shall become exercisable and/or shall vest in whole or in part with respect to the Shares subject to such Option in the event that a Change in Control occurs with respect to the Company before the Optionees Service with the Company terminates, provided that (i) in the case of an ISO, the acceleration of exercisability and/or vesting shall not occur without the Optionees written consent; and (ii) if the Company and the other party to the transaction constituting a Change in Control agree that such transaction is to be treated as a pooling of interests for financial reporting purposes, and if such transaction in fact is so treated, then the acceleration of exercisability shall not occur to the extent that the Companys independent accountants and such other partys independent accountants separately determine in good faith that such acceleration would preclude the use of pooling of interests accounting. | |||
7.8 | Payment for Option Shares . The entire Exercise Price shall be payable in cash, cash equivalents or one of the following forms: |
(a) | Surrender of Stock . To the extent that a Stock Option Agreement so provides, payment may be made all or in part with Shares which have already been owned by the Optionee or the Optionees representative for at least six (6) months (or any other time period specified by Board) and which are surrendered to the Company in good form for transfer. Such Shares shall be valued at their Fair Market Value on the date when the new Shares are purchased under the Plan. | |||
(b) | Promissory Notes . To the extent that a Stock Option Agreement so provides, payment may be made in whole or in part with a full-recourse promissory note executed by the Optionee. The interest rate and other terms and conditions of such note shall be determined by the Board. The Board may require that the Optionee pledge his or her Shares to the Company for the purpose of securing the payment of |
No Early Exercise
such note. In no event shall the stock certificate(s) representing such Shares be released to the Optionee until such note is paid in full.
(c) | Cashless Exercise . To the extent that a Stock Option Agreement so provides and a public market for the Shares exists, payment may be made in whole or in part by delivery (on a form prescribed by the Board) of an irrevocable direction to a securities broker to sell Shares and to deliver all or part of the sale proceeds to the Company in payment of the aggregate Exercise Price. | |||
(d) | Exercise/Pledge . To the extent that a Stock Option Agreement so provides and a public market for the Shares exists, payment may be made in whole or in part by delivery (on a form prescribed by the Committee) of an irrevocable direction to a securities broker or lender to pledge Shares, as security for a loan, and to deliver all or part of the loan proceeds to the Company in payment of the aggregate Exercise Price. | |||
(e) | Other Forms of Payment . To the extent provided in the Stock Option Agreement, payment may be made in any other form that is consistent with applicable laws, regulations and rules. |
7.9
Leaves of Absence
. An Employees Service shall cease when such
Employee ceases to be actively employed by, or ceases to be a consultant or adviser to, the
Company (or any subsidiary) as determined in the sole discretion of the Board. For purposes
of Options, Service does not terminate when an Employee goes on a bona fide leave of
absence, that was approved by the Company in writing, if the terms of the leave provide for
continued service crediting, or when continued service crediting is required by applicable
law. However, for purposes of determining whether an Option is entitled to ISO status, an
Employees Service will be treated as terminating ninety (90) days after such Employee went
on leave, unless such Employees right to return to active work is guaranteed by law or by a
contract. Service terminates in any event when the approved leave ends, unless such
Employee immediately returns to active work. The Board determines which leaves count toward
Service, and when Service terminates for all purposes under the Plan.
7.10
Exercise of Options on Termination of Service
. Each Option shall set
forth the extent to which the Optionee shall have the right to exercise the Option following
termination of the Optionees Service with the Company and its Subsidiaries. Each Stock
Option Agreement shall provide the Optionee with the right to exercise the Option following
the Optionees termination of Service during the Option term for at least thirty (30) days
if termination of Service is due to any reason other than cause, death or Disability, and
for at least six (6) months after termination of Service if due to death or Disability. If
the Optionees Service is terminated for cause, the Stock Option Agreement may provide that
the Optionees right to exercise the Option terminates immediately on the effective date of
the Optionees termination. Subject to the foregoing, such provisions shall be determined
in the sole discretion of the Board, need not be uniform among all Options issued pursuant
to the Plan, and may reflect distinctions based on the reasons for termination of
employment.
No Early Exercise
7.11 | No Rights as a Stockholder . An Optionee, or a transferee of an Optionee, shall have no rights as a stockholder with respect to any Shares covered by his or her Option until the date of the issuance of a stock certificate for such Shares. No adjustments shall be made, except as provided in Section 8. | |||
7.12 | Modification, Extension and Renewal of Options . Within the limitations of the Plan, the Board may modify, extend or renew outstanding Options or may accept the cancellation of outstanding Options (to the extent not previously exercised), whether or not granted hereunder, in return for the grant of new Options for the same or a different number of Shares and at the same or a different Exercise Price. The foregoing notwithstanding, no modification of an Option shall, without the consent of the Optionee, alter or impair his or her rights or obligations under such Option. | |||
7.13 | Buyout Provisions . The Board may at any time (a) offer to buy out for a payment in cash or cash equivalents an Option previously granted or (b) authorize an Optionee to elect to cash out an Option previously granted, in either case at such time and based upon such terms and conditions as the Committee shall establish. |
SECTION 8. ADJUSTMENT OF SHARES .
8.1 | Adjustments . In the event of a subdivision of the outstanding Stock, a declaration of a dividend payable in Shares, a declaration of a dividend payable in a form other than Shares in an amount that has a material effect on the price of Shares, a combination or consolidation of the outstanding Stock (by reclassification or otherwise) into a lesser number of Shares, a recapitalization, a spin-off or a similar occurrence, the Board shall make such adjustments as it, in its sole discretion, deems appropriate to one or more of the following: (i) the number of Options or Restricted Shares available for future awards under Section 5; (ii) the number of Shares covered by each outstanding Option; or (iii) the Exercise Price under each outstanding Option. Except as provided in this Section 8, an individual shall have no rights by reason of any issue by the Company of stock of any class or securities convertible into stock of any class, any subdivision or consolidation of shares of stock of any class, the payment of any stock dividend or any other increase or decrease in the number of shares of stock of any class. | |||
8.2 | Dissolution or Liquidation . To the extent not previously exercised or settled, Options shall terminate immediately prior to the dissolution or liquidation of the Company. | |||
8.3 | Reorganizations . In the event that the Company is a party to a merger or other reorganization, outstanding Awards and Options shall be subject to the agreement of merger or reorganization. Such agreement may provide for one or more of the following: (i) the continuation of the outstanding Awards and Options by the Company, if the Company is a surviving corporation; (ii) the assumption of the outstanding Awards and Options by the surviving corporation or its parent or subsidiary; (iii) the substitution by the surviving corporation or its parent or subsidiary of its own awards or options for the outstanding Awards and Options; (iv) immediate exercisability or vesting and accelerated expiration of the outstanding Awards or Options; or (v) settlement of the full value of the |
No Early Exercise
outstanding Awards or Options in cash or cash equivalents followed by cancellation of such Awards or Options.
8.4 | Reservation of Rights . Except as provided in this Section 8, an Optionee or Offeree shall have no rights by reason of any subdivision or consolidation of shares of stock of any class, the payment of any dividend or any other increase or decrease in the number of shares of stock of any class. Any issue by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall not affect, and no adjustment by reason thereof shall be made with respect to, the number or Exercise Price of Shares subject to an Option. The grant of an Option pursuant to the Plan shall not affect in any way the right or power of the Company to make adjustments, reclassifications, reorganizations or changes of its capital or business structure, to merge or consolidate or to dissolve, liquidate, sell or transfer all or any part of its business or assets. |
SECTION 9. TRANSFER RESTRICTIONS AND REPURCHASE RIGHTS .
9.1 | Nontransferability of Rights . Any right to acquire Restricted Shares shall not be transferable and shall be exercisable only by the Offeree to whom such right was granted. | |||
9.2 | Transfer of Restricted Shares to Trusts . To the extent approved by the Board in writing, a Purchaser may transfer or assign Restricted Shares to (a) the trustee of a trust that is revocable by such Purchaser alone, both at the time of the transfer or assignment and at all times thereafter prior to such Purchasers death, or (b) the trustee of any other trust established for the benefit of a family member of the Purchaser. A transfer or assignment of Restricted Shares from such trustee to any other person than the Purchaser shall be permitted only to the extent approved in advance by the Board in writing, and Restricted Shares held by such trustee shall be subject to all the conditions and restrictions set forth in the Plan and in the applicable Restricted Share Agreement, as if such trustee were a party to such Agreement. | |||
9.3 | Transferability of Options . During an Optionees lifetime, his or her Options shall be exercisable only by the Optionee and shall not be transferable other than by will or by the laws of descent and distribution. Notwithstanding the foregoing, however, to the extent that a Stock Option Agreement so provides, an NSO may be transferred to a family member or a trust established for the benefit of a family member of the Purchaser to the extent permitted by section 260.140.41(d) of Title 10 of the California Code of Regulations and Rule 701 of the Securities Act. | |||
9.4 | Assignment . Options and Shares acquired under the Plan shall not be anticipated, assigned, attached, garnished, optioned, transferred or made subject to any creditors process, whether voluntarily, involuntarily or by operation of law, except as approved by the Board. | |||
9.5 | Restrictions on Transfer of Shares . Any Shares acquired under the Plan through an Award or an Option shall be subject to such special forfeiture conditions, rights of repurchase, rights of first refusal and other transfer restrictions as the Board may |
No Early Exercise
determine. Such restrictions shall be set forth in the applicable Stock Option Agreement or Restricted Share Agreement and shall apply in addition to any restrictions that may apply to holders of Shares generally.
9.6 | Companys Right To Repurchase Shares . The Company shall have the right to repurchase a Purchasers Shares that have been acquired through an Award or an Option upon termination of the Purchasers Service if provided in the applicable Restricted Share Agreement or Stock Option Agreement. |
(a) | Repurchase Price . If the Company retains a right to repurchase the Shares at the greater of the Exercise Price or Fair Market Value of the Shares on the date that the Purchasers Service terminates, then such repurchase right shall terminate when the Companys Stock becomes publicly traded. If the Company retains a right to repurchase Shares at the greater of the original Purchase Price or Exercise Price, then such repurchase right shall lapse at the minimum rate of twenty percent (20%) per year over the five (5) year period starting on the date that the Award or Option was granted. The foregoing restrictions on the Companys right of repurchase shall not apply to Options and Restricted Shares granted to Outside Directors, Consultants or officers of the Company, a Parent or Subsidiary and such repurchase rights may be subject to additional or greater restrictions, as determined by the Board. | |||
(b) | Exercise of Repurchase Price . The Companys right of repurchase under this Section 9.6 may be exercised only within ninety (90) days of the date on which the Purchasers Service terminates or, if later, ninety (90) days from the date on which the Purchaser acquired the Shares to be repurchased by the Company. | |||
(c) | Payment of Repurchase Price . The Company shall pay the repurchase price in cash, cash equivalents or for cancellation of indebtedness incurred by the Purchaser in purchasing the Shares. |
SECTION 10. WITHHOLDING TAXES .
10.1 | General . To the extent required by applicable federal, state, local or foreign law, an Offeree or Optionee or his or her successor shall make arrangements satisfactory to the Board for the satisfaction of any withholding tax obligations that arise in connection with the Plan. The Company shall not be required to issue any Shares or make any cash payment under the Plan until such obligations are satisfied. | |||
10.2 | Share Withholding . The Board may permit an Offeree or Optionee to satisfy all or part of his or her withholding or income tax obligations by having the Company withhold all or a portion of any Shares that otherwise would be issued to him or her or by surrendering all or a portion of any Shares that he or she previously acquired; provided, however, that in no event may an Offeree or Optionee surrender Shares in excess of the legally required withholding amount. Such Shares shall be valued at their Fair Market Value on the date when taxes otherwise would be withheld in cash. Any payment of |
No Early Exercise
taxes by assigning Shares to the Company may be subject to restrictions, including any restrictions required by rules of any federal or state regulatory body or other authority.
10.3 | Cashless Exercise/Pledge . The Board may provide that if Company Shares are publicly traded at the time of exercise, arrangements may be made to meet the Optionees or Offerees withholding obligation by cashless exercise or pledge. | |||
10.4 | Other Forms of Payment . The Board may permit such other means of tax withholding as it deems appropriate. |
SECTION 11. SECURITIES LAW REQUIREMENTS .
11.1 | General . Shares shall not be issued under the Plan unless the issuance and delivery of such Shares complies with (or is exempt from) all applicable requirements of law, including (without limitation) the Securities Act, the rules and regulations promulgated thereunder, state securities laws and regulations, and the regulations of any stock exchange on which the Companys securities may then be listed. | |||
11.2 | Voting and Dividend Rights . The holders of Shares acquired under the Plan shall have the same voting, dividend and other rights as the Companys other stockholders. A Restricted Share Agreement, however, may require that the holders of Restricted Shares invest any cash dividends received in additional Restricted Shares. Such additional Restricted Shares shall be subject to the same conditions and restrictions as the Award with respect to which the dividends were paid. | |||
11.3 | Financial Reports . At least annually, the Company shall furnish its financial statements, including a balance sheet regarding the Companys financial condition and results of operations, to Offerees, Optionees and Purchasers whose duties at the Company do not assure them access to equivalent information. Financial statements need not be audited. |
SECTION 12. NO EMPLOYMENT RIGHTS .
No provision of the Plan, or any right or Option granted under the Plan, shall be construed to
give any person any right to become an Employee, to be treated as an Employee, or to remain in the
Service of the Company. The Company and its Subsidiaries reserve the right to terminate any
persons Service at any time and for any reason.
SECTION 13.
DURATION AND AMENDMENTS
.
13.1
Term of the Plan
. The Plan, as set forth herein, shall become
effective on the date of its adoption by the Board, subject to the approval of the Companys
stockholders. In the event that the stockholders fail to approve the Plan within twelve
(12) months after its adoption by the Board, any grants already made shall be null and void,
and no additional grants shall be made after such date. The Plan shall terminate
automatically on January 2, 2011 and may be terminated on any earlier date pursuant to
Section 13.2 below.
No Early Exercise
13.2 | Right to Amend or Terminate the Plan . The Board may amend the Plan at any time and from time to time, except for Sections 8.2 and 8.3 hereof which may not be amended. Rights and obligations under any right or Option granted before amendment of the Plan shall not be materially altered, or impaired adversely, by such amendment, except with consent of the person to whom the right or Option was granted. An amendment of the Plan shall be subject to the approval of the Companys stockholders only to the extent required by applicable laws, regulations or rules, including the rules of any applicable exchange. | |||
13.3 | Effect of Amendment or Termination . No Shares shall be issued or sold under the Plan after the termination thereof, except upon exercise of an Option granted prior to such termination. The termination of the Plan, or any amendment thereof, shall not affect any Shares previously issued or any Option previously granted under the Plan. |
SECTION 14. EXECUTION .
To record the adoption of the Plan by the Board on January 2, 2001, effective on such date, the Company has caused its authorized officer to execute the same.
|
GENOMIC HEALTH, INC. | |||
|
||||
|
By | /s/ Randal W. Scott | ||
|
||||
|
Randal W. Scott | |||
|
President and Chief Executive Officer |
[Form of Stock Option
Agreement]
No Early Exercise
THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED OR QUALIFIED UNDER THE
SECURITIES ACT OF 1933 OR THE SECURITIES LAWS OF ANY STATE, AND MAY BE OFFERED AND SOLD ONLY
IF REGISTERED AND QUALIFIED PURSUANT TO THE RELEVANT PROVISIONS OF FEDERAL AND STATE
SECURITIES LAWS OR IF THE COMPANY IS PROVIDED AN OPINION OF COUNSEL SATISFACTORY TO THE
COMPANY THAT REGISTRATION AND QUALIFICATION UNDER FEDERAL AND STATE SECURITIES LAWS IS NOT
REQUIRED.
GENOMIC HEALTH, INC.
Genomic Health, Inc. (the Company), hereby grants an Option to purchase shares of its
common stock (Shares) to . The terms and conditions of the Option
are set forth in this cover sheet, in the attached Stock Option Agreement and in the Genomic
Health, Inc. 2001 Stock Incentive Plan the Plan).
2001 STOCK INCENTIVE PLAN
STOCK OPTION AGREEMENT
(If Optionee is a Ten-Percent Shareholder, the Exercise Price
must be at least 110% of Fair Market Value).
Your Option vests over a -year period
By cash, cash equivalents and, if the Companys Shares become
publicly traded, by cashless exercise, as described in the
Stock Option Agreement.
By signing this cover sheet, you agree that (a) you have carefully read, fully understand and agree to all of the terms and conditions described in the attached option agreement, Plan document and Notice of Exercise and Common Stock Purchase Agreement (the Exercise Notice); (b) you hereby make the purchasers investment representations contained in the Exercise Notice with respect to the grant of this Option; (c) you understand and agree that this Agreement, including its attachments, constitute the entire understanding between you and the Company regarding this Option, and that any prior agreements, commitments or negotiations concerning this Option are replaced and superseded; and (d) you have been given an opportunity to consult legal counsel with respect to all matters relating to this Option prior to signing this cover sheet and that you have either consulted such counsel or voluntarily declined to consult such counsel.
GENOMIC HEALTH, INC. | ||||
|
||||
|
||||
|
By: | |||
|
||||
|
||||
|
Its: | |||
|
GENOMIC HEALTH, INC.
2001 STOCK INCENTIVE PLAN
STOCK OPTION AGREEMENT
SECTION 1. KIND OF OPTION.
This Option is intended to be either an incentive stock option intended to meet the requirements of section 422 of the Internal Revenue Code (an ISO) or a non-statutory option (an NSO), which is not intended to meet the requirements of an ISO, as indicated on the cover sheet.
SECTION 2. VESTING.
Your Option vests over a ___-year period. After you complete twelve months of continuous Service after _____, ____of the Shares covered by your Option will be vested and an additional _____ of the Shares will be vested for each full month of Service that you complete thereafter. After your Service terminates for any reason, vesting of your Option immediately stops and your Option expires immediately as to the number of Shares that are not vested as of your Service termination date.
SECTION 3. TERM.
Your Option will expire in any event at the close of business at Company headquarters on _________. Your Option will expire within five (5) years of the Date of Grant if you are a 10% owner of the Company. Also, your Option will expire earlier if your Service terminates, as described below.
SECTION 4. REGULAR TERMINATION.
If your Service terminates for any reason except death or Disability, your Option will expire at the close of business at Company headquarters on the date three months after your termination of Service. During that three-month period, you may exercise the portion of your Option that was vested on your termination date.
SECTION 5. DEATH.
If you die while in Service with the Company, your Option will expire at the close of business at Company headquarters on the date twelve months after the date of your death. During that twelve-month period, your estate, legatees or heirs may exercise that portion of your Option that was vested on the date of your death.
SECTION 6. DISABILITY.
6.1 If your Service terminates because of a Disability, your Option will expire at the close of business at Company headquarters on the date six months after your termination date. During that six-month period, you may exercise that portion of your Option that was vested on
-1-
the date of your Disability. Disability means that you are unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment.
6.2 If your Option is an ISO and your Disability is not expected to result in death or to last for a continuous period of at least 12 months, your Option will be eligible for ISO tax treatment only if it is exercised within three months following the termination of your Service as an Employee.
SECTION 7. EXERCISING YOUR OPTION.
To exercise your Option, you must execute the Notice of Exercise and Common Stock Purchase Agreement, attached as Exhibit A. You must submit this form, together with full payment, to the Company. Your exercise will be effective when it is received by the Company. If someone else wants to exercise your Option after your death, that person must prove to the Companys satisfaction that he or she is entitled to do so.
SECTION 8. PAYMENT FORMS.
When you exercise your Option, you must include payment of the Exercise Price for the Shares you are purchasing in one of the payment forms indicated in the cover sheet. When the Companys Shares are publicly traded, payment may be made by a so-called cashless exercise. In a cashless exercise, you can pay the Exercise Price in full or in part by directing a broker to sell your Option Shares and to deliver all or part of the sale proceeds to the Company in payment of the Exercise Price and any withholding taxes and to deliver the balance to you. The Company will provide the forms necessary to make a cashless exercise.
SECTION 9. WITHHOLDING.
If your Option is an NSO you will not be allowed to exercise this Option unless you make acceptable arrangements to pay any withholding or other taxes that may be due as a result of the Option exercise or the sale of Shares acquired upon exercise of this Option.
SECTION 10. RIGHT OF FIRST REFUSAL.
10.1 In the event that you propose to sell, pledge or otherwise transfer to a third party any Shares acquired under this Agreement, or any interest in such Shares, the Company shall have the Right of First Refusal with respect to all (and not less than all) of such Shares. If you desire to transfer Shares acquired under this Agreement, you must give a written Transfer Notice to the Company describing fully the proposed transfer, including the number of Shares proposed to be transferred, the proposed transfer price and the name and address of the proposed transferee. The Transfer Notice shall be signed both by you and by the proposed transferee and must constitute a binding commitment of both parties to the transfer of the Shares.
The Company and its assignees shall have the right to purchase all or any portion of the Shares on the terms described in the Transfer Notice (subject, however, to any change in such terms permitted in the next paragraph) by delivery of a Notice of Exercise of the Right of First
-2-
Refusal within 30 days after the date when the Transfer Notice was received by the Company. The Companys rights under this Subsection shall be freely assignable, in whole or in part.
If the Company or its assignees fail to exercise its Right of First Refusal within 30 days after the date when it received the Transfer Notice, you may, not later than 60 days following receipt of the Transfer Notice by the Company, conclude a transfer of the Shares subject to the Transfer Notice on the terms and conditions described in the Transfer Notice. Any proposed transfer on terms and conditions different from those described in the Transfer Notice, as well as any subsequent proposed transfer by you, shall again be subject to the Right of First Refusal and shall require compliance with the procedure described in the paragraph above. If the Company exercises its Right of First Refusal, you and the Company (or its assignees) shall consummate the sale of the Shares on the terms set forth in the Transfer Notice.
The Companys Right of First Refusal shall inure to the benefit of its successors and assigns and shall be binding upon any transferee of the Shares. The Companys Right of First Refusal shall terminate upon the consummation of the initial public offering of the Companys Common Stock.
SECTION 11. RESALE RESTRICTIONS/MARKET STAND-OFF .
In connection with any underwritten public offering by the Company of its equity securities pursuant to an effective registration statement filed under the Securities Act, including the Companys initial public offering, you shall not, directly or indirectly, engage in any transaction prohibited by the underwriter, nor shall you sell, make any short sale of, contract to sell, transfer the economic risk of ownership in, loan, hypothecate, pledge, grant any option for the purchase of, or otherwise dispose or transfer for value or agree to engage in any of the foregoing transactions with respect to any Common Stock without the prior written consent of the Company or its underwriters, for such period of time after the effective date of such registration statement as may be requested by the Company or such underwriters. Such period of time shall not exceed one hundred eighty (180) days and may be required by the underwriter as a market condition of the offering. By signing this Agreement you agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriter which are consistent with the foregoing or which are necessary to give further effect thereto. To enforce the provisions of this Section, the Company may impose stop-transfer instructions with respect to the Common Stock until the end of the applicable stand-off period.
SECTION 12. TRANSFER OF OPTION.
Prior to your death, only you may exercise this Option. You cannot transfer or assign this Option. For instance, you may not sell this Option or use it as security for a loan. If you attempt to do any of these things, this Option will immediately become invalid. You may, however, dispose of this Option in your will. Regardless of any marital property settlement agreement, the Company is not obligated to honor a Notice of Exercise from your spouse or former spouse, nor is the Company obligated to recognize such individuals interest in your Option in any other way.
-3-
SECTION 13. RETENTION RIGHTS.
This Agreement does not give you the right to be retained by the Company in any capacity. The Company reserves the right to terminate your Service at any time and for any reason.
SECTION 14. STOCKHOLDER RIGHTS.
Neither you nor your estate or heirs have any rights as a stockholder of the Company until a certificate for the Shares acquired upon exercise of this Option has been issued. No adjustments are made for dividends or other rights if the applicable record date occurs before your stock certificate is issued, except as described in the Plan.
SECTION 15. ADJUSTMENTS.
In the event of a stock split, a stock dividend or a similar change in the Companys Stock, the number of Shares covered by this Option and the Exercise Price per share may be adjusted pursuant to the Plan. Your Option shall be subject to the terms of the agreement of merger, liquidation or reorganization in the event the Company is subject to such corporate activity.
SECTION 16. LEGENDS.
All certificates representing the Shares issued upon exercise of this Option shall, where applicable, have endorsed thereon the following legends:
THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED OR QUALIFIED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE, AND MAY BE OFFERED AND SOLD ONLY IF REGISTERED AND QUALIFIED PURSUANT TO THE RELEVANT PROVISIONS OF FEDERAL AND STATE SECURITIES LAWS OR IF THE COMPANY IS PROVIDED AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION AND QUALIFICATION UNDER FEDERAL AND STATE SECURITIES LAWS IS NOT REQUIRED.
THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD, TRANSFERRED, ENCUMBERED OR IN ANY MANNER DISPOSED OF, EXCEPT IN COMPLIANCE WITH THE TERMS OF A WRITTEN AGREEMENT BETWEEN THE COMPANY AND THE INITIAL HOLDER HEREOF. SUCH AGREEMENT PROVIDES FOR CERTAIN TRANSFER RESTRICTIONS, INCLUDING RIGHTS OF FIRST REFUSAL UPON AN ATTEMPTED TRANSFER OF THE SECURITIES IN FAVOR OF THE COMPANY. THE SECRETARY OF THE COMPANY WILL UPON WRITTEN REQUEST FURNISH A COPY OF SUCH AGREEMENT TO THE HOLDER HEREOF WITHOUT CHARGE.
If the Option is an ISO, then the following legend should be included:
THE SHARES REPRESENTED BY THIS CERTIFICATE WERE ISSUED UPON EXERCISE OF AN INCENTIVE STOCK OPTION, AND THE COMPANY MUST BE NOTIFIED IF THE SHARES SHALL BE TRANSFERRED BEFORE THE LATER OF THE TWO-YEAR ANNIVERSARY OF THE DATE OF GRANT OF THE OPTION OR THE ONE-YEAR ANNIVERSARY OF THE DATE ON WHICH THE OPTION WAS EXERCISED. THE REGISTERED HOLDER MAY RECOGNIZE ORDINARY INCOME IF THE SHARES ARE TRANSFERRED BEFORE SUCH DATE.
-4-
SECTION 17. APPLICABLE LAW AND TAXES DISCLAIMER.
This Agreement will be interpreted and enforced under the laws of the State of California (without regard to their choice of law provisions). You agree that you are responsible for consulting your own tax advisor as to the tax consequences associated with your Option. The tax rules governing options are complex, change frequently and depend on the individual taxpayers situation. Although the Company will make available to you general tax information about stock options, you agree that the Company shall not be held liable or responsible for making such information available to you and any tax or financial consequences that you may incur in connection with your Option.
SECTION 18. THE PLAN AND OTHER AGREEMENTS.
The text of the Plan is incorporated in this Agreement by reference. Certain capitalized terms used in this Agreement are defined in the Plan. This Agreement, including its attachments, and the Plan constitute the entire understanding between you and the Company regarding this Option. Any prior agreements, commitments or negotiations concerning this Option are superseded.
-5-
EXHIBIT A
Genomic Health, Inc. 2001 Stock Incentive Plan
Notice of Exercise and Common Stock Purchase Agreement
THIS AGREEMENT is dated as of _________, ______, between Genomic Health, Inc. (the Company), and (Purchaser).
W I T N E S S E T H:
WHEREAS, the Company and Purchaser are parties to a stock option agreement dated as of _________, ______(the Option Agreement) under which the Purchaser has the right to purchase up to ______ shares of the Companys common stock (the Option Shares); and
WHEREAS, the Option is exercisable with respect to certain of the Option Shares as of the date hereof; and
WHEREAS, pursuant to the Option Agreement, Purchaser desires to purchase shares of the Company as herein described, on the terms and conditions set forth in this Agreement, the Option Agreement and the Genomic Health, Inc. 2001 Stock Incentive Plan (the Plan). Certain capitalized terms used in this Agreement are defined in the Plan.
NOW, THEREFORE, it is agreed between the parties as follows:
PURCHASE OF SHARES.
18.1 Pursuant to the terms of the Option Agreement, Purchaser hereby agrees to purchase from the Company and the Company agrees to sell and issue to Purchaser _________shares of the Companys common stock (the Common Stock) for the Exercise Price per share specified in the Option Agreement payable by personal check, cashiers check, money order or any other form specified on the cover sheet of the Option Agreement. Payment shall be delivered at the Closing, as such term is defined below.
The closing under (the Closing) this Agreement will occur at the offices of the Company as of the date hereof, or such other time and place as may be designated by the Company (the Closing Date).
SECTION 19. THE COMPANYS RIGHT OF FIRST REFUSAL.
Before any shares of Common Stock registered in the name of Purchaser may be sold or transferred, such shares shall first be offered to the Company as follows:
19.1 Purchaser shall promptly deliver a notice (Notice) to the Company stating (i) Purchasers bona fide intention to sell or transfer such shares, (ii) the number of such shares to be sold or transferred, and the basic terms and conditions of such sale or transfer, (iii) the
A-1
price for which Purchaser proposes to sell or transfer such shares, (iv) the name of the proposed purchaser or transferee, and (v) proof satisfactory to the Company that the proposed sale or transfer will not violate any applicable federal or state securities laws. The Notice shall be signed by both Purchaser and the proposed purchaser or transferee and must constitute a binding commitment subject to the Companys right of first offer as set forth herein.
Within 30 days after receipt of the Notice, the Company may elect to purchase all or none of the shares to which the Notice refers, at the price per share specified in the Notice. If the Company elects not to purchase all such shares, the Company may assign its right to purchase all such shares. The assignees may elect within 30 days after receipt by the Company of the Notice to purchase all or none of the shares to which the Notice refers, at the price per share specified in the Notice. An election to purchase shall be made by written notice to Purchaser. Payment for shares purchased pursuant to this Section 2 shall be made within 30 days after receipt of the Notice by the Company and, at the option of the Company, may be made by cancellation of all or a portion of outstanding indebtedness, if any, or in cash or both.
19.2 If all of the shares to which the Notice refers are not elected to be purchased, as provided in subparagraph 2(b) , Purchaser may sell all of the shares to any person named in the Notice at the price specified in the Notice, provided that such sale or transfer is consummated within three months of the date of said Notice to the Company, and provided, further, that any such sale is made in compliance with applicable federal and state securities laws and not in violation of any other contractual restrictions to which Purchaser is bound. The third-party purchaser shall acquire the shares of stock free and clear of the Companys right of first offer.
19.3 Any proposed transfer on terms and conditions different from those set forth in the Notice, as well as any subsequent proposed transfer shall again be subject to the Companys right of first offer and shall require compliance with the procedures described in this Section 2.
19.4 Purchaser agrees to cooperate affirmatively with the Company, to the extent reasonably requested by the Company, to enforce rights and obligations pursuant to this Agreement.
19.5 Notwithstanding the above, neither the Company nor any assignee of the Company under this Section 2 shall have any right under this Section 2 at any time subsequent to the closing of a public offering of the common stock of the Company pursuant to a registration statement declared effective under the Securities Act of 1933, as amended (the Securities Act).
19.6 This Section 2 shall not apply to a transfer by will or intestate succession, provided that the transferee shall execute a copy of the attached Exhibit B and file the same with the Secretary of the Company.
SECTION 20. PURCHASERS RIGHTS AFTER EXERCISE OF RIGHT OF FIRST REFUSAL.
If the Company makes available, at the time and place and in the amount and form provided in this Agreement, the consideration for the Common Stock to be repurchased in accordance with the provisions of Section 2 of this Agreement, then from and after
A-2
such time the person from whom such shares are to be repurchased shall no longer have any rights as a holder of such shares (other than the right to receive payment of such consideration in accordance with this Agreement). Such shares shall be deemed to have been repurchased in accordance with the applicable provisions hereof, whether or not the certificate(s) therefor have been delivered as required by this Agreement.
SECTION 21. TRANSFER BY PURCHASER TO CERTAIN TRUSTS.
Purchaser shall have the right to transfer all or any portion of Purchasers interest in the shares issued under this Agreement which have been delivered to Purchaser to a trust established by Purchaser for the benefit of Purchaser, Purchasers spouse or Purchasers children, without being subject to the provisions of Section 2 hereof, provided that the trustee on behalf of the trust shall agree in writing to be bound by the terms and conditions of this Agreement. The transferee shall execute a copy of Exhibit B and file the same with the Secretary of the Company.
SECTION 22. LEGEND OF SHARES.
All certificates representing the Common Stock purchased under this Agreement shall, where applicable, have endorsed thereon the following legends and any other legends required by applicable securities laws:
THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED OR QUALIFIED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE, AND MAY BE OFFERED AND SOLD ONLY IF REGISTERED AND QUALIFIED PURSUANT TO THE RELEVANT PROVISIONS OF FEDERAL AND STATE SECURITIES LAWS OR IF THE COMPANY IS PROVIDED AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION AND QUALIFICATION UNDER FEDERAL AND STATE SECURITIES LAWS IS NOT REQUIRED.
THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD, TRANSFERRED, ENCUMBERED OR IN ANY MANNER DISPOSED OF, EXCEPT IN COMPLIANCE WITH THE TERMS OF A WRITTEN AGREEMENT BETWEEN THE COMPANY AND THE INITIAL HOLDER HEREOF. SUCH AGREEMENT PROVIDES FOR CERTAIN TRANSFER RESTRICTIONS, INCLUDING RIGHTS OF FIRST REFUSAL UPON AN ATTEMPTED TRANSFER OF THE SECURITIES. THE SECRETARY OF THE COMPANY WILL UPON WRITTEN REQUEST FURNISH A COPY OF SUCH AGREEMENT TO THE HOLDER HEREOF WITHOUT CHARGE.
For an Incentive Stock Option:
THE SHARES REPRESENTED BY THIS CERTIFICATE WERE ISSUED UPON EXERCISE OF AN INCENTIVE STOCK OPTION, AND THE COMPANY MUST BE NOTIFIED IF THE SHARES SHALL BE TRANSFERRED BEFORE THE LATER OF THE TWO-YEAR ANNIVERSARY OF THE DATE OF GRANT OF THE OPTION OR THE ONE-YEAR ANNIVERSARY OF THE DATE ON WHICH THE OPTION WAS EXERCISED. THE REGISTERED HOLDER MAY RECOGNIZE ORDINARY INCOME IF THE SHARES ARE TRANSFERRED BEFORE SUCH DATE.
A-3
SECTION 23. PURCHASERS INVESTMENT REPRESENTATIONS.
23.1 This Agreement is made with Purchaser in reliance upon Purchasers representation to the Company, which by Purchasers acceptance hereof Purchaser confirms, that the Common Stock which Purchaser will receive will be acquired with Purchasers own funds for investment for an indefinite period for Purchasers own account, not as a nominee or agent, and not with a view to the sale or distribution of any part thereof, and that Purchaser has no present intention of selling, granting participation in, or otherwise distributing the same, but subject, nevertheless, to any requirement of law that the disposition of Purchasers property shall at all times be within Purchasers control. By executing this Agreement, Purchaser further represents that Purchaser does not have any contract, understanding or agreement with any person to sell, transfer, or grant participation, to such person or to any third person, with respect to any of the Common Stock.
23.2 Purchaser understands that the Common Stock will not be registered or qualified under federal or state securities laws on the ground that the sale provided for in this Agreement is exempt from registration or qualification under federal or state securities laws and that the Companys reliance on such exemption is predicated on Purchasers representations set forth herein.
Purchaser agrees that in no event will Purchaser make a disposition of any of the Common Stock (including a disposition under Section 4 of this Agreement), unless and until (i) Purchaser shall have notified the Company of the proposed disposition and shall have furnished the Company with a statement of the circumstances surrounding the proposed disposition and (ii) Purchaser shall have furnished the Company with an opinion of counsel satisfactory to the Company to the effect that (A) such disposition will not require registration or qualification of such Common Stock under federal or state securities laws or (B) appropriate action necessary for compliance with the federal or state securities laws has been taken or (iii) the Company shall have waived, expressly and in writing, its rights under clauses (i) and (ii) of this section.
With respect to a transaction occurring prior to such date as the Plan and Common Stock thereunder are covered by a valid Form S-8 or similar federal registration statement, this subsection shall apply unless the transaction is covered by the exemption in California Corporations Code § 25102(o) or a similar broad based exemption. In connection with the investment representations made herein, Purchaser represents that Purchaser is able to fend for himself or herself in the transactions contemplated by this Agreement, has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of Purchasers investment, has the ability to bear the economic risks of Purchasers investment and has been furnished with and has had access to such information as would be made available in the form of a registration statement together with such additional information as is necessary to verify the accuracy of the information supplied and to have all questions answered by the Company.
Purchaser understands that if the Company does not register with the Securities and Exchange Commission pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or if a registration statement covering the Common Stock (or a
A-4
filing pursuant to the exemption from registration under Regulation A of the Securities Act of 1933) under the Securities Act of 1933 is not in effect when Purchaser desires to sell the Common Stock, Purchaser may be required to hold the Common Stock for an indeterminate period. Purchaser also acknowledges that Purchaser understands that any sale of the Common Stock which might be made by Purchaser in reliance upon Rule 144 under the Securities Act of 1933 may be made only in limited amounts in accordance with the terms and conditions of that Rule.
SECTION 24. NO DUTY TO TRANSFER IN VIOLATION UNDER THIS AGREEMENT.
The Company shall not be required (a) to transfer on its books any shares of Common Stock of the Company which shall have been sold or transferred in violation of any of the provisions set forth in this Agreement or (b) to treat as owner of such shares or to accord the right to vote as such owner or to pay dividends to any transferee to whom such shares shall have been so transferred.
SECTION 25. RIGHTS OF PURCHASER.
Purchaser shall, during the term of this Agreement, exercise all rights and privileges of a stockholder of the Company with respect to the Common Stock.
SECTION 26. RESALE RESTRICTIONS/MARKET STAND-OFF.
Purchaser hereby agrees that in connection with any underwritten public offering by the Company of its equity securities pursuant to an effective registration statement filed under the Securities Act, including the Companys initial public offering, to the extent requested by the Company and an underwriter of common stock or other securities of the Company, purchaser shall not, directly or indirectly, engage in any transaction prohibited by the underwriter, or sell, make any short sale of, contract to sell, transfer the economic risk of ownership in, loan, hypothecate, pledge, grant any option for the purchase of, or otherwise dispose or transfer for value or agree to engage in any of the foregoing transactions with respect to any Common Stock without the prior written consent of the Company or its underwriters, for such period of time after the effective date of such registration statement as may be requested by the Company or such underwriters. Such period of time shall not exceed one hundred eighty (180) days and may be required by the underwriter as a market condition of the offering. Purchaser hereby agrees to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriter which are consistent with the foregoing or which are necessary to give further effect thereto. To enforce the provisions of this Section, the Company may impose stop-transfer instructions with respect to the Common Stock until the end of the applicable stand-off period.
SECTION 27. OTHER NECESSARY ACTIONS.
The parties agree to execute such further instruments and to take such further action as may reasonably be necessary to carry out the intent of this Agreement.
A-5
SECTION 28. NOTICE.
Any notice required or permitted under this Agreement shall be given in writing and shall be deemed effectively given upon the earliest of personal delivery, receipt or the third full day following deposit in the United States Post Office with postage and fees prepaid, addressed to the other party hereto at the address last known or at such other address as such party may designate by 10 days advance written notice to the other party hereto.
SECTION 29. SUCCESSORS AND ASSIGNS.
This Agreement shall inure to the benefit of the successors and assigns of the Company and, subject to the restrictions on transfer herein set forth, be binding upon Purchaser and Purchasers heirs, executors, administrators, successors and assigns. The failure of the Company in any instance to exercise the rights of first refusal described herein shall not constitute a waiver of any other right of first refusal that may subsequently arise under the provisions of this Agreement. No waiver of any breach or condition of this Agreement shall be deemed to be a waiver of any other or subsequent breach or condition, whether of a like or different nature.
SECTION 30. APPLICABLE LAW.
This Agreement shall be governed by, and construed in accordance with, the laws of the State of California, as such laws are applied to contracts entered into and performed in such state.
SECTION 31. NO STATE QUALIFICATION.
THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION THEREFOR PRIOR TO SUCH QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SECURITIES IS EXEMPT FROM THE QUALIFICATION BY SECTION 25100, 25102 OR 25105 OF THE CALIFORNIA CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED, UNLESS THE SALE IS SO EXEMPT.
SECTION 32. NO ORAL MODIFICATION.
No modification of this Agreement shall be valid unless made in writing and signed by the parties hereto.
A-6
SECTION 33. ENTIRE AGREEMENT.
This Agreement and the Option Agreement constitute the entire complete and final agreement between the parties hereto with regard to the subject matter hereof.
IN WITNESS WHEREOF, the parties have executed this Agreement as of the day and year first above written.
GENOMIC HEALTH, INC.
|
(PURCHASER) | |||||
|
||||||
By
|
||||||
|
||||||
|
Signature | |||||
|
||||||
Its
|
||||||
|
A-7
EXHIBIT B
Acknowledgment of and Agreement to be Bound
By the Notice of Exercise and Common Stock Purchase
Agreement of Genomic Health
The undersigned, as transferee of shares of Genomic Health, Inc., hereby acknowledges that he or she has read and reviewed the terms of the Notice of Exercise and Common Stock Purchase Agreement of Genomic Health, Inc. and hereby agrees to be bound by the terms and conditions thereof, as if the undersigned had executed said Agreement as an original party thereto.
Dated: , .
|
Signature of Transferee | |||
|
||||
|
Printed Name of Transferee |
B-1
No Early Exercise
EXHIBIT C
FEDERAL TAX INFORMATION
(Current as of June 2000)
The following memorandum briefly summarizes current federal income tax law. The discussion is intended to be used solely for general information purposes and does not make specific representations to any participant. A taxpayers particular situation may be such that some variation of the basic rules is applicable to him or her. In addition, the federal income tax laws and regulations are revised frequently and may change again in the future. Each participant is urged to consult a tax adviser, both with respect to federal income tax consequences as well as any foreign, state or local tax consequences, before exercising any option or before disposing of any shares of stock acquired under the Plan.
Initial Grant of Options
The grant of an option, whether a nonqualified or nonstatutory stock option (NSO) or an incentive stock option (ISO), is not a taxable event for the optionee, and the Company obtains no deduction for the grant of the option.
Nonqualified or Nonstatutory Stock Options
The exercise of an NSO is a taxable event to the optionee. The amount by which the fair market value of the shares on the date of exercise exceeds the exercise price will be taxed to the optionee as ordinary income. The Company will be entitled to a deduction in the same amount, provided it makes all required withholdings on the difference between the fair market value and the exercise price, as though this amount had been paid as compensation. In general, the optionees tax basis in the shares acquired by exercising an NSO is equal to the fair market value of such shares on the date of exercise. Upon a subsequent sale of any such shares in a taxable transaction, the optionee will realize capital gain or loss (long-term or short-term, depending on whether the shares were held for the required holding period before the sale) in an amount equal to the difference between his or her basis in the shares and the sale price.
The capital gains holding periods are complex. If shares are held for at least one year, the maximum tax rate on the gain is generally 20%. Furthermore, if an option is granted after December 31, 2000, and the underlying stock is then held for at least five years after exercise, the maximum capital gain rate is 18%. Because the rules are complex and can vary in individual circumstances, each participant should consider consulting his or her own tax advisor.
If an optionee exercises an NSO and pays the exercise price with previously acquired shares of stock, special rules apply. The transaction is treated as a tax-free exchange of the old shares for the same number of new shares, except as described below with respect to shares acquired pursuant to ISOs. The optionees basis in the new shares is the same
C-1
as his or her basis in the old shares, and the capital gain holding period runs without interruption from the date when the old shares were acquired. The value of any new shares received by the optionee in excess of the number of old shares surrendered plus any cash the optionee pays for the new shares will be taxed as ordinary income. The optionees basis in the additional shares is equal to the fair market value of such shares on the date the shares were transferred, and the capital gain holding period commences on the same date. The effect of these rules is to defer recognition of any gain in the old shares when those shares are used to buy new shares. Stated differently, these rules allow an optionee to finance the exercise of an NSO by using shares of stock that he or she already owns, without paying current tax on any unrealized appreciation in those old shares.
Incentive Stock Options
The holder of an ISO will not be subject to federal income tax upon the exercise of the ISO, and the Company will not be entitled to a tax deduction by reason of such exercise, provided that the holder is employed by the Company on the exercise date (or the holders employment terminated within the three months preceding the exercise date). Exceptions to this exercise timing requirement apply in the event the optionee dies or becomes disabled. A subsequent sale of the shares received upon the exercise of an ISO will result in the realization of long-term capital gain or loss in the amount of the difference between the amount realized on the sale and the exercise price for such shares, provided that the sale occurs more than one year after the exercise of the ISO and more than two years after the grant of the ISO. In general, if a sale or disposition of the shares occurs prior to satisfaction of the foregoing holding periods (referred to as a disqualifying disposition), the optionee will recognize ordinary income. In this event, the Company will be entitled to a corresponding deduction equal to the lesser of (i) the excess of the fair market value of the shares on the date of transfer over the exercise price, or (ii) the excess of the amount realized on the disposition over the exercise price for such shares.
Favorable tax treatment is accorded to an optionee only to the extent that the value of the shares (determined at the time of grant) covered by an ISO first exercisable in any single calendar year does not exceed $100,000. If ISOs for shares whose aggregate value exceeds $100,000 become exercisable in the same calendar year, the excess will be treated as NSOs.
A special Rule applies if an optionee pays all or part of the exercise price of an ISO by surrendering shares of stock that he or she previously acquired by exercising any other ISO. If the optionee has not held the old shares for the full duration of the applicable holding periods, then the surrender of such shares to fund the exercise of the new ISO will be treated as a disqualifying disposition of the old shares. As described above, the result of a disqualifying disposition is the loss of favorable tax treatment with respect to the acquisition of the old shares pursuant to the previously exercised ISO.
C-2
Where the applicable holding period requirements have been met, the use of previously acquired shares of stock to pay all or a portion of the exercise price of an ISO may offer significant tax advantages. In particular, a deferral of the recognition of any appreciation in the surrendered shares is available in the same manner as discussed above with respect to NSOs.
Alternative Minimum Tax
Alternative minimum tax is paid when such tax exceeds a taxpayers regular federal income tax. Alternative minimum tax is calculated based on alternative minimum taxable income, which is taxable income for federal income tax purposes, modified by certain adjustments and increased by tax preference items.
The spread under an ISOthat is, the difference between (a) the fair market value of the shares of stock at exercise and (b) the exercise priceis classified as alternative minimum taxable income for the year of exercise. Alternative minimum taxable income may be subject to the alternative minimum tax. However, a disqualifying disposition of the shares of stock subject to the ISO during the same year in which the ISO was exercised will generally negate the alternative minimum taxable income generated upon exercise of the ISO.
In general, when a taxpayer sells stock acquired through the exercise of an ISO, only the difference between the fair market value of the shares on the date of exercise and the date of sale is used in computing any alternative minimum tax for the year of the sale. The portion of a taxpayers alternative minimum tax attributable to certain items of tax preference (including the spread upon the exercise of an ISO) can be credited against the taxpayers regular liability in later years to the extent that liability exceeds the alternative minimum tax.
Withholding Taxes
Exercise of an NSO produces taxable income which is subject to withholding. The Company will not deliver shares to the optionee unless the optionee has agreed to satisfactory arrangements for meeting all applicable federal, state and local withholding tax requirements.
Early Exercise
If an optionee is permitted to exercise an option before the optionees rights in the shares subject to the option are vested, the tax aspects of such an early exercise will be as follows:
Incentive Stock Options
When an ISO is exercised, the spread is a preference item in the year of exercise, which is taken into account in computing an optionees alternative minimum tax. One technique which might enable an optionee to avoid the inclusion of the spread in the
C-3
alternative minimum tax calculation is to exercise the option at grant, pay the exercise price and make an election under Section 83(b) of the Code within thirty (30) days after the date of exercise. The exercise of the option also begins the various holding requirements for long-term capital gain treatment and the one-year holding requirement that applies after the exercise of an ISO.
Nonstatutory Stock Options
If the option is not an ISO but instead is an NSO, exercise prior to vesting will accomplish two things: (1) it will start the capital gains holding period running, and (2) it will prevent the optionee from being taxed (at ordinary income tax rates) upon vesting, if, at that time, the fair market value of the stock has increased from the date of grant. Of course, when the shares are sold, the gain will be taxed according to how long the shares have been held.
Payment for Shares
Whether the option is an ISO or an NSO, to exercise the option, the purchase price must be paid. If service with the Company terminates before the shares are vested, the Company may repurchase the shares at the original purchase price.
C-4
Exhibit 10.4.1
SUBLEASE AGREEMENT
THIS SUBLEASE AGREEMENT ( Sublease Agreement ), effective June 1, 2001 is entered into by and between Corixa Corporation and its affiliates, a Delaware corporation ( Tenant ), having its principal place of business at 1124 Columbia Street, Suite 200, Seattle, Washington 98104, and Genomic Health, Inc., a Delaware corporation having its principal place of business after the Commencement Date at the Sublease Premises ( Subtenant ).
RECITALS
A. WHEREAS , The predecessor in interest of Tenant and the predecessor in interest of Metropolitan Life Insurance Company, a New York corporation ( Landlord ), have entered into that certain lease dated January 3, 1992, as amended by (i) that certain First Amendment dated January 5, 1993, (ii) that certain Second Amendment dated January 10, 1995, (iii) that certain Third Amendment dated March 24, 1995, (iv) that certain holdover letter agreement dated February 12, 1999, (v) that certain Fifth Amendment dated February 26, 1999 and (vi) that certain Sixth Amendment dated September 29, 2000 (collectively referred to herein as the Lease ), whereby Landlord leases to Tenant that certain premises in Building 11 of Phase II, with the current street address of 301 Penobscot Drive, Redwood City, CA, ( Premises ).
B. WHEREAS , Tenant has the right to grant subleases pursuant to Section 15 of the Lease.
C. WHEREAS , Subtenant desires to sublease from Tenant and Tenant desires to sublease to Subtenant, certain of the Premises on the terms and conditions contained herein.
NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Tenant and Subtenant agree as follows:
AGREEMENT
1. Sublease Premises . Tenant hereby subleases to Subtenant and Subtenant subleases from Tenant on the terms and conditions stated in this Sublease Agreement that portion of the Premises and all fixtures and improvements thereto, depicted on Schedule 1 attached hereto (the Sublease Premises ) and pursuant to Section 15 of the Lease. Subtenant acknowledges and agrees that the Sublease Premises consists of 19,872 rentable square feet ( RSF ) of space as of the commencement of this Sublease Agreement.
2. Rent .
2.1 Subtenant agrees to pay rent to Tenant for the Sublease Premises in the following amounts
(Rent):
Period
Amount Per Month
$109,296.00 per month
$113,667.84 per month
$118,238.40 per month
$123,007.68 per month
Notwithstanding anything to the contrary set forth in the Lease, the Rent set forth in this Section 2.1 shall be the total monthly amount due to Tenant for rental of the Sublease Premises.
2.2 All Rent payments shall be (a) payable on the first day of each month during the term of this Sublease Agreement, (b) payable in United States dollars, and (c) sent to Tenant at the address stated above or to such other persons or at such other places as Tenant may designate in writing.
3. Security Deposit . Upon full execution of this Sublease Agreement, Subtenant shall pay to Tenant the first months Rent together with an additional check for the same amount as a security deposit (the Security Deposit ). Within thirty (30) days following the expiration of the term of this Sublease Agreement, Tenant shall return to Subtenant the Security Deposit, net of (a) any Tenant expenses required to return the Sublease Premises to its as-is condition at the time of Subtenants initial occupation of the Sublease Premises, reasonable wear and tear excepted, and (b) any other outstanding payments owed by Subtenant to Tenant hereunder.
4. Term .
4.1 The term of this Sublease Agreement shall commence on May 15, 2001 Commencement Date and end on May 30, 2004 (the Term ), unless sooner terminated pursuant to any provision hereof and Subtenants obligations to pay any Rent hereunder shall commence on June 15, 2001 the ( Rent Commencement Date ). Notwithstanding the foregoing, this Sublease Agreement shall have no force and effect prior to the written consent to this Sublease Agreement.
4.2 Option to Extend .
(a) Tenant hereby grants Subtenant a single option to extend the Term through February 28, 2006 (the Option Term ) as to the Sublease Premises as it may then exist, upon and subject to the terms and conditions of this Section 4.2 (the Option to Extend ), and provided that at the time of exercise of such right there has been no material adverse change in Subtenants financial position from such position as of the date of execution of the Sublease Agreement, as certified by Subtenants independent certified public accountants and by Subtenants certified financial statements, copies of which shall be delivered to Tenant with Subtenants written notice exercising its right hereunder.
(b) Subtenants election (the Election Notice ) to exercise the Option to Extend must be given to Tenant in writing no later than six (6) months before the expiration of the Term. If Subtenant either fails or elects not to exercise its Option to Extend by not giving its Election Notice, then the Option to Extend shall be null and void.
(c) The Option Term shall commence immediately after the expiration of the Term. Subtenants leasing of the Premises during the Option Term shall be upon and subject to the same terms and conditions contained in the Sublease Agreement except there shall be no further option or right to extend the Term of the Sublease Agreement and the Rent shall be as follows:
Period | Amount Per Month | |||
June 1, 2004 February 28, 2005
|
$123,007.68 per month | |||
March 1, 2005 February 28, 2006
|
$127,776.96 per month |
If Subtenant timely and properly exercises the Option to Extend, references in the Sublease Agreement to the Term shall be deemed to mean the then-current Term as extended by the Option Term unless the context clearly requires otherwise.
(d) This Option to Extend is personal to Genomic Health, Inc. and may not be used by, and shall not be transferable or assignable (voluntarily or involuntarily) to any person or entity.
(e) Upon the occurrence of any of the following events, Tenant shall have the option, exercisable at any time prior to commencement of the Option Term, to terminate all of the provisions of this Section with respect to the Option to Extend, with the effect of canceling and voiding any prior or subsequent exercise so this Option to Extend is of no force or effect:
(i) Subtenants failure to timely exercise the Option to Extend in accordance with the provisions of this Section.
(ii) The existence at the time Subtenant exercises the Option to Extend or at the commencement of the Option Term of any default on the part of Subtenant under the Sublease Agreement.
(iii) Subtenants third default under the Sublease Agreement prior to the commencement of the option Term, notwithstanding that all such defaults may subsequently be cured. In the event of Tenants termination of the Option to Extend pursuant to this subsection subsequent to Subtenants exercise of the Option to Extend, Subtenant shall reimburse Tenant for all reasonable costs and expenses Tenant incurs in connection with Subtenants exercise of the Option to Extend.
(f) Without limiting the generality of any provision of the Sublease Agreement, time shall be of the essence with respect to all of the provisions of this Section.
5. Use .
5.1 The Sublease Premises shall be used and occupied as offices and laboratory space for Subtenants business, which is defined as light manufacturing, laboratory research, development and diagnostics, general administration and storage.
5.2 Subtenants occupation of the Sublease Premises and all of the terms and conditions of this Sublease Agreement shall be subject to all terms and conditions of the Lease.
6. Parking . Subtenant shall have the right to use, on a non-exclusive basis, the parking spaces attributed to the Premises, prorated not to exceed eighty percent (80%) of such parking spaces, provided in the event that Subtenant and Tenant mutually agree in writing to
increase the square footage of the Sublease Premises, Subtenants number of allotted parking spaces shall be increased prorata with such increase in the Sublease Premises.
7. Services .
7.1 Subtenant shall be responsible for obtaining general building HVAC, electrical, janitorial and all other services. Payment for all such services shall be made directly by Subtenant to the service providers.
7.2 Subtenant will provide, at its own cost of installation, maintenance and subsequent removal, telephone systems, computer networks and any special modifications to the building security system. No such modifications may be made without the prior written approval of Tenant, which approval shall not be unreasonably withheld, conditioned, or delayed however any such approval shall be subject to all applicable terms and conditions of the Lease.
8. Signage . Subtenant signage is expressly limited to reasonably sized signage, affixed to the inside of Subtenants entry door or window area.
9. Condition of and Improvement to Premises .
9.1 Tenant shall deliver the Sublease Premises clean and free of debris. Tenant warrants that to Tenants knowledge the improvements on the Sublease Premises comply with all applicable covenants and restrictions of record and applicable building codes, regulations and ordinances ( Applicable Requirements ) in effect on the Commencement Date and Tenant warrants that the Subleased Premises is free and clear of all liens and encumbrances attributable to Tenant. Said warranty does not apply to the use to which Subtenant will put the Sublease Premises or to any alterations or utility installations made or to be made by Subtenant.
9.2 Except for the warranties expressly set forth in this Sublease Agreement, Subtenant shall accept the Sublease Premises As-Is, per the floor plan attached as Schedule 1; provided , however , that Tenant hereby acknowledges and agrees that all existing services and systems, as set forth on Schedule 2, are in good working condition as of the date of Subtenants occupancy and Tenant warrants that existing plumbing, fire sprinkler systems, lighting, air conditioning and heating systems are in good operating condition on the Commencement Date. Subtenant acknowledges that, at Subtenants expense, Subtenant has hired any consultants and made such inquiries as Subtenant deemed desirable prior to Sublease Agreement execution and Subtenant has determined that the Sublease Premises is suitable for its intended use. Tenant acknowledges and agrees that all lab benches and vented fume hoods shall remain in place as part of the Subleased Premises.
9.3 If Subtenant, at any time during the term of the Sublease, desires to make any alterations or improvements to the Sublease Premises, or any part or parts thereof, the same shall require Tenants prior written approval to the extent Tenant is required to seek approval of the Landlord pursuant to the Lease and shall be constructed by a licensed contractor without cost or expense to Tenant, in accordance with the requirements of all laws, ordinances, codes, orders, rules and regulations of all governmental authorities having jurisdiction over the Sublease Premises, or as otherwise required by the Landlord pursuant to the Lease. Any additions or improvements to the Sublease Premises, except Subtenants removable trade fixtures (as defined
in the Lease), furniture, shelving and equipment, shall become part of the Sublease Premises upon termination of the Sublease Agreement and be surrendered to Tenant. Subtenant shall have no obligation when the Sublease Agreement expires to restore the Sublease Premises to its original condition as existing on the date of initial occupancy by Subtenant, unless Tenant or Subtenant are so required by the Landlord under the Lease.
9.4 Subtenant shall be obligated to maintain the Sublease Premises and all equipment and utility services in good condition and repair, reasonable wear and tear excepted, and to surrender the same to Tenant in such condition and broom-clean upon the expiration or termination of this Sublease Agreement.
10. Hazardous Material Indemnification .
10.1 Subtenant shall indemnify, defend and hold Tenant harmless from and against any and all claims, judgments, damages, penalties, fines, costs, liabilities, or losses, including but not limited to attorneys fees, that arise during or after the Sublease Agreement term from or in connection with any handling, transportation, storage, treatment, generation, manufacture, discharge disposal or use of Hazardous Materials (as such term is defined in the Lease) that has occurred on the Sublease Premises by Subtenant, its employees, agents, contractors, licensees, invitees, or any other persons or entity during the term of the Sublease Agreement that has not been in compliance with (i) any law regulating the Hazardous Materials and (ii) the Lease. Subtenant will provide Tenant and Landlord with the initial listing (attached hereto as Schedule 2 ) of quantities, class and inventory of any Hazardous Materials that they will store at the Sublease Premises (the Inventory ). Tenant and Landlord will require an updated version of this Inventory every six (6) months during the term of this Sublease Agreement to assure compliance with (i) local state and federal codes and requirements and (ii) the Lease. Within thirty (30) days of receipt of such updated Inventory, Tenant and Landlord shall provide written notice to Subtenant of any new items on such updated Inventory to which Tenant or Landlord object to inclusion of such items on the Inventory. Failure to provide such written notice of objection shall conclusively be deemed approval thereof. Notwithstanding any other provisions of this Sublease or the Lease, Tenant and Landlord, by its consent to this Sublease, hereby authorize the storage and use of those items on the Inventory, as updated, throughout the Term of this Sublease. Subtenants obligations under this provision shall survive the expiration or early termination of the Sublease Agreement.
10.2 Tenant shall indemnify, defend and hold Subtenant harmless from and against any and all claims, judgments, damages, penalties, fines, costs, liabilities, or losses, including but not limited to attorneys fees, that arise during or after the Sublease Agreement term from or in connection with any handling, transportation, storage, treatment, generation, manufacture, discharge disposal or use of Hazardous Materials that has occurred on the Sublease Premises by Tenant, its employees, agents, contractors, licensees, invitees, or any other persons or entity prior to the Commencement Date.
11. Maintenance of Lease . Tenant agrees to comply with or perform Tenants obligations under the Lease and to hold Subtenant free and harmless from all liability, judgments, costs, damages, claims or demands arising out of Tenants failure to so comply with or perform Tenants obligations.
12. Attornment of Subtenant to Landlord in Event of Default .
12.1 Tenant hereby authorizes and directs Subtenant, upon receipt of any written notice from the Landlord stating that a default exists in the performance of Tenants obligations under the Lease which notice also demands that Subtenant pay to Landlord the Rent due and/or to become due under this Sublease Agreement, to pay to Landlord the Rent due and to become due under this Sublease Agreement. Tenant agrees that Subtenant shall have the right to rely upon any such statement and request from Landlord, and that Subtenant shall pay such rent to Landlord without any obligation or right to inquire as to whether such default exists and notwithstanding any notice or claim from Tenant to the contrary, Tenant shall have no right or claim against Subtenant for any such Rent so paid to Landlord.
12.2 No material changes or modifications shall be made to this Sublease without the consent of the Landlord.
13. Right to Assign or Sublease the Sublease Premises . Subtenant shall be required to obtain the prior written approval of Tenant for any subletting or assignment of Sublease Premises or Sublease Agreement, respectively, which approval shall not be unreasonably withheld; provided that any such approval shall be subject to further approvals as may be required by the Lease. Tenant further agrees that, should Subtenant locate a potential new subtenant ( Replacement Subtenant ), which Replacement Subtenant is financially equivalent to or better than Subtenant and is willing to enter into a new Sublease with Tenant on terms reasonably satisfactory to Tenant (for which purposes the same terms of this Sublease shall be deemed satisfactory), Tenant shall enter into such a Sublease with Replacement Subtenant.
14. Real Estate Leasing Commissions . Tenant and Subtenant acknowledge that Tenant shall pay the subleasing commission of six percent (6%) of the first months Rent due hereunder to Cornish & Carey Commercial Real Estate upon full execution of this Sublease Agreement.
15. Termination .
15.1 This Sublease Agreement shall be terminable by Tenant in the event Subtenant committed an Event of Default. Subtenant shall have committed an Event of Default if:
(a) Subtenant has not paid the monthly rent so due for a period of thirty (30) days; or
(b) Subtenant has materially breached an obligation of Subtenant under this Sublease Agreement, which breach has continued for a period of thirty (30) days after written notice thereof by Tenant to Subtenant; provided, however, that if the nature of Subtenants breach is such that more than thirty (30) days are reasonably required for its cure, then Subtenant shall not bee deemed to have committed an Event of Default if Subtenant commences such cure within such thirty (30) day period and thereafter diligently prosecutes such cure to its completion.;
15.2 This Sublease Agreement may be terminated by Subtenant in the event that Tenant has failed to provide the Sublease Premises set forth on Schedule 1 for an uncured period of more than thirty (30) days.
16. Lease as Governing Document . This Sublease Agreement is subject to all terms and conditions of the Lease, a copy of which is attached hereto as Schedule 3 .
17. General . This Sublease Agreement, together with all Schedules attached hereto, represents the entire agreement between the parties with respect to the matters covered herein and may not be amended, except in a writing duly executed by both parties. This Sublease Agreement shall be governed by, administered under and construed in accordance with the laws of the state of Washington without giving effect to its or any other jurisdictions principles of conflicts of laws.
IN WITNESS WHEREOF, the undersigned parties have caused this Sublease Agreement to be executed and delivered by the respective, duly authorized representatives thereon as of the date first above written.
TENANT: | SUBTENANT: | |||||||
|
||||||||
CORIXA CORPORATION | GENOMIC HEALTH, INC. | |||||||
|
||||||||
By:
|
/s/ Michelle Burris | By: | /s/ Randy Scott | |||||
|
||||||||
|
||||||||
Name:
|
Michelle Burris | Name: | Randy Scott | |||||
|
||||||||
Title:
|
SVP, CFO | Title: | Chairman & C.E.O. |
Exhibit 10.4.2
AMENDMENT TO SUBLEASE
THIS AMENDMENT TO SUBLEASE (Amendment) is entered into as of October 29, 2003 between Corixa Corporation and its affiliates, a Delaware corporation ( Tenant ) and Genomic Health, Inc., a Delaware corporation ( Subtenant ).
Recitals
A. The predecessor in interest of Tenant and the predecessor in interest of Metropolitan Life Insurance Company, a New York corporation ( Landlord ), have entered into that certain lease dated January 3, 1992, as amended by (i) that certain First Amendment dated January 5, 1993, (ii) that certain Second Amendment dated January 10, 1995, (iii) that certain Third Amendment dated March 24, 1995, (iv) that certain holdover letter agreement dated February 12, 1999, (v) that certain Fifth Amendment dated February 26, 1999 and (vi) that certain Sixth Amendment dated September 29, 2000 (collectively referred to herein as the Lease ), whereby Landlord leases to Tenant that certain premises in Building 11 of Phase II, with the current street address of 301 Penobscot Drive, Redwood City, CA, ( Premises ).
B. Tenant and Subtenant entered into a sublease dated June 1, 2001 (the Existing Sublease ), respecting a portion of the Premises (the Sublease Premises ). Capitalized terms not otherwise defined herein shall have the meanings set forth in the Existing Sublease. The term Sublease Agreement shall mean the Existing Sublease as amended hereby.
C. Tenant and Subtenant wish to hereby modify certain terms and provisions under the Sublease Agreement and are executing this Amendment to effectuate said modifications.
NOW, THEREFORE, in consideration of the covenants set forth herein, Tenant and Subtenant hereby agree as follows:
1. | Term . | |||
1.1 | Extension of Sublease Term . The Term of the Sublease is hereby extended for the period (the Extension Term) commencing on May 31, 2004, and ending on May 31, 2005 (the New Expiration Date). Effective as of the date hereof, all references in the Sublease to the Term shall be deemed to be references to the period through the New Expiration Date. | |||
1.2 | Option to Extend . The Option to Extend granted to Subtenant in Section 4.2 of the Existing Sublease is not exercised hereby and remains in full force and effect; provided that such Option to Extend is hereby revised to provide that the Rent for the Option Term shall be the then fair market rent for the Sublease Premises based upon the terms of the Sublease, as extended. Fair market rent shall include the periodic rental increases, if any, that would be included for space leased for the period the space will be covered by the Sublease. For purposes of this Section 1.2, the term fair market rent shall mean the rental rate for comparable space under sublease to new subtenants, taking into consideration the quality of the Sublease Premises and any amenities such as existing improvements, view, floor |
on which the Sublease Premises are situated and the like, situated comparable buildings in comparable locations on the San Francisco Bay peninsula, in comparable physical and economic condition, taking into consideration the then prevailing ordinary rental market practices with respect to tenant concessions (if any). The fair market rent shall be mutually agreed upon by Tenant and Subtenant in writing within the thirty (30) calendar day period commencing six (6) months prior to commencement of the renewal period. If Landlord and Tenant are unable to agree upon the fair market monthly rent within said thirty (30)-day period, then the fair market rent shall be established by appraisal in accordance with the procedures set forth in Exhibit A attached hereto. |
2. Rent . Section 2.1 of the Existing Sublease is hereby revised to provide that commencing as of October 1, 2003 and continuing through the New Expiration Date, the Rent for the Sublease Premises shall be in the amount of $74,838 per month. The Rent as so revised shall continue to be the total monthly amount due to Tenant for rental of the Sublease Premises.
3. Consent of Landlord . This Amendment is subject to the written consent of Landlord in accordance with the terms of the Lease, which consent, Tenant shall diligently pursue, at no cost to Subtenant.
4. Counterparts . This Amendment may be executed in counterparts, each of which shall be an original, but all of which shall constitute one and the same Amendment.
5. Confirmation of Existing Sublease Agreement . Except as amended by this Amendment, the Existing Sublease is unmodified, and as amended hereby, the Sublease Agreement remains in full force and effect.
IN WITNESS WHEREOF, Tenant and Subtenant have executed this Amendment as of the date first above written.
CORIXA CORPORATION, a Delaware corporation | ||||
|
||||
|
By | /s/ Steven Gillis | ||
|
||||
|
||||
|
Its CEO | |||
|
||||
GENOMIC HEALTH, INC., a Delaware corporation | ||||
|
||||
|
By | /s/ Randy Scott | ||
|
||||
|
||||
|
Its CEO |
- 2 -
Exhibit 10.4.3
SECOND AMENDMENT TO SUBLEASE
THIS SECOND AMENDMENT TO SUBLEASE ( Amendment ) is entered into as of January 31, 2005, between Corixa Corporation and its affiliates, a Delaware corporation ( Tenant ) and Genomic Health, Inc., a Delaware corporation ( Subtenant ).
Recitals
A. The predecessor in interest of Tenant and the predecessor in interest of Metropolitan Life Insurance Company, a New York corporation ( Landlord ), have entered into that certain lease dated January 3, 1992, as amended by (i) that certain First Amendment dated January 5, 1993, (ii) that certain Second Amendment dated January 10, 1995, (iii) that certain Third Amendment dated March 24, 1995, (iv) that certain holdover letter agreement dated February 12, 1999, (v) that certain Fifth Amendment dated February 26, 1999 and (vi) that certain Sixth Amendment dated September 29, 2000 (collectively referred to herein as the Lease ), whereby Landlord leases to Tenant that certain premises in Building 11 of Phase II, with the current street address of 301 and 333 Penobscot Drive, Redwood City, CA, ( Premises ).
B. Tenant and Subtenant entered into a sublease dated June 1, 2001, as amended by that certain Amendment to Sublease, entered into as of October 29, 2003 (the Existing Sublease ), respecting a portion of the Premises (the Original Sublease Premises ). Capitalized terms not otherwise defined herein shall have the meanings set forth in the Existing Sublease. The term Sublease Agreement shall mean the Existing Sublease as amended hereby.
C. Tenant currently subleases the remainder of the Premises, depicted on Exhibit A hereto (the Additional Sublease Premises ) to Discovery Laboratories, Inc. a Delaware corporation ( Discovery ), pursuant to that certain Sublease Agreement effective as of January 18, 2002, by and between Tenant and Discovery (the Discovery Sublease ).
D. Tenant and Subtenant wish to hereby add the Additional Sublease Premises to the space subleased under the Existing Sublease and are executing this Amendment to effectuate said modifications.
NOW, THEREFORE, in consideration of the covenants set forth herein, Tenant and Subtenant hereby agree as follows:
1. Additional Subleased Premises . Effective as of the Effective Date (as defined below), the Additional Subleased Premises shall be added to the premises covered by the Sublease. Commencing on the Effective Date, all references in the Sublease Agreement to the Sublease Premises shall be deemed to include the Additional Sublease Premises, and Subtenants lease of the Additional Sublease Premises shall be on all of the terms, covenants and conditions of the Existing Sublease applicable to the Original Sublease Premises, except as hereinafter provided. Tenant and Subtenant hereby stipulate for all purposes of the Sublease Agreement that the Additional Sublease Premises contain 4,963 rentable square feet. The Effective Date shall occur (and such date shall be the Commencement Date with respect to the Additional Sublease Premises) on the later of: (a) the date of receipt of the Landlord Consent (as defined below), provided that such Landlord Consent need not include approval to the removal
- 1 -
of walls described in Section 7(c) below; and (b) receipt of a closure letter from the County of San Mateo in a form acceptable to Genomic and approved by Tenant.
2. Term . Effective as of the Effective Date, the Term of the Sublease Agreement is extended for an additional period (the Extension Period ) commencing on May 1, 2005 and ending on February 28, 2006 (the New Expiration Date ). During the Extension Period, all of the terms, covenants and conditions of the Existing Sublease shall be applicable, except as set forth herein. Effective as of the Effective Date, the Option to Extend granted to Subtenant in Section 4.2 of the Existing Sublease and Section 1.2 of the Amendment to Sublease shall be deleted in their entirety.
3. Condition of the Additional Sublease Premises . On the Effective Date, Tenant shall deliver the Additional Sublease Premises clean and free of debris with all existing services and systems in good working condition. Tenant acknowledges that all vented fume hoods shall remain in place as part of the Additional Sublease Premises. On the New Expiration Date, or earlier termination of the Sublease Agreement, Subtenant shall surrender the Additional Sublease Premises to Tenant in substantially the condition they are delivered to Subtenant, wear and tear excepted.
4. Rent .
(a) Original Sublease Premises . Effective as of the Effective Date, commencing as of the June 1, 2005 through the New Expiration Date, Subtenant shall pay Rent for the Original Sublease Premises in the amount of $39,744.00 per month.
(b)
Additional Sublease Premises
. Commencing as of the Effective Date through the New
Expiration Date, in addition to the Rent payable for the Original Sublease Premises, Subtenant
shall pay Rent for the Additional Sublease Premises in the following amounts:
Period
Amount Per Month
$
13,163.12
$
13,558.01
$
13,964.75
5. Security Deposit . Upon the Effective Date, the Security Deposit under the Sublease Agreement shall be increased by Eighteen Thousand Six Hundred Eleven and Twenty-Five One-Hundredths Dollars ($18,611.25), and Subtenant shall pay the amount of such increase to Tenant on or before the Effective Date.
6. Parking . Subtenants rights to parking provided in Section 6 of the Existing Sublease shall not be prorated but shall be 100% of the parking spaces attributed to the Premises.
7. Landlord Consent . Tenant shall promptly request from Landlord and use commercially reasonable efforts to obtain Landlords consent (the Landlord Consent ) to: (a) this Amendment in accordance with the terms of the Lease; (b) Subtenants use in the Sublease Premises of the Hazardous Materials listed in Exhibit B hereto; and (c) Subtenants removal of the interior walls as shown on Exhibit C hereto.
- 2 -
8. Tenant Consent . Tenant hereby consents to Subtenants use in the Sublease Premises of the Hazardous Materials listed in Exhibit B hereto in accordance with applicable law and the terms and conditions of the Lease.
9. Reimbursement for Expenses . Subtenant shall reimburse Tenant for the reasonable expenses incurred by Tenant in connection with the review and negotiation of this Amendment, including, by not limited to, attorneys fees and disbursements, within 30 days following Tenants receipt of an invoice therefor.
10. Brokers . Tenant and Subtenant each represents and warrants that it has negotiated this Amendment directly with each other and has not authorized or employed, or acted by implication to authorize or to employ, any other real estate broker or salesman to act on its behalf in connection with this Amendment. Tenant and Subtenant shall indemnify, defend and hold each other harmless from and against any and all claims by any other real estate broker or salesman for a commission, finders fee or other compensation through it as a result of entering into this Amendment.
11. Counterparts . This Amendment may be executed in counterparts, each of which shall be an original, but all of which shall constitute one and the same Amendment.
12. Confirmation of Existing Sublease Agreement . Except as amended by this Amendment, the Existing Sublease is unmodified, and as amended hereby, the Sublease Agreement remains in full force and effect.
- 3 -
\
IN WITNESS WHEREOF, Tenant and Subtenant have executed this Amendment as of the date first above written.
CORIXA CORPORATION, a Delaware corporation | ||||
|
||||
|
By | /s/ Gregory Cox | ||
|
||||
|
||||
|
Its TREASURER | |||
|
||||
GENOMIC HEALTH, INC., a Delaware corporation | ||||
|
||||
|
By | /s/ Randal W. Scott | ||
|
||||
|
||||
|
Its Chairman & CEO |
- 4 -
Exhibit 10.5.1
*** Confidential Treatment Requested. Confidential portions of this document have been
redacted and have been separately filed with the Commission.
LIFESEQ COLLABORATIVE AGREEMENT
between
INCYTE GENOMICS, INC.
And
GENOMIC HEALTH, INC.
Page 1
This Agreement is entered into as of this 30th day of March, 2001 (the Effective Date) by and between Genomic Health, Inc., a Delaware corporation (GHI), having its principal place of business at 101 University Ave., Suite 220, Palo Alto, CA 94301, and Incyte Genomics, Inc., a Delaware corporation (Incyte), having its principal place of business at 3160 Porter Drive, Palo Alto, CA 94304.
RECITALS
WHEREAS INCYTE owns or has rights in certain patent rights and know-how regarding certain high-throughput partial cDNA sequencing, full length clones, cloning, and data analysis technologies; and
WHEREAS, Incyte has compiled and is compiling, and owns, certain information and data regarding certain cDNAs in confidential databases which may be useful in the study of biological phenomena; and
WHEREAS, Incyte owns or has rights in certain patent rights and know-how regarding certain cDNAs as well as certain of the proteins they encode; and
WHEREAS, GHI desires to obtain access to Incytes LifeSeq®Database Product(s) (as defined below), and to obtain licenses to use Incytes patent rights and know-how in the LifeSeq® Database Products, to conduct research and development of diagnostics and pharmaceuticals;
NOW, THEREFORE, the Parties agree as follows:
1.0 DEFINITIONS .
The following terms shall have the following meanings:
Access Term : shall mean the period commencing on the Effective Date and ending April 30, 2005.
Affiliate : shall mean any corporation, firm, partnership, or other legal entity, which, directly or indirectly is owned or under common ownership by a party to the extent of which the common stock or other equity ownership thereof is One Hundred percent (100%) owned by such party; provided however, that where local laws require a minimum percentage of local ownership, the status of Affiliate will be established if such party directly or indirectly owns or controls the maximum ownership percentage that may, under such local laws, be owned or controlled by foreign interests.
Page 2
Annotation Information : shall mean the information associated with individual cDNAs contained in each and/or all of the LifeSeq® Database Product(s), as applicable including, but not limited to, Gene Expression Profiles, homology information, gene cluster identifiers, SNPs, etc.
Antisense Field of Use : shall mean the treatment or prevention of any disease, state or condition in humans by use of one or more oligonucleotides or modified oligonucleotides which bind either (i) to mRNA to block the translation of mRNA in vivo to inhibit, prevent and/or alter protein production, or (ii) to DNA to prevent the transcription of DNA into the mRNA copy of the gene in vivo. The Antisense Field of Use does not include the sale or license to third parties of Database Information or Gene/Gene Derivative(s) as research tools, or the use of Database Information or Gene/Gene Derivative(s) to develop database products or services.
Antisense Product(s) : shall mean oligonucleotides or modified oligonucleotides derived from or targeted to Gene/Gene Derivative(s) for use in the Antisense Field of Use.
cDNA : shall mean a complementary DNA copy of messenger RNA.
cDNA Clone : shall mean an individual plasmid vector and cDNA insert, which cDNA is usually a partial gene, and not necessarily a full length gene.
Cancer Expression TAB : shall mean the microarray-based expression data related to cancer and generated by Incyte for inclusion in the cancer module of its LifeExpress expression database.
Database Information : shall mean all or any part of the Annotation Information and DNA Sequence Information which is contained in each and/or all of the LifeSeq® Database Product(s), as applicable.
Designated Gene : shall mean a given Gene/Gene Derivative which is selected for research and development, or other use by GHI in accordance with the terms and conditions of this Agreement, and is or has been Used By GHI, as defined below, during the Access Term.
Diagnostic Field of Use : shall mean the research, development, manufacture, importation. use and/or sale of Diagnostic Product(s). The Diagnostic Field of Use excludes the Personalized Research Field of Use, the Homebrew Field of Use and the Internal Research Field of Use.
Diagnostic Product(s) : shall mean an assay provided as a product or service performed on a human tissue or other human biological sample containing nucleic acids or proteins that are collectively intended to establish or identify an association between the presence or absence of such nucleic acids or proteins and:
Page 3
(i) | diagnosis of the presence of, or absence of, a specific disease(s), state(s) or condition(s) in humans; | |||
(ii) | predisposition to the presence of, or absence of, a specific disease(s), state(s) or condition(s) in humans; | |||
(iii) | response or lack of response to disease therapy(ies) in humans or preventative strategies in humans; | |||
(iv) | prediction of the disease course in humans, and or other changes in state(s) or condition(s) in humans over time; | |||
(v) | clinical traits in humans for which a medical professional should be consulted; | |||
(vi) | variation(s) in specific trait(s) and/or characteristics among individuals; and/or | |||
(vii) | predisposition to development of toxicities to disease therapies or preventative strategies in humans. |
the results of which are provided to payors, providers or patients, and for which FDA approval (or comparable regulatory agency in other jurisdictions) is required. Diagnostic Products exclude Homebrew Products, Personalized Research Products and GHI Database Products.
DNA Sequence Information : shall mean human nucleotide sequences incorporated into the LifeSeq® Database Product(s) provided by Incyte to GHI pursuant to this Agreement.
Drug Product(s) : shall mean compositions of matter which are ligands or inhibitors of Gene/Gene Derivative(s), which are small molecules or antibodies, and which are agonists, antagonists and/or modulators of Gene/Gene Derivative(s) for use in the treatment or prevention of any disease in humans.
Full Length Clone : shall mean, with respect to a given human gene, a specific, purified cDNA Clone developed or acquired by Incyte, containing the nucleotide sequence of the entire amino acid coding region of such human gene.
Full Length Contig : shall mean, with respect to a given human gene, DNA Sequence Information contained in the LifeSeq® Database Product(s) corresponds to the entire amino acid coding region of such human gene.
Frequency and Confirmation Dataset : shall mean the data relating to (i) confirmation of the existence of SNPs in the isSNP Dataset and (ii) allele frequency of such SNPs generated by or for Incyte.
GUI Database Field of Use : shall mean the research, development, manufacture, importation, use and/or sale of GHI Database Product(s) to end users.
GHI Database Product(s) : shall mean a collection of information derived from or by testing a person or persons in the Diagnostic Field of Use, Homebrew Field of Use or the Personalized Research Field of Use, provided that such information shall exclude any information that constitutes Database Information or
Page 4
Gene/Gene Derivative(s) other than Gene/Gene Derivative Identifier(s). GHI Database Products exclude Diagnostic Products, Homebrew Products, and Personalized Research Products.
Gene Bin(s) : shall mean a collection of nucleotide sequences including RNA derived consensus sequence(s) with sequence quality vectors, cDNA sequences, full length gene sequences, exons detected in genomic DNA sequences, and integrated RNA and genomic DNA based consensus sequences, the peptides, polypeptides and proteins putatively encoded thereby, believed, based on the Incyte cleaning and clustering process, to be derived from a individual transcription unit in the human genome. Each Gene Bin also contains IDs indicating the individual consensus sequences and some (but not all) of the individual component sequences which were assembled together in the Gene Bin.
Gene Expression Profiles) : shall mean a listing of cDNAs by name with each cDNA assessed by a homology score to be:
an exact match to a known gene sequence, or
a match to a proprietary Incyte cDNA, or
a homolog of a known gene or proprietary Incyte cDNA, or
a new clone with no prior identified homology or overlap.
This profile includes transcript abundance and certain annotation information regarding such cDNA derived from Incyte and public databases, but does not include DNA Sequence Information.
Gene/Gene Derivative(s) : shall mean (i) Incytes proprietary cDNA Clone(s) and Full Length Clones corresponding to a given cDNA in the DNA Sequence Information and (ii) any partial cDNAs, DNA sequences, genes, and full length cDNAs corresponding to such genes, or any RNA sequences, SNP(s), peptides, polypeptides and proteins encoded thereby, in each case which are derived from material use by GHI or a GHI Affiliate of Database Information or the cDNA Clone(s) in (i) above.
Gene/Gene Derivative Identifier : shall mean Incytes unique identifier for each Gene Bin included by Incyte in the Database Information. Where the DNA sequence of a Gene/Gene Derivative is publicly available, then the Gene Identifier for such Gene Product will be, or will be linked to, the GI number (Genbank identifier).
Homebrew Field of Use : shall mean the research, development, manufacture, importation, use and/or sale of Homebrew Product(s). The Homebrew Field of Use excludes the Diagnostic Field of Use, the Internal Research Field of Use and the Personalized Research Field of Use.
Homebrew Product(s) : shall mean a Single Analyte Assay(s) provided as a product or a service performed by a service provider that would constitute a Diagnostic Product with the sole exception that it is provided prior to receipt of
Page 5
approval by the FDA or comparable regulatory agency in any jurisdiction outside of the United States. Homebrew Products exclude Diagnostic Products, Personalized Research Products and GHI Database Products. For purposes of the foregoing, Single-Analyte Assays shall mean an assay designed for testing or measuring only a single analyte.
Incyte Know-How : shall mean the information, software, data and biological materials consisting of or directly and solely relating to Database Information, and which are proprietary to Incyte either at the time of disclosure to GHI and not already known to GHI (with the right to use) independent of the Database Information, as can be demonstrated by tangible records of GHI existing prior to such time of disclosure, all to the extent and only to the extent that Incyte has the right to grant licenses, immunities or other rights to GHI thereunder; provided, however , that Incyte Know-How shall exclude Incyte Patent Rights and all Incyte Proprietary Programs; and further provided that genomic DNA sequence information which is part of the public domain or was already known to GHI (with the right to use) does not render Database Information non-proprietary or non-confidential except to the extent that such genomic DNA sequence information has been specifically and materially established as exon region(s)](i) via standard molecular biology laboratory techniques, or (ii) through the use of a suitable computer algorithm with subsequent confirmation through laboratory research, as can be demonstrated by GHIs tangible records existing prior to the time of disclosure of Database Information.
Incyte Patent Rights : shall mean the patents and/or patent applications owned or controlled by Incyte which (i) claim the composition of matter of Gene/Gene Derivative(s) or any other cDNAs identified in the DNA Sequence Information, and/or (ii) arise solely from the generation of Database Information and claim the use of Gene/Gene Derivative(s) with respect to Product(s), throughout the world as well as reissues, reexaminations, divisionals, provisionals, continuations or continuations-in-part thereof or therefor, all to the extent and only to the extent Incyte has the right to grant licenses, immunities or other rights thereunder; provided, however , that Incyte Patent Rights shall exclude all patent rights arising under Incyte Proprietary Programs.
Incyte Proprietary Program(s) : shall mean a research and development program of Incyte which involves investment by Incyte intended to develop discoveries, inventions, data or information (whether or not patentable) beyond that consisting of Database Information. Incyte Proprietary Programs are independent of those services regularly performed by Incyte to produce or generate DNA Sequence Information and Annotation Information intended to be released to the LifeSeq® Database Product(s).
Incyte Technology : shall mean, collectively, Incyte Know-How and Incyte Patent Rights.
Installation Site(s) : shall mean the research facilities of Genomic Health located in Palo Alto, California and any additional sites noticed to Incyte in accordance with 2.1.2.
Page 6
*** Confidential material redacted and filed separately with the Commission.
isSNP Dataset : shall mean Incytes set of in-silico SNPs derived from the LifeSeq® Gold Database and delivered to Genomic Health in flat-file format.
LifeSeq® Gold Database : shall mean Incytes proprietary database of human Annotation Information and DNA Sequence Information and corresponding cDNA Clones and Full Length Clones as of the Effective Date, and as updated thereafter during the Access Term to include additional Annotation Information and/or DNA Sequence Information and corresponding cDNA Clones, together with related software and documentation, as described generally in Exhibit A.
LifeSeq® Database Product(s) : shall mean the LifeSeq® Gold Database the isSNP Dataset, the Cancer Expression TAB and the Frequency and Confirmation Dataset.
Net Sales : shall mean invoiced sales by GHI, GHI Affiliates or sublicensees on all sales of Product (in final form for end use) to an unaffiliated third party (whether an end-user, a distributor or otherwise), and exclusive of intercompany transfers or sales, less the following deductions from such invoiced sales which are actually incurred, to the extent that they are reasonable and customary, and to the extent that they do not exceed *** percent (***%) of invoiced sales in a calendar quarter:
(a) | credits or allowances actually granted for damaged Products, returns or rejections of Product and retroactive price reductions; | |||
(b) | freight, postage, shipping, customs duties and insurance charges; | |||
(c) | normal and customary trade, cash and quantity discounts, allowances and credits; | |||
(d) | uncollected amounts to the extent not exceeding *** percent (***%) of invoiced sales for a calendar quarter; and | |||
(e) | sales, value added or similar taxes measured by the billing amount, when included in billing. |
Personalized Research Field of Use : shall mean the research, development, manufacture, importation, use and/or sale of Personalized Research Product(s). The Personalized Research Field of Use excludes the Diagnostic Field of Use, the Homebrew Field of Use, and the Internal Research Field of Use.
Personalized Research Product(s) : shall mean a Multi-Analyte Assay(s) provided as a product or a service containing nucleic acids or proteins that are collectively intended to establish or identify an association between the presence or absence of such nucleic acids or proteins and:
(i) | diagnosis of the presence of, or absence of, a specific disease(s), state(s) or condition(s) in humans; |
Page 7
(ii) | predisposition to the presence of, or absence of, a specific disease(s), state(s) or condition(s) in humans; | |||
(iii) | response or lack of response to disease therapy(ies) in humans or preventative strategies in humans; | |||
(iv) | prediction of the disease course in humans, and or other changes in state(s) or condition(s) in humans over time; | |||
(v) | clinical traits in humans for which a medical professional should be consulted; | |||
(vi) | variation(s) in specific trait(s) and/or characteristics among individuals; and/or | |||
(vii) | predisposition to development of toxicities to disease therapies or preventative strategies in humans. |
Such an assay will be considered a Personalized Research Product only where the results are provided directly to the tested individual and/or to the tested individuals health care provider, and where the approval by the FDA or comparable regulatory agency in any jurisdiction outside of the United States is not required. Personalized Research Products exclude Homebrew Products, Diagnostic Products and GHI Database Products. For purposes of the foregoing, Multi-Analyte Assay(s) shall mean an assay designed for testing or measuring more than a single analyte.
Product(s) : shall mean GHI Database Products, Personalized Research Products, Homebrew Products and/or Diagnostic Products.
Regulatory Approval : shall mean, with respect to any country in the world, applications or approvals of any national, supra-national , regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity, necessary for the lawful manufacture, distribution, use, import, export or sale of Product(s) in such country.
Research Field of Use : shall mean (a) research, development, manufacture, use, import ation and/or sale of Research Products; and (b) all internal research applications of Gene/Gene Derivative(s), associated with conducting research in the Antisense Field of Use, the Therapeutic Field of Use and in the identification, development and commercialization of Drug Products. The Research Field of Use does not include the sale or license of Database Information or Gene/Gene Derivative(s) as research tools, or the use of Database Information or Gene/Gene Derivative(s) to develop database products or services.
Research Product(s) : shall mean all internal research applications of Gene/Gene Derivative(s), associated with conducting research in the Antisense Field of Use, the Therapeutic Field of Use and in the identification, development and commercialization of Drug Products, Antisense Product(s) and Therapeutic
Page 8
Protein Product(s). Research Product(s) exclude Diagnostic Product(s), Personalized Research Product(s), and GHI Database Products.
SNP : shall mean a single nucleotide polymorphism.
Therapeutic Field of Use : shall mean the treatment or prevention of any disease, state or condition in humans by any means, (including without limitation, gene therapy), excluding the Antisense Field of Use. The Therapeutic Field of Use does not include the sale or license of Database Information or Gene /Gene Derivative(s) as research tools, or the use of Database Information or Gene/Gene Derivative(s) to develop database products or services. Therapeutic Protein Product(s) : shall mean any product or service, including gene therapy, which uses a protein, peptide or polypeptide which is a Gene/Gene Derivative in the treatment or prevention of any disease, state or condition in humans, including gene therapy products; provided however, that Therapeutic Protein Product(s) does not include Antisense Product(s).
Used or Use By GHI : shall mean the first use by GHI or a GHI Affiliate of Database Information or a proprietary cDNA Clone obtained from Incyte hereunder, in each case which at the time of such use is either included in the Incyte Know-How or the Incyte Patent Rights, and provided that such first use by GHI meets any or all of the following criteria:
(a) | GHI uses such cDNA Clone from the LifeSeq® Database Product(s) which contains DNA Sequence Information that partially or completely codes for a Gene/Gene Derivative to test as a marker for a disease, state or condition; or | |||
(b) | GHI uses such cDNA Clone or sequence from the LifeSeq® Database Product(s) which contains DNA Sequence Information that partially or completely codes for a Gene to synthesize or have synthesized a peptide or polypeptide or protein or oligonucleotide or antibody to test as a marker for a disease, state or condition; or | |||
(c) | such Database Information or such cDNA Clone which contains the Database Information is disclosed or otherwise transferred to a third party including but not limited to consultants and GHIs; but not including consultants of GHI that (i) are individuals who primarily work on site at GHI or GHIs Affiliate(s) facilities and (ii) have entered into a confidentiality agreement with GHI or GHIs Affiliate(s) on terms substantially similar to the terms contained in GHIs form Consultant Confidentiality Agreement, attached hereto as Exhibit C; or | |||
(d) | such Database Information is specifically disclosed in a GHI patent or patent application |
provided, however that if GHI and/or a GHI Affiliate has independently discovered, developed and/or acquired from an unaffiliated third party (in each case without use of Incyte Technology and as documented by GHIs, and/or a |
Page 9
*** Confidential material redacted and filed separately with the Commission.
GHI Affiliates, the public domains and/or such unaffiliated third partys tangible records generated at the time of such discovery, development or acquisition) the same sequence information and/or other information with respect to a specific Gene as is contained in the LifeSeq® Database Products, GHIs and GHI Affiliates use or disclosure of such independently discovered, developed or acquired information shall not constitute Use By GHI. | ||||
Valid Claim : shall mean a claim of an issued and unexpired Incyte Patent Right which has not been held unenforceable, unpatentable or invalid by a decision of a court or governmental body of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, which has not been lost through an interference proceeding. |
2.0 DATABASE ACCESS .
2.1 | Access to the LifeSeq® Database Product(s) . |
2.1.1 Access Grant . Incyte hereby agrees to provide to GHI access to the LifeSeq® Database Product(s) solely in accordance with the terms and conditions of this Agreement. Each Installation Site shall have on-site access to the LifeSeq® Database Product(s).
2.1.2
Installation
. At a date and time mutually acceptable (the Installation
Date), Incyte agrees to provide GHI with on-site access to the LifeSeq® Database Product(s)
at the first Installation Site. During the Access Term, GHI shall have the right to
designate one or more additional Installation Sites, with installation to be provided at a
time mutually acceptable; provided that GHI has obtained the prior written consent of Incyte
regarding such sites, which consent will not be unreasonably withheld. If the total number
of Installation Sites is greater than one, then GHI shall pay Incyte *** Dollars (US$ ***)
per year for each additional Installation Site. Any additional implementation or support
services provided by Incyte to GHI shall be in a manner consistent with and under terms
consistent with those of comparable users of the LifeSeq® Database Product(s). The LifeSeq®
Database Product(s) will be transferred to GHI either digitally via the Internet or modem to
GHI or via the load and leave process, where the database products will be installed by
Incyte onto GHIs equipment. Incyte will retain title, possession, and control over all
physical forms of property at all times during the installation process. Upon completion of
the installation of the technology, Incyte shall not leave with GHI any form of tangible
personal property other than instruction documentation. GHI is authorized to make a backup
copy of the database products for archival purposes.
Access at Incyte, Palo Alto
. For the period from the Effective Date to December 31,
2001, GHI shall be able to obtain access to the LifeSeq® Gold Database at Incytes facility
in Palo Alto, California. The timing and frequency of such access to be mutually agreed upon
by the Parties. Any access shall be governed by this Agreement.
Page 10
2.1.3 Updated Releases and Updates . During the Access Term, Incyte shall provide GHI Installation Site(s) with data updates of newly released Database Information, and such updated software releases of the LifeSeq® Gold Database, as Incyte provides generally to its LifeSeq® Gold Database collaborators. During the Access Term, Incyte shall have the right to commence providing access and updates to the LifeSeq® Gold Database via on-line services via secure connections. Incyte shall have no obligation to update the isSNP Dataset and shall make updates to the Frequency and Confirmation Dataset and to the Cancer Expression TAB to Genomic Health as they become commercially available during the Access Term.
2.2 Database Access Plan . Throughout the Access Term, GHI shall implement a Database Access Plan, which shall be subject to Incytes prior, written approval (not to be unreasonably withheld), which shall implement the provisions of this Agreement, including without limitation those in Section 2.1 with respect to Installation Sites and Remote Access Sites, and the provisions of Section 2.2. Within thirty (30) days after the Effective Date, and in any case prior to the Installation Date, GHI shall provide Incyte with a copy of the Database Access Plan, and Incyte shall have the right to require changes to the Database Access Plan only to the extent reasonably required to enable Incyte to verify GHIs compliance with the terms of this Agreement.
2.3 | Use Restrictions and Security Requirements |
2.3.1 Ownership . GHI hereby acknowledges that (a) Incyte has expended significant resources and efforts to develop the LifeSeq® Database Product(s) and the Database Information, (b) the LifeSeq® Database Product(s) represent highly valuable and confidential assets, and are the principal products of Incyte, (c) Incyte is willing to grant GHI access to the LifeSeq® Database Product(s) in reliance upon the agreement by GHI that it shall protect the LifeSeq® Database Product(s) from unauthorized disclosure or use at each Installation Site, and (d) the LifeSeq® Database Product(s) at all times during the term of this Agreement shall remain, the sole and exclusive property of Incyte.
2.3.2 Designated CPUs at the Installation Sites . The LifeSeq® Database Product(s), including the DNA Sequence Information, shall only be installed at each Installation Site on the hard disk of a designated file server whereby multiple workstation(s) do not contain copy(s) of the LifeSeq® Database Product(s) installed, other than ephemerally, on the workstation hard disk(s). A second copy of the database(s) may reside on the same computer or file server provided that this copy is solely used to install and test new versions and releases of the database. A back-up computer or file server may be designated such that a copy of the database may be installed on this computer in the event that the primary computer fails. Under no circumstances will the LifeSeq® Database Product(s), be installed on any designated CPU(s) in a manner which would allow unauthorized access (e.g. third party access via the Internet). All other database access is prohibited.
Page 11
2.3.3 Permitted Use .
(a) During the Access Term, GHI shall have the right to use the LifeSeq® Database Product(s) solely for its own internal use by authorized personnel of GHI at the Installation Site(s) in secure work facilities of GHI in accordance with the terms and conditions of this Agreement and the Database Access Plan. Authorized personnel of GHI shall include those consultants of GHI who (i) are individuals who primarily work on site at GHI or GHIs Affiliate(s) facilities and (ii) have entered into a confidentiality agreement with GHI or GHIs Affiliate(s) on terms substantially similar to the terms contained in GHIs form Consultant Confidentiality Agreement, attached hereto as Exhibit C.
(b) GHI shall not disclose or transfer Database Information which would constitute Incyte Know-How, or any portion thereof, to any third party, except for Database Information and corresponding cDNA Clone(s) specifically regarding a Designated Gene or a Product and in each event solely in accordance with the provisions of Sections 2.3.3(c), 2.3.4 and 5.0.
(c) Solely for purposes of system integration and/or to facilitate data analysis and relational analysis (e.g. extraction of DNA Sequence Information for homology analysis by GHI search algorithms), GHI shall have the right to reproduce, adapt, modify and prepare derivative works based upon the LifeSeq® Database Product(s) (Modifications) solely for internal use by GHI in its research and development programs. GHI shall own all right, title and interest in and to such Modifications, provided; Modifications shall be kept in confidence in the same manner as, and shall be subject to the same terms and conditions as apply to use of, the LifeSeq® Database Product(s), including, but not limited to Section 2.3.7. Incyte shall have no obligations to support any such Modifications. GHI shall not acquire by reason of this subsection (d) any ownership of any LifeSeq® Database Product(s), any portions thereof or any title or rights therein. GHI shall not distribute copies of, or provide access to, any Modifications to any third party without the prior written approval of Incyte.
(d) Except as expressly set forth herein, or as otherwise agreed by Incyte in writing, GHI shall not reproduce, adapt, modify, prepare derivative works based upon or distribute copies (in whatever form whether tangible or intangible, by any means whatsoever whether now known or hereafter invented) of the LifeSeq® Database Product(s), including any substantial portion of the Database Information from any field of the database.
2.3.4 Designated Gene/Gene Derivative(s) . During the Access Term and pursuant to the escrow agreement, GHI shall make a deposit into escrow of the identity of each Designated Gene/Gene Derivative in accordance with the terms and conditions of this Agreement. GHI shall then have the right to use, disclose and transfer Database Information specifically regarding such Designated Gene/Gene Derivative, including to GHI Affiliates, academic and third party
Page 12
collaborators, licensees, governmental agencies or offices or otherwise for use in the discovery, research, development and/or commercialization of Products, subject to the appropriate terms and conditions of this Agreement, including Article 5.0. Any use of Database Information not in accordance with the above is expressly prohibited.
2.3.5 Records . GHI shall maintain records of access to and use of the LifeSeq® Database Product(s) and the Database Information, sufficient to enable GHI and Incyte to determine, and monitor compliance with, their respective rights and obligations under this Agreement (e.g. laboratory notebooks and such other records as are customary for documenting research and product development activities). No more than once a year unless as otherwise agreed in writing, at the request and the expense of Incyte, upon at least forty-five (45) days prior notice, GHI shall permit an agent appointed by Incyte and acceptable to GHI to examine these records solely to the extent necessary to verify the fulfillment of GHIs obligations under this Agreement, provided that such agent has entered into a suitable confidentiality agreement with GHI. Incytes agent shall only report to Incyte the results of such examination (i.e., whether or not GHI is in compliance with its obligations under this Agreement), and shall not disclose to Incyte any of GHIs Confidential Information provided to it or to which it may have access during the conduct of the examination.
2.3.6 Loss, Theft, Unauthorized Disclosure or Use . GHI promptly shall notify Incyte of any loss, theft or unauthorized disclosure or use of the LifeSeq® Database Product(s) or the Database Information which comes to GHIs attention.
2.3.7 Termination of the Access Term . Upon termination or expiration of the Access Term with respect to the applicable LifeSeq® Database Product(s), GHI, at its election:
(a) shall have the option of extending the term of such LifeSeq® Database Product(s) subscription or individual database module thereof under terms demonstrably consistent with and comparable to those secured by comparable users of the LifeSeq® Database Product(s) at the time of extension; or
(b) shall discontinue use of such LifeSeq® Database Product(s) and Database Information, and remove such LifeSeq® Database Product(s) from each Installation Site(s), and promptly return to Incyte, or upon Incytes written instruction destroy, all portions and copies of such LifeSeq® Database Product(s) and the Database Information; except for that certain Database Information specific to Designated Gene/Gene Derivative(s) which are the subject of one or more of the licenses granted to GHI under Article 3.0 below.
GHI agrees to perform with Incyte a mutually acceptable final accounting of those Designated Gene/Gene Derivative(s) which are subject to one or more of the licenses granted to GHI under Article 3.0 below.
Page 13
2.3.8 Notification of Clinical Development . GHI agrees to keep Incyte reasonably informed of all Product(s) resulting from the use of the LifeSeq® Database Product(s), including notification when a given Product triggered a milestone pursuant to Section 4.2. All information provided by GHI to Incyte pursuant to this Section 2.3.8 shall be treated as GHIs Confidential Information. Notification of Product Development. GHI agrees to keep Incyte reasonably informed of all Product(s) resulting from the use of the LifeSeq® Database Product(s), including notification when a given Designated Gene/Gene Derivative has been elected to be a Product, triggering a milestone payment pursuant to Section 4.2. All information provided by GHI to Incyte pursuant to this Section 2.3.8 shall be treated as GHIs Confidential Information.
(a) | With respect to Homebrew Products or Personalized Research Products, a Designated Gene shall have been elected to be a Product upon the earlier of (i) the first commercial sale of a Product incorporating or using such Designated Gene/Gene Derivative, (ii) GHI or a GHI Affiliate entering into a written agreement with a third party to manufacture a Product incorporating or using such Designated Gene/Gene Derivative for GHI or GHIs Affiliate, or (iii) GHI sublicensing, pursuant to Section 3.2, a Product incorporating or using such Designated Gene/Gene Derivative; and | |||
(b) | With respect to Diagnostic Products, a Designated Gene/Gene Derivative shall have been elected to be a Product upon submission to the FDA, or a comparable regulatory agency in any other jurisdiction, for approval of a Product incorporating or using such Designated Gene/Gene Derivative. |
2.4 | Training . |
2.4.1 At times mutually acceptable to Incyte and GHI, Incyte shall provide GHI with two (2) days of training services at Incytes training facility in Palo Alto, California, regarding the use of the LifeSeq® Database Product(s). GHI may designate not more than twelve (12) employees to attend each such training at Incyte, or such other number as mutually agreed. Each party shall bear all accrued and out-of-pocket expenses of its own employees in connection therewith.
2.4.2 At times mutually acceptable to Incyte and GHI after the Installation Date, Incyte shall provide GHI with two (2) days of training services at the Installation Site, regarding the use of the LifeSeq® Database Product(s). The number of employees to receive such training shall be in the reasonable discretion of GHI. Each party shall bear all accrued and out-of-pocket expenses of its own employees in connection therewith.
2.4.3 Incyte shall provide GHI with such additional training services in such manner and on such terms and conditions as Incyte makes generally available to comparable GHIs to the LifeSeq® Database Product(s).
Page 14
3.0 LICENSE AND OPTION GRANTS .
3.1 | Non-Exclusive Licenses |
3.1.1
Non-Exclusive License Under Incyte Know-How in the Personalized Research,
Homebrew, GHI Database Field of Use and Diagnostic Fields of Use
. Incyte hereby
grants to GHI a worldwide, non-exclusive license (with a right to sublicense as
provided in Section 3.2) under the Incyte Know-How to conduct research with respect
to Designated Gene(s) and Product(s) in the Personalized Research Field of Use,
Homebrew Field of Use and Diagnostic Field of Use and to discover, develop, make,
have made, use, offer to sell, sell, import, and distribute GHI Database Product(s)
in the GHI Database Field of Use, Personalized Research Product(s) in the
Personalized Research Field of Use, Homebrew Product(s) in the Homebrew Field of Use
and Diagnostic Product(s) in the Diagnostic Field of use; provided however, that
except as provided expressly herein, such grant does not include the right to sell
Gene(s)/Gene Derivative(s).
3.1.2
Non-Exclusive License Under Incyte Patents in the Personalized Research,
Homebrew, GHI Database Field of Use and Diagnostic Fields of Use
. During the
Access term and upon Incytes receipt of written notice of election to license a
Product under Incyte Patent Rights, Incyte hereby grants to GHI a worldwide
non-exclusive license (with a right to sublicense as provided in Section 3.2) under
the Incyte Patent rights directed to such Designated Gene/Gene Derivative to
discover, develop, make, have made, use, offer to sell, sell, import, and distribute
GHI Database Product(s) in the GHI Database Field of Use, Personalized Research
Product(s) in the Personalized Research Field of Use, Homebrew Product(s) in the
Homebrew Field of use and Diagnostic Product(s) in the Diagnostic Field of Use.
3.1.3
No grant of rights to grant licenses, other than to GHI Affiliates, to
Database Information, Designated Gene/Gene Derivative(s) or the Incyte Technology
relating thereto in the GHI Database Field of Use, to discover or research Personalized
Research Products, Homebrew Products, Diagnostic Products, is provided by Incyte to GHI
herein.
3.2 | Sublicensing . |
3.2.1 On an individual Product-by-Product basis, GHI may sublicense to any third party in the direct chain of manufacturing, distribution and use of a Product, the rights to Designated Gene/Gene Derivative(s) and the Incyte Technology relating thereto granted under this Article 3.0 to the extent necessary in order to permit the third party to develop, make, have made, use, offer to sell, sell, import, export and distribute such Product as appropriate according to the role assigned to that third party by GHIs plan for the commercialization of such
Page 15
*** Confidential material redacted and filed separately with the Commission.
Product; provided , however , that without the prior written consent of Incyte, no sublicense of Incyte Technology will be granted to any third party in the absence of a corresponding license or sublicense of rights to a given Product and the license or sublicense of patent rights pertaining thereto owned by, licensed to or controlled by GHI; and further provided that each sublicense has a grant which is consistent with the terms herein and that GHI shall be responsible for payments and royalties due to Incyte under Article 4.0. GHI shall obtain the written commitment of any sublicensee to abide by all applicable terms and conditions of this Agreement. Promptly upon execution of any permitted sublicense, GHI shall provide notice thereof to Incyte and reasonable satisfactory evidence that such sublicense is in compliance with this Section 3.2.
3.2.2 No grant of right to sublicense rights to Database Information, Designated Gene/Gene Derivative(s) and the Incyte Technology relating thereto in the Internal Research Field of Use in order to discover or research Drug Products, Personalized Research Products, Homebrew Products, Diagnostic Products, Antisense Products and Therapeutic Protein Products is provided by Incyte to GHI herein.
3.3 | Supply of cDNA Clones . Upon the written request of GHI and subject to the grant of license rights as described in Section 3.1 and 3.2, Incyte shall provide to GHI, one or more isolated cDNA Clones from the LifeSeq® Database Product(s) under the following terms and conditions: | |||
Shipments usually occur within twelve (12)
business days of the receipt of the order.
For this service, a fee of $*** per
verified clone Full Length Clone and $***
per non-Full Length Clone will be payable.
If the clone cannot be verified, there is
no charge and GHI may request an
alternative clone, or request failure
analysis on the cDNA Clone at a cost of
$*** per clone. In failure analysis Incyte
will review the clone retrieval process to
determine the failure point and proceed to
re-process, including searching an entire
96-well plate in the case of gel tracking
error or electroporating from master
archives if the clone will not transform.
There is no refund of the failure analysis
fee if Incyte remains unsuccessful in
obtaining a verified clone.
GHI agrees to submit any payments due within thirty (30) days from receipt of invoice from Incyte in reasonably detailed form regarding such clone supply. GHI agrees that such cDNA Clone(s) are provided to GHI on a nonexclusive basis and subject to any license(s) granted under Article 3.0. |
4.0 SCHEDULE OF PAYMENTS; ROYALTIES.
4.1 | Access Fee(s) . | |||
Access Fees for the LifeSeq® Database Product(s) subscription are as follows: |
Page 16
*** Confidential material redacted and filed separately with the Commission.
*** dollars (US $***) for the period from the Effective Date up to April 30, 2002;
*** dollars (US $***) for the period from May 1, 2002 up to April 30, 2003;
*** dollars (US $***) for the period from May 1, 2003 up to April 30, 2004.
*** dollars (US $***) for the period from May 1, 2004 up April 30, 2005.
Each of the above Access Fees shall be payable, on the following schedule:
*** dollars ($***) during the 2002 calendar year;
*** dollars ($***) during the 2003 calendar year; and
*** dollars ($***) during the 2004 calendar year.
The foregoing payments shall be made in equal quarterly installments during the calendar years in which they are due, with each such quarterly installment to be paid within the first ten (10) business days of each such calendar quarter.
4.2 | Milestone Payments and Royalties . Contingent on the following events, and subject to Sections 4.6 and 4.7, the following payments and royalties shall be paid by GHI (within thirty (30) days of such event) to Incyte for each Product with respect to Designated Gene/Gene Derivatives under respective license(s) as applicable. |
Remainder of the page intentionally left blank.
Page 17
*** Confidential material redacted and filed separately with the Commission.
Table 4.2
Notes:: All payments are to be made in United States dollars.
Notes:
(a) | Paid within thirty (30) days after the first to occur of (i) point at which Genomic Health has a Product or (ii) the first Regulatory Approval granted to Genomic Health or a Genomic Health Affiliate for each given Licensed Product. | |||
(b) | Single Payment Obligation . Each of the above milestone payments shall be payable once with respect to Products relating to a given Designated Gene/Gene Derivative, upon the first occurrence of the indicated milestone for such Product, and no additional payments shall be due upon subsequent or repeated achievement of the same milestone for a different Product in the same Field of Use under the same Designated Gene/Gene Derivative license. For example, if GHI develops two Diagnostic Products relating to the same Designated Gene and both such Diagnostic Products achieve a given milestone, the applicable payment will only be made once upon the first such occurrence. | |||
(c) | The above % of Net Sales royalty will be paid with respect to each Product in each given country where, but for the patent license(s) granted herein, such sales would otherwise infringe a Valid Claim. | |||
(d) | The above % of Net Sales royalty will be paid with respect to each Product in each given country where such sales are covered by a claim of a pending patent application in the Incyte Patent Rights. | |||
4.3 | Payment Obligation . The foregoing payments under Section 4.2 will accrue or become due or payable with respect to Product(s) which are: |
(a) materially based on a Designated Gene/Gene Derivative(s), which was Used By GHI; or
Page 18
*** Confidential material redacted and filed separately with the Commission.
(b) are covered by a Valid Claim of Incyte Patent Rights and/or which Product is identified or discovered by process which utilizes a Gene which is covered by a Valid Claim of Incyte Patent Rights.
If a Product would be covered by more than one of the licenses referred to in Section 4.2 (e.g., where an IND is filed with respect to a Product that is covered by two or more of the licenses granted to GHI under Sections 3.1 through 3.4), only the largest of the milestone payments or royalties called for in such applicable Sections shall be payable, and there will be no multiple royalties due under such Section 4.2. | ||||
4.4 | In the event that a Product is sold in combination with other product(s) and/or service(s) for which no royalty would be due hereunder if sold separately, Net Sales from such combination sales for purposes of calculating the amounts due under this Article 4 shall be calculated by multiplying the Net Sales of the combination product by the fraction A/(A + B), where A is the average gross selling price during the applicable calendar quarter of the Product sold separately to the same category of customers (e.g. patients, health care providers, or Diagnostic Product distributors) and B is the average gross selling price during the applicable calendar quarter of the other product(s) and/or services. In the event that such separate sales were not made during the previous calendar quarter then the Net Sales shall be calculated by multiplying the Net Sales of the combination product by the fraction C/ (C + D), where C is the average cost of goods sold during the applicable calendar quarter of the Product and D is the average cost of good sold during the applicable calendar quarter of the other product(s) and/or service(s) , in each case calculated in accordance with standard and customary accounting principles. | |||
4.5 | In the event that GHI pays royalties to third parties in connection with the sale of Diagnostic Products either under agreements for patent rights (including applications therefor) or other technologies which GHI, in GHI reasonable judgement, determines are necessary or desirable to license or acquire with respect to such Diagnostic Products, including joint owners of patent applications or patents within the Patent Rights, GHI may deduct up to *** percent (***%) of such royalties which are due Incyte hereunder; provided, |
(i) | in no event shall the royalties which are due Incyte hereunder be reduced by reason of this Section 4.5 to less than *** percent (***%) of the amount that would otherwise by payable to Incyte without any deduction under this Section 4.5; and | |||
(ii) | provided further that GHI shall be entitled to deduct from royalties payable on account of its licenses under the Incyte Patent Rights only royalties payable for use of patents directed toward composition of matter or use of nucleic acids or proteins. |
4.4 | Duration of Payment Obligation . Royalty obligations with respect to each Product under any portion of this Article 4.0 shall terminate on a country-by-country and product-by-product basis on the later of (i) ten (10) years after the |
Page 19
first country-wide launch of each Product in each country or (ii) expiration of the last-to expire Valid Claim which covers such product in each country. | ||||
Upon termination of the royalty payment obligation, GHI shall thereafter have in perpetuity a royalty-free, fully paid-up, worldwide license under the Incyte Know How to make, use, sell, publish, and disclose such Product in the specified field(s) of use without any accounting to Incyte. | ||||
4.5 | Mode of Payment . For purposes of determining when a sale of a royalty-bearing Product occurs, the sale shall be deemed to occur on the date of the invoice to the purchaser of the Product. All royalty payments shall be made within ninety (90) days of the end of each calendar quarter in which the sale was made. Any royalty payment that is not paid on or before the date such payment is due under this Agreement shall bear interest to the extent permitted by applicable law, at two percentage points over the prime rate of interest as reported by Bank of America NT&SA in San Francisco, California, from time to time, calculated on the number of days such payment is delinquent. Royalties shall be deemed payable by the entity making the Net Sales from the country in which earned in local currency and subject to foreign exchange regulations then prevailing. Royalty payments shall be made to Incyte in United States dollars. The rate of exchange to be used in any such conversion from the currency in the country where such Net Sales are made shall be the rate of exchange used by GHI for reporting such sales for United States financial statement purposes. | |||
4.6 | Records Retention . GHI agrees to keep for at least three (3) years records of all sales of Products in sufficient detail to permit Incyte to confirm the accuracy of GHI royalty calculations. Once a year, at the request and the expense of Incyte, upon at least forty-five (45) days prior written notice, GHI shall permit a nationally recognized, independent, certified public accountant appointed by Incyte and acceptable to GHI, to examine these records solely to the extent necessary to verify such calculations, provided that such accountant has entered into a confidentiality agreement with GHI substantially similar to the confidentiality provisions of this agreement, limiting the use and disclosure of such information to purposes germane hereto. The examination shall be limited to pertinent books and records for any year ending not more than twenty-four (24) months prior to the date of such request. GHI may designate competitively sensitive information which such auditor may not disclose to Incyte, provided , however , that such designation shall not encompass the auditors conclusions. The accounting firm shall disclose to Incyte only whether the royalty reports are correct or incorrect and the specific details concerning any discrepancies. No other information shall be provided to Incyte. If such accounting firm correctly concludes that there was an underpayment of royalties by five percent (5%) or more, GHI shall pay all costs of such examination. If such accounting firm concludes that additional royalties were owed, the additional royalties shall be paid within thirty (30) days of the date Incyte delivers to GHI such accountants written report so concluding. Any overpayments by GHI will be credited against future royalty obligations. This section shall survive the cessation of payment obligations under Section 4.3 for a period of two (2) years. |
Page 20
4.7 | Shipping . GHI shall pay, for its own account, any shipping, freight, mailing expenses and the like payable to third parties not affiliated with Incyte and arising out of obtaining tangible materials under this Agreement and the transactions contemplated herein. | |||
4.8 | Payments and Taxes . Unless otherwise provided in this Agreement, GHI agrees to submit payments for services and materials provided by Incyte within thirty (30) days from receipt of invoice. All payments hereunder shall be made by bank wire transfer in immediately available funds to such account as Incyte shall designate in writing from time to time. All payments by GHI to Incyte under this Agreement shall be paid from a GHI account in a banking institution located in the United States. | |||
GHI shall pay, or reimburse Incyte, as appropriate, and indemnify Incyte against any sales, use, value added/ad valorum, surtax and personal property taxes, customs, duties, registration fees and the like including interest and penalties arising out of this Agreement and the transactions contemplated herein, including the costs and responsibility of any withholding taxes. |
5.0 CONFIDENTIALITY AND PUBLICATION .
5.1 | Confidentiality . The Parties acknowledge that during the course of this Agreement they will each receive from the other information which is proprietary, confidential and of commercial value to the disclosing Party. For purposes of this Agreement, Confidential Information shall mean scientific, technical or business information belonging to the disclosing Party, which the disclosing Party marks Confidential if disclosed in writing, or which the disclosing Party identifies as confidential at the time of any visual or oral disclosure and promptly confirms in writing to have been confidential. Except to the extent expressly authorized by this Agreement, the Parties agree that, for the Access Term and for five (5) years thereafter, the receiving Party shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose (except those expressly permitted under this Agreement) any Confidential Information furnished to it by the other Party pursuant to this Agreement, and regardless of the medium on which it is provided, including any know-how and/or Incyte Know-How, except to the extent that it can be established by the receiving Party by competent proof that such information: |
(a) was already known to the receiving Party, other than under an obligation of confidentiality, at the time of disclosure by the other Party;
(b) was generally known to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party;
(c) became generally available to the public or otherwise part of the public domain after its disclosure other than through any act or omission of the receiving Party in breach of this Agreement;
Page 21
(d) was subsequently lawfully disclosed to the receiving Party by a third party having no confidentiality obligations to the disclosing Party with respect thereto;
(e) was independently discovered or developed by the receiving Party without the use of the other Partys Confidential Information, and such independent discovery or development can be documented by the receiving Partys tangible records created at the time of such independent development.
Each Party may disclose the others Confidential Information to the extent such disclosure is reasonably necessary in (i) filing and prosecuting patent applications, and maintaining patents, or (ii) prosecuting or defending litigation or (iii) complying with applicable governmental laws and regulations governing the testing, approval, manufacture and marketing of Products; provided, however, that prior to disclosure of the other Partys Confidential Information it will give reasonable advance notice to such Party, will only disclose the minimum Confidential Information necessary, and will use reasonable efforts to secure confidential treatment of such Confidential Information. | ||||
It is understood that patent applications are filed with the expectation and intention that such applications will, upon publication of the applications and/or issuance of the resulting patents, result in the publication or public accessibility of all information disclosed in the underlying application and prosecution documents; provided, however, that publication of such Confidential Information shall not affect either Partys ongoing obligations to the other Party with respect to Confidential Information not so disclosed. | ||||
5.2 | Disclosure; Third Party Access . Except as provided for in Sections 2.3.4 and 3.2.2 above, and this Section 5.2, Confidential Information of Incyte will not be published or disclosed in any form without the written authorization of Incyte. |
(a) GHI, GHI Affiliate(s) and its sublicensees may publish their own scientific results and the conduct of their work within the scope of the licenses granted under this Agreement, provided, however, that:
(i) any such publication by GHI, GHI Affiliates or sublicensees that would disclose Confidential Information of Incyte shall require the prior written consent of Incyte, which consent will not be unreasonably withheld or delayed, provided that GHI has given Incyte a copy of each such publication for diligent review at least thirty (30) days prior to its submission for publication; and
(ii) such disclosure is on an individual Gene/Gene Derivative-by-Gene/Gene Derivative-basis and reflects research results which have involved material investment above and beyond Database Information; and
Page 22
(iii) a deposit in escrow has been made prior to disclosure in accordance with the provisions of Section 2.3.4 and Exhibit B with respect to Designated Gene/Gene Derivative(s) which are the subject of such Confidential Information; and
(iv) Incyte has had the opportunity to file applications for protection of subject matter that is proprietary to Incyte; and
(v) any such publications will include recognition of the contributions of Incyte according to standard practice for assigning scientific credit, either through authorship or acknowledgment as may be appropriate.
(b) Any scientific publications that would disclose Confidential Information of Incyte on other than an individual Designated Gene/Gene Derivative-by-Designated Gene/Gene Derivative or Product-by-Product basis shall be under reasonable terms and conditions mutually agreed between the Parties, including the provisions of subparagraphs 5.2(a) (i) to (v) above.
(c) Incyte recognizes that GHI, in the normal course of business, utilizes consultants, academic and third party collaborators who are bound by a contractual obligation to GHI, including an obligation of confidentiality to GHI. GHI may disclose Confidential Information of Incyte on an Gene/Gene Derivative-by-Gene/Gene Derivative basis, Designated Gene/Gene Derivative-by-Designated Gene/Gene Derivative, or Product-by-Product to such consultants and academic and third party collaborators in the context of the disclosure of GHIs own scientific results or the conduct of its work within the scope of the licenses granted herein, provided, however, that:
(i) GHI has obtained a written obligation of confidentiality and appropriate use restrictions no less restrictive than those set forth herein and provided that such third party shall not further disclose Confidential Information; and
(ii) any such disclosure of Confidential Information which includes the transfer of DNA Sequence Information or biological materials shall be subject to a written materials transfer agreement which protects the intellectual property rights of Incyte and GHI as set forth herein, such agreement to include customary provisions regarding scope of work, publication, protection of proprietary subject matter and ownership of inventions; and
(iii) a deposit in escrow has been made prior to disclosure in accordance with the provisions of Section 2.3.4 and Exhibit B with respect to Designated Gene/Gene Derivative(s) which are the subject of such Confidential Information; and
Page 23
(iv) GHI has obtained a written obligation from such third party regarding Incytes right to review publications as under the provisions of Section 5.2(a) herein.
(d) With respect to the transfer of DNA Sequence Information or biological materials on other than a Gene/Gene Derivative-by-Gene/Gene Derivative, Designated Gene/Gene Derivative-by-Designated Gene/Gene Derivative, or Product-by-Product basis, the provisions of Sections 5.2(c) sub-paragraphs (i) to (iv) above shall apply and GHI agrees to obtain the prior written consent of Incyte with respect to such third party transfer, and Incyte retains the right to review and approve the relevant sections of the written materials transfer agreement between GHI and such third party, with such consent and approval not to be unreasonably withheld.
(e) Incyte shall not publish any of GHIs Confidential Information without the prior written consent of GHI.
5.3 | Notwithstanding anything to the contrary set forth herein, this Article 5.0 shall not be construed to allow GHI, GHI Affiliates, sublicensees, collaborators or consultants to publish or disclose the contents of LifeSeq® Database Product(s), or any Incyte software or hardware configurations, at any time without the express written consent of Incyte. |
6.0 INTELLECTUAL PROPERTY .
6.1 | Incyte Rights . With the exception of intellectual property rights granted to GHI under the nonexclusive or exclusive license(s) granted under this Agreement, Incyte retains all rights it has to the Incyte Technology, Database Information and the LifeSeq® Database Product(s) and no licenses are granted herein except for those expressly provided in Article 3.0. | |||
GHI Rights . Except as otherwise expressly provided herein, GHI, GHI Affiliates, licensees, or sublicensees, as applicable, shall respectively retain all intellectual property rights and title in and to any Gene/Gene Derivative(s), Product(s), and inventions relating thereto, discovered or developed by or for GHI,; provided, however, that with respect to Full Length Clones or Full Length Contigs provided to GHI by Incyte hereunder, Incyte retains the right to file patent application(s) with claims directed to composition of matter covering such Full Length Clones or Full Length Contigs. | ||||
6.2 | Patent Prosecution . Except as provided herein, the filing, prosecution, maintenance and enforcement of patent(s), copyrights, and other proprietary rights regarding the Incyte Technology shall be the responsibility of, and at the discretion of Incyte. Both parties shall share equally the responsibility and expense of filing, prosecuting, maintaining and enforcing any patents, copyrights and other proprietary rights created jointly by employees of both Parties. |
Page 24
6.3 | Cooperation . With respect to a Gene under Non-Exclusive Patent License in the Personalized Research Field of Use, Homebrew Field of Use or Diagnostics Field of Use, and for the duration of such license, patent costs, upon the mutual written agreement of the Parties, will be shared equally by GHI, Incyte and any other Non-Exclusive licensee(s). | |||
6.4 | Except as otherwise set forth below, with respect to claims within patent applications owned and controlled by GHI claiming a composition of matter of the coding region of a Designated Gene/Gene Derivative, disclosed under Section 5.2 (, GHI hereby grants Incyte a perpetual, nonexclusive worldwide royalty-free license, with the right to sublicense solely in conjunction with the grant of license rights by Incyte to third parties under Incyte Patent Rights, conduct research solely in the Internal Research Field of Use. GHI agrees to notify Incyte of any decision to abandon a pending patent application or an issued patent directed to such Designated Gene/Gene Derivative. In such event, Incyte shall have the option, at its expense, of continuing to prosecute any such pending patent application (except for subject matter contained in such pending patent application which GHI has filed, or in good faith intends to file, in a subsequent patent application) or of maintaining the issued patent in GHIs name. | |||
6.5 |
Freedom From Suit
. Consistent with the license grant of Incyte Patent Rights to
GHI as provided in Section 3.1 herein, with respect to composition of matter or use claims
directed to Designated Gene/Gene Derivative(s) owned and controlled by GHI, GHI Affiliate(s)
or GHIs sublicensee(s) under this Agreement (collectively the GHI Patents). GHI (or GHI
Affiliate(s) or such sublicensee(s) (other than Incyte under Section 6.4 above), as the case
may be, GHI agrees not to sue or bring any action in any court or administrative agency or
any other government authority alleging infringement of said patents as a result of
activities of Incyte or its Affiliate(s) or (sub)licensee(s) in the Research Field of Use
and (ii) research with respect to the Personalized Research Field of Use, Homebrew Field of
Use and the Diagnostic Field of Use which would constitute an infringement of said GHI
Patents (provided such Affiliate(s) and sublicensees are sublicensees under the LifeSeq®
Database Product(s)), and further, GHI (or such GHI Affiliate(s) or such sublicensee(s) as
the case may be) agrees to extend such freedom from suit or action to further
(sub)licensee(s) of Incyte, its Affiliate(s), licensees or other collaborators of LifeSeq®
Database Product(s). The foregoing freedom from suit provisions shall only apply with
respect to such parties which have executed an agreement which contains a provision with
substantially
similar rights to Incyte, its Affiliate(s), licensees and collaborators with respect to any
similar patents rights of said Affiliate, (sub)licensee or collaborator.
|
|||
Research Tools and Database Products or Services . With respect to GHI Patents, GHI (or GHI Affiliate(s) or sublicensee(s) of the GHI Patents (other than Incyte under 6.4 above) as the case may be) agrees not to sue or bring any action in any court or administrative agency or any other government authority alleging infringement of said GHI Patents as a result of activities of Incyte or its Affiliate(s) or (sub)licensee(s) with respect to commercialization of research tools |
Page 25
*** Confidential material redacted and filed separately with the Commission.
or database products or services, including microarray-based research tools or database products or services, by Incyte or its Affiliate(s) or (sub)licensee(s), which would constitute an infringement of said patents, and further, GHI (or such GHI Affiliate(s) or sublicensee(s) under the GHI Patents (other than Incyte under 6.4 above) as the case may be) agrees to extend such freedom from suit or action to further (sub)licensee(s)s of Incyte, its Affiliate(s) or licensees with respect to commercialization of research tools or database products or services.
Retained Rights . Notwithstanding the foregoing, it is understood and agreed that the foregoing provisions do not include any grant of rights by GHI to Incyte, its Affiliate(s), or its sublicensee(s) under the GHI Patents to practice or use such GHI Patents in the Personalized Research Field of Use.
Disclosure . GHI will provide Incyte with a list of the serial numbers of all issued patents or published patent applications (GHI Patent Information) claiming a composition of matter of the coding region of a Designated Gene(s) owned and controlled by GHI or GHI Affiliate(s), and shall update the GHI Patent Information on a quarterly basis. Incyte will make GHI Patent Information accessible to all licensees and collaborators of the LifeSeq® Database Product(s) which have executed an agreement which contains a provision which grants substantially similar rights to Incyte, its Affiliate(s), licensees and collaborators with respect to any similar patents rights of said Affiliate, (sub)licensee or collaborator.
6.6 | Third Party Patents . Subject to the warranties made hereunder as to each Partys knowledge of any third party rights that may be infringed by the uses of the Database Information as contemplated herein, the Parties acknowledge that, in order to discover, develop, and/or commercialize one or more Gene/Gene Derivatives, they may require licenses under third party patent rights or such other rights, and it is hereby agreed that it shall be each Partys responsibility to satisfy itself as to the need for such licenses and, if necessary, to obtain such licenses. To the extent that GHI obtains any such third party licenses, it shall have no obligation to grant any sublicense or other rights to Incyte or any third party with respect thereto. |
7.0 TERM; TERMINATION .
7.1 | Termination at Full Term . This Agreement shall commence as of the Effective Date and shall expire on the last day of the Access Term, unless terminated earlier as provided for herein. | |||
7.2 | Term of License(s) . Upon termination or expiration of the Access Term, to retain any license procured under Sections 3.1 and 3.2 inclusive, GHI shall, on a Designated Gene/Gene Derivative by Designated Gene/Gene Derivative basis, pay to Incyte an annual license maintenance fee of *** dollars (US $***) until: |
Page 26
(a) | Genomic Health has developed a Product for which a milestone payment has been made to Incyte pursuant to Article 4.0 in which case such license shall then be in effect in perpetuity | |||
(b) | the license is terminated (which may only occur on a April 30 of any calendar year ), prior to the development of a Product for which a milestone payment has been made to Incyte pursuant to Article 4.0. |
7.4 | Breach . Material failure by either Party to comply with any of its obligations under this Agreement shall entitle the other Party to give to the Party in default notice specifying the nature of the default and requiring it to cure such default. If such default is not cured within ninety (90) days after the receipt of such notice, the notifying Party shall be entitled, without prejudice to any of its other rights conferred on it by this Agreement, in addition to any other remedies available to it by law or in equity, immediately to terminate this Agreement by giving notice to the other Party. The right of a Party to terminate this Agreement, as hereinafter provided, shall not be affected in any way by its waiver or failure to take action with respect to any previous default. | |||
7.5 | Accrued Rights Surviving Obligations . Termination, relinquishment or expiration of this Agreement for any reason shall be without prejudice to any rights which shall have accrued to the benefit of either Party prior to such termination, or expiration. Upon any termination, relinquishment or expiration of this Agreement, the following provisions will not terminate, but will continue in full force and effect: Articles 2 (database access), 5 (confidentiality), 6 (intellectual property), 8 (representations/warranties), 9 (indemnity), 10 (miscellaneous) and Exhibit B (Escrow), and any licenses or options entered, and any payment obligations thereunder pursuant to GHIs rights under Articles 3 and 4. |
8.0 REPRESENTATIONS AND WARRANTIES; COVENANTS .
8.1 | Representations and Warranties . Each Party represents and warrants to the other Party that: |
(a) it is a corporation or entity duly organized and validly existing under the laws of the state or other jurisdiction of incorporation or formation;
(b) it has the corporate power and authority and the legal right to enter into this Agreement and to perform its obligations hereunder;
(c) the execution and delivery of this Agreement and the performance by such Party of the transactions contemplated hereby have been duly authorized by all necessary corporate action of such Party; and
(d) except for the governmental and Regulatory Approvals required to market the Product(s), the execution, delivery and performance of this Agreement by such party does not require the consent, approval or
Page 27
authorization of, or notice, declaration, filing or registration with, any governmental or regulatory authority and the execution, delivery or performance of this Agreement by such party does not violate any law, rule or regulation applicable to such party.
8.2 | Incytes Representations Incyte hereby represents, warrants and covenants to GHI as follows: |
(a) to the best of Incytes knowledge, as of the Effective Date it is the owner, or licensee (with the right to grant sublicenses), of the Incyte Patent Rights and Incyte Know-How, and no other person, corporate or other private entity, or governmental entity or subdivision thereof, has or shall have any claim of an ownership interest with respect to those Incyte Patent Rights and Incyte Know-How owned by Incyte, whatsoever;
(b) Upon Incytes receipt of notice of election to license a Designated Gene/Gene Derivative under Incyte Patent Rights in the Personalized Research, Homebrew or Diagnostic Field of Use pursuant to Section 3.1.2, Incyte agrees to notify GHI of any notice of infringement, claims, judgments or settlements against or owed by the Incyte, or any pending or threatened claims or litigation, known to Incyte without undertaking a special investigation, relating to such Incyte Patent Rights.
For purposes of this Section 8.2, the term to the best of Incytes knowledge shall mean in each case Incytes best knowledge without undertaking any special investigation with respect to such subject matter beyond the scope of those diligent investigations normally performed by Incyte in the course of its own business operations. | ||||
8.3 | No Conflicting Agreements . Neither Party has in effect and after the Effective Date neither Party shall enter into any oral or written agreement or arrangement that would conflict with its obligations under this Agreement. | |||
8.4 | Compliance with Law . Each Party shall be responsible for compliance with all applicable product safety, product testing, product labeling, package marking, and product advertising laws and regulations with respect to its own activities and Products. Further, GHI and Incyte shall each comply with the regulations of the United States and any other relevant nation concerning any export or other transfer of technology, services, or products. | |||
8.5 | Disclaimers . |
(a) EXCEPT AS EXPLICITLY STATED HEREIN, NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE OR WARRANTY GIVEN BY EITHER PARTY THAT ANY PATENT WILL ISSUE BASED UPON ANY PENDING PATENT APPLICATION WITHIN ITS PATENT RIGHTS, THAT ANY PATENT WITHIN THE INCYTE PATENT RIGHTS OR GHI PATENTS HAS ISSUED OR WILL ISSUE OR WILL BE VALID, OR THAT THE USE OF
Page 28
ANY LICENSE GRANTED HEREUNDER OR THAT THE USE OFS.CONTANY INCYTE PATENT RIGHTS OR GHI PATENTS WILL NOT INFRINGE THE PATENT OR PROPRIETARY RIGHTS OF ANY THIRD PARTY. NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES WITH RESPECT TO USE OF THE INFORMATION TO BE PROVIDED TO IT HEREUNDER. EXCEPT AS EXPLICITLY STATED HEREIN, ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, NOVELTY OR FITNESS OF GENE/GENE DERIVATIVES OR DATABASE INFORMATION OR GHI PATENT INFORMATION FOR ANY PARTICULAR PURPOSE, ARE EXCLUDED. INCYTE MAKES NO WARRANTY THAT THE DATABASE INFORMATION DOES NOT CONTAIN ERRORS.
(b) EXCEPT AS EXPLICITLY STATED HEREIN NEITHER PARTY WILL BE LIABLE FOR CONSEQUENTIAL OR INCIDENTAL DAMAGES OF ANY NATURE ARISING FROM SUCH PARTYS ACTIVITIES UNDER THIS AGREEMENT; PROVIDED, HOWEVER, THAT THIS LIMITATION SHALL NOT LIMIT THE INDEMNIFICATION OBLIGATION OF SUCH PARTY UNDER SECTION 9.2 BELOW FOR CONSEQUENTIAL OR INCIDENTAL DAMAGES RECOVERED BY A THIRD PARTY.
9.0 INDEMNITY .
9.1 | Indemnification by GHI . GHI shall indemnify, defend and hold Incyte, its Affiliate(s) and licensees (other than Incyte) harmless from and against any and all losses, liabilities, damages and expenses (including reasonable attorneys fees and costs) as the result of claims, demands, actions or other proceedings which may be made or instituted by any third party against any of them arising out of (i) a material breach of GHIs representations, warranties or covenants under this Agreement, (ii) the development, manufacture, possession, distribution, use, testing, sale or other disposition of any Product by GHI, GHI Affiliates or licensees, (iii) products liability arising from the use by any third party of Product(s) sold by or on behalf GHI, its Affiliates or licensees, or (iv) the gross negligence, recklessness or intentional misconduct of GHI or GHI Affiliates in connection with activities to be performed under this Agreement, except to the extent such losses, liabilities, damages and expenses (including reasonable attorneys fees and costs) resulted from the gross negligence, recklessness or intentional misconduct of Incyte. | |||
9.2 | Indemnification by Incyte . Incyte shall indemnify, defend and hold GHI, GHI Affiliates and licensees harmless from and against any and all losses, liabilities, damages and expenses (including reasonable attorneys fees and costs) as the result of claims, demands, actions or proceedings which may be made or instituted by any third party against any of them arising out of (i) a material breach of Incytes representations, warranties or covenants under this Agreement, (ii) the development, manufacture, possession, distribution, use, testing, sale or other disposition of any product by Incyte, its Affiliate(s) or licensees (other than GHI, GHI Affiliates or their sublicensees), (iii) products liability arising from any use or practice of the GHI Patents by or under the authority of Incyte, or (iv) the gross negligence, recklessness or intentional |
Page 29
misconduct of Incyte or its Affiliate(s) in connection with activities to be performed under this Agreement. | ||||
9.3 | Procedure . A Party that intends to claim indemnification under this Article 9 (the Indemnitee ) shall promptly notify the indemnifying Party (the Indemnitor ) of any loss, liability, damage, expense, claim, demand, action or other proceeding in respect of which the Indemnitee or any of its Affiliate(s) intend to claim such indemnification, and the Indemnitor shall have the right to participate in, and, to the extent the Indemnitor so desires, jointly with any other Indemnitor similarly noticed, to assume the defense thereof with counsel selected by the Indemnitor and reasonably satisfactory to the Indemnitee; provided, however, that the Indemnitee shall have the right to retain its own counsel, with the fees and expenses to be paid by the Indemnitee. The indemnity provisions in this Article 9 shall not apply to amounts paid in settlement of any loss, liability, damage, expense, claim, demand, action or other proceeding if such settlement is effected without the consent of the Indemnitor, which consent shall not be withheld unreasonably. The failure to deliver notice to the Indemnitor within a reasonable time after the commencement of any such action, if prejudicial to the Indemnitors ability to defend such action, shall relieve such Indemnitor of any liability to the Indemnitee under this Article 9, but the omission so to deliver notice to the Indemnitor will not relieve it of any liability that it may have to any Indemnitee otherwise than under this Article 9. The Indemnitor may not settle the action or otherwise consent to an adverse judgment in action or other proceeding that materially diminishes the rights or interests of the Indemnitee without the express written consent of the Indemnitee. The Indemnitee under this Article 9 and its employees and agents, shall cooperate fully with the Indemnitor and its legal representatives in the investigation of any action, claim or liability covered by this indemnification. |
10.0 MISCELLANEOUS PROVISIONS .
10.1 | No Partnership . Nothing in this Agreement is intended or shall be deemed to constitute a partnership, agency, distributorship, employer-employee or joint venture relationship between the Parties. No Party shall incur any debts or make any commitments for the other, except to the extent, if at all, specifically provided herein. | |||
10.2 | Assignments . Neither Party shall assign any of its rights or obligations hereunder except: (i) as incident to the merger, consolidation, reorganization or acquisition of stock or assets or similar transaction affecting all or substantially all of the assets or voting control of the assigning Party; (ii) in the case of GHI, to any GHI Affiliate, or, in the case of Incyte, to any Incyte Affiliate, and in either case, provided that the assigning Party remains liable and responsible for such GHI Affiliates or Incyte Affiliates performance hereunder, as applicable; (iii) with respect to either Party as the assignor, as incident to the acquisition or transfer of the assets affecting all or substantially all of the assets of the business of the Party relating to a given field of use, provided that the acquiring entity or transferee continues to fulfill its obligations to the other Party hereunder; (iv) with the consent of the other Party, which consent shall not be withheld |
Page 30
unreasonably. This Agreement shall be binding, upon the successors and permitted assigns of the Parties. Any assignment not in accordance with the above shall be void. To the extent that any assignment by GHI hereunder would directly result in an increase in any withholding taxes for which Incyte is responsible under this Agreement, GHI shall be responsible for such additional taxes.
In the event of GHIs merger with or acquisition of or by a third party entity, if GHIs (or its successor entitys) annual R&D expenditures in the Personalized Research Field of Use, Homebrew Field of Use or Diagnostic Field of Use (singly or in combination) will increase by twenty percent (20%) or more as a result of such merger or acquisition, then the fees payable by GHI under Section 4.1 shall automatically increase pro rata with the increase in GHIs R&D budget for Product(s) as a result of such merger or acquisition commencing on the date of closing of the merger or acquisition and continuing throughout the balance of the Access Terms. It is agreed that this paragraph shall not apply in the event that the other pharmaceutical entity involved in such merger or acquisition is also a collaborator to the LifeSeq® Database Product(s) or individual database modules thereof, provided that both this Agreement and such other pharmaceutical entitys agreement with Incyte remain in full force and effect.
In no event will GHIs LifeSeq® Database Product(s) access rights be assignable to a successor or permitted assign if Incytes obligations thereunder would increase materially as a result of the assignment (e.g. by having to service additional sites, or where Incyte would incur a material increase in expenses and/or services over those provided to GHI hereunder), unless such successor or permitted assign provides appropriate pro-rated adjustment of the access fees, service charges or Incyte costs incurred, and consistent with access fees, service charges or Incyte costs incurred pertaining to comparable database services customers.
10.3
No Trademark Rights
. Except as otherwise provided herein, no right, express or
implied, is granted by this Agreement to use in any manner the names Incyte or GHI, or
any other trade name or trademark of Incyte or GHI or their Affiliate(s) in connection with
the performance of this Agreement.
10.4
Public Announcements
. Except as may otherwise be required by law or regulation,
neither Party shall make any public announcement concerning this Agreement or the subject
matter hereof without the prior consent of the other Party, such consent not to be
unreasonably withheld. If this Agreement is determined to be material to the business of
Incyte (or GHI) so that its disclosure is required by law or regulation, GHI (or Incyte)
shall have the right to review and comment of the text of the disclosure prior to its
release to the public.
10.5
Entire Agreement of the Parties; Amendments
. This Agreement and the
Collaboration and Technology Transfer Agreement and Patent License Agreement of even date
herewith constitute and contain the entire understanding and agreement of the Parties and
cancels and supersedes any and all prior negotiations, correspondence, representations,
understandings and
Page 31
agreements, whether verbal or written, between the Parties
respecting the subject matter hereof. No waiver, modification or amendment of any provision
of this Agreement shall be valid or effective unless made in writing and signed by a duly
authorized officer of each of the Parties.
10.6
Applicable Law
. This Agreement shall be governed by and interpreted in
accordance with the laws of the State of California, without reference to the conflicts of
law principles thereof. The parties expressly exclude application of the United Nations
Convention for the International Sale of Goods.
10.7
Notices and Deliveries
. Any notice, requests, delivery, approval or consent
required or permitted to be given under this Agreement shall be in writing and shall be
deemed to have been sufficiently given if delivered in person, transmitted by commercial
overnight courier, or transmitted by telex telegram or telecopy (facsimile, with confirmed
receipt) to the Party to whom it is directed at its address shown below or such other
address as such Party shall have last given by notice to the other Party (referred to herein
as notice). All notices shall be effective upon receipt.
If to Incyte, addressed to: | ||||
|
Incyte Genomics, Inc. | |||
|
3174 Porter Drive | |||
|
Palo Alto, CA 94304 | |||
|
Attn: Roy Whitfield, Chief Executive Officer | |||
|
||||
If to GHI, addressed to: | ||||
|
Genomic Health, Inc. | |||
|
101 University Ave., Suite 220 | |||
|
Palo Alto, CA 94301 | |||
|
Attn: Randy Scott, PhD, Chief Executive Officer |
10.8
Counterparts
. This Agreement may be executed in two or more counterparts, each
of which shall be deemed an original, but all of which together shall constitute one and the
same instrument.
10.9
Force Majeure
. Force Majeure shall mean an Act of God, flood, fire, explosion,
earthquake, strike, lockout, casualty or accident, war, civil commotion, act of public
enemies, blockage or embargo, or any injunction, law, order, proclamation, regulation,
ordinance, demand or requirement of any government or any subdivision, authority
representative thereof, or the inability to procure or use materials, labor, equipment,
transportation or energy sufficient to meet manufacturing needs without the necessity of
allocation, or any other cause whatsoever, whether similar or dissimilar to those enumerated
above, which are beyond the reasonable control of such Party, which the Party affected has
used its reasonable best efforts to avoid, and which prevent, restrict or interfere with the
performance by a Party of its obligations hereunder. The Party affected by Force Majeure
shall give notice to the other Party promptly in writing and whereupon shall be excused from
those obligations hereunder, to the extent of such prevention, restriction or interference,
provided that the affected party shall
Page 32
use its commercially reasonable efforts to overcome, avoid or remove such cause(s) of
non-performance and shall continue performance whenever such cause(s) is removed with all
possible speed. Nothing herein shall be deemed to require any party to settle on terms
unsatisfactory to such party with regard to any strike, lock-out or other labor difficulty,
any investigation or proceeding by any public authority or any litigation by any third
party.
10.10
Affiliate Performance
. To the extent that any GHI Affiliate has access to any
LifeSeq® Database Product(s), has the right to receive any other rights or benefits under
this Agreement or otherwise is obligated to perform any obligations under this Agreement,
GHI shall cause such GHI Affiliate to perform in full, when due, all applicable obligations
under this Agreement to the same extent as if such GHI Affiliate were a party to this
Agreement; provided, however, that nothing in this Section 10.15 shall expand the rights or
benefits of GHI or GHI Affiliates, or the obligations of Incyte, beyond those otherwise
expressly set forth in this Agreement. GHI shall guaranty timely performance in full by such
GHI Affiliate of all such obligations. A breach by such GHI Affiliate of any such obligation
shall constitute a breach by GHI of this Agreement.
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized officers as of the Effective Date.
INCYTE GENOMICS, INC. | ||||
|
||||
By:
|
/s/ Lee Bendekgey | |||
|
||||
|
||||
Name:
|
Lee Bendekgey | |||
|
||||
Title:
|
EVP and General Counsel | |||
|
||||
GENOMIC HEALTH, INC. | ||||
|
||||
By:
|
/s/ Randy Scott | |||
|
||||
|
||||
Name:
|
Randy Scott | |||
|
||||
Title:
|
CEO |
Page 33
Exhibit 10.5.2
AMENDMENT TO THE LIFESEQ COLLABORATIVE AGREEMENT
This Amendment to the LifeSeq Collaborative Agreement (the LifeSeq Amendment) effective as of December 21, 2001 (the Amendment Effective Date), is entered into by and between Incyte Genomics, Inc., a Delaware corporation, with a place of business at 3160 Porter Drive, Palo Alto, CA 94304 (Incyte) and Genomic Health, Inc., a Delaware corporation, with a place of business at 301 Penobscot Drive, Redwood City, CA 94063 (GHI).
A. WHEREAS, the parties to this LifeSeq Amendment entered into that certain LifeSeq Collaborative Agreement executed on March 30, 2001 by Incyte and GHI (the Agreement), pursuant to which Incyte granted certain licenses to GHI in certain fields therein.
B. WHEREAS, the parties wish to enter into an amendment to the Agreement in order to amend certain definitions defined, and rights granted, therein.
NOW THEREFORE, for and in consideration of the covenants, conditions, and undertakings hereinafter set forth it is agree by and between the Parties as follows:
1. | All capitalized terms not defined in this LifeSeq Amendment shall have the meanings given to them in the Agreement. | |||
2. | Article 1.0 Research Field of Use is amended in its entirety to read as follows: | |||
Research Field of Use or Internal Research Field of Use : shall mean (a) research, development, manufacture, use, importation and/or sale of Research Products; and (b) all internal research applications of Gene/Gene Derivative(s), associated with conducting research in the Antisense Field of Use, the Therapeutic Field of Use and research in the identification, development and commercialization of Drug Products. The Research Field of Use excludes the Diagnostic Field of Use, the Homebrew Field of Use, the Personalized Research Field of Use, and the GHI Database Field of Use. | ||||
3. | Article 1.0 Research Products is amended in its entirety to read as follows: | |||
Research Product(s) : shall mean all internal research applications of Gene/Gene Derivative(s), associated with conducting research in the Antisense Field of Use, the Therapeutic Field of Use and in the identification, development and commercialization of Drug Products, Antisense Product(s) and Therapeutic Protein Product(s). Research Product(s) exclude Diagnostic Product(s), Personalized Research Product(s), Homebrew Product(s) and GHI Database Product(s). |
1 of 3
4. | Section 6.4 is amended in its entirety to read as follows: | |||
Except as otherwise set forth below, with respect to claims within patent applications owned and controlled by GHI claiming a composition of matter of the coding region of a Designated Gene/Gene Derivative, GHI hereby grants Incyte a perpetual, nonexclusive worldwide royalty-free license, with the right to sublicense solely in conjunction with the grant of license rights by Incyte to third parties under Incyte Patent Rights, to conduct the activities expressly authorized under the Internal Research Field of Use. GHI agrees to notify Incyte of any decision to abandon a pending patent application or an issued patent directed to such Designated Gene/Gene Derivative. In such event, Incyte shall have the option, at its expense, of continuing to prosecute any such pending patent application (except for subject matter contained in such pending patent application which GHI has filed, or in good faith intends to file, in a subsequent patent application) or of maintaining the issued patent in GHIs name. | ||||
5. | The first paragraph of Section 6.5 is amended in its entirety to read as follows: | |||
Freedom From Suit . Consistent with the license grant of Incyte Patent Rights to GHI as provided in Section 3.1 herein, with respect to composition of matter or use claims directed to Designated Gene/Gene Derivative(s) owned and controlled by GHI, GHI Affiliate(s) or GHIs sublicensee(s) under this Agreement (other than Incyte under Section 6.4 above) (collectively, the GHI Patent Holders) (collectively the GHI Patents), the GHI Patent Holders agree not to sue or bring any action in any court or administrative agency or any other government authority alleging infringement of said patents as a result of the conduct of activities of Incyte or its Affiliate(s) or (sub)licensee(s) (provided such Affiliate(s) and sublicensees are sublicensees under the LifeSeq® Database Product(s)) expressly authorized in the Research Field of Use, which activities would constitute an infringement of said GHI Patents. Further, such GHI Patent Holders agree to extend such freedom from suit or action to further (sub)licensee(s) of Incyte, its Affiliate(s), licensees or other collaborators of LifeSeq® Database Product(s) conducting activities expressly authorized in the Research Field of Use, which activities would constitute an infringement of said GHI Patents. The foregoing freedom from suit provisions shall only apply with respect to such parties which have executed an agreement which contains a provision with substantially similar rights to Incyte, its Affiliate(s), licensees and collaborators with respect to any similar patents rights of said Affiliate, (sub)licensee or collaborator. | ||||
6. | The second paragraph of Section 6.5 is deleted in its entirety. |
2 of 3
7. | Except as specifically modified or amended hereby, the Agreement shall remain in full force and effect and, as modified or amended, is hereby ratified, confirmed and approved. No provision of this LifeSeq Amendment may be modified or amended except expressly in a writing signed by both parties nor shall any terms be waived except expressly in a writing signed by the party charged therewith. This LifeSeq Amendment shall be governed in accordance with the laws of the State of California, without regard to principles of conflicts of laws. |
IN WITNESS WHEREOF, each of the parties has executed this LifeSeq Amendment as of the Amendment Effective Date.
INCYTE GENOMICS, INC. | GENOMIC HEALTH, INC. | |||||||||
|
||||||||||
By:
|
/s/ Lee Bendekgey | By: | /s/ Randy Scott | |||||||
|
||||||||||
|
||||||||||
Name:
|
Lee Bendekgey | Name: | Randy Scott | |||||||
|
||||||||||
Title:
|
EVP & General Counsel | Title: | CEO |
3 of 3
[Incyte Company Logo]
Exhibit 10.5.3
*** Confidential Treatment Requested. Confidential portions of this document have been redacted
and have been separately filed with the Commission.
July 19, 2002
Genomic Health, Inc.
301 Penobscot Drive
Redwood City, CA 94063
Attn:
|
Randy Scott | |
|
Chief Executive Officer |
Re: Collaborative Agreement between Genomic Health, Inc. ( GHI ) and Incyte Genomics, Inc. ( Incyte )
Dear Randy:
On March 30, 2001, GHI and Incyte entered into a Collaborative Agreement (the Original Agreement ); and on December 21, 2001, GHI and Incyte amended the Original Agreement.
This letter amendment ( Second Amendment ) when signed on behalf of GHI as of the date hereof shall further amend the terms of the Original Agreement.
Except as expressly set forth in this Second Amendment all capitalized terms used herein shall have the meanings set forth in the Original Agreement.
THEREFORE, GHI and Incyte agree to amend Section 4.1 of the Original Agreement as set forth below.
1. Deferral
As further set forth in the schedule attached hereto as Exhibit A, GHI shall defer payment of *** Dollars (US $***) of the *** Dollars (US $***) in Access Fee(s) due Incyte during the 2002 calendar year per Section 4.1. Such deferred amount shall be deferred by GHI on a quarterly basis; accordingly, subject to the terms set forth below, GHI shall pay Incyte *** Dollars (US $***) less per quarter than originally owed Incyte in 2002 under the Original Agreement.
2. Interest
The deferred *** Dollars (US $***) shall accrue interest at a fixed rate of *** percent (***%), which equals a total sum of *** Dollars (US $***) upon completion of timely repayment.
[Incyte Company Logo]
*** Confidential material redacted and filed separately with the Commission.
3. Repayment
In addition to the Access Fees of *** Dollars (US $***) due Incyte during the 2003 and 2004 calendar years, GHI shall pay Incyte *** Dollars (US $***) per quarter (starting Q1, 2003) towards repayment of the deferred amount plus accrued interest.
Except as expressly amended hereby, all other terms of the Original Agreement shall remain in full force and effect. This Second Amendment may be executed in counterparts, each of which shall be an original, but such counterparts shall together constitute but one and the same document.
IN WITNESS THEREOF, the parties hereto have caused this Second Amendment to be executed in duplicate by their duly authorized representatives.
INCYTE GENOMICS, INC. | GENOMIC HEALTH, INC. | |||||||
|
||||||||
Signed:
|
/s/ James Merryweather | Signed: | /s/ Randy Scott | |||||
|
||||||||
|
||||||||
James Merryweather, Ph.D. | Name: | Randy Scott | ||||||
|
||||||||
Executive Vice President, Business Development | Title: | CEO | ||||||
and Commercial Operations |
[Incyte Company Logo]
Exhibit A
Deferral, Interest and Repayment Schedule
*** Confidential material redacted and filed separately with the Commission.
GHI Incyte Payment Deferral Note
***
%
***
%
***
%
Fixed Rate for Duration of Deferral
Beginning
Principal
Period
Balance
Payment
Interest
Amortization
Ending Balance
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
***
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
***
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
***
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
***
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
*
**
***
*
**
*
**
*
**
*
**
*
**
***
*
**
*
**
*
**
*
**
*
**
Exhibit 10.5.4
*** Confidential Treatment Requested. Confidential portions of this document have been redacted
and have been separately filed with the Commission.
Amendment #3 to LifeSeq® Collaborative Agreement
This Amendment to the LifeSeq ® Collaborative Agreement (this Amendment ) is entered into as of October 25,2004 (the Amendment Effective Date ) by and between Incyte Corporation (f/k/a Incyte Genomics, Inc.), a Delaware Corporation ( Incyte ) and Genomic Health, Inc., a Delaware corporation ( GHI ).
Recitals
WHEREAS, Incyte and GHI are parties to the LifeSeq ® Collaborative Agreement between Incyte Genomics, Inc. and Genomic Health, Inc. dated March 30,2001 (the Agreement ) as amended December 21,2001 and further amended on July 19,2002; and
WHEREAS, Incyte and GHI desire to amend and supplement of the Agreement as set forth below.
NOW, THEREFORE, in consideration of the premises and the mutual agreements and covenants set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:
Amendment as of the Amendment Effective Date
1. The definition of Access Term ?in Article 1.0 of the Agreement is hereby deleted and replaced with the following:
Access Term shall mean the period commencing on the Effective Date and continuing in perpetuity, unless the Agreement is earlier terminated pursuant to Article 7.0.
2. The definition of Designated Gene in Article 1.0 of the Agreement is hereby deleted in its entirety and Incyte and GHI hereby agree to the following procedure for identification of a Designated Gene:
(a) | In the event GHI desires to acquire a nonexclusive license in respect of a GenelGene Derivative that has been Used by GHI, in accordance with Article 3 of the Agreement, during the License Term GHI shall make a written request to Incyte identifying such Gene/Gene Derivative. | |||
(b) | Incyte shall, within thirty (30) days, from the date of receipt of such written request respond to GHI and advise whether or not GHI may acquire a nonexclusive license in respect of such Gene/Gene Derivative. Incyte may only advise GHI that it may not acquire a non-exclusive license in respect of such Gene/Gene Derivative if (i) Incyte has already exclusively licensed such Gene/Gene Derivative to another, or (ii) Incyte has committed to exclusively license such Gene/Gene Derivative to another, or (iii) Incyte is in bona fide negotiations with another to exclusively license such Gene/Gene Derivative. |
1
*** Confidential material redacted and filed separately with the Commission.
(c) | GHI shall have fifteen (15) days from the date of receipt of Incytes response that such Gene/Gene Derivative is available for licensing to respond in writing that it wants to acquire a nonexclusive license in respect of such Gene/Gene Derivative. Upon Incytes receipt of such response, the specified Gene/Gene Derivative shall be deemed a Designated Gene. |
3. All references to the term Designated Gene/Gene Derivative throughout the Agreement are hereby replaced with the term Designated Gene.
4. The definition of LifeSeq ® Gold Database in Article 1.0 and the corresponding Exhibit A are hereby deleted in their entirety.
5. The definition of LifeSeq ® Database Product(s) in Article 1.0 is hereby deleted and replaced with the following:
LifeSeq ® Database Products shall mean the March 2004 release of Incytes proprietary database of Database Information, any LifeSeq ® Database Products previously provided to GHI, and the December 2003 release of Incytes database of expressed sequence tags from rat, mouse, monkey and dog, including any gene assemblies with any derived tissue specific expression information, and referred to as ZooSeq ® , all as provided to GHI.
6. The following definition is hereby added to Article 1.0 of the Agreement:
License Term shall mean three years beginning on the Amendment Effective Date unless earlier terminated pursuant to Article 7.0 or extended pursuant to Section 7.2.
7. The definition of Net Sales in Article 1.0 is hereby deleted and replaced with the following:
Net Sales : shall mean:
with respect to Products that are provided as products, invoiced sales by GHI, GHI Affiliates or sublicensees on all sales of Product (in final form for end use) to an unaffiliated third party (whether an end-user, a distributor or otherwise), and exclusive of intercompany transfers or sales, less the following deductions from such invoiced sales which are actually incurred, to the extent that they are reasonable and customary, and to the extent that they do not exceed *** percent (***%) of invoiced sales in a calendar quarter:
a) | credits or allowances actually granted for damaged Products, returns or rejections of Product and retroactive price reductions; | |||
b) | freight, postage, shipping, customs duties and insurance charges; | |||
c) | normal and customary trade, cash and quantity discounts, allowances and credits; |
2
*** Confidential material redacted and filed separately with the Commission.
d) | uncollected amounts to the extent not exceeding *** percent (***%) of invoiced sales for a calendar quarter; and | |||
e) | sales, value added or similar taxes measured by the billing amount, when included in billing. |
with respect to Products that are provided as services, the gross invoice price for such services performed by GHI, less the following deductions where they are factually applicable and are not already reflected in the gross invoice price:
a) | discounts allowed and taken, in amounts customary in the trade (which shall include the difference between the dollar amount charged by GHI for a Licensed Service and the Medicare and/or Medicaid Limits of Allowance and/or reimbursement limitations of a Third Party insurance program, each to the extent specifically applicable to a particular sale, and only if no payment beyond such limits is received by GHI in any form for such service); and | |||
b) | actual bad debt, calculated in accordance with GAAP, not exceeding ***% of gross invoice price for such services, provided that such ***% limitation shall not apply in the event that GHI can demonstrate by reasonably satisfactory evidence that it was reasonable and diligent in its debt collection practices. |
8. Section 2.1.3 of the Agreement is hereby deleted and replaced with the following:
2.1.3 No Updated Releases or Updates . Notwithstanding anything in this Agreement to the contrary, Incyte shall have no obligation to provide GHI with any updates to, updated releases of or support to the LifeSeq ® Database Products.
9. In Section 2.3.4 of the Agreement, the term Access Term is hereby replaced with the term License Term.
10. Section 2.3.7 of the Agreement is hereby deleted and replaced with the following:
2.3.7 Termination of Access Term and/or License Term . Upon any termination of the Access Term, GHI shall discontinue use of all LifeSeq Database Products and Database Information and remove each LifeSeq ® Database Product(s) from each Installation Site(s), and promptly return to Incyte, or upon Incytes written instruction, destroy all portions and copies of LifeSeq ® Database Products and the Database Information. Upon expiration or termination of the License Term, GHI shall perform with Incyte a mutually acceptable final accounting of those Designated Genes which are subject to one or more of the licenses granted to GHI under Article 3 below.
11. Section 3.1.2 is hereby deleted in its entirety.
12. Section 3.3 is hereby deleted in its entirety.
3
*** Confidential material redacted and filed separately with the Commission.
13. Incyte and GHI hereby agree that within thirty (30) days after the Amendment Effective Date, GHI shall pay to Incyte $*** and upon Incytes receipt of such payment, GHI shall have no further obligation to make any payments to Incyte under Section 4.1 of the Agreement.
14. Note (d) below Table 4.2 is hereby deleted.
15. The first paragraph of Section 4.3 is hereby deleted and replaced with the following:
The foregoing payments under Section 4.2 will accrue or become due or payable with respect to Product(s) which are covered by a Valid Claim of Incyte Patent Rights and/or to Products which are identified or discovered by a process which (i) utilizes a Gene which is covered by a Valid Claim of Incyte Patent Rights and (ii) where the use of such Gene for such identification or discovery would have constituted an infringement of Incyte Patent Rights but for licenses granted hereunder.
16. The first sentence of Section 4.5 Mode of Payment is hereby deleted and replaced with the following:
For the purposes of determining when a sale of a royalty-bearingProduct occurs, the sale shall be deemed to occur on the date that revenue resulting from such sale is recorded on GHI books in accordance with Generally Accepted Accounting Principles.
17. GHI acknowledges that Incyte has delivered to GHI as part of the LifeSeq ® Database Product, a version of SRS Runtime ( SRS ") developed by LION bioscience, Inc. which may be used by GHI in connection with the LifeSeq ® Database Products by entering into an agreement with LION bioscience, Inc. GHI shall have no obligation to use SRS. GHI shall have the option to use the LifeSeq ® Database Product in flat file format at GHIs sole discretion. If GHI does not use SRS, GHI shall have no obligation to enter into an agreement with LION bioscience, Inc. with regard to the use of SRS.
18. Incyte and GHI hereby agree that notwithstanding anything in the Agreement to the contrary, GHI shall have no access to LifeSeq ® Database Products via the Internet and Incyte shall have no obligation to provide such.
19. Article 7.0 (including Sections 7.1, 7.2, 7.4 and 7.5) is hereby deleted and replaced with the following:
7.0 TERM; TERMINATION .
7.1 | Termination of Agreement . This Agreement shall continue in perpetuity unless earlier terminated in accordance with Section 7.4. Upon any such termination of this Agreement, the License Term and Access Term shall also be terminated as of the date of termination of this Agreement. | |||
7.2 | Extension of License Term . During the term of this Agreement, GHI shall have the right to extend the License Term for additional one-year terms by |
4
*** Confidential material redacted and filed separately with the Commission.
(i) providing written notice to Incyte at least ninety (90) days prior to the end of the then current License Term and (ii) payment to Incyte of a License Term Extension Fee of US$*** at least thirty (30) days prior to the end of the then current License Term. For the avoidance of doubt, the License Term Extension Fee is an annual fee that shall be due to Incyte for each year that GHI desires to extend the initial three-year License Term. |
7.3 | Maintenance of Licenses . Effective on the one year anniversary of the expiration of the License Term ( Maintenance Fee Date ), to retain any license procured under Sections 3.1 and 3.2 inclusive, GHI shall on a Designated Gene by Designated Gene basis, pay to Incyte a non-refundable Annual License Maintenance Fee. The Annual License Maintenance Fee is *** Dollars (US$***) per year per Designated Gene. The Annual License Maintenance Fee shall be paid to Incyte at least thirty (30) days prior to the anniversary of the Maintenance Fee Date until: |
(a) | GHI has developed a Product for which a milestone payment has been made to Incyte pursuant to Article 4.0 in which case such license shall then be in effect in perpetuity; or | |||
(b) | GHI no longer desires to retain such license in which case (i) GHI shall provide written notification to Incyte and the Escrow Agent of such desire; (ii) GHI shall not be obligated to pay any more Annual License Maintenance Fees in respect of the license for the Designated Gene; and (iii) such license shall be terminated. |
7.4 | Breach . Material failure by either Party to comply with any of its obligations under this Agreement shall entitle the other Party to give to the Party in default notice specifying the nature of the default and requiring it to cure such default. If such default is not cured within ninety (90) days after the receipt of such notice, the notifying Party shall be entitled, without prejudice to any of its other rights conferred on it by this Agreement, in addition to any other remedies available to it by law or in equity, immediately to terminate this Agreement by giving notice to the other Party. The right of a Party to terminate this Agreement, as hereinafter provided, shall not be affected in any way by its waiver or failure to take action with respect to any previous default. | |||
7.5 | Accrued Rights Surviving Obligations . Termination, relinquishment or expiration of this Agreement for any reason shall be without prejudice to any rights which shall have accrued to the benefit of either Party prior to such termination, or expiration. Upon any termination, relinquishment or expiration of this Agreement, the following provisions will not terminate, but will continue in full force and effect: Section 2.3.7 and Articles 5 |
5
(Confidentiality),6 (IntellectualProperty), 7 (Term), 8 (Representations/Warranties), 9 (Indemnity), and 10 (Miscellaneous), and any licenses under Article 3 which have become perpetual pursuant to Sections 4.4 or 7.3 and any corresponding payment obligations and terms under Article 4. |
20. | Section 10.7 is hereby amended to update the address of Incyte as follows: |
|
Incyte Corporation
Experimental Station E336 Route 141 and Henry Clay Boulevard Wilmington, Delaware 19880 Attn: General Counsel Fax: 302-425-2722 |
21. Except as specifically modified or amended by this Amendment which Amendment is effective as of Amendment Effective Date, the Agreement shall remain in full force and effect. For purposes of clarity, this Amendment is not retroactive, therefore as of prior to the Amendment Effective Date, the Agreement shall remain in full force and effect as it existed prior to this Amendment.
IN WITNESS WHEREOF, Incyte and GHI have caused this Amendment to be executed by their respective duly authorized officers as of the Amendment Effective Date.
Incyte Corporation | Genomic Health, Inc. | |||||||
|
||||||||
By:
|
/s/ John Keller | By: | /s/ Randy Scott | |||||
|
||||||||
|
||||||||
Name:
|
John Keller | Name: | Randy Scott | |||||
|
||||||||
Title:
|
EVP & CBO | Title: | CEO |
6
Exhibit 10.6.1
*** Confidential Treatment Requested. Confidential portions of this document have been
redacted and have been separately filed with the Commission.
PATENT LICENSE AGREEMENT
THIS LICENSE AGREEMENT, dated as of March 30, 2001, is entered into between INCYTE GENOMICS, a Delaware corporation, with offices at 3160 Porter Drive, Palo Alto, California 94303 (Incyte), and Genomic Health, Inc., a Delaware corporation with offices at 101 University Avenue, Suite 220, Palo Alto, California 94301 (GHI).
BACKGROUND
WHEREAS, Incyte has the right to grant licenses under certain patent applications and patents that have application to Diagnostic Products (as defined herein) and Personalized Research Products (as defined herein).
WHEREAS, GHI is interested in obtaining, and Incyte has agreed to grant licenses under certain of these patents and patent applications for use in the fields described herein, subject to the terms and conditions of this Agreement.
NOW THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, the parties hereby agree as follows:
ARTICLE
1
DEFINITIONS
In this Agreement the following words and expressions have the following meanings:
1.1 | Affiliate : shall mean any corporation or other entity that is directly or indirectly controlled by GHI. For the purpose of this agreement, control means ownership of one hundred percent (100%), or in the case of foreign corporations or entities the greatest percentage that may be owned by foreign interests, of the shares or other equity interests entitled to vote for the election of directors, in the case of a corporation, or equivalent governing body in the case of any other entity. | |||
1.2 | Calendar Quarter : shall mean a period of three consecutive calendar months ending on March 31, June 30, September 30 or December 31. | |||
1.3 | Cancer Marker Patent Rights : shall mean all claims listed in any of the following patents and patent applications, to the extent that they are owned by Incyte with the right to license under this Agreement, and to the extent that they claim the composition of matter or use of any nucleic acids or proteins as markers or diagnostics for cancer: (a) the patents and patent applications listed in Schedule A to this Agreement, and (b) all counterpart foreign patent applications claiming priority of the patents and patent applications described in clause (a) above, together with all continuations, continuations-in-part and divisions of such patents and patent applications, (c) all patents issuing from any patent |
Page 1
application described in clause (a) or (b) above, and (d) all reissues and re-examinations of any of the foregoing patents. | ||||
1.4 | Control or Controlled shall mean possession of the ability to grant the right and licenses provided for herein, without violating the terms of any agreement or other arrangement with any third party, and which a party has the right to disclose or provide to the other party without a resulting obligation to pay royalties or other amounts to a third party. | |||
1.5 | Database Patent : shall mean (a) the patents listed in Schedule D to this Agreement, and (b) all counterpart foreign patent applications claiming priority of the patents and patent applications described in clause (a) above, together with all continuations, continuations-in-part and divisions of such patents and patent applications, (c) all patents issuing from any patent application described in clause (a) or (b) above, and (d) all reissues and re-examinations of any of the foregoing patents. | |||
1.6 | Diagnostic Field of Use : shall mean the research, development, manufacture, importation. use and/or sale of Diagnostic Product(s). The Diagnostic Field of Use excludes the Personalized Research Field of Use, the Homebrew Field of Use and the Internal Research Field of Use. | |||
1.7 | Diagnostic Product(s) : shall mean an assay provided as a product or service performed on a human tissue or other human biological sample containing nucleic acids or proteins that are collectively intended to establish or identify an association between the presence or absence of such nucleic acids or proteins and: |
(i) | diagnosis of the presence of, or absence of, a specific disease(s), state(s) or condition(s) in humans; | |||
(ii) | predisposition to the presence of, or absence of, a specific disease(s), state(s) or condition(s) in humans; | |||
(iii) | response or lack of response to disease therapy(ies) in humans or preventative strategies in humans; | |||
(iv) | prediction of the disease course in humans, and or other changes in state(s) or condition(s) in humans over time; | |||
(v) | clinical traits in humans for which a medical professional should be consulted; | |||
(vi) | variation(s) in specific trait(s) and/or characteristics among individuals; and/or | |||
(vii) | predisposition to development of toxicities to disease therapies or preventative strategies in humans, |
the results of which are provided to payors, providers or patients, and for which FDA approval (or comparable regulatory agency in other jurisdictions) is required. Diagnostic Products exclude Homebrew Products, Personalized Research Products and GHI Database Products. |
Page 2
1.8
Effective Date
: shall mean the date first set forth above.
1.9
GHI Database Field of Use
: shall mean the research, development, manufacture,
importation, use and/or sale of GHI Database Product(s) to end users.
1.10
GHI Database Product
: GHI Database Product shall mean a collection of information
derived from or by testing a person or persons in the Diagnostic Field of Use, Homebrew Field
of Use or the Personalized Research Field of Use. GHI Database Products exclude Diagnostic
Products, Homebrew Products, and Personalized Research Products.
1.11
Homebrew Field of Use
: shall mean the research, development, manufacture,
importation, use and/or sale of Homebrew Product(s). The Homebrew Field of Use excludes the
Diagnostic Field of Use, the Internal Research Field of Use and the Personalized Research
Field of Use.
1.12
Homebrew Product(s)
shall mean a Single Analyte Assay(s) provided as a product or a
service performed by a service provider that would constitute a Diagnostic Product with the
sole exception that it is provided prior to receipt of approval by the FDA or comparable
regulatory agency in any jurisdiction outside of the United States. Homebrew Products exclude
Diagnostic Products, Personalized Research Products and GHI Database Products. For purposes
of the foregoing, Single-Analyte Assays shall mean an assay designed for testing or
measuring only a single analyte.
1.13
Incyte Research Product
shall have the meaning set forth in Section 2.8.
1.14
Internal Research Field of Use
: shall mean (a) internal research, development,
manufacture, use, importation and/or sale of Internal Research Products; and (b) internal
research and development purposes (including without limitation, drug discovery, development,
commercialization and regulatory filings), including the development of databases and other
products and tools marketed for use in internal research and development purposes, including
without limitation, drug discovery, development. commercialization and regulatory filings.
The Internal Research Field of Use excludes the Diagnostic Field of Use, the Homebrew Field of
Use, and the Personalised Research Field of Use.
1.15
Internal Research Product(s)
: shall mean internal research and development
purposes (including without limitation, drug discovery, development, commercialization
and regulatory filings), including the development of databases and other products and
tools marketed for use in internal research and development purposes, including without
limitation, drug discovery, development. commercialization and regulatory filings.
Internal Research
Page 3
*** Confidential material redacted and filed separately with the Commission.
Product(s) exclude Diagnostic Product(s), Homebrew Product(s) and Personalized Research Product(s). | ||||
1.16 | Layton Patent Rights : shall mean (a) U.S. Patent No. 5,716,785 , Processes for Genetic Manipulations Using Promoters issued February 1, 1998; U.S. Patent No. 5,891,636 , Processes for Genetic Manipulations Using Promoters issued April 6, 1999 (b) all counterpart foreign patent applications claiming priority of the patent described in clause (a) above, together with all continuations, continuations-in-part and divisions of such patent applications, (c) all patents issuing from any patent application described in clause (b) above and (d) all reissues and re-examinations of any of the foregoing patents. | |||
1.17 | Montefiore Patent Rights : shall mean U.S. Patent No. 4,981,783 , Method for Detecting Pathological Conditions, issued Jan. 1, 1991. | |||
1.18 | Net Sales : shall mean invoiced sales by a party or a partys Affiliate on all sales of Products (in final form for end use) to an unaffiliated third party, and exclusive of intercompany transfers or sales, less the following deductions from such invoiced sales, which are actually incurred, to the extent that they are reasonable and customary, and to the extent that they do not exceed *** percent (***%) of invoiced sales during any Calendar Quarter: |
(i) credits or allowances actually granted for damaged Products, returns or rejections of Product and retroactive price reductions;
(ii) freight, postage, shipping, customs duties and insurance charges;
(iii) normal and customary trade, cash and quantity discounts, allowances and credits;
(iv) uncollected amounts to the extent not exceeding *** percent (***%) of invoiced sales for a calendar quarter; and
(v) sales, value added or similar taxes measured by the billing amount, when included in billing.
1.19
Patent Rights
: shall mean collectively, the Cancer Marker Patent Rights, Database
Patent Rights, Layton Patent Rights, the Montefiore Patent Rights, the Seilhamer/Scott Patent
Rights, and the Stanford Patent Rights;
1.20
Personalized Research Field of Use
: shall mean the research, development,
manufacture, importation, use and/or sale of Personalized Research Product(s). The
Personalized Research Field of Use excludes the Diagnostic Field of Use, the Homebrew Field of
Use, and the Internal Research Field of Use.
Page 4
Page 5
1.21
Personalized Research Product(s)
: shall mean a Multi-Analyte Assay(s) provided as a
product or a service containing nucleic acids or proteins that are collectively intended to
establish or identify an association between the presence or absence of such nucleic acids or
proteins and:
(i)
diagnosis of the presence of, or absence of, a specific disease(s),
state(s) or condition(s) in humans;
(ii)
predisposition to the presence of, or absence of, a specific
disease(s), state(s) or condition(s) in humans;
(iii)
response or lack of response to disease therapy(ies) in humans or
preventative strategies in humans;
(iv)
prediction of the disease course in humans, and or other changes in
state(s) or condition(s) in humans over time;
(v)
clinical traits in humans for which a medical professional should be
consulted;
(vi)
variation(s) in specific trait(s) and/or characteristics among
individuals; and/or
(vii)
predisposition to development of toxicities to disease therapies or
preventative strategies in humans,
Such an assay will be considered a Personalized Research Product only where the results
are provided directly to the tested individual and/or to the tested individuals health
care provider, and where the approval by the FDA or comparable regulatory agency in any
jurisdiction outside of the United States is not required. Personalized Research
Products exclude Homebrew Products, Diagnostic Products and GHI Database Products. For
purposes of the foregoing, Multi-Analyte Assay(s) shall mean an assay designed for
testing or measuring more than a single analyte.
1.22
Product(s)
: shall mean GHI Database Products, Personalized Research Products,
Homebrew Products, Incyte Research Products, Therapeutic Products and/or Diagnostic Products.
1.23
Seilhamer/Scott Patent Rights
: shall mean (a)
US Patent No. 6,114,114
Comparative Gene Transcript Analysis issued September 5, 2000, (b)
US Patent No.
5,840,484
Comparative Gene Transcript Analysis issued November 24, 1998 (c) all
counterpart foreign patent applications claiming priority to the patents described in clauses
(a)and (b) above, together with all continuations, continuations-in-part and divisions of such
patents, and (d) all reissues and re-examinations of any of the foregoing patents.
1.24
Stanford Patent Rights
: shall mean (a)
US Patent No. 5,807,522
Methods for
Fabricating Micro Arrays of Biological Samples issued September 15, 1998 (b) all counterpart
foreign patent applications claiming priority of the patent described in clause (a) above,
together with all continuations, continuations-in-part and divisions of such patent
applications, (c) all patents issuing from any patent
application described in clause (b) above and (d) all reissues and re-examinations of any
of the foregoing patents.
1.25
Therapeutic Product
shall have the meaning set forth in Section 2.8.
1.26
Valid Claim
: shall mean a claim of an issued and unexpired patent which has not
been held unenforceable, unpatentable or invalid by a decision of a court or governmental body
of competent jurisdiction, unappealable or unappealed within the time allowed for appeal,
rendered unenforceable due to disclaimer or otherwise, or lost through an interference
proceeding.
ARTICLE
2
LICENSE GRANT
2.1 | Layton and Stanford Patent Rights . Subject to the terms of this Agreement, Incyte hereby grants to GHI and its Affiliates, and GHI and its Affiliates accept from Incyte a nonexclusive, non-transferrable, limited sublicenseable (only as set forth in Sections 2.5 and 2.6 below), world-wide license under the Layton Patent Rights and the Stanford Patent Rights to practice and use the subject matter within the Layton Patent Rights and the Stanford Patent Rights in the GHI Database Field of Use, Diagnostic Field of Use, the Homebrew Field of Use and the Personalized Research Field of Use. |
2.2 | Montefiore Patent Rights . Subject to the terms of this Agreement, Incyte hereby grants to GHI and its Affiliates, and GHI and its Affiliates accept from Incyte a non-transferrable, limited sublicenseable (only as set forth in Sections 2.5 and 2.6 below), world-wide license under the Montefiore Patent Rights to practice and use the subject matter within the Montefiore Patent Rights in the GHI Database Field of Use, the Diagnostic Field of Use, the Homebrew Field of Use and the Personalized Research Field of Use. The license under the Montefiore Patent Rights shall be exclusive in the Personalized Research Field of Use and Co-exclusive (as described in Section 2.6) in the GHI Database Field of Use, the Homebrew Field of Use and the Diagnostic Field of Use. |
2.3 | Cancer Marker Patent Rights . Subject to the terms of this Agreement, Incyte hereby grants to GHI and its Affiliates, and GHI and its Affiliates accept from Incyte a non-transferrable, limited sublicenseable (only as set forth in Sections 2.5 and 2.6 below), world-wide license under the Cancer Marker Patent Rights to practice and use the subject matter within the Cancer Marker Patent Rights in the GHI Database Field of Use, the Diagnostic Field of Use, the Homebrew Field of Use and the Personalized Research Field of Use, only with respect to cancer. The license under the Cancer Marker Patent Rights shall be exclusive in the Personalized Research Field of Use with respect to cancer, and co-exclusive (as described in Section 2.6) in the GHI Database Field of Use, Diagnostic Field of Use and the Homebrew Field of Use with respect to cancer. |
Page 6
2.4 | Database Patent Rights and Seilhamer/Scott Patent Rights . Subject to the terms of this Agreement, Incyte hereby grants to GHI and its Affiliates, and GHI and its Affiliates accept from Incyte a non-exclusive, non-transferable, non-sublicenseable , world-wide license under the Database Patent Rights and Seilhamer/Scott Patent Rights to practice and use the subject matter within the Database Patent Rights and the Seilhamer/Scott Patent Rights in the GHI Database Field of Use, the Diagnostic Field of Use, the Homebrew Field of Use, and the Personalized Research Field of Use. |
2.5 | Sublicenses . Except as provided in Section 2.6 and this Section 2.5, the rights granted in Section 2.1 through 2.3 above shall not be sublicensable; provided, GHI shall have the right to grant sublicenses to third parties under such Patent Rights on a Product-by-Product basis to make, use, import, sell, and offer for sale Product(s) developed by GHI or its Affiliates. | |||
2.6 | Co-Exclusive License(s) Homebrew and Diagnostic Fields of Use . For the purposes of this Article 2.0, Co-Exclusive shall mean that (a) each Party has the right to exercise all of the rights under the Patent Rights in question in the field of use for which the parties have co-exclusive rights, without obligation to the other except to the extent provided in this Agreement, and (b) neither Party alone has the right to grant sublicenses to third parties under such Patent Rights without express written consent of the other Party with the following exceptions: |
(v) | GHI shall have the right to grant sublicenses as provided in Section 2.5 above; | |||
(w) | Incyte shall have the right to grant licenses in the Homebrew Field of Use and the Diagnostic Field of Use on a Product-by-Product basis to make, use, import, sell, and offer for sale Product(s) developed by Incyte or its Affiliates. | |||
(x) | Incyte shall have the right to grant sublicenses with respect to the Cancer Marker Patent Rights in the Homebrew and Diagnostic Fields of Use) with respect to individual nucleic acids or proteins in connection with Incyte licenses of nucleic acids or proteins for use as targets for the development of vaccines or therapeutic products; | |||
(y) | GHI shall have the right to request that Incyte grant a sublicense under the Montefiore Patent Rights in the Diagnostic Field of Use and/or the Homebrew Field of Use to one (1) third party with which GHI enters into a cross license agreement involving the Montefiore Patent Rights, and Incyte agrees to grant such a sublicense; | |||
(z) | Incyte shall have the right to grant a sublicense under the Montefiore Patent Rights in the Diagnostic Field of Use and/or the Homebrew Field of Use to one (1) third party with which Incyte enters into a cross license agreement involving the Montefiore Patent Rights; and |
Page 7
(zz) | Any additional licenses under the Montefiore Patent Rights granted by the Parties shall be subject to mutual written agreement of the parties, and the parties shall share all revenues received from licensees for licenses under the Montfiore Patent Rights, after deduction of all amounts owed to the owner of the Montefiore Patent Rights. |
2.7
No Implied Licenses
. Incyte grants no licenses to GHI under any Patent Rights except
as expressly granted under this Agreement. There are no other licenses granted by Incyte to
GHI under this Agreement, whether by implication, estoppel or otherwise. GHI shall not use
any Patent Rights for any purpose or in any field other than as described in Sections 2.1
through 2.6.
2.8
Grant Back
. GHI hereby grants to Incyte, and Incyte hereby accepts, an exclusive,
paid up, non-transferable, sublicensable, worldwide license under GHI patent rights and trade
secret rights owned and Controlled by GHI, with respect to any discoveries (to the extent such
discoveries relate to the composition of matter or use of any nucleic acids or proteins
claimed in the Cancer Marker Patent Rights) made by GHI in connection with GHIs use of the
Cancer Marker Patent Rights (the Cancer Marker Improvements) for use by Incyte and Incytes
sublicensees in the (i) Internal Research Field of Use, (ii) in connection with the
manufacture, use and sale of vaccines and therapeutic products (each therapeutic product a
Therapeutic Product), and (iii) Diagnostic Products in connection with the exercise of
rights under (ii).
GHI hereby grants to Incyte, and Incyte hereby accepts, a non-exclusive, royalty-bearing,
non-transferable, non-sublicensable, worldwide license under GHI patent rights and trade
secret rights owned and Controlled by GHI, with respect to Personalized Research Products
developed by GHI and licensed under this Agreement or the LifeSeq Collaborative Agreement
of even date herewith (the GHI PRx Improvements), to manufacture,have manufactured,
sell, offer for sale, and use such Personalized Research Products in the Internal
Research Field of Use (each an Incyte Research Product).
2.9
GHI grants no licenses to Incyte under this Agreement except as expressly granted herein.
There are no other licenses granted by GHI to Incyte under this Agreement, whether by
implication, estoppel or otherwise. Incyte shall not use any GHI patent rights and trade
secrets for any purpose or in any other field other than described in Section 2.8.
2.10
After the Effective Date and for a period of two (2) years thereafter, Incyte shall use
reasonable efforts to notify GHI and discuss with GHI any additional patents or patent
applications Controlled by Incyte that Incyte intends to make available for exclusive or
co-exclusive use in the Diagnostic Field of Use, the Homebrew Field of Use or Personalized
Research Field of Use.
Page 8
*** Confidential material redacted and filed separately with the Commission .
ARTICLE
3
LICENSE FEES
3.1 | In consideration for Incytes agreement under Section 2.3 hereof, on the Effective Date, GHI shall pay to Incyte each of the License Issuance fees and Royalties on Net Sales specified on Schedule B. | |||
In consideration for GHIs agreement under Section 2.8 hereof, Incyte shall pay to GHI each of the Royalties on Net Sales specified on Schedule C. | ||||
3.2 | In the event that a Product is sold in combination with other product(s) and/or service(s) for which no royalty would be due hereunder if sold separately, Net Sales from such combination sales for purposes of calculating the amounts due under this Article 3 shall be calculated by multiplying the Net Sales of the combination product by the fraction A/(A+B), where A is the average gross selling price during the applicable calendar quarter of the Product sold separately to the same category of customers (e.g. patients, health care providers, or Diagnostic Product distributors) and B is the average gross selling price during the applicable calendar quarter of the other product(s) and/or services. In the event that such separate sales were not made during the previous calendar quarter then the Net Sales shall be calculated by multiplying the Net Sales of the combination product by the fraction C/(C+D), where C is the average cost of goods sold during the applicable calendar quarter of the Product and D is the average cost of good sold during the applicable calendar quarter of the other product(s) and/or service(s) , in each case calculated in accordance with standard and customary accounting principles. | |||
3.3 | In the event that GHI pays royalties to third parties in connection with the sale of Diagnostic Products either under agreements for patent rights (including applications therefor) or other technologies which GHI, in GHIs reasonable judgment, determines are necessary or desirable to license or acquire with respect to such Diagnostic Products, including joint owners of patent applications or patents within the Patent Rights, GHI may deduct up to *** percent (***%) of such royalties which are due Incyte hereunder; provided, |
(i) | in no event shall the royalties which are due Incyte hereunder be reduced by reason of this Section 3.3 to less than *** percent (***%) of the amount that would otherwise by payable to Incyte without any deduction under this Section 3.3; and | |||
(ii) | provided further that GHI shall be entitled to deduct from royalties payable on account of its licenses under (a) the Layton Patent Rights only royalties payable for use of patents or other technologies directed toward sample preparation; (b) the Stanford Patent Rights only |
Page 9
*** Confidential material redacted and filed separately with the Commission .
royalties payable for use of patents or other technologies directed toward microarray manufacture, use and/or sale; and (c) the Cancer Marker Patent Rights only royalties payable for use of patents or know-how rights directed toward the composition of matter or use of nucleic acids or proteins. |
3.4 | In the event that Incyte pays royalties to third parties in connection with the sale of Therapeutic Products, Diagnostic Products or Incyte Research Products either under agreements for patent rights (including applications therefor) or other technologies which Incyte, in Incytes reasonable judgement, determines are necessary or desirable to license or acquire with respect to such Therapeutic Products, Diagnostic Products and Incyte Research Products, Incyte may deduct up to *** percent (***%) of such royalties which are due GHI hereunder; provided, |
(i) | in no event shall the royalties which are due GHI hereunder be reduced by reason of this Section 3.4 to less than *** percent (***%) of the amount that would otherwise by payable to GHI without any deduction under this Section 3.4; and | |||
(ii) | provided further that Incyte shall be entitled to deduct from royalties payable on account of its licenses hereunder only royalties payable for use of patents or know-how rights directed toward the composition of matter or use of nucleic acids or proteins. |
3.5 | Even if a Product is covered by more than one Valid Claim within each of the Layton Patent Rights, the Stanford Patent Rights and the Cancer Marker Patent Rights, GHI shall be obligated to pay only one royalty under each of the Cancer Marker Patent Rights, the Layton Patent Rights, and the Stanford Patent Rights, as applicable. Likewise, even if a Product is covered by more than one Valid Claim within the Cancer Marker Improvements and the GHI PRx Improvements, Incyte shall be obligated to pay only one royalty under each of Cancer Marker Improvements and the GHI PRx Improvements, as applicable. It is understood that no royalty shall be due hereunder with respect to sales or other transfers of Products for use as promotional samples if such Products are provided without charge. | |||
3.6 | Each party owing amounts hereunder shall make quarterly written reports to the other party within sixty (60) days after the end of each calendar quarter, stating in each such report the aggregate Net Sales of Products sold during the calendar quarter. Simultaneously with the delivery of each such report, the reporting party shall pay to the other party the total royalties, if any, due to such party for the period of such report. If no royalties are due, the reporting party shall so report. Neither party shall provide to third parties any information contained in reports provided to such party pursuant to this Section 3.6, except as required by a partys agreements with its licensors. |
Page 10
3.7 | All such payments shall be paid in United States Dollars, originated from a United States bank located in the United States and made by bank wire transfer in immediately available funds to such account as the receiving party shall designate. |
3.8 | Each party shall permit an independent certified public accounting firm of nationally recognized standing appointed by the inspecting party, and reasonably acceptable to other party, to examine and audit its records during reasonable business hours upon at least fifteen (15) days prior written notice to the extent necessary to verify the accuracy of the reports delivered under Section 3.6 above for three (3) years after the date of such reports. Such inspections may be made no more than once each calendar year, at reasonable times and on reasonable notice. Inspections conducted under this Section 3.8 shall be at the expense of inspecting Party, provided, if such an audit correctly uncovers a deficiency in payment of royalties payable by a party hereunder, such audited party shall immediately pay to the other party such deficient amount, and if the amount of any such deficiency is greater than 5% of the total amount due during the audited period, such audited party shall bear the reasonable out of pocket expenses of such accounting firm to conduct such audit. |
3.9 | Each party owing amounts hereunder shall pay, or reimburse the other party, as appropriate, and indemnify the other party against any sales, use, value added/ad valorum, surtax and personal property taxes, customs, duties, registration fees and the like including interest and penalties arising out of this Agreement and the transactions contemplated herein, including the costs and responsibility of any withholding taxes. |
ARTICLE
4
PATENT PROSECUTION AND ENFORCEMENT
4.1 | As between Incyte and GHI only, Incyte shall have the sole right (in its sole discretion), but not the obligation, to control the preparation, filing, prosecution, maintenance and enforcement of the Patent Rights. Incyte shall consult with GHI no less than once in any calendar quarter regarding its filing and prosecution strategies with respect to the Cancer Marker Patent Rights, including with respect to all decisions regarding the filing of patent applications directed to the Cancer Marker Patent Rights in jurisdictions outside of the United States. Prior to abandoning any patent applications included in the Cancer Marker Patent Rights, or forefeiting potential patent claims directed to any nucleic acid or protein sequence included in the Cancer Marker Patent Rights, Incyte shall notify GHI and provide GHI with a reasonable opportunity to assume responsibility for the prosecution of any such application or patent claims, at GHIs expense. Upon issuance of any patents included within the Cancer Marker |
Page 11
*** Confidential material redacted and filed separately with the Commission .
Patent Rights, Incyte shall pay all maintenance fees required to maintain such patents. Incyte shall remain the owner of record for all such Cancer Marker Patent Rights. GHI shall execute such documents and take such additional steps as Incyte may reasonably request to enable Incyte to exercise its rights and to perform its obligations under this Section 4.1. | ||||
4.2 | Incyte shall have no obligation to take any action whether through the institution of legal proceedings or otherwise with respect to any infringement or suspected infringement of the Patent Rights. Without prejudice to any separate agreement that may be or have been reached between the parties, if Incyte in its sole discretion decides to take any such action it shall do so at its own cost, and GHI shall have no claim to any sums received by Incyte. GHI shall provide reasonable assistance to Incyte at no out-of-pocket expense to GHI. In the event Incyte declines to take any action with respect to any infringement or suspected infringement of the Montefiore Patent Rights or the Cancer Marker Patent Rights, and such infringement results in commercial loss in value of GHIs rights under the applicable Patent Rights, Incyte shall take reasonable steps to enable GHI to sue to terminate the infringement at GHIs expense, provided that GHI shall defend, indemnify Incyte and the owner of the Montefiore Patent Rights, if applicable, against any cross-claims or counterclaims asserted by the defendant in any such action brought by GHI. If GHI recovers any amounts as a consequence of the filing of such infringement suits, GHI shall first be entitled to recover its fees for bringing the action or actions, amounts owed to Incytes licensors, if any, shall then be deducted, and GHI shall pay to Incyte *** percent (***%) of any remaining recovery. |
ARTICLE
5
WARRANTIES AND WARRANTY DISCLAIMERS
5.1 | Each party represents and warrants to the other that: |
(a) | it is a corporation or entity duly organized and validly existing under the laws of the state or other jurisdiction of incorporation or formation; | |||
(b) | it has the corporate power and authority and the legal right to enter into this Agreement and to perform its obligations hereunder; | |||
(c) | the execution and delivery of this Agreement and the performance by such Party of the transactions contemplated hereby have been duly authorized by all necessary action of such party; | |||
(d) | it has not prior to the Effective Date, nor will it after the Effective Date, enter into any oral or written agreement or arrangement that would conflict with its obligations under this Agreement. |
5.2 | Incyte makes no warranty, representation or undertaking: |
(a) | as to the efficacy or usefulness of the Patent Rights or any discovery or invention covered thereby; |
Page 12
(b) | that any of the Patent Rights are or will be valid or subsisting or (in the case of applications) will proceed to grant; | |||
(c) | that the exploitation of the Patent Rights, or the exercise of any rights licensed hereunder, will not infringe any other intellectual property or other rights of any other person or entity; or | |||
(d) | as imposing any obligation on Incyte to bring or prosecute actions or proceedings against third parties for infringement or to defend any actions or proceedings for revocation of any of the Patent Rights. |
5.3 | GHI makes no warranty, representation or undertaking: |
(a) | as to the efficacy or usefulness of the Cancer Marker Improvements and the GHI PRx Improvements (collectively, the GHI Patent Rights) or any discovery or invention covered thereby; | |||
(b) | that any of the GHI Patent Rights are or will be valid or subsisting or (in the case of applications) will proceed to grant; | |||
(c) | that the exploitation of the GHI Patent Rights , or the exercise of any rights licensed hereunder, will not infringe any other intellectual property or other rights of any other person or entity; or | |||
(d) | as imposing any obligation on GHI to bring or prosecute actions or proceedings against third parties for infringement or to defend any actions or proceedings for revocation of any of the GHI Patent Rights. |
5.4 | EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, ANY AND ALL RIGHTS LICENSED AND PATENTS MADE AVAILABLE BY EITHER PARTY TO THE OTHER PARTY ARE LICENSED OR MADE AVAILABLE AS IS. NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND (OTHER THAN AS SET FORTH IN PARAGRAPH 5.1). EXCEPT AS EXPRESSLY STATED HEREIN, INCYTE AND GHI DISCLAIM ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF QUALITY, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE. OR NONINFRINGEMENT. |
ARTICLE
6
TERM AND TERMINATION
6.1 | This Agreement and the license granted under hereby shall be effective as of the Effective Date and unless terminated earlier in accordance with this Article 6 shall continue in force on a country by country basis until the last to expire of the Patent Rights in such country. | |||
6.2 | If GHI fails to timely satisfy its payment obligations under this Agreement, or is otherwise in material breach of this Agreement, and such failure or breach is not |
Page 13
cured within ninety (90) days after written notice from Incyte specifying the breach, then Incyte shall have the right in its sole discretion to terminate this Agreement upon written notice to GHI (without prejudice to any other right or remedy Incyte may have), provided that such ninety (90) day notice specifies the nature of the breach; and provided further that GHI may avoid such termination if before the end of such ninety (90) day period GHI notifies Incyte in writing that such breach or default has been cured and states the manner of such cure. | ||||
6.3 | On a patent-by-patent basis, GHI shall have the right to terminate this Agreement with respect to any patent(s) within the Patent Rights for any reason effective immediately; provided, if GHI terminates this Agreement with respect to a particular patent, all rights granted to GHI with respect to such patent shall immediately terminate. GHI shall also have the right to terminate this Agreement in its entirety for any reason, effective immediately. If GHI terminates the Agreement in it entirety under this Article 6.3, then all rights granted to GHI shall immediately terminate; however all royalty obligations incurred by GHI prior to expiration or termination shall survive such termination | |||
6.4 | No termination of this Agreement, other than a termination by GHI for Incytes material breach, shall in any way affect the licenses granted to Incyte under Section 2.8 or GHIs obligations pursuant to Article 3 to pay any amounts accrued prior to such termination of this Agreement. Furthermore, no termination of this Agreement shall in any way affect either partys obligations under Article 7 with respect to any claims that arise from acts or omissions of such party that occurred prior to the effective date of such termination. In the event this Agreement is terminated by GHI due to Incytes material breach, the licenses and rights granted by GHI to Incyte under Sections 2.8 shall terminate concurrently. | |||
6.5 | In the event Incyte materially breaches, the right and license granted by GHI to Incyte pursuant to Section 2.8, and such breach shall have continued for ninety (90) days after written notice thereof was provide by GHI to Incyte, GHI shall be entitiled to terminate such rights and licenses. Any termination shall become effective at the end of such ninety (90) day period unless Incyte (or any other party on its behalf) has cured any such breach prior to the expiration of the ninety (90) day period. | |||
6.5 | Incyte agrees not to enter into amendment of any agreement between Incyte and the owners of the Montefiore Patent Rights, the Layton Patent Rights or the Stanford Patent Rights that would result in any lessening of the rights granted to GHI, or greater obligations on GHI, under this Agreement, without GHIs prior written consent. In the event that Incytes license(s) under the Layton Patent Rights and/or Stanford Patent Rights terminate, the assignment restrictions under Section 8.6 shall terminate with respect to the Layton Patent Rights or Stanford Patent Rights respectively. |
Page 14
6.6 | This Agreement shall survive the expiration and any termination of any agreement between Incyte and its licensor(s), or between such licensor(s) and their licensor(s), and so on, with respect to the Layton Patent Rights, the Montefiore Patent Rights and/or the Stanford Patent Rights, to the extent GHI is not in breach of this Agreement, and only to the extent this Agreement is consistent with the rights and obligation under such agreement between Incyte and its respective licensor. All obligations of GHI including the obligation to pay royalties hereunder shall be assigned to Incytes licensor(s) in the event of any such termination. | |||
6.7 | Sublicenses which are validly granted by a party under this Agreement shall survive any termination, provided that such sublicense(s) are not inconsistent with the terms of this Agreement and the respective sublicensee(s) is in full compliance with the terms of such sublicense and the applicable provisions of this Agreement at all times, and the sublicensee(s) promptly agrees in writing to be bound by the applicable terms of this Agreement. |
ARTICLE
7
INDEMNIFICATION
7.1 | GHI shall indemnify and hold Incyte harmless from all losses, liabilities, damages and expenses (including reasonable attorneys fees and costs) arising from any claims, demands, actions or other proceedings by any third party arising out of or relating to (a) any breach of any representation, warranty or covenant of GHI under this Agreement, or (b) any practice or use by GHI or its Affiliates of the Patent Rights, except to the extent caused by the negligence or willful misconduct of Incyte. |
7.2 | Incyte shall indemnify and hold GHI harmless from all losses, liabilities, damages and expenses (including reasonable attorneys fees and costs) arising from any claims, demands, actions or other proceedings by any third party arising out of or relating to (a) any breach of any representation, warranty or covenant of Incyte under this Agreement, or (b) any practice or use by Incyte, its Affiliates or their sublicensees of the rights granted by GHI to Incyte under Section 2.8, except to the extent caused by the negligence or willful misconduct of GHI. |
7.3 | A party that intends to claim indemnification (the Indemnitee) under this Article 7 shall promptly notify the other party (the Indemnitor) in writing of any claim, complaint, suit, proceeding or cause of action with respect to which the Indemnitee intends to claim such indemnification (for purposes of this Section 7.3, each a Claim), and the Indemnitor shall have sole control of the |
Page 15
defense and/or settlement thereof; provided that the Indemnitee shall have the right to participate, at its own expense, with counsel of its own choosing in the defense and/or settlement of such Claim. The indemnification obligations of the Parties under this Article 7 shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the consent of the Indemnitor, which consent shall not be withheld or delayed unreasonably. The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any such Claim, if prejudicial to its ability to defend such action, shall relieve such Indemnitor of any liability to the Indemnitee under this Article 7, but the omission so to deliver written notice to the Indemnitor shall not relieve the Indemnitor of any liability to any Indemnitee otherwise than under this Article 7. The Indemnitee under this Article 7, and its employees, at the Indemnitors request and expense, shall provide full information and reasonable assistance to Indemnitor and its legal representatives with respect to such Claims covered by this indemnification. |
ARTICLE
8
MISCELLANEOUS
8.1 | No failure or delay on the part of either Party to exercise any right or remedy under this Agreement shall be construed or operate as a waiver thereof, nor shall any single or partial exercise of any right or remedy preclude the further exercise of such right or remedy. |
8.2 | Neither Party shall act or describe itself as the agent of the other, nor shall it make or represent that it has authority to make any commitments on the others behalf. |
8.3 | Any consent, notice or report required or permitted to be given or made under this Agreement by one of the parties hereto to the other party shall be in writing, sent to such other party at its address and fax number indicated below, or to such other address as the addressee shall have last furnished in writing to the addresser, and shall be effective upon receipt by the addressee. |
|
If to Incyte: | FAX Number: 650-845-4500 | ||
|
Incyte Genomics, Inc. | |||
|
3160 Porter Drive | |||
|
Palo Alto, California 94303 | |||
|
Attention: Roy Whitfield, CEO | |||
|
||||
|
with a copy to: | Incyte Genomics, Inc. | ||
|
3160 Porter Drive | |||
|
Palo Alto, California 94303 | |||
|
Attention: Lee Bendekgey, General Counsel |
Page 16
|
If to GHI: | FAX number: 650-322-8124 | ||
|
Genomic Health, Inc. | |||
|
101 University Ave., Suite 220 | |||
|
Palo Alto , CA 94301 | |||
|
Attention: Randy Scott, PhD, Chief Executive Officer | |||
|
||||
|
with a copy to: | Pillsbury Winthrop, LLP | ||
|
50 Fremont Street | |||
|
San Francisco, CA 94105 | |||
|
Attention: Stan Wong, Corporate Counsel |
8.4 | Each party may announce the existence of this Agreement promptly following its execution, subject to approval by the other party of any such announcement, which approval will not be unreasonably withheld. Except as contemplated by the last sentence or as may otherwise be required by law or regulation, neither party shall make any public announcement concerning this Agreement or the subject matter hereof without the prior consent of the other party. If this Agreement is determined to be material to the business of Incyte (or GHI) so that its disclosure is required by law or regulation, GHI (or Incyte) shall have the right to review and comment on the text of the disclosure prior to its release to the public. | |||
8.5 | This Agreement, including its Schedules, the Stock Purchase Agreement, the Collaboration and Technology Transfer Agreement,, and the LifeSeq Collaborative Agreement, all of even date herewith, sets out the entire agreement between the parties relating to its subject matter and supersedes all prior oral or written representations, agreements, arrangements or understandings between them relating to such subject matter. | |||
8.6 | GHI shall not directly or indirectly assign or otherwise transfer this Agreement, or its rights or obligations under this Agreement, in whole or in part, whether voluntarily, by operation of law or otherwise, without the prior written consent of Incyte. Notwithstanding the foregoing, GHI may assign or transfer this Agreement without such consent to a third party in connection with a merger, consolidation, reorganization, acquisition or similar transaction involving all or substantially all of GHIs voting stock or assets relating to this Agreement; provided that , if GHI assigns or transfer this Agreement to any third party that is either a party to litigation with Incyte regarding patent rights or other intellectual property rights, or has advised Incyte in writing of the existence of patents or other intellectual property rights controlled by the third party, that such third party suggests that Incyte should license, then GHI shall not have the right to |
Page 17
assign or otherwise transfer this Agreement, or any rights or obligations under this Agreement to such third party (other than with respect to those Products (i) under development by GHI or GHIs Affiliate (as evidenced by records of experimental testing of such Product(s) by GHI or GHIs Affiliate) prior to such assignment or transfer, (ii) already commercially sold, or (iii) already licensed to a third party), unless the third party first grants Incyte either a license or freedom from suit with regard to any intellectual property controlled by such third party that is the subject of such litigation or written communication. Any purported assignment or transfer in violation of this Section 8.6 shall be void. This Agreement shall be binding upon and inure to the benefit of a party and its permitted assignees. | ||||
8.7 | This Agreement shall be governed by and construed in accordance with the local laws of the State of California, USA, without ,regard to the conflicts of law principles thereof. | |||
8.8 | Sections 3.5, 3.6, 3.7, 3.8, 3.9, and 5.4 and Article 8 of this Agreement shall survive termination of this Agreement for any reason. Sections 3.1, 3.2, 3.3 and 3.4 shall survive with regard to Net Sales of Products prior to termination of this Agreement. Except as otherwise expressly provided in Section 6.4 and this Section 8.8, all other rights and obligations of the parties shall terminate upon termination of this Agreement. |
In WITNESS WHEREOF, the parties have executelbd this agreement as of the date first set forth above.
GENOMIC HEALTH, INC. | ||||
|
Signature: | /s/ Randy Scott | ||
|
||||
|
Print Name: | Randy Scott | ||
|
Title: | CEO | ||
|
||||
INCYTE GENOMICS, INC | ||||
|
Signature: | /s/ Lee Bendekgey | ||
|
||||
|
Print Name: | Lee Bendekgey | ||
|
Title: | EVP and General Counsel |
Page 18
*** Confidential material redacted and filed separately with the Commission .
SCHEDULE A
CANCER MARKER PATENT RIGHTS
(SEE ATTACHED)
***
Page 19
*** Confidential material redacted and filed separately with the Commission .
SCHEDULE B
(Payments)
1. GHI and GHI Affiliate s
A. Payments Under Layton Patent Rights
(a) | one-time, nonrefundable license fee of *** Dollars ($***), payable within thirty (30) days after the Effective days after the Effective Date; and | |||
(b) | royalties on Net Sales of *** percent (***%) for Personalized Research Product(s) and Homebrew Product(s) and *** percent (***%) for Diagnostic Product(s), in each case, which Product(s) would, but for the licenses granted herein, infringe a Valid Claim under the Layton Patent Rights. |
B. Payments Under Stanford Patent Rights
(a) | a one time, nonrefundable license fee of *** Dollars ($***), payable within thirty (30) days after the Effective Date; and | |||
(b) | royalties Net Sales of *** percent (***%) for Personalized Research Product(s) and Homebrew Product(s) and *** percent (***%) for Diagnostic Product(s), in each case, which Product(s) would, but for the licenses granted herein, infringe a Valid Claim under the Stanford Patent Rights. |
C. Payments under Cancer Marker Patent Rights
(a) | one-time, nonrefundable license fee of *** Dollars ($***), payable within thirty (30) days after the Effective Date; and | |||
(b) | royalties on Net Sales of *** percent (***%) for Personalized Research Product(s) and Homebrew Product(s) and *** percent (***%) for Diagnostic Product(s), provided, however, that beginning five (5) years after the Effective Date, royalties on Net Sales of Personalized Research Product(s), Homebrew Product(s) and Diagnostic Product(s) shall be payable only in each case, on account of Product(s) which would, but for the licenses granted herein, infringe a Valid Claim under the Cancer Marker Patent Rights. |
Page 20
*** Confidential material redacted and filed separately with the Commission .
(c) | beginning on the third (3rd) anniversary of the Effective Date, minimum royalties of *** U.S. Dollars ($***) per year for each year thereafter during the term of the Agreement to maintain GHIs licenses under Section 2.3. | |||
(d) | Minimum royalties paid in any year are creditable only against royalties due in that year, and may not be credited against royalties due in subsequent years. |
C. Payments under Montefiore Patent Rights
(a) | one-time, non-refundable license fee of *** Dollars ($***), payable within thirty (30) days after the Effective Date |
D. Payments under Database Patent Rights
(a) | one-time, non-refundable license fee of *** Dollars ($***), payable within thirty (30) days after the Effective Date | |||
(b) | royalties on Net Sales of *** percent (***%) for GHI Database Product(s) which would, but for the licenses granted herein, infringe a Valid Claim of the Database Patent Rights (the Database Patent Royalties). | |||
(c) | Notwithstanding the foregoing, no royalties are payable on the use of a GHI Database Product by GHI where such use by GHI involves is within the Personalized Research Field of Use, Diagnostic Field of Use or the Homebrew Field of Use. |
E. Payments under Seilhamer/Scott Patent Rights
(a) | one-time, non-refundable license fee of *** Dollars ($***), payable within thirty (30) days after the Effective Date. |
Page 21
*** Confidential material redacted and filed separately with the Commission .
SCHEDULE C
(Payments)
1. Incyte and Incyte Affiliates
A. Payments under the Cancer Marker Improvements
(a) | royalties on Net Sales by Incyte and its Affiliates of *** percent (***%) for Therapeutic Product(s) and Diagnostic Product(s), in each case, which Product(s) would, but for the licenses granted herein, infringe a Valid Claim under the Cancer Marker Improvements; and/or | |||
(b) | *** percent (***%) of any license fees or royalties received by Incyte from sublicensing such Valid Claims under the Cancer Marker Improvements for use in connection with the manufacture, use or sale of Therapeutic Products or Diagnostic Products. |
B. Payments under GHI Prx Improvements
(a) | royalties on Net Sales by Incyte and its Affiliates of *** percent (***%) for Incyte Research Product(s), which Product(s) would, but for the licenses granted herein, infringe a Valid Claim under the GHI PRx Improvements. |
Page 22
*** Confidential material redacted and filed separately with the Commission .
SCHEDULE D
DATABASE PATENT RIGHTS
***
Page 23
Exhibit 10.6.2
*** Confidential Treatment Requested. Confidential portions of this document have been redacted
and have been separately filed with the Commission.
AMENDMENT TO THE PATENT LICENSE AGREEMENT
This Amendment to the Patent License Agreement (the License Amendment) effective as of December 21, 2001 (the Amendment Effective Date), is entered into by and between Incyte Genomics, Inc., a Delaware corporation, with a place of business at 3160 Porter Drive, Palo Alto, CA 94304 (Incyte) and Genomic Health, Inc., a Delaware corporation, with a place of business at 301 Penobscot Drive, Redwood City, CA 94063 (GHI).
A. WHEREAS, the parties to this License Amendment entered into that certain Patent License Agreement executed on March 30, 2001 by Incyte and GHI (the Agreement), pursuant to which Incyte granted certain licenses to GHI in certain fields therein.
B. WHEREAS, the parties wish to enter into an amendment to the Agreement in order to amend certain definitions defined, and rights granted, therein.
NOW THEREFORE, for and in consideration of the covenants, conditions, and undertakings hereinafter set forth it is agree by and between the Parties as follows:
1. | All capitalized terms not defined in this License Amendment shall have the meanings given to them in the Agreement. | |||
2. | Section 1.3 is amended in the first part of the first sentence to read as follows: | |||
Cancer Marker Patent Rights : shall mean all Valid Claims listed in any of the following patents and patent applications... | ||||
3. | Section 1.14 is amended in its entirety to read as follows: | |||
Internal Research Field of Use : shall mean (a) internal research, development, manufacture, use, importation and/or sale of Internal Research Products; and (b) internal research and development purposes (including without limitation, drug discovery, development, and regulatory filings), including the development of databases and other products and tools marketed for use in internal research and development purposes, including without limitation, drug discovery, development, and regulatory filings. The Internal Research Field of Use excludes the Diagnostic Field of Use, the Homebrew Field of Use, and the Personalized Research Field of Use. | ||||
4. | Section 1.15 is amended in its entirety to read as follows: | |||
Internal Research Product(s) : shall mean internal research and development purposes (including without limitation, drug discovery, development and regulatory filings), including the development of databases and other products and tools marketed for use in internal research and development purposes, including without limitation, drug discovery, development and regulatory filings. Internal Research Product(s) exclude Diagnostic Product(s), Homebrew Product(s) and Personalized Research Product(s). |
5. | Section 2.8 is amended in its entirety to read as follows: |
2.8 Grantbacks .
2.8.1 Cancer Marker Improvement Patents. GHI hereby grants to Incyte, and Incyte hereby accepts, an exclusive (except with respect to subsection (iii) below, for which the grant shall be nonexclusive), royalty bearing, non-transferable, sublicensable, worldwide license under GHI patent rights owned and Controlled by GHI, with respect to any discoveries (to the extent such discoveries relate to the composition of matter or use of any nucleic acids or proteins claimed in the Cancer Marker Patent Rights) made by GHI in connection with GHIs use of Valid Claims within the Cancer Marker Patent Rights (the Cancer Marker Improvements) for use by Incyte and Incytes sublicensees in the (i) Internal Research Field of Use, (ii) in connection with the manufacture, use and sale of vaccines and therapeutic products (each therapeutic product a Therapeutic Product), and (iii) on a Diagnostic Product-by-Diagnostic Product basis, to manufacture, use and sell a Diagnostic Product that tests for the same disease, state or condition as the Therapeutic Product under (ii) above. | ||||
2.8.2 GHI PRx Improvement Patents. GHI hereby grants to Incyte, and Incyte hereby accepts, a non-exclusive, royalty-bearing, non-transferable, non-sublicensable, worldwide license under GHI PRx Improvement Patents owned and Controlled by GHI to practice and use the inventions claimed therein in the Internal Research Field of Use. | ||||
For purposes of this Section 2.8.2: | ||||
GHI PRx Improvement Patents shall mean, with respect to Personalized Research Products made by GHI under this Agreement or the LifeSeq Collaborative Agreement and claimed within an issued patent, those Personalized Research Products for which the practice or use thereof would, but for a license granted by Incyte to GHI under this Agreement or the LifeSeq Collaborative Agreement, infringe the patent rights granted by Incyte to GHI under this Agreement or the LifeSeq Collaborative Agreement; and | ||||
LifeSeq Collaborative Agreement shall mean that certain license agreement titled the LifeSeq Collaborative Agreement by and between Incyte and GHI of even date March 30, 2001, including any amendments thereto. | ||||
6. | Schedule B section 1.C.(b) Payments Under Cancer Marker Patent Rights is amended in its entirety to read as follows: |
2 of 3
*** Confidential material redacted and filed separately with the Commission.
(b) royalties on Net Sales of *** percent (***%) for Personalized Research Product(s) and Homebrew Product(s) and *** percent (***%) for Diagnostic Product(s), which Product(s) would, but for the licenses granted herein, infringe a Valid Claim under the Cancer Marker Patent Rights.
7. | Except as specifically modified or amended hereby, the Agreement shall remain in full force and effect and, as modified or amended, is hereby ratified, confirmed and approved. No provision of this License Amendment may be modified or amended except expressly in a writing signed by both parties nor shall any terms be waived except expressly in a writing signed by the party charged therewith. This License Amendment shall be governed in accordance with the laws of the State of California, without regard to principles of conflicts of laws. |
IN WITNESS WHEREOF, each of the parties has executed this License Amendment as of the Amendment Effective Date.
INCYTE GENOMICS, INC. | GENOMIC HEALTH, INC. | ||||||
|
|||||||
By:
|
/s/ Lee Bendekgey | By: | /s/ Randy Scott | ||||
|
|||||||
|
|||||||
Name:
|
Lee Bendekgey | Name: | Randy Scott | ||||
|
|||||||
|
|||||||
Title:
|
EVP & General Counsel | Title: | CEO | ||||
|
Exhibit 10.7.1
*** Confidential Treatment Requested. Confidential portions of this document have been redacted
and have been separately filed with the Commission.
COLLABORATION AND TECHNOLOGY TRANSFER AGREEMENT
This Collaboration and Technology Transfer Agreement (the Agreement), effective as of March 30, 2001 (the Effective Date ), is made by and between Genomic Health, Inc., a Delaware corporation, with a place of business at 101 University Ave, Suite 220, Palo Alto, CA 94301 (GHI) , and Incyte Genomics, Inc., a Delaware corporation, with a place of business at 3160 Porter Drive, Palo Alto, CA 94304 (Incyte).
BACKGROUND
Incyte and GHI wish to collaborate on a research and development relating to Paraffin Extraction Technology (as defined below); and
GHI desires to receive from Incyte, and Incyte desires to transfer to GHI, certain Technology and Materials (as defined below); and
The parties wish to grant each other certain rights and licenses on the terms set forth in this Agreement.
NOW THEREFORE , for and in consideration of the covenants, conditions, and undertakings hereinafter set forth, it is agreed by and between the parties as follows:
1. DEFINITIONS
1.1 Control or Controlled shall mean possession of the ability to grant the right and licenses provided for herein, without violating the terms of any agreement or other arrangement with any Third Party, and which a Party has the right to disclose or provide to the other Party without a resulting obligation to pay royalties or other amounts to a Third Party.
1.2 Development Period shall mean the period commencing on the Effective Date and ending fifteen (15) months after the Effective Date, unless earlier terminated or extended by mutual written agreement of the Parties in accordance with the terms of this Agreement.
1.3 Development Program shall mean the activities conducted pursuant to this Agreement, which activities are primarily directed to the development of Paraffin Extraction Technology.
1.4 Diagnostic Field of Use shall mean the research, development, manufacture, importation, use and/or sale of Diagnostic Product(s). The Diagnostic Field of Use excludes the Personalized Research Field of Use, the Incyte Field of Use and the Homebrew Field of Use.
1.5 Diagnostic Product(s ): shall mean an assay provided as a product or service performed on a human tissue or other human biological sample containing nucleic acids or proteins that are collectively intended to establish or identify an association between the presence or absence of such nucleic acids or proteins and
Page 1
(a) diagnosis of the presence of, or absence of, a specific disease(s), state(s) or condition(s) in humans;
(b) predisposition to the presence of, or absence of, a specific disease(s), state(s) or condition(s) in humans;
(c) response or lack of response to disease therapy(ies) in humans or preventative strategies in humans;
(d) prediction of the disease course in humans, and or other changes in state(s) or condition(s) in humans over time;
(e) clinical traits in humans for which a medical professional should be consulted; or variation(s) in specific trait(s) and/or characteristics among individuals;
(f) variation(s) in specific trait(s) and/or characteristics among individuals; and/or
(g) predisposition to development of toxicities to disease therapies or preventative strategies in humans.
the results of which are provided to payors, providers or patients, and for which FDA approval (or comparable regulatory agency in other jurisdictions) is required. Diagnostic Products exclude Homebrew Products, Personalized Research Products and GHI Database Products.
1.6 Full-Time Equivalent or FTE shall mean a full-time employee, or in the case of less than a full-time dedicated person, a full-time, equivalent person-year performing activities under the Development Program.
1.7 GHI Database Field of Use shall mean the research, development, manufacture, importation, use and/or sale of GHI Database Product(s) to end users.
1.8 GHI Database Products shall mean a collection of information derived from or by testing a person or persons in the Diagnostic Field of Use, Homebrew Field of Use or the Personalized Research Field of Use. GHI Database Products exclude Diagnostic Products, Homebrew Products, and Personalized Research Products.
1.9 Homebrew Field of Use shall mean the research, development, manufacture, importation, use and/or sale of Homebrew Product(s). The Homebrew Field of Use excludes the Diagnostic Field of Use, the Internal Research Field of Use and the Personalized Research Field of Use.
1.10 Homebrew Product(s ): shall mean a Single Analyte Assay(s) provided as a product or a service performed by a service provider that would constitute a Diagnostic Product with the sole exception that it is provided prior to receipt of approval by the FDA or comparable regulatory agency in any jurisdiction outside of the United States. Homebrew Products exclude Diagnostic Products, Personalized Research Products and GHI Database Products. For purposes of the
Page 2
foregoing, Single-Analyte Assays shall mean a assay designed for testing or measuring only a single analyte.
1.11 Improvements shall mean any all inventions and all associated Intellectual Property: (a) made by Incyte or GHI commencing on the Effective Date and continuing until twelve (12) months after the expiration or termination of the Development Period using (i) the Program Technology, and/or (ii) Confidential Information provided by the other Party to the inventing Party, and in each case, which comprise an improvement, modification, or derivative of any of the foregoing relating to the Program Technology , and (b) Controlled by a Party.
1.12 Incyte Background Technology shall mean the Intellectual Property that Incyte Controls as of the Effective Date and during the Development Program which is necessary for the conduct of the Development Program and the exploitation of the Program Technology and/or the Improvements , and which is directed to (a) the recovery and extraction of native nucleic acids, polypeptides, peptides and/or proteins from tissues embedded in paraffin for use in the research, development and commercialization of assays, including without limitation microarrays (Paraffin Extraction); or (b) the selective amplification, labeling or conjugation of RNA segments in a close to linear fashion (RNA Amplification). Incyte Background Technology shall exclude those patents licensed to GHI under the Patent License Agreement
1.13 Incyte Field shall mean all internal research and development applications of Paraffin Extraction Technology or Improvements, including the use of such technology to develop therapeutic products and the use of such technology in connection with the commercialization of research tools, such as databases, use of a biochemical test for detecting and/or quantifying a specific nucleic acid target sequence within a nucleic acid mixture which is designed and intended For Research Use Only or For Investigational Use Only or as a general purpose laboratory reagent. For the avoidance of doubt, the Incyte Field shall exclude any, Diagnostic Field of Use, Homebrew Field of Use, and Personal Research Field of Use.
1.14 Incyte Technology shall mean any protocols, training materials and computer software listed in Exhibit A to this Agreement, in the form used by Incyte in connection with the conduct of microarray fabrication and gene expression service businesses in Fremont, California and St. Louis, Missouri, as of the date of the technology transfer activities described in Article 3 of this Agreement, which relate to (a) sample storage and tracking; (b) LIMS systems; (c) microarray manufacturing protocols; (d) hybridization protocols; (e) quality control and quality assurance protocols; (f) microarray scanning protocols; and (g) data analysis.
1.15 Intellectual Property shall mean trade secrets, Patents, copyrights, Know-How, and similar rights of any type under the laws of any governmental authority, domestic or foreign, including all applications and registrations relating to any of the foregoing.
(a) Patents shall mean (i) all patents worldwide including without limitation, all substitutions, reissues, renewals, reexaminations, patents of addition, and inventors certificates thereof; (ii) all term extensions or other government action which provides exclusive rights to an Invention beyond the original patent expiration date; and (iii) all pending patent applications (including provisional applications, divisions, continuations, continued prosecutions and continuations-in-part).
Page 3
*** Confidential material redacted and filed separately with the Commission.
(b) Know-How shall mean all knowledge, ideas, inventions, data, instructions, biological or other tangible materials, processes, formulas, expert opinions and information, including, without limitation, biological, chemical, analytical, clinical, manufacturing and quality control data and information, materials, methods, processes, techniques, and data. For the avoidance of doubt, Know-How does not include any Patent Rights.
1.16 Net Sales : shall mean invoiced sales by GHI or a GHI Affiliate on all sales of Products (in final form for end use) to an unaffiliated third party, and exclusive of intercompany transfers or sales, less the following deductions from such invoiced sales, which are actually incurred, to the extent that they are reasonable and customary, and to the extent that they do not exceed *** percent (***%) of invoiced sales during any calendar quarter:
(a) credits or allowances actually granted for damaged Products, returns or rejections of Product and retroactive price reductions;
(b) freight, postage, shipping, customs duties and insurance charges;
(c) normal and customary trade, cash and quantity discounts, allowances and credits; and
(d) uncollected amounts to the extent not exceeding *** percent (***%) of invoiced sales for a calendar quarter; and
(e) sales, value added or similar taxes measured by the billing amount, when included in billing.
1.17 Paraffin Extraction shall mean the recovery and extraction of native nucleic acids, polypeptides, peptides and/or proteins from tissues embedded in paraffin.
1.18 Paraffin Extraction Technology shall mean all Program Technology relating to the recovery and extraction of native nucleic acids, polypeptides, peptides and/or proteins from tissues embedded in paraffin and its use in the research, development and commercialization of assays, including without limitation microarrays. Paraffin Extraction Technology excludes RNA Amplification Technology.
1.19 Party or Parties shall mean individually Incyte or GHI, and collectively Incyte and GHI.
1.20 Patent License Agreement shall mean that certain patent license agreement by and between Incyte and GHI, titled the Patent License Agreement, as of March 30, 2001, including without limitation the rights granted thereunder in and to the Cancer Marker Patent Rights, Layton Patent Rights, Montefiore Patent Rights, and Stanford Patent Rights (each as defined therein).
1.21 Personal Research Field of Use shall mean the research, development, manufacture, importation, use and/or sale of Personalized Research Product(s). The Personalized Research Field of Use excludes the Diagnostic Field of Use, the Homebrew Field of Use, and the Incyte Field of Use.
Page 4
1.22 Personal Research Products shall mean shall mean a Multi-Analyte Assay(s) provided as a product or a service containing nucleic acids or proteins that are collectively intended to establish or identify an association between the presence or absence of such nucleic acids or proteins and:
(a) diagnosis of the presence of, or absence of, a specific disease(s), state(s) or condition(s) in humans;
(b) predisposition to the presence of, or absence of, a specific disease(s), state(s) or condition(s) in humans;
(c) response or lack of response to disease therapy(ies) in humans or preventative strategies in humans;
(d) prediction of the disease course in humans, and or other changes in state(s) or condition(s) in humans over time;
(e) clinical traits in humans for which a medical professional should be consulted;
(f) variation(s) in specific trait(s) and/or characteristics among individuals; and/or
(g) predisposition to development of toxicities to disease therapies or preventative strategies in humans.
Such an assay will be considered a Personalized Research Product only where the results are provided directly to the tested individual and/or to the tested individuals health care provider, and where the approval by the FDA or comparable regulatory agency in any jurisdiction outside of the United States is not required. Personalized Research Products exclude Homebrew Products, Diagnostic Products and GHI Database Products. For purposes of the foregoing, Multi-Analyte Assay(s) shall mean an assay designed for testing or measuring more than a single analyte.
1.23 Products shall mean GHI Database Products, Personalized Research Products, Homebrew Products and/or Diagnostic Products.
1.24 Program Technology shall mean all Intellectual Property created by Incyte or GHI after the Effective Date and during the Development Period (i) in the course of performing the Development Program, or (ii) using Confidential Information provided by the other Party to the inventing Party in connection with the Development Program.
1.25 RNA Amplification shall mean the selective amplification, labeling or conjugation of RNA segments in a close to linear fashion.
1.26 RNA Amplification Technology shall mean all Program Technology relating to the selective amplification, labeling or conjugation of RNA segments in a close to linear fashion.
1.27 Term shall mean the period set forth in Section 12.1.
Page 5
*** Confidential material redacted and filed separately with the Commission.
1.28 Third Party shall mean any Party other than Incyte or GHI.
1.29 Valid Claim shall mean a claim of an issued and unexpired patent which has not been held unenforceable, unpatentable or invalid by a decision of a court or governmental body of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, rendered unenforceable due to disclaimer or otherwise, or lost through an interference proceeding.
2. DEVELOPMENT PROGRAM
2.1 Development Program .
2.1.1 Development Program . The parties shall conduct the Development Program during the Development Period. Each Party agrees to use diligent efforts to conduct the Development Program in accordance with the terms of this Agreement. Subject to the terms of this Agreement, including without limitation the definition of the field of research and the provisions of Section 2.1.3 regarding Development Program Staffing, GHI shall control decisions regarding the direction of research efforts undertaken in connection with the Development Program.
2.1.2 Substitution and Addition of Projects . Upon notice from GHI to Incyte, individual projects in the Development Program may be dropped, added or changed, provided that such changes do not extend the Development Program into areas other than Paraffin Extraction Technology, and provided further that such changes shall not affect the resources to be provided by Incyte under this Agreement or the duration of the Development Period unless Incyte has agreed in writing to such changes.
2.1.3 Development Program Staffing .
(a) During the Development Program, unless otherwise agreed in writing by Incyte and GHI, Incyte will devote to the conduct of the Development Program three (3) Incyte FTEs during the Development Period. In addition, in GHIs sole discretion, GHI may provide up to three (3) GHI FTEs to assist with the Development Program.
(b) The Development Program will be conducted at Incyte under the direction of *** (the Principal Director). In the event the Principal Director becomes unavailable to participate in the Development Program for any reason, and the parties are unable to agree on a reasonable successor with comparable skills and qualifications within ninety (90) days following the date he becomes unavailable, GHI may terminate this Agreement . GHIs payment obligations under Section 4.1.1 shall be suspended during any such period of unavailability or until the parties agree on such reasonable successor.
(c) Incyte and GHI shall agree in advance on the technical and scientific qualifications of the GHI FTEs and other Incyte FTEs who will participate in the Development Program. If GHI becomes dissatisfied with the work of any Incyte FTE participating in the Development Program, GHI shall have the right to so notify Incyte in writing, and Incyte will use reasonable efforts to identify an alternate FTE with appropriate qualifications.
2.1.4 Visiting Personnel . It is understood that in the course of the Development Program there may be occasions where one Partys personnel (Visiting Personnel) may be
Page 6
stationed at the other Partys facilities on a temporary basis. Such Visiting Personnel shall agree to be bound by all orders, rules and regulations pertaining to the hosting Partys facilities during the entire time at such facilities.
2.2 Development Program Funding .
2.2.1 Funding . Except for the amounts provided by GHI pursuant to Article 4 to fund the Development Program, each Party shall bear its own costs in conducting the Development Program.
2.2.2 Third Party Technology . GHI will be responsible for determining whether the parties should cooperate in obtaining licenses to Intellectual Property or technology of one or more Third Parties for the conduct of the Development Program and for acquiring such licenses for purposes of the Development Program. Each Party shall be responsible for acquiring such Intellectual Property or technology of one or more Third Parties as it considers necessary or desirable in connection with its use of Program Technology following completion or other termination of the Development Program.
2.2.3 Capital Expenditures . If GHI determines that the conduct of the Development Program can be facilitated by the purchase of specialized capital equipment, GHI shall be responsible for obtaining such equipment, at GHIs expense, and GHI shall own all such equipment.
2.3 Record Keeping: Reports .
2.3.1 Records . Each Party shall maintain records of its activities under the Development Program in sufficient detail and in good scientific manner as will properly reflect all work done and results achieved in the performance of the Development Program. Each Party shall provide the other with access to all records, materials and data generated with respect to the Development Program at reasonable times and in a reasonable manner.
2.3.2 Reports . Each Party shall report and provide to the other Party with copies of all data, results, information, inventions, discoveries and developments achieved or obtained in the course of performing the Development Program, on an on-going basis throughout the Development Period or as otherwise specified as part of the Development Program.
3. TECHNOLOGY TRANSFER
3.1 Disclosures . Incyte shall provide the Incyte Technology to GHI according to a schedule described generally in Exhibit A, as such schedule may be modified by mutual agreement of Incyte and GHI. The LIMS system portion of the Incyte Technology will be transferred to GHI either digitally via the internet or modem to GHI or via the load and leave process, where the LIMS system will be installed by Incyte onto GHIs equipment. Incyte will retain title, possession and control over all physical forms of property at all times during the installation process. Upon completion of the installation, Incyte shall not leave with GHI any form of tangible personal property other than instruction documentation. GHI is authorized to make a backup copy of the LMIS system for archival purposes.
Page 7
*** Confidential material redacted and filed separately with the Commission.
3.2 Assistance . Incyte agrees to provide GHI with up to three (3) days of training, as GHI may reasonably request, following installation of the LIMS system at GHI (to occur during 2001), to understand and implement the sample storage and tracking and LIMS system portions of the Incyte Technology. Prior to December 31, 2002, at GHIs reasonable request, and subject to availability, Incyte shall allow up to five (5) GHI employees to participate in Incytes periodically scheduled training sessions for new Incyte employees or customers with respect to microarray manufacturing protocols, hybridization protocols, quality control and quality assurance protocols, microarray scanning protocols, and data analysis portions of the Incyte Technology. Upon mutual agreement of Incyte and GHI, GHI employees may also visit Incyte facilities for such periods as GHI and Incyte may agree to observe Incytes use of the Incyte Technology. If GHI wishes to obtain any additional services from Incyte regarding GHIs implementation or modification of the Incyte Technology, Incytes obligation to provide such services will be subject to a separate, written agreement between the parties that will describe the services to be provided by Incyte and the fees payable by GHI.
3.3 Incyte Know How License . Incyte hereby grants to GHI a worldwide, perpetual, irrevocable, non-transferable (except as provided in Section 14.6, below), royalty-free, fully paid-up, non-exclusive license under the Incyte Know-How, as is Controlled by Incyte, to develop, make, use, duplicate, modify, make derivative works, publicly perform, display, and disclose the Incyte Technology for the internal operation of GHIs businesses, to exploit the rights and license granted under the Patent License Agreement and/or granted herein this Agreement, in each case in the GHI Database Field of Use, Diagnostic Field of Use, Homebrew Field of Use, and Personal Research Field of Use.
3.4 Retained Rights . It is understood and agreed that no license or right is granted by Incyte to GHI under this Article 3 other than as expressly granted herein. No other license or rights, including without limitation any license or right to any other intellectual property owned or controlled by Incyte, shall be granted or created by implication, estoppel or otherwise.
4. PAYMENTS; CONSIDERATION
4.1 Development Program Funding .
4.1.1 Funding . In full consideration for Incytes undertaking the Development Program, GHI shall pay to Incyte *** Dollars ($***). GHI shall pay the foregoing amount in equal quarterly installments during the 2002 calendar year, with each such payment due during the first ten (10) business days of each such quarter.
4.1.2 Limitations . Except as provided in Section 2.2 or this Section 4.1, in no event shall GHI be responsible for any other costs, expenses or obligations incurred by Incyte in performing the Development Program without GHIs prior written consent.
4.2 Technology Transfer Payment . In full consideration for the disclosure and transfer of the Incyte Technology pursuant to Section 3.1, the assistance provided by Incyte pursuant to Section 3.2, and the rights and licenses granted to GHI under Section 3.3, GHI shall pay to Incyte *** Dollars ($***). GHI shall pay the foregoing amount
Page 8
*** Confidential material redacted and filed separately with the Commission.
in equal quarterly installments during the 2002 calendar year, with each such payment due during the first ten (10) business days of each such quarter.
4.3 Royalties . In consideration for the licenses granted to GHI by Incyte under Section 6.2.2(b) hereof, on the Effective Date, GHI shall pay to Incyte royalties on Net Sales of *** percent (***%) for Personalized Research Product(s) and Homebrew Product(s) and *** percent (***%) for Diagnostic Product(s), in each case, which Product(s) would, but for the licenses granted herein, infringe a Valid Claim under (i) the Incyte Background Technology directed to RNA Amplification and/or (ii) the RNA Amplification Technology.
4.3.1 Combination Products . In the event that a Product is sold in combination with other product(s) and/or service(s) for which no royalty would be due hereunder if sold separately, Net Sales from such combination sales for purposes of calculating the amounts due under this Section 4.3 shall be calculated by multiplying the Net Sales of the combination product by the fraction A/(A + B), where A is the average gross selling price during the applicable calendar quarter of the Product sold separately to the same category of customers (e.g. patients, health care providers, or Diagnostic Product distributors) and B is the average gross selling price during the applicable calendar quarter of the other product(s) and/or services. In the event that such separate sales were not made during the previous calendar quarter then the Net Sales shall be calculated by multiplying the Net Sales of the combination product by the fraction C/(C + D), where C is the average cost of goods sold during the applicable calendar quarter of the Product and D is the average cost of good sold during the applicable calendar quarter of the other product(s) and/or service(s) , in each case calculated in accordance with standard and customary accounting principles.
4.3.2 Third Party Royalties . In the event that GHI pays royalties to third parties in connection with the sale of Products either under agreements for patent rights (including applications therefor) or other technologies which GHI, in GHI reasonable judgement, determines are necessary or desirable to license or acquire with respect to such Products, including joint owners of patent applications or patents within the Patent Rights, GHI may deduct up to *** percent (***%) of such royalties which are due Incyte hereunder; provided,
(a) in no event shall the royalties which are due Incyte hereunder be reduced by reason of this Section 4.3 to less than *** percent (***%) of the amount that would otherwise by payable to Incyte without any deduction under this Section 4.3; and
(b) provided further that GHI shall be entitled to deduct from royalties payable under this Section 4.3 only royalties payable to third parties for use of patents or other technologies directed toward sample preparation.
4.3.3 One Royalty . Even if a Product is covered by more than one Valid Claim within each of the Incyte Background Technology and RNA Amplification Technology, GHI shall be obligated to pay only one royalty. It is understood that no royalty shall be due hereunder with respect to sales or other transfers of Products for use as promotional samples if such Products are provided without charge.
4.3.4 Reports . GHI shall make quarterly written reports to Incyte within sixty (60) days after the end of each calendar quarter, stating in each such report the aggregate Net Sales of
Page 9
Products sold during the calendar quarter. Simultaneously with the delivery of each such report, GHI shall pay to Incyte the total royalties, if any, due to Incyte for the period of such report. If no royalties are due, GHI shall so report. Incyte shall not provide to third parties any information contained in reports provided to Incyte pursuant to this Section 4.3.4, except as required by Incytes agreements with its licensors.
4.3.5 Form of Payment . All such payments shall be paid in United States Dollars, originated from a United States bank located in the United States and made by bank wire transfer in immediately available funds to such account as Incyte shall designate.
4.3.6 Inspection; Audit . GHI shall permit an independent certified public accounting firm of nationally recognized standing appointed by Incyte, and reasonably acceptable to GHI, to examine and audit GHIs records during reasonable business hours upon at least fifteen (15) days prior written notice to the extent necessary to verify the accuracy of the reports delivered under Section 4.3.4 above for three (3) years after the date of such reports. If such an audit correctly uncovers a deficiency in payment of License Fees payable by Incyte hereunder, GHI shall immediately pay such deficient amount, and if the amount of any such deficiency is greater than 5% of the total amount due during the audited period, GHI shall bear the reasonable out of pocket expenses of such accounting firm to conduct such audit, otherwise Incyte shall bear the costs of such audit.
4.3.7 GHI shall pay, or reimburse Incyte, as appropriate, and indemnify Incyte against any sales, use, value added/ad valorum, surtax and personal property taxes, customs, duties, registration fees and the like including interest and penalties arising out of this Agreement and the transactions contemplated herein, including the costs and responsibility of any withholding taxes.
5. PROGRAM TECHNOLOGY
5.1 Disclosure . Each Party shall promptly disclose to the other Party in reasonable detail any inventions and other intellectual property conceived and/or reduced to practice by such Party in connection with the Development Program.
5.2 Inventorship . Subject to the terms and conditions of this Agreement, inventorship shall be determined in accordance with the patent and other intellectual property laws of the United States, to the extent the laws of a particular country permit application of such laws.
5.3 Ownership of Inventions .
5.3.1 Ownership of Paraffin Extraction Technology . Notwithstanding Section 5.2, all right, title and interest to all Paraffin Extraction Technology created solely by GHI or Incyte, or jointly by GHI and Incyte, or its employees or agents, in connection with the Development Program, shall be owned by GHI. At GHIs request, Incyte shall cooperate with GHI and undertake to execute all such documents and to perform all further acts as may be necessary or convenient to cause all right, title and interest in or to the Paraffin Extraction Technology to vest in GHI pursuant to this Section 6.3.1.
5.3.2 Ownership RNA Amplification Technology . Notwithstanding Section 6.2, all right, title and interest to all RNA Amplification Technology created solely by GHI or Incyte, or
Page 10
jointly by GHI and Incyte, or its employees or agents, in connection with the Development Program, shall be owned by Incyte. At Incytes request, GHI shall cooperate with Incyte and undertake to execute all such documents and to perform all further acts as may be necessary or convenient to cause all right, title and interest in or to RNA Amplification Technology to vest in Incyte pursuant to this Section 6.3.2.
5.3.3 Ownership Program Technology . Notwithstanding Section 6.2, all right, title and interest to all Program Technology, other than RNA Amplification Technology and Paraffin Extraction Technology, created solely by GHI or Incyte, or jointly by GHI and Incyte, or its employees or agents, in connection with the Development Program (Other Program Technology), shall be jointly owned. Except as expressly provided in this Agreement, it is understood that neither party shall have any obligation to account to the other for profits, or to obtain any approval of the other party to license or exploit Other Program Technology, by reason of joint ownership-of any such Other Program Technology and each party waives any right it may have under the laws of any country to require such accounting or approval.
6. LICENSES
6.1 Development License .
6.1.1 Grant to GHI . Incyte hereby grants to GHI a worldwide, non-sublicenseable, royalty-free, fully paid-up, non-exclusive license under the Incyte Background Technology and the Program Technology owned by Incyte to practice and use the subject matter within the Incyte Background Technology and Program Technology to conduct its activities under the Development Program.
6.1.2 Grant to Incyte . GHI hereby grants to Incyte a worldwide, non-sublicenseable, royalty-free, fully paid-up, non-exclusive license under the Program Technology owned by GHI to practice and use the subject matter within the Program Technology to conduct its activities under the Development Program.
6.1.3 Restriction of Rights . It is understood and agreed that the foregoing licenses shall terminate upon the completion or termination of the Development Program.
6.2 Commercialization Licenses .
6.2.1 GHI License to Incyte . GHI hereby grants to Incyte a worldwide, non-transferable (except as provided in Section 14.6), royalty-free, fully paid-up, non-sublicensable, non-exclusive license under the Paraffin Extraction Technology to research, develop, make, have made, import, use, offer for sale, and sell products for use in the Incyte Field and to conduct internal research.
6.2.2 Incyte Licenses to GHI .
(a) Paraffin Extraction Technology . Incyte hereby grants to GHI a worldwide, non-transferable (except as provided in Section 14.6), royalty-free, fully paid-up, non-sublicensable, non-exclusive license under Incytes Background Technology directed to Paraffin Extraction to practice and use the subject matter within the foregoing to research, develop, make,
Page 11
have made, import, use, offer for sale, and sell products for use in the GHI Database Field of Use, Diagnostic Field of Use, Homebrew Field of Use, and Personal Research Field of Use.
(b) RNA Amplification Technology . Incyte hereby grants to GHI a worldwide, non-transferable (except as provided in Section 14.6), royalty-bearing, non-sublicensable, non-exclusive license under (i) the Incyte Background Technology directed to RNA Amplification and (ii) the RNA Amplification Technology, in each case, to practice and use the subject matter within the foregoing to research, develop, make, have made, import, use, offer for sale, and sell products for use in the GHI Database Field of Use, Diagnostic Field of Use, Homebrew Field of Use, and Personal Research Field of Use.
(c) Research License . Incyte hereby grants to GHI a worldwide, non-transferable (except at provided in Section 14.6), royalty-free, fully paid-up, non-sublicensable, non-exclusive license under the Incyte Background Technology and the Program Technology owned by Incyte to practice and use the subject matter within the Incyte Background Technology and the Program Technology to conduct internal research.
6.3 Retained Rights . No other license or rights, including without limitation any license or right to any other intellectual property owned or controlled by either party, shall be granted or created by implication, estoppel or otherwise. Without limiting the foregoing, it is understood and agreed that no license or right is granted by Incyte to GHI under this Article 6 to practice or use the Program Technology, and/or RNA Amplification Technology, in the Incyte Field. It is also understood and agreed that no license or right is granted by GHI to Incyte under this Article 6 to practice or use the Paraffin Extraction Technology in the GHI Database Field of Use, Diagnostic Field of Use, Homebrew Field of Use, and/or Personal Research Field of Use.
7. IMPROVEMENTS
7.1 Grant to Incyte . Subject to the terms and conditions of this Agreement, GHI hereby grants to Incyte a worldwide, perpetual, irrevocable, fully paid up, royalty-free, non-transferable (except as provided in Section 14.6), non-exclusive license, under the Improvements Controlled by GHI to practice and use the subject matter within such Improvements to research, develop, make, have made, import, use, offer for sale, and sell products, in each case, for use in the Incyte Field.
7.2 Grant to GHI . Subject to the terms and conditions of this Agreement, Incyte hereby grants to GHI a worldwide, perpetual, irrevocable, fully paid up, royalty-free, non-transferable (except as provided in Section 14.6), non-exclusive license under the Improvements Controlled by Incyte to practice and use the subject matter within such Improvements to research, develop, make, have made, import, use, offer for sale, and sell products, in each case, for use in the GHI Database Field of Use, Diagnostic Field of Use, Homebrew Field of Use, and Personal Research Field of Use..
7.3 Retained Rights . No right or license under Intellectual Property of either Party is granted hereunder, other than the licenses expressly granted under Section 3.3, Article 6, and this Article 7. No other license or rights, including without limitation any license or right to any other intellectual property owned or controlled by Incyte or GHI, shall be granted or created by implication, estoppel or otherwise.
Page 12
8. INTELLECTUAL PROPERTY PROSECUTION; DEFENSE AND ENFORCEMENT
8.1 Patent Prosecution .
8.1.1 Paraffin Extraction Technology and Other Program Technology .
(a) Prosecution . GHI shall have the sole right, at GHIs expense, to control the preparation, filing, prosecution and maintenance of any patents or patent applications within the Paraffin Extraction Technology and Other Program Technology, and for conducting any interferences, reexaminations, reissues, oppositions, or request for patent term extensions relating thereto.
(b) GHI Failure to Prosecute . In the event that GHI declines to file or, having filed, declines to further prosecute and maintain any patent applications or patents subject to Section 8.1.1(a) above, GHI shall provide Incyte notice thereof prior to the expiration of any deadline relating to such activities, but in any event at least thirty (30) days prior notice, and Incyte shall have the right to file, prosecute and maintain such patent applications (except for subject matter contained in such pending patent application which GHI has filed, or in good faith intends to file, in a subsequent patent application) or patents in the name of GHI, at Incytes expense, using counsel of its choice.
(c) Cooperation . GHI will keep Incyte reasonably informed and will respond to all reasonable requests for information made by Incyte, with regard to GHIs activities pursuant to Section 8.1.1(a) above as they relate to the Incyte Field.
8.1.2 RNA Amplification Technology .
(a) Prosecution . Incyte shall have the sole right, at Incytes expense, to control the preparation, filing, prosecution and maintenance of any patents or patent applications within the RNA Amplification Technology, and for conducting any interferences, reexaminations, reissues, oppositions, or request for patent term extensions relating thereto.
(b) Incyte Failure to Prosecute . In the event that Incyte declines to file or, having filed, declines to further prosecute and maintain any patent applications or patents subject to Section 8.1.2(a) above, Incyte shall provide GHI notice thereof prior to the expiration of any deadline relating to such activities, but in any event at least thirty (30) days prior notice, and GHI shall have the right to file, prosecute and maintain such patent applications (except for subject matter contained in such pending patent application which Incyte has filed, or in good faith intends to file, in a subsequent patent application) or patents in the name of Incyte, at GHIs expense, using counsel of its choice.
(c) Cooperation . GHI will keep Incyte reasonably informed and will respond to all reasonable requests for information made by Incyte, with regard to GHIs activities pursuant to Section 8.1.2(a) above as they relate to the GHI Database Field of Use, Diagnostic Field of Use, Homebrew Field of Use, and/or Personal Research Field of Use.
Page 13
8.1.3 Improvements .
(a) Improvements . Each Party shall have the sole right, at own expense, to control the preparation, filing, prosecution and maintenance of any patents or patent applications within the Improvements Controlled by such Party, and for conducting any interferences, reexaminations, reissues, oppositions, or request for patent term extensions relating thereto.
(b) Cooperation . Incyte will keep GHI reasonably informed and will respond to all reasonable requests for information made by GHI, with regard to Incytes activities pursuant to Section 8.1.3(a) above. Likewise, GHI will keep Incyte reasonably informed and will respond to all reasonable requests for information made by Incyte with regard to GHIs activities pursuant to Section 8.1.3(a) above as they relate to Incyte Field.
8.2 Infringement Claims . If the manufacture, importation, sale or use of a product utilizing the Program Technology and/or Improvements Controlled by a Party, results in any claim, suit or proceeding alleging patent infringement against GHI or Incyte, such Party shall promptly notify the other Party hereto. The defendant shall keep each other Party hereto reasonably informed of all material developments in connection with any such claim, suit or proceeding.
8.3 Enforcement . In the event that either Party reasonably believes that any Program Technology and/or Improvements Controlled by a Party, is infringed or misappropriated by a third Party or is subject to a declaratory judgment action arising from such infringement in such country, in each case with respect to the development, manufacture, sale or use of a product, such Party shall promptly notify the other Party hereto. Promptly after such notice, the Parties shall meet to discuss the course of action to be taken with respect to an enforcement action with respect to such infringement or misappropriation, including the control thereof and the sharing of costs and expenses related thereto. In connection therewith, (i) GHI shall have the sole right to make decisions regarding the enforcement of the Paraffin Extraction Technology and the Other Program Technology, (ii) Incyte shall have the sole right to make decisions regarding the enforcement of RNA Amplification Technology and the Incyte Background Technology, and (iii) each Party shall have the sole right to make decisions regarding the enforcement of the Improvements Controlled by that Party.
9. CONFIDENTIALITY
9.1 Confidential Information . Except as provided herein, each Party shall maintain in confidence, and shall not use for any purpose or disclose to any Third Party, information disclosed by the other Party in writing and marked Confidential or a similar manner to indicate its confidential nature or that is disclosed orally, identified as confidential at the time of oral disclosure and confirmed in writing as confidential within forty-five (45) days following such disclosure (collectively, Confidential Information). Confidential Information shall not include any information that is: (i) already known to the receiving Party at the time of disclosure hereunder, or (ii) now or hereafter becomes publicly known other than through acts or omissions of the receiving Party, or (iii) is disclosed to the receiving Party by a Third Party under no obligation of confidentiality to the disclosing Party or (iv) independently developed by the receiving Party without reliance on the Confidential Information of the disclosing Party.
Page 14
9.2 Permitted Usage . Notwithstanding the provisions of Section 9.1 above, the receiving Party may use or disclose Confidential Information of the disclosing Party to the extent necessary to exercise the rights granted to it hereunder (provided it uses reasonable efforts to protect such information commensurate with the efforts used to protect its own information) in prosecuting or defending litigation, complying with applicable governmental regulations and/or submitting information to tax or other governmental authorities; provided that if the receiving Party is required by law to make any public disclosures of Confidential Information of the disclosing Party, to the extent it may legally do so, it will give reasonable advance notice to the disclosing Party of such disclosure and will use its reasonable efforts to secure confidential treatment of Confidential Information prior to its disclosure (whether through protective orders or otherwise).
9.3 Confidential Terms/Publicity . Except as expressly provided herein, each Party agrees not to disclose any financial terms of this Agreement to any Third Party without the consent of the other Party, except as required by securities or other applicable laws, or in connection with the registration of securities, in which case the disclosing Party shall seek confidential treatment to the extent available, or to others, under conditions that reasonably protect the confidentiality thereof.
9.4 Publication . The Parties (through their Development Committee members for so long as it exists, and afterward through such representatives as each Party may designate) will cooperate in appropriate publication of the results of research and development work performed pursuant to the Development Program, but subject to the predominating interest to obtain patent protection for any patentable Invention. To this end, it is agreed that prior to any public disclosure of such results, the Party proposing disclosure will send the representatives of the other Party described above a copy of the information to be disclosed, and will allow the other Party thirty (30) days from the date of receipt in which to determine whether the information to be disclosed contains Confidential Information of the reviewing Party which such Party desires to maintain as a trade secret. If notification is not received during the thirty (30) day period, the Party proposing disclosure will be free to proceed with the disclosure. The determination of authorship for any paper will be in accordance with accepted scientific practice.
10. REPRESENTATIONS AND WARRANTIES.
10.1 Representations and Warranties . Each of GHI and Incyte hereby represents, warrants and covenants to the other, as of the Effective Date, as follows:
(a) it is a corporation duly organized and validly existing under the laws of the state of its incorporation;
(b) the execution, delivery and performance of this Agreement by such Party has been duly authorized by all requisite corporate action;
(c) it has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder;
(d) it has the right to grant the rights and licenses granted herein;
Page 15
(e) it has not previously granted, and will not grant during the Term any right, license or interest to a Third Party in conflict with the rights and licenses granted under this Agreement;
(f) the execution, delivery and performance by such Party of this Agreement and its compliance with the terms and provisions hereof to such Partys best knowledge does not conflict with or result in a breach of any of the terms and provisions of or constitute a default under (i) a loan agreement, guaranty, financial agreement, agreement affecting a product or other agreement or instrument binding or affecting it or its property; (ii) the provisions of its charter documents or bylaws; or (iii) any order, writ, injunction or decree of any court or governmental authority entered against it or by which any of its property is bound;
(g) this Agreement constitutes such Partys legal, valid and binding obligation enforceable against it in accordance with its terms subject, as to enforcement, to bankruptcy, insolvency, reorganization and other laws of general applicability relating to or affecting creditors rights and to the availability of particular remedies under general equity principles.
10.2 Disclaimer . Neither Party makes any representation or warranty or guaranty that the Development Program will be successful, in whole or part. INCYTE AND GHI EXPRESSLY DISCLAIM ALL OTHER WARRANTIES OR CONDITIONS, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE WITH RESPECT TO THE CONFIDENTIAL INFORMATION, INCYTE BACKGROUND TECHNOLOGY, INCYTE TECHNOLOGY, PROGRAM TECHNOLOGY AND IMPROVEMENTS, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, VALIDITY OF INTELLECTUAL PROPERTY RIGHTS IN INCYTE BACKGROUND TECHNOLOGY, PROGRAM TECHNOLOGY AND IMPROVEMENTS, OR NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.
11. INDEMNIFICATION
11.1 Incyte . Subject to the requirements in Section 11.3 below, Incyte shall indemnify each of GHI and its directors, officers, and employees of GHI and the successors and assigns of any of the foregoing (each a GHI Indemnitee), and hold each GHI Indemnitee harmless from and against (a) any liabilities, damages, settlements, penalties, fines, expenses or costs (including, without limitation, reasonable attorneys fees and other costs of litigation) arising out of any claim, complaint, suit, proceeding or cause of action against a GHI Indemnitee by a Third Party resulting from (i) Incytes conduct of the Development Program or the use, marketing, sale or distribution of products incorporating Program Technology or GHI Improvements, by Incyte or by Third Parties under authority of Incyte (except to the extent such claim results for any breach by GHI of any of its representations and warranties under Sections 10.1), or (ii) any breach by Incyte of its representations and warranties under Section 10.1 above.
11.2 GHI . Subject to the requirements in Section 11.3 below, GHI shall indemnify each of Incyte and its directors, officers, and employees of Incyte and the successors and assigns of any of the foregoing (each a Incyte Indemnitee), and hold each Incyte Indemnitee harmless from and against (a) any liabilities, damages, settlements, penalties, fines, expenses or costs (including, without limitation, reasonable attorneys fees and other costs of litigation) arising out of any claim,
Page 16
complaint, suit, proceeding or cause of action against a Incyte Indemnitee by a Third Party resulting from (i) GHIs conduct of the Development Program or the use, marketing, sale or distribution of products incorporating Incyte Technology, Program Technology or Incyte Improvements, by GHI or by Third Parties under authority of GHI (except to the extent such claim results for any breach by Incyte of any of its representations and warranties under Sections 10.1), or (ii) any breach by GHI of its representations and warranties under Section 10.1 above.
11.3 Indemnification Procedure . A Party that intends to claim indemnification (the Indemnitee) under this Article 11 shall promptly notify the other Party (the Indemnitor) in writing of any claim, complaint, suit, proceeding or cause of action with respect to which the Indemnitee intends to claim such indemnification (for purposes of this Section 11.3, each a Claim), and the Indemnitor shall have sole control of the defense and/or settlement thereof; provided that the Indemnitee shall have the right to participate, at its own expense, with counsel of its own choosing in the defense and/or settlement of such Claim. The indemnification obligations of the Parties under this Article 11 shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the consent of the Indemnitor, which consent shall not be withheld or delayed unreasonably. The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any such Claim, if prejudicial to its ability to defend such action, shall relieve such Indemnitor of any liability to the Indemnitee under this Article 11, but the omission so to deliver written notice to the Indemnitor shall not relieve the Indemnitor of any liability to any Indemnitee otherwise than under this Article 11. The Indemnitee under this Article 11, and its employees, at the Indemnitors request and expense, shall provide full information and reasonable assistance to Indemnitor and its legal representatives with respect to such Claims covered by this indemnification. It is understood that only Incyte may claim indemnity under this Article 10 (on its own behalf or on behalf of an Incyte Indemnitee), and other Incyte Indemnitees may not directly claim indemnity hereunder. Likewise, it is understood that only GHI may claim indemnity under this Article 10 (on its own behalf or on behalf of a GHI Indemnitee), and other GHI Indemnitees may not directly claim indemnity hereunder.
12. LIMITATIONS ON LIABILITY. IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, OR PUNITIVE DAMAGES INCURRED BY SUCH PARTY ARISING UNDER OR AS A RESULT OF THIS AGREEMENT (OR THE TERMINATION HEREOF) INCLUDING, BUT NOT LIMITED TO, THE LOSS OF PROSPECTIVE PROFITS OR ANTICIPATED SALES, OR ON ACCOUNT OF EXPENSES, INVESTMENTS, OR COMMITMENTS IN CONNECTION WITH THE BUSINESS OR GOODWILL OR OTHERWISE.
13. TERM AND TERMINATION
13.1 Term . The term of this Agreement (the Term) shall commence on the Effective Date and shall expire upon the earlier of: (i) the termination of this Agreement pursuant to this Article 13, or (ii) fifth anniversary of the Effective Date. The Parties may terminate the Development Program prior to the end of the Development Period by mutual written agreement.
13.2 Termination for Breach . Either Party to this Agreement may terminate this Agreement in the event the other Party hereto shall have materially breached or defaulted in the
Page 17
performance of any of its material obligations hereunder, and such default shall have continued for sixty (60) days after written notice thereof was provided to the breaching Party by the non-breaching Party. Any termination shall become effective at the end of such sixty (60) day period unless the breaching Party (or any other Party on its behalf) has cured any such breach or default prior to the expiration of the sixty (60) day period; provided, if the alleged breaching Party disputes in good faith the alleged material breach, the non-breaching Party shall have no right to terminate this Agreement until finally determined hereunder that the Party was in material breach and it has failed to cure such breach.
13.3 Termination for Insolvency . If voluntary or involuntary proceedings by or against a Party are instituted in bankruptcy under any insolvency law, or a receiver or custodian is appointed for such Party, or proceedings are instituted by or against such Party for corporate reorganization or the dissolution of such Party, which proceedings, if involuntary, shall not have been dismissed within sixty (60) days after the date of filing, or if such Party makes an assignment for the benefit of creditors, or substantially all of the assets of such Party are seized or attached and not released within sixty (60) days thereafter, the other Party may immediately terminate this Agreement effective upon notice of such termination.
13.4 Effect of Termination Accrued Rights and Obligations . Termination of this Agreement for any reason shall not release any Party hereto from any liability which, at the time of such termination, has already accrued to the other Party or which is attributable to a period prior to such termination nor preclude either Party from pursuing any rights and remedies it may have hereunder or at law or in equity with respect to any breach of, or default under, this Agreement. It is understood and agreed that monetary damages may not be a sufficient remedy for any breach of this Agreement and that the non-breaching Party may be entitled to injunctive relief as a remedy for any such breach.
13.5 Survival . Sections 3.3, 4.1.1 (with respect to periods prior to termination) 4.1.2, 13.4, and 13.5 and Articles 5, 6, 7, 8, 9, 11 (but only to those claims which arise from acts or omissions that occurred prior to the Effective Date of termination or expiration), 12, and 14 of this Agreement shall survive the expiration or any termination of this Agreement for any reason. Except as otherwise expressly provided in this Section 13.5, all other rights and obligations of the parties shall terminate upon termination of this Agreement.
14. GENERAL
14.1 Governing Law . This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of California without reference to conflict of laws principles.
14.2 Disputes .
14.2.1 Chief Executive Officers . If Incyte and GHI, are unable to resolve any dispute between them, whether in Development Committee deliberations or otherwise, either Incyte or GHI may, by written notice to the other, have such dispute referred to the Chief Executive Officers (or equivalent) of Incyte and GHI, for attempted resolution by good faith negotiations within thirty (30) days after such notice is received.
Page 18
14.2.2 Injunctive Relief . This Section 14.2 shall not be construed to prohibit either Party from seeking preliminary or permanent injunctive relief, restraining order or degree of specific performance in any court of competent jurisdiction to the extent not prohibited by this Agreement. For avoidance of doubt, any such equitable remedies provided under this Section 14.2.3 shall be cumulative and not exclusive and are in addition to any other remedies which either Party may have under this Agreement or applicable law.
14.3 Solicitation of Employees . The Parties acknowledge that the activities contemplated by this Agreement will involve extensive contact among the employees of the Parties, and that information regarding the backgrounds, skills, and terms of employment of such Parties constitute the Confidential Information of the Party who is the employer of each such employee. As a consequence, and as an inducement to each party to enter into the relationship contemplated by this Agreement, the Parties agree that during the term of this Agreement and for a period of one (1) year following any termination or expiration of this Agreement, neither party shall solicit or offer to employ any employee of the other Party who has participated in the Development Program described in Article 2 or the Technology Transfer described in Article 3 without the express written consent of the other Party. The obligations of each Party under this Section 13.3 shall only apply to employees of the other Party for so long as they remain employed by the other Party.
14.4 Implied Obligations . This Agreement sets forth all of the rights and obligations of the parties with respect to the subject matter hereof. Without limiting the foregoing, nothing in this Agreement shall be deemed to prevent either Party from engaging in activities outside of the Development Program, alone or with Third Parties, subject to the restrictions in this Agreement on use of Confidential Information of the other Party and any license limitations herein.
14.5
Notices
. Any notice or report required or permitted to be given or made under
this Agreement by either Party shall be in writing and delivered to the other Party at its address
indicated below (or to such other address as a Party may specify by notice hereunder) by courier or
by registered or certified airmail, postage prepaid, courier service, or by facsimile; provided,
however, that all facsimile notices shall be promptly confirmed, in writing, by registered or
certified airmail, postage prepaid. All notices shall be effective as of the date received by the
addressee.
If to Incyte:
Incyte Genomics, Inc.
3160 Porter Drive
Palo Alto, CA 94304
Attn: Chief Executive Officer
Fax: 650-621-7647
with a copy to:
Incyte Genomics, Inc.
3160 Porter Drive
Palo Alto, CA 94304
Attn: General Counsel
Fax: 650-845-4166
If to GHI:
Genomic Health, Inc.
Page 19
|
101 University Ave., Suite 220 | |||
|
Palo Alto, Ca 94301 | |||
|
Attn: Chief Executive Officer | |||
|
Fax: 650-322-8124 | |||
|
||||
|
with a copy to: | Pillsbury Winthrop, LLP | ||
|
50 Fremont Street | |||
|
San Francisco, CA 94105 | |||
|
Attention: Stan Wong, Corporate Counsel. | |||
|
Fax: (415) 983-1200 |
14.6 Assignment . Neither Party may assign this Agreement without the prior written consent of the other Party, such consent not to be unreasonably withheld; provided, that each Party may assign this Agreement to a person or entity that acquires all or substantially all of the business or assets of that Party (or that portion thereof to which this Agreement pertains), in each case whether by merger, acquisition, operation of law or otherwise, provided that such assignee agrees in writing to be bound by the terms and conditions of this Agreement. Any purported assignment in violation of this Agreement will be null and void. Subject to the foregoing, the provisions of this Agreement shall apply to and bind the successors and permitted assigns of the parties. Upon a permitted assignment of this Agreement, all references to the assigning Party shall be deemed references to the assignee.
14.7 Headings . Headings included herein are for convenience only, do not form a part of this Agreement and shall not be used in any way to construe or interpret this Agreement.
14.8 Non-Waiver . Any waiver of the terms and conditions hereof must be explicitly in writing. The waiver by either of the parties of any breach of any provision hereof by the other shall not be construed to be a waiver of any succeeding breach of such provision or a waiver of the provision itself.
14.9 Severability . If any provision hereof should be held invalid, illegal or unenforceable in any jurisdiction, the parties shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the parties and all other provisions hereof shall remain in full force and effect in such jurisdiction and shall be liberally construed in order to carry out the intentions of the parties hereto as nearly as may be possible. Such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such provision in any other jurisdiction. In the event a Party seeks to avoid a provision of this Agreement by asserting that such provision is invalid, illegal or otherwise unenforceable, the other Party shall have the right to terminate this Agreement upon sixty (60) days prior written notice to the asserting Party, unless such assertion is eliminated and cured within such sixty (60)-day period.
14.10 Independent Contractors . The relationship of GHI and Incyte established by this Agreement is that of independent contractors. Nothing in this Agreement shall be construed to create any other relationship between GHI and Incyte. Neither Party shall have any right, power or
Page 20
authority to assume, create or incur any expense, liability or obligation, express or implied, on behalf of the other.
14.11 Modification . No amendment or modification of any provision of this Agreement shall be effective unless in writing signed by all parties hereto.
14.12 Entire Agreement . The terms and provisions contained in the Agreement, including the Exhibits hereto, constitute the entire agreement between the parties and shall supersede all previous communications, representations, agreements or understandings, either oral or written, between the parties. No agreement or understanding varying or extending this Agreement shall be binding upon either Party hereto, unless set forth in a writing which specifically refers to the Agreement signed by duly authorized officers or representatives of the respective parties, and the provisions hereof not specifically amended thereby shall remain in full force and effect.
14.13 Counterparts . This Agreement may be executed in counterparts, each of which shall be deemed an original, but which together shall constitute one and the same instrument.
IN WITNESS WHEREOF , the parties hereto have caused their duly authorized representatives to execute this Agreement.
GENOMIC HEALTH, INC. | INCYTE GENOMICS, INC. | ||||||
|
|||||||
By:
|
/s/ Randy Scott | By: | /s/ Lee Bendekgey | ||||
|
|||||||
|
|||||||
Name:
|
Randy Scott | Name: | Lee Bendekgey | ||||
|
|||||||
|
|||||||
Title:
|
CEO | Title: | EVP and General Counsel | ||||
|
Page 21
Exhibit 10.7.2
*** Confidential Treatment Requested. Confidential portions of this document have been
redacted and have been separately filed with the Commission.
AMENDMENT TO COLLABORATION AND TECHNOLOGY TRANSFER AGREEMENT
This Amendment to Collaboration and Technology Transfer Agreement (the Collaboration Amendment) effective as of December 21, 2001 (the Amendment Effective Date), is entered into by and between Incyte Genomics, Inc., a Delaware corporation, with a place of business at 3160 Porter Drive, Palo Alto, CA 94304 (Incyte) and Genomic Health, Inc., a Delaware corporation, with a place of business at 301 Penobscot Drive, Redwood City, CA 94063 (GHI).
A. | WHEREAS, the parties to this Collaboration Amendment entered into that certain Collaboration and Technology Transfer Agreement executed on March 30, 2001 by Incyte and GHI (the Agreement), pursuant to which the Parties were to collaborate on research and development relating to Paraffin Extraction Technology (as defined in the Agreement) and grant each other certain rights and licenses on the terms set forth therein. |
B. | WHEREAS, the Parties wish to enter into an amendment to the Agreement in order to terminate such collaboration and amend the Agreement prior to terminating the Agreement. |
NOW THEREFORE, for and in consideration of the covenants, conditions, and undertakings hereinafter set forth it is agree by and between the parties as follows:
1. | All capitalized terms not defined in this Collaboration Amendment shall have the meanings given to them in the Agreement. | |||
2. | Section 1.14 is amended in its entirety to read as follows: | |||
Incyte Technology shall mean any protocols, training materials and computer software listed in Exhibit A to this Agreement and associated source code (specifically including the GEMtools client, Material Manager, GEM Explorer, and Online Courier packages), in the form used by Incyte in connection with the conduct of microarray fabrication and gene expression service businesses in Fremont, California and St. Louis, Missouri, as of the date of the technology transfer activities described in Article 3 of this Agreement, which relate to (a) sample storage and tracking; (b) LIMS systems; (c) microarray manufacturing protocols; (d) hybridization protocols; (e) quality control and quality assurance protocols; (f) microarray scanning protocols; and (g) data analysis. | ||||
3. | Incyte shall deliver all Incyte Technology to GHI by December 31, 2001 and GHI shall consider such delivery complete under the terms of this agreement. | |||
4. | The Development Program is hereby terminated as of the Amendment Effective Date, including without limitation all obligations of either Party under Section 2.1 and 2.2 of the Agreement. | |||
5. | Within thirty (30) days after the Amendment Effective Date, each Party shall disclose to the other Party in reasonable detail all inventions conceived and/or reduced to practice by such Party in connection with the Development Program. | |||
6. | Section 3.2 of the Agreement is deleted in its entirety. | |||
7. | The first sentence of Section 4.1.1 of the Agreement is amended to read as follows: |
1 of 2
*** Confidential material redacted and filed separately with the Commission.
Funding . In full consideration for Incytes undertaking the Development Program, GHI shall pay to Incyte *** Dollars ($***). GHI shall pay the foregoing amount in equal quarterly installments during the 2002 calendar year, with each such payment due during the first ten (10) business days of each such quarter. | ||||
8. | The first sentence of Section 4.2 of the Agreement is amended to read as follows: | |||
Technology Transfer Payment . In full consideration for the disclosure and transfer of the Incyte Technology pursuant to Section 3.1, and the rights and licenses granted to GHI under Section 3.3, GHI shall pay to Incyte *** Dollars ($***). GHI shall pay the foregoing amount in equal quarterly installments during the 2002 calendar year, with each such payment due during the first ten (10) days of each such quarter. | ||||
9. | Except as specifically modified or amended hereby, the Agreement shall remain in full force and effect and, as modified or amended, is hereby ratified, confirmed and approved. No provision of this Collaboration Amendment may be modified or amended except expressly in a writing signed by both parties nor shall any terms be waived except expressly in a writing signed by the party charged therewith. This Collaboration Amendment shall be governed in accordance with the laws of the State of California, without regard to principles of conflicts of laws. |
IN WITNESS WHEREOF, each of the parties has executed this Collaboration Amendment as of the Amendment Effective Date.
INCYTE GENOMICS, INC. | GENOMIC HEALTH, INC | ||||||
|
|||||||
By:
|
/s/ Lee Bendekgey | By: | /s/ Randy Scott | ||||
|
|||||||
|
|||||||
Name:
|
Lee Bendekgey | Name: | Randy Scott | ||||
|
|||||||
Title:
|
EVP & General Counsel | Title: | CEO |
2 of 2
Exhibit 10.8
*** Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission.
PCR
BY AND BETWEEN
Roche Molecular Systems, Inc.
AND
Genomic Health, Inc.
PATENT LICENSE AGREEMENT
(HUMAN)
CONTENTS
Page | ||||
Background
|
2 | |||
|
||||
Section 1
|
Definitions | 3 | ||
|
||||
Section 2
|
Grant | 5 | ||
|
||||
Section 3
|
Additional Limitations & Acknowledgment re Diagnostic Products | 6 | ||
|
||||
Section 4
|
Royalties, Records and Reports | 6 | ||
|
||||
Section 5
|
Technology Notification | 8 | ||
|
||||
Section 6
|
Diligence | 8 | ||
|
||||
Section 7
|
Term and Termination | 9 | ||
|
||||
Section 8
|
Confidentiality-Publicity | 10 | ||
|
||||
Section 9
|
Compliance | 11 | ||
|
||||
Section 10
|
Assignment | 12 | ||
|
||||
Section 11
|
Negation of Warranties and Indemnity | 12 | ||
|
||||
Section 12
|
General | 13 |
Attachments:
|
||
|
||
Attachment I
|
List of Licensed Technology | |
|
||
Attachment II
|
Combination Services | |
|
||
Attachment III
|
Summary Royalty Report Form | |
|
||
Attachment IV
|
Collection Rate |
1
PATENT LICENSE AGREEMENT
. (Human)
This Agreement is made by and between
Roche Molecular Systems, Inc., 4300 Hacienda Drive, Pleasanton, California 94588
and
Genomic Health, Inc., 301 Penobscot Drive, Redwood City, California 94604
hereafter individually referred
********
BACKGROUND
A. | RMS owns and has the right to grant licenses to practice under certain United States Patents describing and claiming, inter alia, nucleic acid amplification processes known as polymerase chain reaction (PCR), homogeneous PCR, and RT-PCR (reverse transcription PCR). | |||
B. | GH desires to obtain a non-exclusive license from RMS to use the Licensed Technology to perform certain PCR-based human in vitro clinical laboratory services, and RMS is willing to grant such a license to GH on the terms and subject to the conditions provided exclusively in this Agreement. |
NOW, THEREFORE, for and in consideration of the mutual covenants contained herein, RMS and GH agree as follows:
1. | Definitions |
For the purpose of this Agreement, and solely for that purpose, the terms set forth hereinafter shall be defined as follows:
1.1 | The term Affiliate shall mean with respect to a given Party: |
a) | an organization which, directly or indirectly, controls such Party; | |||
b) | an organization which is, directly or indirectly, controlled by such Party; or | |||
c) | an organization which is controlled, directly or indirectly, by the ultimate parent company which controls, directly or indirectly, such Party. |
For purposes of this paragraph, control shall mean the ownership of fifty percent (50%) or more of the voting stock or equity interests of an organization or otherwise having the power to govern or direct the financial and the operating policies or to appoint the management of such organization. | ||||
With respect to RMS, the term Affiliate shall not include Genentech, Inc., 1 DNA Way, South San Francisco, California 94080-4990, U.S.A. (Genentech) nor Chugai Pharmaceutical Co., Ltd, 1-9, Kyobashi 2-chome, Chuo-ku, Tokyo, 104-8301 Japan (Chugai). | ||||
1.2 | Combination Service shall mean a Licensed Service offered in combination with another non-PCR testing service or together with a non-testing service(s) such as a specialized interpretive service or a consultative service (e.g., genetic counseling) as part of a package, where the Licensed Service is not separately billed. | |||
1.3 | Diagnostic Product shall mean an assemblage of reagents, including but not limited to reagents packaged in the form of a kit, useful in performing a Licensed Service. | |||
1.4 | Effective Date shall mean the date on which the last signatory to this Agreement signs this Agreement. | |||
1.5 | Licensed Field shall mean the field of clinical laboratory services that detect the presence, absence and/or quantity of a nucleic acid sequence for the detection, diagnosis, confirmation, prognosis, management and/or treatment of a human disease or condition, including, but not limited to, such services: to identify predisposition to disease, disease susceptibility, confirm disease, predict therapeutic effectiveness or monitor disease progress; used in the course of human clinical trials; for Parentage Determination; and for tissue transplant typing, including testing performed on animal tissue intended for use in xenotransplantation. Licensed Field shall specifically exclude any services performed for the screening of blood and/or blood products. |
2
1.6 | Licensed Service(s) shall mean the performance by GH of an in vitro procedure within the Licensed Field which utilizes the Licensed Technology. Licensed Services include, but are not limited to, any combination of the steps of collecting a sample for analysis, isolating nucleic acid sequences from the sample, amplifying one or more desired sequences, analyzing the amplified material, including sequence analysis, and reporting the results. | |||
1.7 | Licensed Technology shall mean, subject to the following limitations, the Valid Claims of the United States patents listed in Attachment I to this Agreement and any reissue or reexamination patents thereof. No rights under any kit claims of such patents are included in this definition or licensed under this Agreement. With the exception of the reaction mixture claims of United States Patents Nos. 5,804,375, 5,693,517, 5,476,774 and 6,127,155, the plasmid claims of the 5,476,774 patent, the primer claims of United States Patent No. 5,573,906, and the probe claims of United States Patent No. 5,110,920, no rights under any apparatus, device, composition of matter, reagent or substance claims of such patents are included in this definition or licensed under this Agreement. | |||
1.8 | Net Service Revenues shall mean the gross invoice price for the Licensed Services performed by GH (or the fair market value for any nonmonetary consideration which GH agrees to receive in exchange for Licensed Services), less the following deductions where they are factually applicable and are not already reflected in the gross invoice price: |
a) | discounts allowed and taken, in amounts customary in the trade (which shall include the difference between the dollar amount charged by GH for a Licensed Service and the Medicare and/or Medicaid Limits of Allowance and/or reimbursement limitations of a Third Party insurance program); and | |||
b) | actual bad debt which bad debt GH can prove and document that it was reasonable and diligent in its efforts to collect payment. |
1.8.1
The Net Service Revenues of those Licensed Services that are
performed by GH for any person, firm or corporation controlling, controlled by
or under common control with GH, or enjoying a special course of dealing with
GH, shall be determined based on the average selling price of such Licensed
Services to all Third Parties during the period in question.
1.8.2
It is hereby understood and agreed that, to the extent feasible,
Licensed Services and Combination Services shall at all times be invoiced,
listed and billed by GH as
.
a separate item in GHs invoices, bills
and reports to customers. Net Service Revenues for determining royalties with
respect to a Licensed Service which is part of a Combination Service shall be
determined by multiplying the gross invoice price of the Combination Service,
less applicable deductions, by the appropriate fraction in Attachment II hereto.
The fraction specified in Attachment II for a particular Licensed Service
included in a Combination Service shall be set by RMS after consultation
3
with GH, as accurately reflecting the value contributed by the Licensed Service to the overall value of the Combination Service as offered by GH, and as provided in Section 2.4. Attachment II hereto shall be modified as new Combination Services are identified and new royalty-bearing fractions set, and as set forth in Section 2.4. |
1.9
Parentage Determination
shall mean analysis of human genetic material to ascertain
whether two or more individuals are biologically related, but specifically excludes analysis
of forensic evidence for a sexual assault investigation.
1.10
Territory
shall mean the United States and its possessions and the Commonwealth of Puerto
Rico.
1.11
Third Party
shall mean an entity other than an Affiliate of either Party to this
Agreement.
1.12
"
Valid Claim
shall mean a claim of a patent which has not expired or been disclaimed,
cancelled, held invalid or held unenforceable by a decision of a court or other governmental
agency of competent jurisdiction, from which no further appeal is possible or has
been taken within the time period provided under applicable law for such an appeal.
2.
Grant
2.1
Grant
. Upon the terms and subject to the conditions and restrictions of this
Agreement, RMS hereby grants to GH, and GH hereby accepts from RMS, a royalty-bearing,
non-exclusive, personal, non-transferable license under the Licensed Technology solely to
perform Licensed Services within the Territory.
2.2
Performance of Licensed Services Only
. The Licensed Technology may be used solely
for the performance of Licensed Services and for no other purpose whatsoever, and no other
right, immunity or license is granted to GH expressly, impliedly or by estoppel.
2.3
Personal License
. GH expressly acknowledges and agrees that the license granted
hereunder is personal to GH alone and GH shall have no right to sublicense, assign or
otherwise transfer or share its rights under the foregoing license.
2.4
Combination Service(s)
. For each Combination Service that GH intends to offer
pursuant to this Agreement, and at least sixty (60) days before GH intends to offer any such
Combination Service, GH shall:
a)
notify RMS of such proposed Combination Service, such notice to include a
complete and detailed description of the proposed Combination Service; and
b)
obtain from RMS a duly authorized agreement, in the form of Attachment II
hereto, for such Combination Service, which agreement shall indicate the fraction or
4
*** Confidential material redacted and filed separately with the Commission.
percentage of the package price of such Combination Service, less appropriate deductions, on which royalties shall be paid hereunder. |
For any Combination Service(s) for which GH has not satisfied the criteria set forth in subsections (a) and (b) above, the royalty payable on such Combination Service shall be assessed on 100% of the package price of such Combination Service, less applicable deductions. As to all other Licensed Services offered by GH which are not part of a Combination Service, GH agrees to inform RMS of the availability from GH of each such Licensed Service within thirty (30) days after GH commences offering the Licensed Service. | ||||
2.5 | Credit for Licensed Technology Rights . RMS hereby grants to GH the right and GH accepts and agrees to credit RMS as the source of its Licensed Technology rights in GHs promotional materials and any other materials intended for distribution to Third Parties as follows: | |||
This service is performed pursuant to an agreement with Roche Molecular Systems, Inc. | ||||
3. | Additional Limitations and Acknowledgment Regarding Diagnostic Products |
GH acknowledges and agrees that the license rights granted hereunder are for the performance of Licensed Services only and do not include any right to make, have made, import, offer to sell or sell any products, including apparatuses, devices, PCR reagents, kits or Diagnostic Products. GH further acknowledges and agrees that RMS and its Affiliates are in the business of providing clinical laboratory testing services and the commercial sale of diagnostic testing systems, kits and reagents and therefore may compete directly with GHs business.
4. | Royalties, Records and Reports | |||
4.1 | Royalties . For the rights and privileges granted under Section 2.1 of this Agreement, GH shall pay to RMS royalties equal to *** percent (***%) of GHs Net Service Revenues. | |||
No royalty is due on PCR-based assays performed solely for the purpose of evaluating a procedure to be used as a Licensed Service after validation. | ||||
No royalty is due on assays performed with Roche labeled diagnostic kits or Third Party diagnostics kits licensed by Roche, which convey human diagnostic label license rights to end users. | ||||
4.2 | Reports . GH shall deliver to RMS, within forty-five (45) days after the end of and for each quarterly calendar period during the Term, i.e. the three (3) month periods that are January 1 through March 31, April 1 through June 30, July 1 through September 30, and October 1 through December 31 (each a Reporting Period), a true and accurate royalty report (Royalty Report). Each Royalty Report shall indicate the number of Licensed Services performed during the relevant Reporting Period and the detail specified on the Summary |
5
Royalty Report, a copy of which is attached hereto as Attachment III, or on a form generated by GH which duplicates the format of the Summary Royalty Report. If no royalties are due for a given Royalty Period, it shall be so reported. The correctness and completeness of each Royalty Report shall be attested to in writing by an authorized representative of GH. | ||||
In the event GH is unable to calculate Net Service Revenues as prescribed in Section 1.8, GH shall so inform RMS, and upon RMSs written consent, GH shall calculate royalties as follows: | ||||
Upon receipt by RMS of satisfactory documentation verifying GHs actual percentage of gross billings for Licensed Services and/or Combination Services collected for GHs most recently ended fiscal year (the Collection Rate), subject to the provisions of Section 2.4 above, GH shall be permitted to calculate Net Service Revenues taking into account the Collection Rate. As of the Effective Date, GH hereby represents and confirms to RMS that its Collection Rate for its fiscal year ending NA was NA percent ( NA %), which rate is specified in Attachment IV. During the Term of this Agreement, and within ninety (90) days after the end of each GH fiscal year, GH shall deliver to RMS satisfactory documentation that verifies the then Collection Rate. If GHs Collection Rate varies by at least five percent (5%) from the rate stated in Attachment IV, RMS shall amend Attachment IV accordingly. Should GH fail to provide the required updated documentation, GH shall calculate Net Service Revenues and royalties due as prescribed in Sections 1.8 and 2.4 for the remaining Term of the Agreement. | ||||
Simultaneously with the delivery of each Royalty Report, GH shall pay to RMS the royalty due under this Agreement for the period covered by such report. All payments due RMS hereunder shall be payable in United States currency and sent together with the Royalty Report by the due date to the following address: |
|
Roche Molecular Systems, Inc. | |
|
P.O. Box 100858 | |
|
Pasadena, CA 91189-0858 |
or to any other address that RMS may advise in writing.
4.3 | Inspection . Within ten (10) days after RMSs written request to GH, RMS or an accounting firm selected by RMS (including, but not limited to, RMSs normal certified public accounting firm), may, at RMS s own expense (except as provided below), inspect the records, books of account and any other materials of GH pertaining to the Royalty Reports, including without limitation any documentation supporting the royalty reports, required in Section 4.2 above, provided that any accounting firm will hold such records in strict confidence, except as necessary to report to RMS and GH on GHs compliance with the terms, conditions and restrictions of this Agreement. If such an inspection shows an underpayment by GH to RMS by more than ten percent (10%) for any Reporting Period, GH will pay, in addition to the amount due, plus interest, the accounting firms reasonable fees and expenses. |
6
4.4 | Prior Licensed Services . Licensed Services performed by GH prior to execution of this Agreement shall be subject to the royalties described in this Agreement and shall be reported and due to RMS with the first Royalty Report due provided under Section 4.2. Provided, however, that where this Agreement replaces an existing license agreement, the royalty obligations of GH under this Agreement commence the first day of the month in which this Agreement is executed. | |||
4.5 | Past Due Amounts Bear Interest . If GH shall fail to pay any amount specified under this Agreement after the due date thereof, the amount owed shall bear interest at the lower of (i) the Citibank, N.A. base lending rate (aka, the Prime Rate), or (ii) the maximum rate allowed by applicable law, from the due date until paid. | |||
4.6 | Survival . The provisions of this Section 4 shall survive any termination or expiration of this Agreement. | |||
5. | Technology Notification | |||
5.1 | Notification. With respect to any invention, improvement or discovery (hereinafter referred to as Discoveries in this Section) of GH made after entering into this Agreement and resulting from work conducted under or in conjunction with this Agreement and being applicable to the Licensed Technology, if GH decides to license said Discoveries to Third Parties, then GH agrees to provide to RMS, unless not possible due to GHs pre-existing commitments to Third Parties relating to said Discoveries, a reasonable opportunity to negotiate a license to use said Discoveries in PCR-based Diagnostic Products and services. In such event, GH will provide written notice to RMS and GH and RMS will negotiate in good faith for a period not to exceed six (6) months from the date of receipt by RMS of such notice, reasonable commercial terms for such a license. If notwithstanding the good faith efforts of the parties to reach agreement upon such terms, the parties are unable to agree within such six (6) month period, then neither party will have any liability to the other for failure to agree. Such Discoveries may include, but are not limited to, improvements of the Licensed Technology or in the performance of Licensed Services, modifications to or new methods of performing the Licensed Services, including the automation of the PCR process or of the Licensed Services. | |||
5.2 | Agreement re Discovery . Any agreement reached between The Parties as a result of GHs notification to RMS of a Discovery pursuant to Section 5.1 hereto shall be upon terms and conditions negotiated in good faith by The Parties. | |||
6. | Diligence . | |||
GH shall exercise reasonable diligence in developing, testing, validating, documenting, promoting and performing the Licensed Services. In the course of such diligence, GH shall implement appropriate procedures and take appropriate steps including, upon reasonable written request of RMS, furnishing RMS with representative copies of all promotional material relating to the Licensed Services. |
7
7. | Term and Termination | |||
7.1 | Term of Agreement . This Agreement shall commence on the Effective Date and, unless terminated earlier as provided herein, shall terminate on the date of expiration of the last to expire of the patents included within the -Licensed Technology, which patent contains at least one Valid Claim covering the performance of a Licensed Service. | |||
7.2 | GH Termination for Convenience . Notwithstanding any other Section of this Agreement, GH may terminate this Agreement for any reason on thirty (30) days written notice to RMS. | |||
7.3 | Termination for Change of Control, Etc . RMS shall have the right to terminate this Agreement and the license rights granted herein immediately upon written notice to GH upon any change in the ownership or control of GH or of its assets or in the event GH breaches the provisions of Section 10 below. For such purposes, a change in ownership or control shall mean that 50% or more of the voting stock of GH becomes subject to the control of a person or entity, or any related group of persons or entities acting in concert, which person(s) or entity(ies) did not control such proportion of voting stock as of the Effective Date of the Agreement. Without limiting the foregoing, RMS shall have the right to terminate this Agreement upon any transfer or sale of 50% or more of the assets of GH to another party. | |||
7.4 | Termination for Insolvency, Etc . This Agreement and the license rights granted hereunder to GH shall automatically terminate upon: (a) an adjudication of GH as bankrupt or insolvent, or GHs admission in writing of its inability to pay its obligations as they mature; or (b) an assignment by GH for the benefit of creditors; or (c) GHs applying for or consenting to the appointment of a receiver, trustee or similar officer for any substantial part of its business or property, or such a receiver, trustee or similar officers appointment without the application or consent of GH, if such appointment shall continue in effect for a period of ninety (90) days; or (d) GHs instituting (by petition, application, answer, consent or otherwise) any bankruptcy, insolvency arrangement or similar proceeding relating to GH or its business or property under the laws of any jurisdiction; or (e) the institution of any such proceeding (by petition, application, answer, consent or otherwise) against GH, if such proceeding shall remain in effect for a period of ninety (90) days; or (f) the issuance or levy of any judgment, writ, warrant of attachment or execution or similar process against a substantial part of the property of GH, if such judgment, writ, or similar process shall not be released, vacated or fully bonded within ninety (90) days after its issue or levy; or (g) the loss of GHs federal or state licenses, permits or accreditation necessary for the operation of GH as a health care institution. | |||
7.5 | Termination for Change of Status . If GH is a government institution or a non-profit entity, this Agreement and the license rights granted to GH herein shall automatically terminate within thirty (30) days of GHs reclassification as a non-government institution, or as a for-profit entity pursuant to the applicable provisions of the United States Internal Revenue |
8
Code, 26 U.S.C. Upon such termination, GH may request a new license pursuant to the same terms and conditions then being offered to other for-profit institutions, although RMS is not obligated by anything contained in this Agreement to grant such a license. | ||||
7.6 | Termination for Breach. Upon any breach of or default by GH of a material term under this Agreement, RMS may terminate this Agreement upon thirty (30) days written notice to GH. Said termination shall become effective at the end of the thirty-day period, unless during said period GH fully cures such breach or default. | |||
7.7 | Effects of Termination . Upon termination of this Agreement as provided herein, all license rights and immunities granted to GH hereunder shall terminate and revert to or be retained by RMS. To the extent RMS has licensed technology or know-how of GH pursuant to Section 5 hereto; those licenses shall remain in force according to their terms. Other provisions of this Agreement which by their nature would reasonably be expected to survive termination shall so survive. Termination of this Agreement shall not relieve either Party from any duty or obligation that had accrued prior to termination. Each Party shall retain all of its rights and remedies in respect of any breach or default by the other party of the terms, conditions and provisions of this Agreement. | |||
7.8 | Duty to Report and Pay Royalties Survives . GHs obligations to report to and pay royalties to RMS as to the Licensed Services performed under the Agreement prior to termination or expiration of the Agreement shall survive such termination or expiration. | |||
8. | Confidentiality-Publicity | |||
8.1 | Publicity . Except as otherwise specifically provided in Section 2.5, GH agrees to obtain RMSs written approval before distributing any written information, such as a press release, to Third Parties which contains references to RMS or this Agreement, with the exception of filings required by securities law whether in connection with issuance of securities or otherwise. RMSs approval shall not be unreasonably withheld or delayed and, in any event, RMSs decision shall be rendered within three (3) weeks of receipt of the written information. Once approved, such materials, or abstracts of such materials, which do not materially alter the context of the material originally approved may be reprinted during the Term of the Agreement without further approval by RMS unless RMS has notified GH in writing of its decision to withdraw permission for such use. | |||
8.2 | Confidentiality Obligations . Each Party agrees that any financial, legal or business information or any technical information marked Confidential or Proprietary and disclosed to it (the Receiving Party) by the other (the Disclosing Party) in connection with this Agreement, shall be considered the confidential and proprietary information of the Disclosing Party, and the Receiving Party shall not disclose same to any Third Party and shall hold it in confidence for a period of five (5) years and will not use it other than in the performance of this Agreement, provided, however, that any information, know-how or data which is orally disclosed to the Receiving Party shall not be considered confidential and |
9
proprietary unless such oral disclosure is stated to be confidential or proprietary prior to disclosure and is reduced to writing and given to the Receiving Party in written form within thirty (30) days after the oral disclosure thereof. Such confidential and proprietary information shall include, without limitation, marketing and sales information, commercialization plans and strategies, research and development work plans, and technical information such as patent applications, inventions, trade secrets, systems, methods, apparatus, designs, tangible material, organisms and products and derivatives thereof. |
8.3 | Exceptions . The above obligations of confidentiality and restrictions on use shall not be applicable to the extent: |
a) | such information is general public knowledge or, after disclosure hereunder, becomes general or public knowledge through no fault of the Receiving Party; | |||
b) | such information can be shown by the Receiving Party by its written records to have been in its possession, with no obligation of confidentiality to a Third Party, prior to receipt thereof hereunder; | |||
c) | such information is received by the Receiving Party from any Third Party for use or disclosure by the Receiving Party without any obligation of confidentiality or restriction on use, provided, however, that information received by the Receiving Party from any Third Party funded by the Disclosing Party (e.g. consultants, subcontractors, etc.) shall not be released from confidentiality under this exception; | |||
d) | such information was independently developed by the Receiving Party without use of the information of the Disclosing Party; or | |||
e) | the disclosure of such information is required or desirable to comply with or fulfill applicable law or court process, governmental requirements, submissions to governmental bodies, or the securing of regulatory approvals. |
8.4 | Confidentiality of Agreement . Each Party shall, to the extent reasonably practicable, maintain the confidentiality of this Agreement and its provisions and shall refrain from making any public announcement or disclosure of the terms of this Agreement without the prior written consent of the other Party, except to the extent a Party concludes in good faith that such disclosure is required under applicable law or regulations, in which case the other Party shall be notified in advance. The Parties hereby acknowledge that this Agreement may be deemed a material agreement by GH, and accordingly must be disclosed in an appropriate public filing or filings with the Securities and Exchange Commission, and/or other regulatory agencies, including on Forms 8-K, 10-Q and 10-K. Furthermore, The Parties acknowledge and agree that GH may file the text of this Agreement in conjunction with such regulatory filings. GH agrees to take reasonable measures to seek confidential treatment of the Agreement in such filings, and redact certain provisions, including the |
10
removal of the royalty rate, as appropriate. No further prior notification to RMS shall be required by GH under this Section 8.4 | ||||
9. | Compliance with Law |
In exercising any and all rights and in performing its obligations hereunder, GH shall comply fully with any and all applicable laws, regulations and ordinances and shall obtain and keep in effect all applicable licenses, permits and other governmental approvals, whether at the federal, state or local levels, necessary or appropriate to perform the Licensed Services and carry on its activities hereunder and GH hereby agrees to defend, indemnify and hold RMS and its Affiliates harmless from and against any and all liability, demands, damages, expenses (including attorneys and experts fees) and losses suffered or incurred by RMS or its Affiliates arising from, resulting from or otherwise concerning any breach by GH of its obligations under this Section 9. GH further agrees to refrain from any activities that would have an adverse effect on the business reputation of RMS. RMS may advise GH of any such activities and GH will have thirty (30) days to correct any such activity.
10. | Assignment |
This Agreement shall not be assigned or transferred by GH (including by merger, operation of law or in any other manner including, without limitation, any purported assignment or transfer that might arise from a sale or transfer of GHs business or assets) without the express written consent of RMS. RMS may assign all or any part of its rights and obligations under this Agreement at any time without the consent of GH. GH agrees to execute such further acknowledgments or other instruments as RMS may reasonably request in connection with any such assignment.
11.
Negation of Warranties and Indemnity
11.1
Nothing in this Agreement shall be construed as:
a)
a warranty or representation by RMS as to the validity or scope of
any patent included within the Licensed Technology;
b)
a warranty or representation that the use of the Licensed
Technology and/or the performance of Licensed Services are or will be free from
infringement of patents of Third Parties;
c)
an obligation to bring or prosecute actions or suits against Third
Parties for infringement; or
d)
conferring by implication, estoppel or otherwise any license, right
or immunity under any patents or patent applications of RMS other than those
patents specified in Licensed Technology, regardless of whether such other
11
patents and patent applications are dominant or subordinate to the patents in Licensed Technology. |
12
11.2
RMS MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE OR NON-INFRINGEMENT.
11.3
GH shall assume full responsibility for its use of the Licensed Technology and shall defend,
indemnify and hold RMS and its Affiliates harmless from and against all liability, demands,
damages, expenses (including attorneys and experts fees) and losses for death, personal
injury, illness, errors, property damage or any other injury or damage, including any damages
or expenses arising in connection with state or federal regulatory action (collectively
Damages), arising or resulting from or otherwise concerning the use by GH, including its
officers, directors, agents and employees, of the Licensed Technology or the performance of
the Licensed Services except, and only to the extent, that such Damages are caused solely by
the negligence or willful misconduct of RMS.
12.
General
12.1
Entire Agreement
. This Agreement constitutes the entire agreement between The
Parties as to the subject matter hereof, and all prior negotiations, representations,
agreements and understandings are merged into, extinguished by and completely expressed by it.
This Agreement may be modified or amended only by a writing executed by an authorized officer
of each of The Parties.
12.2
Notice
. Any notice required or permitted to be sent hereunder shall be given by hand
delivery, by registered, express or certified mail, return receipt requested, postage prepaid,
or by nationally recognized private express courier or by confirmed facsimile to the other
Party at the address listed below, or to such other addresses of which a Party may so notify
the other. Notices will be deemed given when hand delivered if by hand delivery, or when
received if by any other authorized method.
Roche Molecular Systems, Inc.
1145 Atlantic Avenue, Suite 100
Alameda, California 94501
Attn: Licensing Department
Roche Molecular Systems, Inc.
1145 Atlantic Avenue, Suite 100
Alameda, California 94501
Attn: Sr. Vice President, General Counsel
12.3 | No Conflict with Law . Nothing in this Agreement shall be construed so as to require the commission of any act contrary to law, and wherever there is any conflict between any provision of this Agreement or concerning the legal right of The Parties to enter into this Agreement and any statute, law, ordinance or treaty, the latter shall prevail, but in such event the affected provisions of the Agreement shall be curtailed and limited only to the extent necessary to bring it within the applicable legal requirements. In any event, all other provisions of this Agreement shall be deemed valid and enforceable to the fullest extent possible. | |||
12.4 | Superceding Agreement . Concurrent with the execution of this Agreement, and effective as of the Effective Date herein, the Expanded PCR Diagnostic Services Agreement effective October 1, 2002, is hereby superceded and replaced in its entirety by this Agreement. |
IN WITNESS WHEREOF, The Parties hereto have set their hands and seals and duly executed this Agreement on the date(s) indicated below, to be effective as of the Effective Date as defined herein.
Roche Molecular Systems, Inc. | Genomic Health, Inc. | |||||||||
|
||||||||||
By:
|
/s/ Melinda Griffith | By: | /s/ Randy Scott | |||||||
|
||||||||||
|
||||||||||
Name:
|
Melinda Griffith | Name: | Randy Scott | |||||||
|
||||||||||
|
||||||||||
Title:
|
Sr. Vice President & General Counsel | Title: | CEO | |||||||
|
||||||||||
|
||||||||||
Date:
|
Feb. 21, 2005 | Date: | 2/25/05 | |||||||
|
Apprvd As to Form
RMS LAW DEPT.
By: [signature illegible]
13
Exhibit 10.9.1
Master Security Agreement
MASTER SECURITY AGREEMENT
No. 5081084
Dated as of March 30, 2005 (
Agreement
)
THIS AGREEMENT is between Oxford Finance Corporation (together with its successors and assigns, if any, Secured Party ) and Genomic Health, Inc. (Debtor). Secured Party has an office at 133 N. Fairfax Street, Alexandria, VA 22314. Debtor is a corporation organized and existing under the laws of the state of Delaware. Debtors mailing address and chief place of business is 301 Penobscot Drive, Redwood City, CA 94063.
1. CREATION OF SECURITY INTEREST.
Debtor grants to Secured Party, its successors and assigns, a security interest in and against the Collateral (as that term is defined herein). This security interest is given to secure the payment and performance of all debts, obligations and liabilities of any kind whatsoever of Debtor to Secured Party, now existing or arising in the future, including but not limited to the payment and performance of certain Promissory Notes from time to time executed by Debtor (collectively Notes and each a Note ), and any renewals, extensions and modifications of such debts, obligations and liabilities (such Notes, debts, obligations and liabilities are called the Indebtedness ). Unless otherwise provided by applicable law, notwithstanding anything to the contrary contained in this Agreement, to the extent that Secured Party asserts a purchase money security interest in any items of Collateral (the PMSI Collateral): (i) the PMSI Collateral shall secure only that portion of the Indebtedness which has been advanced by Secured Party to enable Debtor to purchase, or acquire rights in or the use of such PMSI Collateral (the PMSI Indebtedness ), and (ii) no other Collateral shall secure the PMSI Indebtedness.
2. REPRESENTATIONS, WARRANTIES AND COVENANTS OF DEBTOR.
Debtor represents, warrants and covenants as of the date of this Agreement and as of the date of each Note that:
(a) | Due Organization . Debtors exact legal name is as set forth in the preamble of this Agreement and Debtor is, duly organized, existing and in good standing under the laws of the State set forth in the preamble of this Agreement, has its chief executive offices at the location specified in the preamble, and is, and will remain duly qualified and licensed in every jurisdiction wherever necessary to carry on its business and operations; | |||
(b) | Power and Capacity to Enter Into and Perform Obligations . Debtor has adequate power and capacity to enter into, and to perform its obligations under this Agreement, each Note and any other documents evidencing, or given in connection with, any of the Indebtedness (all of the foregoing are called the Debt Documents ); | |||
(c) | Due Authorization . This Agreement and the other Debt Documents have been duly authorized, executed and delivered by Debtor and constitute legal, valid and binding agreements enforceable in accordance with their terms, except to the extent that the enforcement of remedies may be limited under applicable bankruptcy and insolvency laws; | |||
(d) | Approvals and Consents . No approval, consent or withholding of objections is required from any governmental authority or instrumentality with respect to the entry into, or performance by Debtor of any of the Debt Documents, except any already obtained; | |||
(e) | No Violations or Defaults . The entry into, and performance by, Debtor of the Debt Documents will not (i) violate any of the organizational documents of Debtor or any judgment, order, law or regulation applicable to Debtor, or (ii) result in any material breach of or constitute a material default under any contract to which Debtor is a party, or result in the creation of any lien, claim or encumbrance on any of Debtors property (except for liens in favor of Secured Party) pursuant to any indenture, mortgage, deed of trust, bank loan, credit agreement, or other agreement or instrument to which Debtor is a party; | |||
(f) | Litigation . There are no suits or proceedings pending in court or before any commission, board or other administrative agency against or affecting Debtor which could, in the aggregate, have a material adverse effect on Debtor, its business or operations, or its ability to perform its obligations under the Debt Documents (a Material Adverse Effect ), nor does Debtor have reason to believe that any such suits or proceedings are threatened; | |||
(g) | Solvency . The fair salable value of Debtors assets (including goodwill minus disposition costs) exceeds the fair value of its liabilities; Debtor is not left with unreasonably small capital after the transactions in this Agreement or any Notes and Debtor is able to pay its debts (including trade debts) as they mature. | |||
(h) | Financial Statements Prepared In Accordance with GAAP . All financial statements delivered to Secured Party in connection with the Indebtedness have been prepared in accordance with generally accepted accounting principles, and since the date of the most recent financial statement, there has been no Material Adverse Change (as hereinafter defined) in Debtors financial condition; | |||
(i) | Use of Collateral . The Collateral is not, and will not be, used by Debtor for personal, family or household purposes; | |||
(j) | Collateral in Good Condition and Repair . The Collateral is, and will remain, in good condition and repair and Debtor will not be negligent in its care and use; | |||
(k) | Ownership of Collateral . Debtor is, and will remain, the sole and lawful owner, and in possession of the Collateral, and has the sole right and lawful authority to grant the security interest described in this Agreement; | |||
(l) | Encumbrances . The Collateral is, and will remain, free and clear of all liens, claims and encumbrances of any kind whatsoever, except for (i) liens in favor of Secured Party, (ii) liens for taxes not yet due or for taxes being contested in good faith and which do not involve, in the reasonable judgment of Debtor, any material risk of the sale, forfeiture or loss of any of the Collateral and for which adequate reserves have been established, and (iii) inchoate material mens, mechanics, repairmens and similar liens arising by operation of law in the normal course of business for amounts which are not delinquent (all of such liens are called Permitted Liens ); |
Page 1 of 9
|
Initial /s/ BC / /s/ MJA | |
|
Master Security Agreement
(m) | Taxes . All federal, state and local tax returns required to be filed by Debtor have been filed with the appropriate governmental agencies and all taxes due and payable by Debtor have been timely paid. Debtor will pay when due all taxes, assessments and other liabilities except as contested in good faith and by appropriate proceedings and for which adequate reserves have been established; | |||
(n) | No Defaults . No event or condition exists under any material agreement, instrument or document to which Debtor is a party or may be subject, or by which Debtor or any of its properties are bound, which constitutes a default or an event of default thereunder, or will, with the giving of notice, passage of time, or both, would constitute a default or event of default thereunder, where such default or event of default would have a Material Adverse Change; | |||
(o) | Certification of Financial Information . All reports, certificates, schedules, notices and financial information submitted by Debtor to the Secured Party pursuant to this Agreement shall be certified as true and correct by the president or chief financial officer of Debtor; and | |||
(p) | Notice of Material Adverse Change . Debtor shall give the Secured Party prompt written notice of any event, occurrence or other matter which has resulted or may result in a material adverse change in its financial condition, business operations, prospects, product development, technology, or business or contractual relations with third parties of Debtor which change would impair the ability of Debtor to perform its obligations hereunder or under any of the other Debt Documents or of Secured Party to enforce the Indebtedness or realize upon the Collateral (a Material Adverse Change ). | |||
(q) | Transactions with Affiliates . Debtor shall not, without the prior written consent of Security Party, directly or indirectly enter into or permit to exist any material transaction with any Affiliate of Debtor except for transactions that are in the ordinary course of Debtors business, upon fair and reasonable terms that are no less favorable to Debtor than would be obtained in an arms length transaction with a nonaffiliated Person. | |||
(r) | Subsidiary . Debtor hereby represents and warrants that it has only one subsidiary, while subsidiarys exact legal name is Oncotype Laboratories, Incorporated (the Subsidiary. Debtor further represents and warrants that the Subsidiary is not currently an active business and owns no assets. The Debtor covenants and agrees not to cause or allow the Subsidiary to become an active business or to owning assets without providing the Secured Party with not less than thirty days prior written notice and executing and delivering such documents, agreements and instruments as Secured Party requests in order to, at Secured Partys option, join the Subsidiary as a co-Debtor hereunder and under the other Debt Documents or cause the Subsidiary to become a guarantor of the Indebtedness, and to grant a lien on all of the Subsidiarys assets in favor of Secured Party. | |||
(s) | Primary Account and Wire Transfer Instructions . Debtor maintains its Primary Account (the Primary Operating Account ) and the Wire Transfer Instructions for the Primary Operating Account are as follows: |
Silicon Valley Bank
3003 Tasman Drive Santa Clara, CA 95054 ABA No.: 121140399 Account No.: 3300248193 Account Name: Genomic Health, Inc. |
Debtor hereby agrees that Loans will be advanced to the account specified above and regularly scheduled payments will be automatically debited from the same account. In addition to the Primary Operating Account identified hereinabove, Debtor maintains the following other deposit and investment accounts: |
a. | Silicon Valley Bank Securities | |||
3003 Tasman Drive
Santa Clara, CA 95054 ABA No.: 121000358 (SVB Securities clears through B of A) Account No.: 886-00767-1-3ZGQ Account Name: Genomic Health, Inc. |
||||
Bank of America
530 Lytton Avenue, 2nd Floor Palo Alto, CA 94301-1539 ABA No.: 121000358 Account No.: 14996-08284 Account Name: Genomic Health, Inc. |
3. COLLATERAL.
The Debtor, covenants and agrees that, so long as any of the Debt Documents shall remain in effect, or unless the Secured Party shall otherwise consent in writing:
(a) | Possession or Control of Collateral; Inspection of Collateral . Except to the extent Secured Party exercises any remedy it may have in connection with a default by Debtor, Debtor shall remain in possession of the Collateral; except that Secured Party shall have the right to possess (i) any chattel paper or instrument that constitutes a part of the Collateral, and (ii) any other Collateral in which Secured Partys security interest may be perfected only by possession. Secured Party may inspect any of the Collateral during normal business hours after giving Debtor reasonable prior notice. | |||
(b) | Maintenance . Debtor shall (i) use the Collateral only in its trade or business, (ii) maintain all of the Equipment in good operating order and repair, normal wear and tear excepted, (iii) use and maintain the Equipment only in compliance with manufacturers recommendations and all applicable laws, and (iv) keep all of the Collateral free and clear of all liens, claims and encumbrances (except for Permitted Liens). | |||
(c) | Disposition of Collateral . Secured Party does not authorize and Debtor agrees it shall not (i) part with posession of any of the Collateral (except to Secured Party), (ii) remove any of the Collateral from the continental United States, or (iii) sell, rent, lease, mortgage, license, grant a security interest in or otherwise transfer or encumber (except for Permitted Liens) any of the Collateral. |
Page 2 of 9
|
Initial /s/ BC / /s/ MJA | |
|
Master Security Agreement
(d) | Taxes . Debtor shall pay promptly when due all taxes, license fees, assessments and public and private charges levied or assessed on any of the Collateral, on its use, or on this Agreement or any of the other Debt Documents, excluding any of the foregoing measured by the income of Secured Party. At its option, while any default hereunder has occurred and is continuing, Secured Party may discharge taxes, liens, security interests or other encumbrances at any time levied or placed on the Collateral and may pay for the maintenance, insurance and preservation of the Collateral and effect compliance with the terms of this Agreement or any of the other Debt Documents. Debtor agrees to reimburse Secured Party, on demand, for all reasonable costs and expenses incurred by Secured Party in connection with such payment or performance and agrees that such reimbursement obligation shall constitute Indebtedness. | |||
(e) | Books and Records . Debtor shall, at all times, keep accurate and complete records of the Collateral, and Secured Party shall have the right to inspect and make copies of all of Debtors books and records relating to the Collateral during normal business hours, after giving Debtor reasonable prior notice. | |||
(f) | Third Party Possession of Collateral . Debtor agrees and acknowledges that any third person who may at any time possess all or any portion of the Collateral shall be deemed to hold, and shall hold, the Collateral as the agent of, and as pledge holder for, Secured Party. Secured Party may at any time give notice to any third person described in the preceding sentence that such third person is holding the Collateral as the agent of, and as pledge holder for, the Secured Party. | |||
(g) | Change of Address . All of the Collateral is located in and will in the future be in the possession of the Debtor at its address stated above or at such other addresses as may be set forth on the attached Schedule A. The Debtor has not at any time within the past four (4) months either (a) maintained Equipment or (b) maintained its chief executive office or its records with respect to the Collateral at any other location and shall not do so hereafter except with the prior written consent of the Secured Party. The Secured Party shall be entitled to rely upon the foregoing unless it receives 14 days advance written notice of a change in the address of the Debtors executive offices or location of the Collateral. | |||
(h) | Fixtures . Not permit any item of the Equipment to become a fixture to real estate or an accession to other property without the prior written consent of the Secured Party, and the Equipment is now and shall at all times remain personal property except with the Secured Partys prior written consent. If any of the Collateral is or will be attached to real estate in such a manner as to become a fixture under applicable state law and if such real estate is encumbered, the Debtor will obtain from the holder of each Lien or encumbrance a written consent and subordination to the security interest hereby granted, or a written disclaimer of any interest in the Collateral, in a form acceptable to the Secured Party. Notwithstanding the forgoing, Secured Party waives the requirement to obtain a waiver from each and every landlord in connection with the first advance and may, at its option, require a waiver for future advances. | |||
(i) | Chattel Paper . Promptly, upon request by the Secured Party, deliver, assign, and endorse to the Secured Party all chattel paper and all other documents included in the Collateral held by the Debtor in connection therewith. | |||
(j) | Cost Accounting and Procurement Systems . The Debtors cost accounting and procurement systems are and at all times have been, and will continue to be, in compliance with all applicable requirements. | |||
(k) | Domain Name . Take the necessary or appropriate steps to ensure that the identity and location of the servers used in connection with the Debtors domain name and the identity of the party having control over the domain name server and of the administrative contact with the registry have been disclosed to the Secured Party. The Debtor shall not change the domain name server without notification to the Secured Party. The Debtor shall maintain the trademark of the domain name by defending against any infringement suits and by policing the trademark. The Debtor shall renew the domain name registration during the loan term. The Debtor shall make all payments to the domain name registrar necessary to maintain the domain name. |
4. INSURANCE.
(a) | Risk of Loss . Debtor shall at all times bear the entire risk of any loss, theft, damage to, or destruction of, any of the Collateral from any cause whatsoever. | |||
(b) | Insurance Requirements . Debtor agrees to maintain general liability insurance and to keep the Collateral insured against loss or damage by fire and extended coverage perils, theft, burglary, risk of loss by collision (for any or all Collateral which are vehicles) and such other risks as Secured Party may reasonably require. The liability insurance coverage shall be in an amount standard for companies similar to Debtor in Debtors industry in Debtors geographic region. The property insurance coverage shall be in an amount no less than the full replacement value of the Collateral. All insurance policies shall be in a form, with companies and with deductible amounts, acceptable to Secured Party. Debtor shall deliver to Secured Party policies or certificates of insurance evidencing such coverage. Each policy shall name Secured Party as a loss payee and an additional insured, shall provide for coverage to Secured Party regardless of the breach by Debtor of any warranty or representation made therein, shall not be subject to co-insurance, and shall provide that coverage may not be canceled or altered by the insurer except upon thirty (30) days prior written notice to Secured Party. Debtor appoints Secured Party as its attorney-in-fact to make proof of loss, claim for insurance and adjustments with insurers, and to receive payment of and execute or endorse all documents, checks or drafts in connection with insurance payments. Secured Party shall not act as Debtors attorney-in-fact unless Debtor is in default. Proceeds of insurance shall be applied, at the option of Secured Party, to repair or replace the Collateral or to reduce any of the Indebtedness. |
5. REPORTS.
(a) | Notice of Events . Debtor shall promptly notify Secured Party of (i) any change in the name of Debtor, (ii) any change in the state of its incorporation or registration, (iii) any relocation of its chief executive offices, (iv) any of the Collateral being lost, stolen, missing, destroyed, materially damaged or worn out, or (v) any lien, claim or encumbrance other than Permitted Liens attaching to or being made against any of the Collateral. | |||
(b) | Financial Statements, Reports and Certificates . Debtor will deliver to Secured Party within one hundred fifty (150) days of the close of each fiscal year of Debtor, Debtors complete financial statements including a balance sheet, income statement, statement of shareholders equity and statement of cash flows, each prepared in accordance with generally accepted accounting principles consistently applied, certified by a recognized firm of certified public accountants satisfactory to Secured Party. Debtor will deliver to Secured Party copies of Debtors quarterly financial statements including a balance sheet, income statement and statement of cash flows, each prepared by Debtor in accordance with generally accepted accounting principles consistently applied by Debtor and certified by Debtors chief financial officer, within ninety (90) days after the close of each of Debtors fiscal quarter. Debtor will deliver to Secured Party copies of all Forms 10-K and 10-Q, if any, within 30 days after the dates on which they are filed with the Securities and Exchange Commission. Debtor will deliver to Secured Party copies of Debtors monthly financial statements including a balance sheet and income statement, each prepared by Debtor in |
Page 3 of 9
|
Initial /s/ BC / /s/ MJA | |
|
Master Security Agreement
accordance with generally accepted accounting principles consistently applied by Debtor and certified by Debtors chief financial officer, within forty-five (45) days after the close of each month. Concurrently with delivery of the foregoing information, and from time to time promptly upon request of Secured Party, Debtor will deliver to Secured Party a Compliance Certificate substantially consistent with the form of the document attached hereto as Schedule B. Debtor will deliver to Secured Party promptly upon request of Secured Party, in form satisfactory to Secured Party, such other and additional information as Secured Party may reasonably request from time to time. |
6. FURTHER ASSURANCES.
(a) | Further Assurances Regarding Security Interests . Debtor shall, upon request of Secured Party, furnish to Secured Party such further information, execute and deliver to Secured Party such documents and instruments (including, without limitation, Uniform Commercial Code financing statements) and shall do such other acts and things as Secured Party may at any time reasonably request relating to the perfection or protection of the security interest created by this Agreement or for the purpose of carrying out the intent of this Agreement. Without limiting the foregoing, Debtor shall cooperate and do all acts reasonably deemed necessary or advisable by Secured Party to continue in Secured Party a perfected first security interest in the Collateral, and shall obtain and furnish to Secured Party any subordinations, releases, landlord waivers, lessor waivers, mortgagee waivers, or control agreements, and similar documents as may be from time to time requested by, and in form and substance satisfactory to, Secured Party. | |||
(b) | Authorization To File Financial Statements . Debtor shall perform any and all acts reasonably requested by the Secured Party to establish, maintain and continue the Secured Partys security interest and liens in the Collateral, including but not limited to, executing or authenticating financing statements and such other instruments and documents when and as reasonably requested by the Secured Party. Debtor hereby authorizes Secured Party through any of Secured Partys employees, agents or attorneys to file any and all financing statements, including, without limitation, any original filings, continuations, transfers or amendments thereof required to perfect Secured Partys security interest and liens in the Collateral under the UCC without authentication or execution by Debtor. Debtor hereby irrevocably authorizes the Secured Party at any time and from time to time to (a) file in any filing office in any Uniform Commercial Code jurisdiction any initial financing statement(s) and amendments thereto that covers the Collateral and (b) provide any other information required by part 5 of Article 9 of the Uniform Commercial Code of the State or such other jurisdiction for the sufficiency or filing office acceptance of any financing statement or amendment, including (i) whether the Debtor is an organization, the type of organization and any organization identification number issued to the Debtor, and (ii) in the case of a financing statement filed as a fixture filing, a sufficient description of real property to which the Collateral relates. The Debtor agrees to furnish any such information to the Secured Party promptly upon the Secured Partys request. | |||
(c) | Indemnification . Debtor shall indemnify and defend the Secured Party, its successors and assigns, and their respective directors, officers and employees (each an Indemnified Party ), from and against all claims, actions and suits (including, without limitation, related reasonable attorneys fees) of any kind whatsoever arising, directly or indirectly, in connection with any of the Collateral, except to the extent any such claim, action or suit arises out of the gross negligence or willful misconduct of an Indemnified Party. |
7. DEFAULT AND REMEDIES.
(a) | Defaults . Debtor shall be in default under this Agreement and each of the other Debt Documents if any of the following events or conditions cannot be cured within 5 days of when the event or condition occurred: |
i. | Debtor breaches its obligation to pay when due any installment or other amount due or coming due under any of the Debt Documents; | |||
ii. | Debtor, without the prior written consent of Secured Party, attempts to or does sell, rent, lease, license, mortgage, grant a security interest in, or otherwise transfer or encumber (except for Permitted Liens) any of the Collateral; | |||
iii. | Debtor breaches the covenant set forth in the fourth sentence of Section 4(b) within 5 days after the written request for such policies or certificate of insurance by Secured Party or Debtor breached any of its other insurance obligations under Section 4; | |||
iv. | Debtor breaches any of its other non-payment obligations under any of the Debt Documents and fails to cure that breach within thirty (30) days after written notice from Secured Party; | |||
v. | Any warranty, representation or statement made by Debtor in any of the Debt Documents or otherwise in connection with any of the Indebtedness shall be false or misleading in any material respect; | |||
vi. | Any of the Collateral is subjected to attachment, execution, levy, seizure or confiscation in any legal proceeding or otherwise, or if any legal or administrative proceeding is commenced against Debtor or any of the Collateral, which in the good faith judgment of Secured Party subjects any of the Collateral to a material risk of attachment, execution, levy, seizure or confiscation and no bond is posted or protective order obtained to negate such risk; | |||
vii. | Debtor breaches or is in default under any other agreement between Debtor and Secured Party and fails to cure that breach within thirty (30) days after written notice from Secured Party; | |||
viii. | Debtor or any guarantor or other obligor for any of the Indebtedness (collectively Guarantor ) dissolves, terminates its existence, becomes insolvent or ceases to do business as a going concern; | |||
ix. | Debtor or any Guarantor is a natural person, Debtor or any such Guarantor dies or becomes incompetent; | |||
x. | A receiver is appointed for all or of any part of the property of Debtor or any Guarantor, or Debtor or any Guarantor makes any assignment for the benefit of creditors; | |||
xi. | Debtor or any Guarantor files a petition under any bankruptcy, insolvency or similar law, or any such petition is filed against Debtor or any Guarantor and is not dismissed within forty-five (45) days; | |||
xii. | Debtors improper filing of an amendment or termination statement relating to a filed financing statement describing the Collateral. |
Page 4 of 9
|
Initial /s/ BC / /s/ MJA | |
|
Master Security Agreement
xiii. | Debtor shall merge with or consolidate into any other entity or sell all or substantially all of its assets or in any manner terminate its existence; | |||
xiv. | If Debtor is a privately held corporation, more than 50% of Debtors voting capital stock, or effective control of Debtors voting capital stock, issued and outstanding from time to time, is not retained by the holders of such stock on the date the Agreement is executed; | |||
xv. | If Debtor is a publicly held corporation, there shall be a change in the ownership of Debtors stock such that Debtor is no longer subject to the reporting requirements of the Securities Exchange Act of 1934 or no longer has a class of equity securities registered under Section 12 of the Securities Act of 1933; | |||
xvi. | Debtor defaults under any other financing arrangement between Debtor and a third party which results in a Material Adverse Change; | |||
xvii. | Secured Party shall have determined in its sole and good faith judgment that (a) it is the clear intention of Debtors investors to not continue to fund the Debtor in the amounts and timeframe necessary to enable Debtor to satisfy the Indebtedness as it becomes due and payable or (b) there is a material impairment in the perfection or priority of the Secured Partys security interest in the Collateral; or | |||
xviii. | Secured Party shall have determined in its sole and good faith judgment that there has been a material adverse change in the financial condition, business, operations, prospects, product development, technology, or business or contractual relations with third parties of Debtor from the date hereof, or a change or event shall have occurred which would impair the ability of Debtor to perform its obligations hereunder or under any of the other financing agreements to which it is a party or of Secured Party to enforce the Indebtedness or realize upon the Collateral; |
(b) | Acceleration . If Debtor is in default, the Secured Party, at its option, may declare any or all of the Indebtedness to be immediately due and payable, without demand or notice to Debtor or any guarantor. The accelerated obligations and liabilities shall bear interest (both before and after any judgment) until paid in full at the lower of eighteen percent (18%) per annum or the maximum rate not prohibited by applicable law. | |||
(c) | Rights and Remedies . Secured Party shall have all of the rights and remedies of a Secured Party under the Uniform Commercial Code, and under any other applicable law. Without limiting the foregoing, Secured Party shall have the right to (i) notify any account debtor of Debtor or any obligor on any instrument which constitutes part of the Collateral to make payment to the Secured Party, (ii) with or without legal process, enter any premises where the Collateral may be and take possession of and remove the Collateral from the premises or store it on the premises, (iii) sell the Collateral at public or private sale, in whole or in part, and have the right to bid and purchase at said sale, (iv) to instruct the bank maintaining any Deposit Account to transfer the funds in the Deposit Account to any account of the Secured Party, or (v) lease or otherwise dispose of all or part of the Collateral, applying proceeds from such disposition to the obligations then in default. If requested by Secured Party, Debtor shall promptly assemble the Collateral and make it available to Secured Party at a place to be designated by Secured Party, which is reasonably convenient to both parties. Secured Party may also render any or all of the Collateral unusable at the Debtors premises and may dispose of such Collateral on such premises without liability for rent or costs. Any notice that Secured Party is required to give to Debtor under the Uniform Commercial Code of the time and place of any public sale or the time after which any private sale or other intended disposition of the Collateral is to be made shall be deemed to constitute reasonable notice if such notice is given to the last known address of Debtor at least five (5) days prior to such action. Upon the occurrence and during the continuation of an Event of Default, Debtor hereby appoints Secured Party as Debtors attorney-in-fact, with full authority in Debtors place and stead and in Debtors name or otherwise, from time to time in Secured Partys sole and arbitrary discretion, to take any action and to execute any instrument which Secured Party may deem necessary or advisable to accomplish the purpose of this Agreement. | |||
(d) | Application of Proceeds . Proceeds from any sale or lease or other disposition shall be applied: first, to all costs of repossession, storage, and disposition including without limitation attorneys, appraisers, and auctioneers fees; second, to discharge the obligations then in default; third, to discharge any other Indebtedness of Debtor to Secured Party, whether as obligor, endorser, guarantor, surety or indemnitor; fourth, to expenses incurred in paying or settling liens and claims against the Collateral; and lastly, to Debtor, if there exists any surplus. Debtor shall remain fully liable for any deficiency. | |||
(e) | Fees and Costs . Debtor agrees to pay all reasonable attorneys fees and other costs incurred by Secured Party in connection with the enforcement, assertion, defense or preservation of Secured Partys rights and remedies under this Agreement, or if prohibited by law, such lesser sum as may be permitted. Debtor further agrees that such fees and costs shall constitute Indebtedness. | |||
(f) | Remedies Cumulative . Secured Partys rights and remedies under this Agreement or otherwise arising are cumulative and may be exercised singularly or concurrently. Neither the failure nor any delay on the part of the Secured Party to exercise any right, power or privilege under this Agreement shall operate as a waiver, nor shall any single or partial exercise of any right, power or privilege preclude any other or further exercise of that or any other right, power or privilege. SECURED PARTY SHALL NOT BE DEEMED TO HAVE WAIVED ANY OF ITS RIGHTS UNDER THIS AGREEMENT OR UNDER ANY OTHER AGREEMENT, INSTRUMENT OR PAPER SIGNED BY DEBTOR UNLESS SUCH WAIVER IS EXPRESSED IN WRITING AND SIGNED BY SECURED PARTY. A waiver on any one occasion shall not be construed as a bar to or waiver of any right or remedy on any future occasion. | |||
(g) | WAIVER OF JURY TRIAL . DEBTOR AND SECURED PARTY UNCONDITIONALLY WAIVE THEIR RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, ANY OF THE OTHER DEBT DOCUMENTS, ANY OF THE INDEBTEDNESS SECURED HEREBY, ANY DEALINGS BETWEEN DEBTOR AND SECURED PARTY RELATING TO THE SUBJECT MATTER OF THIS TRANSACTION OR ANY RELATED TRANSACTIONS, AND/OR THE RELATIONSHIP THAT IS BEING ESTABLISHED BETWEEN DEBTOR AND SECURED PARTY. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT. THIS WAIVER IS IRREVOCABLE. THIS WAIVER MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING. THE WAIVER ALSO SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS AGREEMENT, ANY OTHER DEBT DOCUMENTS, OR TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THIS TRANSACTION OR ANY RELATED TRANSACTION. THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT. |
8. MISCELLANEOUS.
(a) | Assignment . This Agreement, any Note and/or any of the other Debt Documents may be assigned, in whole or in part, by Secured Party without notice to Debtor, and Debtor agrees not to assert against any such assignee, or assignees assigns, any defense, set-off, recoupment claim or counterclaim which Debtor has or may at any time have against Secured Party for any reason whatsoever. Debtor agrees that if Debtor receives written notice of an assignment from |
Page 5 of 9
|
Initial /s/ BC / /s/ MJA | |
|
Master Security Agreement
Secured Party, Debtor will pay all amounts payable under any assigned Debt Documents to such assignee or as instructed by Secured Party. Debtor also agrees to confirm in writing receipt of the notice of assignment as may be reasonably requested by Secured Party or assignee. |
(b) | Notices . All notices to be given in connection with this Agreement shall be in writing, shall be addressed to the parties at their respective addresses set forth in this Agreement (unless and until a different address may be specified in a written notice to the other party), and shall be deemed given (i) on the date of receipt if delivered in hand or by facsimile transmission, (ii) on the next business day after being sent by overnight express mail, and (iii) on the fourth business day after being sent by regular, registered or certified mail. As used herein, the term business day shall mean and include any day other than Saturdays, Sundays, or other days on which commercial banks in New York, New York are required or authorized to be closed. | |||
(c) | Correction of Errors . Secured Party may correct patent errors and fill in all blanks in this Agreement or in any Note consistent with the agreement of the parties. | |||
(d) | Time is of the Essence; Consents . Time is of the essence of this Agreement. This Agreement shall be binding, jointly and severally, upon all parties described as the Debtor and their respective heirs, executors, representatives, successors and assigns, and shall inure to the benefit of Secured Party, its successors and assigns. Whenever the consent or approval of Debtor or Secured Party is required hereunder or under any other Debt Document, such consent shall not be unreasonably withheld or delayed. | |||
(e) | Entire Agreement . This Agreement and its Collateral Schedules constitute the entire agreement between the parties with respect to the subject matter of this Agreement and supersede all prior understandings (whether written, verbal or implied) with respect to such subject matter. THIS AGREEMENT AND ITS COLLATERAL SCHEDULES SHALL NOT BE CHANGED OR TERMINATED ORALLY OR BY COURSE OF CONDUCT, BUT ONLY BY A WRITING SIGNED BY BOTH PARTIES. Section headings contained in this Agreement have been included for convenience only, and shall not affect the construction or interpretation of this Agreement. | |||
(f) | Termination of Agreement . This Agreement shall continue in full force and effect until all of the Indebtedness has been indefeasibly paid in full to Secured Party or its assignee. The surrender, upon payment or otherwise, of any Note or any of the other documents evidencing any of the Indebtedness shall not affect the right of Secured Party to retain the Collateral for such other Indebtedness as may then exist or as it may be reasonably contemplated will exist in the future. This Agreement shall automatically be reinstated if Secured Party is ever required to return or restore the payment of all or any portion of the Indebtedness (all as though such payment had never been made). | |||
(g) | CHOICE OF LAW . THIS AGREEMENT SHALL BE GOVERNED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE COMMONWEALTH OF VIRGINIA. DEBTOR ACKNOWLEDGES THAT THIS AGREEMENT IS BEING SIGNED BY THE SECURED PARTY IN PARTIAL CONSIDERATION OF SECURED PARTYS RIGHT TO ENFORCE IN THE JURISDICTION STATED ABOVE. DEBTOR CONSENTS TO JURISDICTION IN THE COMMONWEALTH OF VIRGINIA, VENUE IN ANY FEDERAL OR STATE COURT IN THE COMMONWEALTH OF VIRGINIA FOR SUCH PURPOSES AND WAIVES ANY AND ALL RIGHTS TO CONTEST SAID JURISDICTION AND VENUE AND ANY OBJECTION THAT SAID JURISDICTION IS NOT CONVENIENT. DEBTOR WAIVES ANY RIGHTS TO COMMENCE ANY ACTION AGAINST SECURED PARTY IN ANY JURISDICTION EXCEPT VIRGINIA. | |||
(h) | Loss, Depreciation or Other Damage . The Secured Party shall not be liable for or prejudiced by any loss, depreciation or other damage to Receivables or other Collateral unless caused by the Secured Partys willful or negligent act, and the Secured Party shall have no duty to take any action to preserve or collect any Collateral. |
9. DEFINITIONS.
As used herein, the following terms, when initial capital letters are used, shall have the respective meanings set forth below. In addition, all terms defined in the Virginia Uniform Commercial Code (including revised Article 9 thereof) shall have the meanings given therein unless otherwise defined herein.
Defined Terms. As used in this Agreement, the following terms shall have the following meanings, unless the context otherwise requires:
Account Debtor shall mean the account debtor or any customer of the Debtor who is obligated or indebted to the Debtor with respect to any of the Receivables and/or the prospective purchaser with respect to any contract right, and/or any party or organization who enters into or proposes to enter into any contract or other arrangement with the Debtor pursuant to which the Debtor is to deliver any personal property or perform any service.
Affiliate of a Person is a Person that owns or controls directly or indirectly the Person, any Person that controls or is controlled by or is under common control with the Person, and each of that Persons senior executive officers, directors, partners and, for any Person that is a limited liability company, that Persons managers and members.
Collateral shall mean all Equipment, instruments, documents, commercial tort claims, investment property and letter of credit rights now owned or hereafter acquired by the Debtor; all guarantees, or other agreements or property securing or relating to any of the items referred to above, or acquired for the purpose of securing and enforcing any of such items; all books of account and documents related thereto; computer tapes, programs, discs and other material, media or documents relating to the recording, billing or analyzing of any of the above; all computers, word processors, printers, switches, interfaces, source codes, mask works, software, web servers, website service contracts, internet connection contract or line lease, website hosting service contract, website license agreements, back-up copies of website content, contracts with website advertisers, scripts, codes or Active-X controls, technology escrow agreements, website content development agreements, all rights, of whatever form, in and to domain names, instructional material, and connectors and all parts, accessories, additions, substitutions, or options together with all property or equipment used in connection with any of the above or which are used to operate or cause to operate any features, special applications, format controls, options or software of any or all of the above- mentioned items; contractual rights, literary rights, all amounts received as an award in or settlement of a suit in damages, proceeds of loans, interests in joint ventures or general or limited partnerships, the sale by the Debtor of any of the foregoing and all proceeds (cash and non- cash) of the foregoing; proceeds of property received wholly or partly in trade or exchange for any of the above and all rents, revenues, issues, profits and proceeds in any form, including cash, insurance proceeds, distributions on stock, negotiable instruments and other evidences of indebtedness, chattel paper, security agreements and other documents arising from the sale, lease, license, encumbrance, collection of, or any other temporary or permanent disposition of, any of the above or any interest therein.
Notwithstanding the foregoing, the Collateral shall not be deemed to include any (i) Receivables, (ii) Government Contracts or Government Accounts, (iii) Inventory, or (iv) any copyrights, copyright applications, copyright registration and like protection in each work of authorship and derivative work thereof, whether published or
Page 6 of 9
|
Initial /s/ BC / /s/ MJA | |
|
Master Security Agreement
unpublished, now owned or hereafter acquired; any patents, patent applications and like protections including without limitation improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, trademarks, servicemarks and applications therefor, whether registered or not, and the goodwill of the business of Debtor connected with and symbolized by such trademarks, any trade secret rights, including any rights to unpatented inventions, know-how, operating manuals, license rights and agreements and confidential information, now owned or hereafter acquired; or any claims for damage by way of any past, present and future infringement of any of the foregoing (collectively, the Intellectual Property ).
Cash Equivalents means the sum outstanding, at any one time, of (i) all cash (in United States dollars) owned by Debtor at such time plus (ii) the fair market value of all cash equivalents and short term investments (as those terms are defined by GAAP) owned by Debtor at such time.
Deposit Account means a demand, time, savings, passbook, or similar account maintained with a bank.
Equipment shall mean (a) all goods and equipment of the Debtor of every type and description, now owned and hereafter acquired and wherever located, including, without limitation, all imbedded software, machinery, motor vehicles and other rolling stock, furniture, furnishings, tools, dies, fittings, accessories, all substitutions therefore, leasehold improvements, fixtures, and materials and supplies relating to any of the foregoing; (b) all present and future documents of title and trust receipts relating to any of the foregoing; (c) all present and future rights, claims and causes of action of Debtor in connection with purchases of (or contracts for the purchase of), or warranties relating to, or damages to, goods held or to be held by the Debtor as equipment; (d) all present and future warranties, manuals and other written materials (and packaging thereof or relating thereto) relating to any of the foregoing; and (e) all present and future general intangibles of the Debtor in any way relating to any of the foregoing. Notwithstanding the foregoing, Equipment shall not include the tradeshow booth.
Government Accounts shall mean all accounts arising out of any Government Contract.
Government Contract shall mean any contract between the Debtor and the United States Government, any state or local government or any agency thereof, and all amendments thereto.
Inventory shall mean and include (a) all goods now owned or hereafter acquired by the Debtor, which are held for sale or lease by the Debtor or are furnished or to be furnished by the Debtor under contracts of service, (b) all raw materials, work in process, finished goods, packaging materials, and other materials and supplies of every kind used or consumed in connection with the manufacture, production, packing, shipping, advertising or sale of such goods, (c) all proceeds and products from the sale or other disposition of such goods, including all goods returned, repossessed, or acquired by the Debtor by way of substitution or replacement, and all additions and accessions thereto, and all documents and instruments (as those terms are defined in the Uniform Commercial Code) covering such goods; (d) all the Debtors rights as an unpaid seller, including stoppage in transit, detinue and reclamation; and (e) all of the above owned by the Debtor or in which the Debtor now has or in which the Debtor may hereafter acquire an interest, whether in transit or in the Debtors constructive or actual possession or held by the Debtor or others for the Debtors account (including any of the above held on consignment), including, without limitation, all of the above which may be located on the Debtors premises or upon the premises of any carriers, forwarding agents, truckers, warehousemen, vendors, selling agents, finishers, converters or other third parties who may have possession, temporary or otherwise, thereof.
Lien(s) shall mean any mortgage, pledge, deed of trust, assignment, security interest, encumbrance, hypothecation, lien, or charge of any kind (including any conditional sale or other title retention agreement, any financing lease having substantially the same economic effect as any of the foregoing, and the filing of, or agreement to give, any financing statement under the Uniform Commercial Code or comparable law of any jurisdiction).
Payment or Payments shall mean any check, draft, cash or any other remittance or credit in payment or on account of any or all of the Receivables and the cash proceeds of any returned, rejected or repossessed goods, the sale or lease of which gave rise to a Receivable.
Person is any individual, sole proprietorship, partnership, limited liability company, joint venture, company association, trust, unincorporated organization, association, corporation, institution, public benefit corporation, firm, joint stock company, estate, entity or government agency.
Receivables shall mean in addition to the definition of account as contained in the Uniform Commercial Code (a) all of the Debtors present and future accounts, contract rights, receivables, promissory notes and other instruments, chattel paper (including tangible and electronic chattel paper), tax refunds, general intangibles (excluding the Intellectual Property) and all rights to receive the payment of money or other consideration under present or future contracts including, without limitation, all of the Debtors rights under each Government Contract and all related Government Accounts now owned or hereafter acquired by the Debtor; (b) all present and future cash of the Debtor; (c) all present and future judgments, orders, awards and decrees in favor of the Debtor and causes of action in favor of the Debtor; (d) all present and future contingent and noncontingent rights of the Debtor to the payment of money for any reason whatsoever, whether arising in contract, tort or otherwise including, without limitation, all rights to receive payments under presently existing or hereafter acquired or created letters of credit; (e) all present and future claims, rights of indemnification and other rights of the Debtor under or in connection with any contracts or agreements to which the Debtor is or becomes a party or third party beneficiary; (f) all goods previously or hereafter returned, repossessed or stopped in transit, the sale, lease or other disposition of which contributed to the creation of any account, instrument or chattel paper of the Debtor; (g) all present and future rights of the Debtor as an unpaid seller of goods, including rights of stoppage in transit, detinue and reclamation; (h) all rights which the Debtor may now or at any time hereafter have, by law or agreement, against any Account Debtor or other obligor of the Debtor, and all rights, liens and security interests which the Debtor may now or at any time hereafter have, by law or agreement, against any property of any Account Debtor or other obligor of the Debtor; (i) all invoices and shipping documents; and (j) all present and future interests and rights of the Debtor, including rights to the payment of money, under or in connection with all present and future leases and subleases of real or personal property to which the Debtor is a party, as lessor, sublessor, lessee or sublessee.
IN WITNESS WHEREOF, Debtor and Secured Party, intending to be legally bound hereby, have duly executed this Agreement in one or more counterparts, each of which shall be deemed to be an original, as of the day and year first aforesaid.
SECURED PARTY:
|
DEBTOR: | |
|
||
Oxford Finance Corporation
|
Genomic Health, Inc. | |
|
||
By: /s/ Michael J. Altenburger
|
By: /s/ Brad Cole | |
|
|
|
|
||
Name: Michael J. Altenburger
|
Name: Brad Cole | |
|
||
Title: Chief Financial Officer
|
Title: Chief Financial Officer |
Page 7 of 9
|
Initial /s/ BC / /s/ MJA | |
|
Master Security Agreement
SCHEDULE A
(Collateral Locations)
Page 8 of 9
|
Initial /s/ BC / /s/ MJA | |
|
Master Security Agreement
SCHEDULE B
(Compliance Certificate)
FORM OF
COMPLIANCE CERTIFICATE
Oxford Finance Corporation
133 N. Fairfax Street
Alexandria, VA 22314
Re: <Debtor>
Gentlemen:
Reference is made to the Master Security Agreement dated as of ___, 200___(as the same have been and may be amended from time to time, the Loan Agreement , the capitalized terms used herein as defined therein), between Oxford Finance Corporation and <Debtor> (the Company ).
The undersigned authorized representative of the Company hereby certifies that in accordance with the terms and conditions of the Loan Agreement, the Company is in complete compliance for the financial reporting period ending ___with all required financial reporting under the Loan Agreement, except as noted below. Attached herewith are the required documents supporting the foregoing certification. The undersigned further certifies that the accompanying financial statements have been prepared in accordance with Generally Accepted Accounting Principles, and are consistent from one period to the next, except as explained below.
Indicate compliance status by circling Yes/No under
Complies
REPORTING REQUIREMENT
REQUIRED
COMPLIES
Quarterly within 90 days
YES/NO
Monthly within 45 days
FYE within 150 days
YES/NO
YES / NO
EXPLANATIONS
Very truly yours, | ||||
|
||||
Genomic Health, Inc. | ||||
|
||||
|
By: | |||
|
||||
|
Name: | |||
|
||||
|
Title:* | |||
|
* | Must be executed by Debtors Chief Financial Officer. |
Page 9 of 9
|
Initial /s/ BC / /s/ MJA | |
|
Exhibit 10.9.2
|
FORM OF PROMISSORY NOTE
(Equipment)
To Master Security Agreement No. _________
FOR VALUE RECEIVED, Genomic Health, Inc., a Delaware corporation, located at the address stated below ( Maker" ) promises, jointly and severally if more than one, to pay to the order of Oxford Finance Corporation or any subsequent holder hereof (each, a Payee" ) at its office located at 133 N. Fairfax Street, Alexandria, VA 22314 or at such other place as Payee or the holder hereof may designate, the principal sum of Dollars ($ ) , with interest on the unpaid principal balance, from the date hereof through and including the dates of payment, at a fixed interest rate of ( %) per annum. Maker shall make three (3) payments of interest only as follows:
Periodic | ||||
Installment | Amount | |||
1-3
|
$ |
Thereafter, commencing on , Maker shall make payments of principal and interest in forty-five (45) consecutive monthly installments of principal and interest as follows:
Periodic | ||||
Installment | Amount | |||
4-48
|
$ |
each (a Periodic Installment" ) and a final installment which shall be in the amount of the total outstanding principal and interest, if any. The first Periodic Installment shall be due and payable on and the following Periodic Installments and the final installment shall be due and payable on the first day of each succeeding month (each, a Payment Date" ) beginning . Such installments have been calculated on the basis of a 360-day year of twelve 30-day months. Each payment may, at the option of the Payee, be calculated and applied on an assumption that such payment would be made on its due date.
The acceptance by Payee of any payment which is less than payment in full of all amounts due and owing at such time shall not constitute a waiver of Payees right to receive payment in full at such time or at any prior or subsequent time.
The Maker hereby expressly authorizes the Payee to insert the date value is actually given in the blank space on the face hereof and on all related documents pertaining hereto.
This Note is secured by that certain Master Security Agreement# 5081084 dated March 30, 2005 between the Maker and Payee (the Security Agreement and together with this Note and any other document evidencing or securing this loan is hereinafter called a Debt Document ).
Time is of the essence hereof. If any installment or any other sum due under this Note or the Security Agreement is not received within 5 business days after the date due (unless caused by any act or omission by Payee relating to any agreement with Maker which allows Payee to obtain such payment through debiting Makers account), the Maker agrees to pay, in addition to the amount of each such installment or other sum, a late payment charge of five percent (5%) of the amount of said installment or other sum, but not exceeding any lawful maximum. If (i) Maker fails to make payment of any amount due hereunder; or (ii) Maker is in default under, or fails to perform under any term or condition contained in any the terms of Section 7 of the Security Agreement, then the entire principal sum remaining unpaid, together with all accrued interest thereon and any other sum payable under this Note or the Security Agreement, at the election of Payee, shall immediately become due and payable, with interest thereon at the lesser of eighteen percent (18%) per annum or the highest rate not prohibited by applicable law from the date of such accelerated maturity until paid (both before and after any judgment).
Notwithstanding anything to the contrary contained herein or in the Security Agreement, Maker may prepay in full, but not in part, and only after the first anniversary of this Note, its entire Indebtedness hereunder by payment of the entire Indebtedness plus an additional sum as a premium equal to the following percentages of the remaining principal balance for the indicated period:
From the first annual anniversary date of this Note until the second annual anniversary date of this Note: six percent (6%)
From the second annual anniversary date of this Note until the third annual anniversary date of this Note: five percent (5%)
From the third annual anniversary date of this Note until the third annual anniversary date of this Note: four percent (4%)
The Maker and all sureties, endorsers, guarantors or any others (each such person, other than the Maker, an Obligor" ) who may at any time become liable for the payment hereof jointly and severally consent hereby to any and all extensions of time, renewals, waivers or modifications of, and all substitutions or releases of, security or of any party primarily or secondarily liable on this Note or the Security Agreement or any term and provision of either, which may be made, granted or consented to by Payee, and agree that suit may be brought and maintained against any one or more of them, at the election of Payee without joinder of any other as a party thereto, and that Payee shall not be required first to foreclose, proceed against, or exhaust any security hereof in order to enforce payment of this Note. The Maker and each Obligor hereby waives presentment, demand for payment, notice of nonpayment, protest, notice of protest, notice of dishonor, and all other notices in connection herewith (except as expressly provided for herein or in any Debt Document, as well as diligence in collecting this Note or enforcing any of the security hereof, and agrees to pay (if and to the extent permitted by law) all reasonable expenses incurred in collection, including Payees reasonable attorneys fees.
Maker and Payee intend to strictly comply with all applicable federal and Virginia laws, including applicable usury laws (or the usury laws of any jurisdiction whose usury laws are deemed to apply to the Note or any other Debt Document despite the intention and desire of the parties to apply the usury laws of the Commonwealth of Virginia). Accordingly, the provisions of this paragraph shall govern and control over every other provision of this Note or any other Debt Document which conflicts or is inconsistent with this Section, even if such provision declares that it controls. As used in this paragraph, the term interest includes the aggregate of all charges, fees, benefits or other compensation which constitute interest under applicable law, provided that, to the maximum extent permitted by applicable law, (a) any non-principal payment shall be characterized as an expense or as compensation for something other than the use, forbearance or detention of money and not as interest, and (b) all interest at any time contracted for, reserved, charged or received shall be amortized, prorated, allocated and spread, in equal parts during the full term of the obligations. In no event shall Maker or any other person be obligated to pay, or Payee have any right or privilege to reserve, receive or retain, (a) any interest in excess of the maximum amount of non-usurious interest permitted under the laws of the Commonwealth of Virginia or the applicable laws (if any) of the United States or of any other state, or (b) total interest in excess of the amount which Payee could lawfully have contracted for, reserved, received, retained or charged had the interest been calculated for the full term of the obligations. On each day, if any, that the interest rate (the Stated Rate ) called for under this Note or any other Debt Document exceeds the maximum non-usurious rate, the rate at which interest shall accrue shall automatically be fixed by operation of this sentence at the maximum non-usurious rate for that day. Thereafter, interest shall accrue at the Stated Rate unless and until the Stated Rate again exceeds the maximum non-usurious rate, in which case, the provisions of the immediately preceding sentence shall again automatically operate to limit the interest accrual rate to the maximum non-usurious rate. The daily interest rates to be used in calculating interest at the maximum non-usurious rate shall be determined by dividing the applicable maximum non-usurious rate by the number of days in the calendar year for which such calculation is being made. None of the terms and provisions contained in this Note or in any other Debt Document which directly or indirectly relate to interest shall ever be construed without reference to this paragraph, or be construed to create a contract to pay for the use, forbearance or detention of money at an interest rate in excess of the maximum non-usurious rate. If the term of any obligation is shortened by reason of acceleration of maturity as a result of any Default or by any other cause, or by reason of any required or permitted prepayment, and if for that (or any other) reason Payee at any time, including but not limited to, the stated maturity, is owed or receives (and/or has received) interest in excess of interest calculated at the maximum non-usurious rate, then and in any such event all of any such excess interest shall be canceled automatically as of the date of such acceleration, prepayment or other event which produces the excess, and, if such excess interest has been paid to Payee, it shall be credited pro tanto against the then-outstanding principal balance of Makers obligations to Payee, effective as of the date or dates when the event occurs which causes it to be excess interest, until such excess is exhausted or all of such principal has been fully paid and satisfied, whichever occurs first, and any remaining balance of such excess shall be promptly refunded to its payor.
THE MAKER HEREBY UNCONDITIONALLY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF, DIRECTLY OR INDIRECTLY, THIS NOTE, ANY OF THE RELATED DOCUMENTS, ANY DEALINGS BETWEEN MAKER AND PAYEE RELATING TO THE SUBJECT MATTER OF THIS TRANSACTION OR ANY RELATED TRANSACTIONS, AND/OR THE RELATIONSHIP THAT IS BEING ESTABLISHED BETWEEN MAKER AND PAYEE. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT (INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS.) THIS WAIVER IS IRREVOCABLE, MEANING THAT IT MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING, AND THE WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS NOTE, ANY RELATED DOCUMENTS, OR TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THIS TRANSACTION OR ANY RELATED TRANSACTION. IN THE EVENT OF LITIGATION, THIS NOTE MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT.
This Note and the Security Agreement constitute the entire agreement of the Maker and Payee with respect to the subject matter hereof and supercedes all prior understandings, agreements and representations, express or implied.
No variation or modification of this Note, or any waiver of any of its provisions or conditions, shall be valid unless in writing and signed by an authorized representative of Maker and Payee. Any such waiver, consent, modification or change shall be effective only in the specific instance and for the specific purpose given.
Any provision in this Note or the Security Agreement which is in conflict with any statute, law or applicable rule shall be deemed omitted, modified or altered to conform thereto.
|
Upon receipt of an affidavit of an officer of Payee as to the loss, theft, destruction or mutilation of this Note or any Debt Document which is not of public record, and, in the case of any such loss, theft, destruction or mutilation, upon surrender and cancellation of such Note or other Debt Document, Maker will issue, in lieu thereof, a replacement Note or other Debt Document in the same principal amount thereof and otherwise of like tenor.
It is understood and agreed that this Note and all of the Debt Documents were negotiated and have been or will be delivered to Payee in the Commonwealth of Virginia, which State the parties agree has a substantial relationship to the parties and to the underlying transactions embodied by this Note and the Debt Documents. Maker agrees to furnish to Payee at Payees office in Alexandria, VA, all further instruments, certifications and documents to be furnished hereunder.
THIS NOTE SHALL BE GOVERNED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE COMMONWEALTH OF VIRGINIA. MAKER AND GUARANTORS HEREBY CONSENT TO THE EXERCISE OF JURISDICTION OVER IT BY ANY FEDERAL COURT SITTING IN VIRGINIA OR ANY VIRGINIA COURT SELECTED BY PAYEE, FOR THE PURPOSES OF ANY AND ALL LEGAL PROCEEDINGS ARISING OUT OF OR RELATING TO THE NOTE, THE SECURITY AGREEMENT AND ALL OTHER DEBT DOCUMENTS. MAKER AND GUARANTORS IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY SUCH PROCEEDING BROUGHT IN ANY SUCH COURT, ANY CLAIM BASED ON THE CONSOLIDATION OF PROCEEDINGS IN SUCH COURTS IN WHICH PROPER VENUE MAY LIE IN DIVERGENT JURISDICTIONS, AND ANY CLAIM THAT ANY SUCH PROCEEDING BROUGHT IN ANY SUCH COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM. MAKER AND GUARANTORS HEREBY IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS NOTE, THE OTHER DEBT DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED THEREBY.
GENOMIC HEALTH, INC. | ||||||||
|
||||||||
|
By: | |||||||
|
||||||||
(Witness)
|
||||||||
|
Name: | |||||||
|
||||||||
(Print name)
|
||||||||
|
Title: | |||||||
|
||||||||
(Address)
|
||||||||
Federal Tax ID #: 77-0552594 |
|
Address: | 301 Penobscot Drive | ||
|
Redwood City, CA 94063 |
Exhibit 10.9.3
|
FORM OF PROMISSORY NOTE
(Computers and Software)
To Master Security Agreement No. _________
FOR VALUE RECEIVED, Genomic Health, Inc., a Delaware corporation, located at the address stated below ( Maker" ) promises, jointly and severally if more than one, to pay to the order of Oxford Finance Corporation or any subsequent holder hereof (each, a Payee" ) at its office located at 133 N. Fairfax Street, Alexandria, VA 22314 or at such other place as Payee or the holder hereof may designate, the principal sum of Dollars ($ ) , with interest on the unpaid principal balance, from the date hereof through and including the dates of payment, at a fixed interest rate of ( %) per annum. Maker shall make three (3) payments of interest only as follows:
Periodic | ||||
Installment | Amount | |||
1-3
|
$ |
Thereafter, commencing on , Maker shall make payments of principal and interest in thirty six (36) consecutive monthly installments of principal and interest as follows:
Periodic | ||||
Installment | Amount | |||
4-39
|
$ |
each (a Periodic Installment" ) and a final installment which shall be in the amount of the total outstanding principal and interest, if any. The first Periodic Installment shall be due and payable on and the following Periodic Installments and the final installment shall be due and payable on the first day of each succeeding month (each, a Payment Date" ) beginning . Such installments have been calculated on the basis of a 360-day year of twelve 30-day months. Each payment may, at the option of the Payee, be calculated and applied on an assumption that such payment would be made on its due date.
The acceptance by Payee of any payment which is less than payment in full of all amounts due and owing at such time shall not constitute a waiver of Payees right to receive payment in full at such time or at any prior or subsequent time.
The Maker hereby expressly authorizes the Payee to insert the date value is actually given in the blank space on the face hereof and on all related documents pertaining hereto.
This Note is secured by that certain Master Security Agreement# 5081084 dated March 30, 2005 between the Maker and Payee (the Security Agreement and together with this Note and any other document evidencing or securing this loan is hereinafter called a Debt Document ).
Time is of the essence hereof. If any installment or any other sum due under this Note or the Security Agreement is not received within 5 business days after the date due (unless caused by any act or omission by Payee relating to any agreement with Maker which allows Payee to obtain such payment through debiting Makers account), the Maker agrees to pay, in addition to the amount of each such installment or other sum, a late payment charge of five percent (5%) of the amount of said installment or other sum, but not exceeding any lawful maximum. If (i) Maker fails to make payment of any amount due hereunder; or (ii) Maker is in default under, or fails to perform under any term or condition contained in any the terms of Section 7 of the Security Agreement, then the entire principal sum remaining unpaid, together with all accrued interest thereon and any other sum payable under this Note or the Security Agreement, at the election of Payee, shall immediately become due and payable, with interest thereon at the lesser of eighteen percent (18%) per annum or the highest rate not prohibited by applicable law from the date of such accelerated maturity until paid (both before and after any judgment).
Notwithstanding anything to the contrary contained herein or in the Security Agreement, Maker may prepay in full, but not in part, and only after the first anniversary of this Note, its entire Indebtedness hereunder by payment of the entire Indebtedness plus an additional sum as a premium equal to the following percentages of the remaining principal balance for the indicated period:
From the first annual anniversary date of this Note until the second annual anniversary date of this Note: six percent (6%)
From the second annual anniversary date of this Note until the third annual anniversary date of this Note: five percent (5%)
From the third annual anniversary date of this Note until the third annual anniversary date of this Note: four percent (4%)
The Maker and all sureties, endorsers, guarantors or any others (each such person, other than the Maker, an Obligor" ) who may at any time become liable for the payment hereof jointly and severally consent hereby to any and all extensions of time, renewals, waivers or modifications of, and all substitutions or releases of, security or of any party primarily or secondarily liable on this Note or the Security Agreement or any term and provision of either, which may be made, granted or consented to by Payee, and agree that suit may be brought and maintained against any one or more of them, at the election of Payee without joinder of any other as a party thereto, and that Payee shall not be required first to foreclose, proceed against, or exhaust any security hereof in order to enforce payment of this Note. The Maker and each Obligor hereby waives presentment, demand for payment, notice of nonpayment, protest, notice of protest, notice of dishonor, and all other notices in connection herewith (except as expressly provided for herein or in any Debt Document, as well as diligence in collecting this Note or enforcing any of the security hereof, and agrees to pay (if and to the extent permitted by law) all reasonable expenses incurred in collection, including Payees reasonable attorneys fees.
Maker and Payee intend to strictly comply with all applicable federal and Virginia laws, including applicable usury laws (or the usury laws of any jurisdiction whose usury laws are deemed to apply to the Note or any other Debt Document despite the intention and desire of the parties to apply the usury laws of the Commonwealth of Virginia). Accordingly, the provisions of this paragraph shall govern and control over every other provision of this Note or any other Debt Document which conflicts or is inconsistent with this Section, even if such provision declares that it controls. As used in this paragraph, the term interest includes the aggregate of all charges, fees, benefits or other compensation which constitute interest under applicable law, provided that, to the maximum extent permitted by applicable law, (a) any non-principal payment shall be characterized as an expense or as compensation for something other than the use, forbearance or detention of money and not as interest, and (b) all interest at any time contracted for, reserved, charged or received shall be amortized, prorated, allocated and spread, in equal parts during the full term of the obligations. In no event shall Maker or any other person be obligated to pay, or Payee have any right or privilege to reserve, receive or retain, (a) any interest in excess of the maximum amount of non-usurious interest permitted under the laws of the Commonwealth of Virginia or the applicable laws (if any) of the United States or of any other state, or (b) total interest in excess of the amount which Payee could lawfully have contracted for, reserved, received, retained or charged had the interest been calculated for the full term of the obligations. On each day, if any, that the interest rate (the Stated Rate ) called for under this Note or any other Debt Document exceeds the maximum non-usurious rate, the rate at which interest shall accrue shall automatically be fixed by operation of this sentence at the maximum non-usurious rate for that day. Thereafter, interest shall accrue at the Stated Rate unless and until the Stated Rate again exceeds the maximum non-usurious rate, in which case, the provisions of the immediately preceding sentence shall again automatically operate to limit the interest accrual rate to the maximum non-usurious rate. The daily interest rates to be used in calculating interest at the maximum non-usurious rate shall be determined by dividing the applicable maximum non-usurious rate by the number of days in the calendar year for which such calculation is being made. None of the terms and provisions contained in this Note or in any other Debt Document which directly or indirectly relate to interest shall ever be construed without reference to this paragraph, or be construed to create a contract to pay for the use, forbearance or detention of money at an interest rate in excess of the maximum non-usurious rate. If the term of any obligation is shortened by reason of acceleration of maturity as a result of any Default or by any other cause, or by reason of any required or permitted prepayment, and if for that (or any other) reason Payee at any time, including but not limited to, the stated maturity, is owed or receives (and/or has received) interest in excess of interest calculated at the maximum non-usurious rate, then and in any such event all of any such excess interest shall be canceled automatically as of the date of such acceleration, prepayment or other event which produces the excess, and, if such excess interest has been paid to Payee, it shall be credited pro tanto against the then-outstanding principal balance of Makers obligations to Payee, effective as of the date or dates when the event occurs which causes it to be excess interest, until such excess is exhausted or all of such principal has been fully paid and satisfied, whichever occurs first, and any remaining balance of such excess sh all be promptly refunded to its payor.
THE MAKER HEREBY UNCONDITIONALLY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF, DIRECTLY OR INDIRECTLY, THIS NOTE, ANY OF THE RELATED DOCUMENTS, ANY DEALINGS BETWEEN MAKER AND PAYEE RELATING TO THE SUBJECT MATTER OF THIS TRANSACTION OR ANY RELATED TRANSACTIONS, AND/OR THE RELATIONSHIP THAT IS BEING ESTABLISHED BETWEEN MAKER AND PAYEE. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT (INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS.) THIS WAIVER IS IRREVOCABLE, MEANING THAT IT MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING, AND THE WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS NOTE, ANY RELATED DOCUMENTS, OR TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THIS TRANSACTION OR ANY RELATED TRANSACTION. IN THE EVENT OF LITIGATION, THIS NOTE MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT.
This Note and the Security Agreement constitute the entire agreement of the Maker and Payee with respect to the subject matter hereof and supercedes all prior understandings, agreements and representations, express or implied.
No variation or modification of this Note, or any waiver of any of its provisions or conditions, shall be valid unless in writing and signed by an authorized representative of Maker and Payee. Any such waiver, consent, modification or change shall be effective only in the specific instance and for the specific purpose given.
Any provision in this Note or the Security Agreement which is in conflict with any statute, law or applicable rule shall be deemed omitted, modified or altered to conform thereto.
Upon receipt of an affidavit of an officer of Payee as to the loss, theft, destruction or mutilation of this Note or any Debt Document which is not of public record, and, in the case of any such loss, theft, destruction or mutilation, upon surrender and cancellation of such Note or other Debt Document, Maker will issue, in lieu thereof, a replacement Note or other Debt Document in the same principal amount thereof and otherwise of like tenor.
It is understood and agreed that this Note and all of the Debt Documents were negotiated and have been or will be delivered to Payee in the Commonwealth of Virginia, which State the parties agree has a substantial relationship to the parties and to the underlying transactions embodied by this Note and the Debt Documents. Maker agrees to furnish to Payee at Payees office in Alexandria, VA, all further instruments, certifications and documents to be furnished hereunder.
THIS NOTE SHALL BE GOVERNED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE COMMONWEALTH OF VIRGINIA. MAKER AND GUARANTORS HEREBY CONSENT TO THE EXERCISE OF JURISDICTION OVER IT BY ANY FEDERAL COURT SITTING IN VIRGINIA OR ANY VIRGINIA COURT SELECTED BY PAYEE, FOR THE PURPOSES OF ANY AND ALL LEGAL PROCEEDINGS ARISING OUT OF OR RELATING TO THE NOTE, THE SECURITY AGREEMENT AND ALL OTHER DEBT DOCUMENTS. MAKER AND GUARANTORS IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY SUCH PROCEEDING BROUGHT IN ANY SUCH COURT, ANY CLAIM BASED ON THE CONSOLIDATION OF PROCEEDINGS IN SUCH COURTS IN WHICH PROPER VENUE MAY LIE IN DIVERGENT JURISDICTIONS, AND ANY CLAIM THAT ANY SUCH PROCEEDING BROUGHT IN ANY SUCH COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM. MAKER AND GUARANTORS HEREBY IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS NOTE, THE OTHER DEBT DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED THEREBY.
GENOMIC HEALTH, INC. | ||||||||
|
||||||||
|
By: | |||||||
|
||||||||
(Witness)
|
||||||||
|
Name: | |||||||
|
||||||||
(Print name)
|
||||||||
|
Title: | |||||||
|
||||||||
(Address)
|
||||||||
Federal Tax ID #: 77-0552594 |
|
Address: | 301 Penobscot Drive | ||
|
Redwood City, CA 94063 |
Exhibit 10.9.4
SCHEDULE OF PROMISSORY NOTES
Containing Provisions Set Forth in Forms of Promissory Note
Filed as Exhibit 10.9.2 and Exhibit 10.9.3
Promissory Note No.
Type of Promissory Note
Date of Issuance
Principal Amount
Interest Rate
Equipment
March 30, 2005
$
1,601,828.65
10.65
%
Computers and
Software
March 30, 2005
$
513,384.10
10.65
%
Equipment
May 4, 2005
$
833,152.88
10.30
%
Computers and
Software
May 4, 2005
$
119,989.15
10.30
%
Equipment
June 27, 2005
$
127,664.50
10.23
%
Computers and
Software
June 27, 2005
$
63,560.15
10.23
%
Exhibit 21.1
SUBSIDIARIES
Oncotype Laboratories, Inc. 100% owned by Genomic Health, Inc.
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption
Experts and to the use of our report dated
May 13, 2005, in the Registration Statement (Form S-1)
and related Prospectus of Genomic Health, Inc. dated
July 15, 2005.
Palo Alto, California
/s/ Ernst & Young LLP